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Summary 
Myopia, as a common ocular disorder, is caused by both genetic and environmental 
factors. Conventional genome-wide association studies (GWAS) in humans have 
limited power to detect myopia genes partly due to the complex interplay between 
genes and environment. Here, I performed a GWAS in a sample of chicks with form 
deprivation (FD) myopia, aiming to reduce environmental complexity and increase 
the statistical power to detect genetic variants that confer susceptibility to this 
environmentally-induced myopia phenotype. 
The degree of FD myopia was quantified by measuring the treatment-induced 
changes in axial length (∆AXL) and mean spherical equivalent (∆MSE). Body weight, 
sex, and batch were evaluated as potential confounding factors. To reduce costs, 
chicks in the phenotype extremes (lowest or highest ∆AXL, within each batch) were 
selected for genotyping. 
To identify genetic variants conferring susceptibility to myopia, GWA analyses for 
∆AXL and ∆MSE were applied to the genotype data. After adjusting for confounding 
factors, genetic variant rs317386235, located between the genes PRKAR2B and 
PIK3CG exceeded the Bonferroni corrected significance threshold for ∆AXL.  
To complement the GWAS findings, an RNA sequencing transcriptomics analysis was 
performed, using retinal tissue from the treated and control eyes of chicks with high 
or low-susceptibility to myopia. This revealed 516 differentially-expressed genes, 
identified using a combination of three analysis tools.   
In order to discover more about the biological function underlying the GWAS and 
transcriptomics analysis results, pathway analyses were conducted. The pathway 
analysis implicated gene sets relating to circadian rhythms, extracellular matrix (ECM) 
and structural remodelling, energy generation, oxidative stress, glycometabolism and 
lipid metabolism.
IV 
 
Table of Contents 
Chapter 1 Introduction ......................................................................... 1 
1.1 Definitions ...............................................................................................2 
1.2 The prevalence of myopia – from the past to the present ......................................2 
1.3 The prevalence of myopia – from the east to the west .........................................5 
1.4 Impact of myopia ......................................................................................7 
1.5 Aetiology of myopia ...................................................................................7 
1.5.1 The genetic theory ..................................................................................7 
1.5.1.1 Heritability of myopia ............................................................................7 
1.5.1.2 Linkage studies and candidate regions ........................................................8 
1.5.1.3 Association studies and GWAS ................................................................ 12 
1.5.1.3.1 Family-based association study ............................................................ 12 
1.5.1.3.2 Population-based association study ....................................................... 13 
1.5.1.4 DNA sequencing ................................................................................. 16 
1.5.1.5 Comparison between linkage analyses, family-based association study, GWAS and 
sequencing ................................................................................................. 16 
1.5.2 Environmental factors ............................................................................ 18 
1.5.2.1 Near work and education ...................................................................... 19 
1.5.2.2 Time spent outdoors ............................................................................ 20 
1.5.2.3 Diet and physical activity ...................................................................... 21 
1.5.2.4 Physical stature and social status ............................................................ 22 
1.5.2.5 Parental factors ................................................................................. 23 
1.5.3 Gene-environment interactions ................................................................. 23 
1.6 Treatment interventions for myopia ............................................................. 24 
1.7 Animal models of myopia ........................................................................... 25 
1.7.1 Key findings from animal experiments ........................................................ 26 
1.7.1.1 Light intensity and wavelength ............................................................... 26 
1.7.1.2 Signalling pathways and molecules .......................................................... 27 
1.7.2 Comparison between different animals ....................................................... 28 
1.7.3 Interventions for inducing myopia .............................................................. 30 
1.7.3.1. Form-deprivation myopia (FDM) ............................................................. 30 
1.7.3.2. Lens-induced myopia (LIM) ................................................................... 30 
1.8 Overview of the research design strategy for the PhD project .............................. 30 
1.8.1 Animal selection for the PhD project .......................................................... 31 
1.8.2 Method to induce myopia ........................................................................ 31 
1.8.2.1 Form-deprivation myopia vs. lens-induced myopia ....................................... 31 
1.8.2.2 Method of attaching occluders to produce form deprivation ........................... 31 
1.8.2.3 Age and duration of form deprivation ....................................................... 32 
V 
 
1.8.3 Method to assess the degree of FD myopia ................................................... 32 
1.8.4 Method used to measure axial length .......................................................... 32 
1.8.5 Method used to measure spherical equivalent ............................................... 34 
1.8.6 Method to detect gene loci influencing susceptibility to form deprivation myopia ... 35 
Chapter 2 Material and methods ........................................................... 36 
2.1 Material ................................................................................................ 37 
2.1.1 Experimental animal .............................................................................. 37 
2.1.2 Occluders ........................................................................................... 37 
2.2 Method ................................................................................................. 37 
2.2.1 Myopia model: Form deprivation ............................................................... 37 
2.2.2 Measurement and quantification of eye parameters ........................................ 38 
2.2.2.1 High-frequency A-scan ultrasonography .................................................... 38 
2.2.2.2 Retinoscopy ...................................................................................... 39 
2.2.2.3 Quantification of eye parameters ............................................................ 39 
2.2.3 Measurement of body weight .................................................................... 40 
2.2.4 Biological sample collection ..................................................................... 40 
2.2.4.1 Blood sample collection ........................................................................ 41 
2.2.4.2 Retina sample collection ...................................................................... 41 
2.2.5 Nucleic acid extractions .......................................................................... 42 
2.2.5.1 DNA extraction .................................................................................. 42 
2.2.5.2 DNA concentration measurement ............................................................ 42 
2.2.5.3 RNA extraction ................................................................................... 43 
2.2.5.4 RNA quality test ................................................................................. 43 
2.2.6 Polymerase chain reaction (PCR) sexing test ................................................. 44 
2.3 Statistics ............................................................................................... 47 
2.4 Ethical statement .................................................................................... 47 
2.6 Flowchart of the experiment design .............................................................. 48 
Chapter 3 Characteristics of myopia in form deprived chicks ........................ 49 
3.1 Introduction ........................................................................................... 50 
3.1.1 Height ................................................................................................ 50 
3.1.2 Body weight and body mass index (BMI) ....................................................... 51 
3.1.3 Sex ................................................................................................... 51 
3.1.4 The influence of body weight and sex on animal ocular biometry. ...................... 56 
3.2 Methods ................................................................................................ 57 
3.2.1 Experiment models ................................................................................ 57 
3.2.2 Statistical Analysis ................................................................................. 57 
3.3 Results ................................................................................................. 58 
3.3.1 Characteristics of chick traits prior to form deprivation ................................... 58 
VI 
 
3.3.2 Characteristics of chick traits after form deprivation ...................................... 60 
3.3.3 Myopia susceptibility in response to form deprivation ...................................... 62 
3.3.3.1 Chick characteristics associated with treatment-induced axial elongation .......... 62 
3.3.3.2. Chick characteristics associated with the treatment-induced degree of myopia  . 66 
3.3.4 Phenotypic characteristics of chicks selected for genotyping ............................. 70 
3.3.5 Myopia susceptibility in response to form deprivation in selected chicks ............... 72 
3.3.5.1 Chick characteristics associated with treatment-induced axial elongation  ......... 72 
3.3.5.2 Chick characteristics associated with treatment-induced degree of myopia  ....... 77 
3.4 Discussion .............................................................................................. 80 
3.4.1 Relationships between body weight, sex and ocular parameters before FD ............ 80 
3.4.2 In FD environment, body weight, sex and ocular parameters ............................. 81 
3.4.3 Differences between right and left eyes ...................................................... 82 
3.5 Conclusions ............................................................................................ 83 
Chapter 4 A genome-wide association study (GWAS) of FD myopia chicks ......... 84 
4.1 Introduction .......................................................................................... 85 
4.1.1 Missing heritability and gene-environment interaction ..................................... 85 
4.1.2 Hypothesis – an animal model to detect G × E interactions ............................... 87 
4.1.3 Comparison between GWAS in chicks and GWAS in human ................................ 87 
4.1.4 Genotyping techniques ......................................................................... 87 
4.1.5 Selection of chick genotyping platform ...................................................... 89 
4.2 Method ................................................................................................. 89 
4.2.1 Sample size ......................................................................................... 89 
4.2.2 Genotyping .......................................................................................... 89 
4.2.3 Quality control ..................................................................................... 90 
4.2.3.1 Quality Control carried out by the genotyping company ................................. 91 
4.2.3.2 Additional Quality Control procedures ...................................................... 91 
4.2.4 Association analysis ............................................................................... 96 
4.3 Results ................................................................................................. 97 
4.3.1 Genotyping data quality .......................................................................... 97 
4.3.2 GWAS for AXL ....................................................................................... 98 
4.3.3 GWAS for MSE ..................................................................................... 105 
4.3.4 Annotation of lead SNPs ......................................................................... 110 
4.4 Discussion ............................................................................................. 111 
4.4.1 PIK3CG .............................................................................................. 111 
4.4.2 PRKAR2B ............................................................................................ 111 
4.4.3 UGT1A1 ............................................................................................. 112 
4.4.4 USP40 ............................................................................................... 112 
4.4.5 LAMB4 .............................................................................................. 112 
4.4.6 Different results from GWAS for AXL and MSE ............................................... 113 
VII 
 
4.4.7 GRM and genomic control correction ......................................................... 114 
4.4.8 Selective genotyping ............................................................................. 115 
4.4.9 Continuous vs. dichotomous phenotype coding ............................................. 115 
4.4.10 Comparison of all models ...................................................................... 115 
4.5 Conclusion ............................................................................................ 116 
Chapter 5 Transcriptomic analysis of retinal gene expression in chicks developing 
form-deprivation myopia ................................................................... 117 
5.1 Introduction .......................................................................................... 118 
5.2 Methods ............................................................................................... 120 
5.2.1 Overview and sample preparation ............................................................. 120 
5.2.2 RNA sequencing and mapping .................................................................. 120 
5.2.3 Analysis pipeline .................................................................................. 123 
5.2.4 Statistical model .................................................................................. 123 
5.2.5 Software ............................................................................................ 124 
5.2.6 Quality control .................................................................................... 125 
5.3 Results ................................................................................................ 125 
5.3.1 Sample information and data structure overview .......................................... 125 
5.3.1.1 Sample information ............................................................................ 125 
5.3.1.2 Library size and normalization factors ..................................................... 126 
5.3.2 Sample quality .................................................................................... 126 
5.3.3 Gene expression mean-variance plots ........................................................ 128 
5.3.4 Dispersion estimation for different models .................................................. 129 
5.3.4 Results for Model 1 ............................................................................... 130 
5.3.4.1 DEG between FD eyes and control eyes .................................................... 130 
5.3.4.2 Genes differentially expressed between High and Low myopia susceptibility 
groups ...................................................................................................... 133 
5.3.5 Results for Model 2 ............................................................................... 135 
5.3.6 Results for Model 3 ............................................................................... 136 
5.4 Discussion ............................................................................................. 139 
5.4.1 Retinal gene expression differences induced by form deprivation ...................... 139 
5.4.1.1 Comparison between Model 1 and Model 2 ................................................ 139 
5.4.1.2 Comparison with previous findings .......................................................... 139 
5.4.1.3 Noteworthy genes .............................................................................. 140 
5.4.2 Retinal gene expression differences between the High and Low myopia 
susceptibility groups .................................................................................... 141 
5.4.2.1 Comparison between Model 1 and Model 3 ................................................ 141 
5.4.2.2 Comparison between Model 2 and Model 3 ................................................ 141 
5.4.2.3 Comparison with previous findings .......................................................... 142 
5.4.2.4 Noteworthy genes .............................................................................. 142 
VIII 
 
5.4.3 Transcript analysis .............................................................................. 145 
5.4.4 Comparison of analytical software packages ................................................ 145 
5.5 Conclusion ............................................................................................ 146 
Chapter 6 Pathway analysis ................................................................ 148 
6.1 Introduction .......................................................................................... 149 
6.1.1 Pathway analyses for GWAS results ........................................................... 149 
6.1.1.1 Features of post-GWAS pathway analysis .................................................. 150 
6.1.1.2 Software ......................................................................................... 151 
6.1.2 Pathway analysis for RNA-seq results ......................................................... 151 
6.1.2.1 Over-Representation Analysis (ORA) ........................................................ 151 
6.1.2.2 Functional Class Scoring (FCS) ............................................................... 151 
6.2 Methods ............................................................................................... 152 
6.2.1 Pathway analysis for GWAS ..................................................................... 152 
6.2.2 Pathway analysis for RNA-seq results ......................................................... 153 
6.2.2.1 DAVID ............................................................................................. 153 
6.2.2.2 GSEA .............................................................................................. 153 
6.2.3 Other software packages ........................................................................ 154 
6.3. Results ............................................................................................... 154 
6.3.1 MAGMA analysis ................................................................................... 154 
6.3.1.1 Annotation ....................................................................................... 154 
6.3.1.2 Gene-based analysis ........................................................................... 154 
6.3.1.3 Gene set analysis ............................................................................... 155 
6.3.2 Results for RNA-Seq data ........................................................................ 157 
6.3.2.1 KEGG analysis using DAVID ................................................................... 157 
6.3.2.2 GO term analysis using DAVID ................................................................ 161 
6.3.2.3 KEGG analysis using Gene Set Enrichment Analysis (GSEA) ............................. 166 
6.3.2.4 GO term analysis using Gene Set Enrichment Analysis (GSEA) ......................... 168 
6.4 Discussion ............................................................................................. 171 
6.4.1 Gene-based association study .................................................................. 171 
6.4.2 Gene-set-based association study ............................................................. 172 
6.4.2.1 Circadian rhythms .............................................................................. 172 
6.4.2.2 Gene sets relating to extracellular matrix (ECM) and structural remodelling ...... 172 
6.4.2.3 Energy generation and oxidative stress .................................................... 173 
6.4.2.4 Glycometabolism and lipid metabolism .................................................... 173 
6.4.2.5 Other terms ..................................................................................... 173 
6.4.3 KEGG and GO ...................................................................................... 174 
6.4.4 Comparison of pathway analysis methods .................................................... 174 
6.5 Limitations ........................................................................................... 174 
IX 
 
Chapter 7 General discussion and future work ......................................... 176 
7.1 Discussion of the key results ...................................................................... 177 
7.2 Pathways controlling myopia susceptibility .................................................... 178 
7.2.1 Insulin – PI3K – AKT signalling ................................................................... 178 
7.2.2 PI3K and scleral extracellular matrix remodelling .......................................... 179 
7.3 Strengths of the study .............................................................................. 180 
7.4 Limitations of the study ........................................................................... 182 
7.5 Future work .......................................................................................... 183 
7.5.1 Expanding the number of genotyped chicks ................................................. 183 
7.5.2 eQTL analysis and validation of RNA-Seq results ........................................... 183 
7.5.3 Integration of findings from this study of chicks with human myopia studies ......... 184 
References ............................................................................................... 185 
Appendices ............................................................................................... 206 
Appendix 5.1. ............................................................................................. 206 
Appendix 5.2. ............................................................................................. 217 
Appendix 5.3. ............................................................................................. 227 
Appendix 5.4 .............................................................................................. 230 
Appendix 5.5. ............................................................................................. 231 
Appendix 5.6. ............................................................................................. 234 
Appendix 6.1 .............................................................................................. 238 
Appendix 6.2 .............................................................................................. 252 
Appendix 6.3 .............................................................................................. 255 
 
X 
 
List of Figures 
Figure 1.1. In the myopic eye, parallel light focuses in front of the retina. .................................................. 2 
Figure 1.2．Prevalence of myopia in European adults. ............................................................................... 3 
Figure 1.3. The prevalence of myopia in age cohorts older than 25 years in epidemiological studies in the 
USA and Australia (Taken from Rose et al, page 118. (17)). ......................................................................... 4 
Figure 1.4. Prevalence of myopia in different countries or ethnicities. (Modified from (26)) ....................... 6 
Figure 1.5. Gene effect size and frequency in the population for different study designs(63). .................. 12 
Figure 1.6. Illustration of Population stratification (85). ............................................................................ 17 
Figure 1.7 Mendelian randomization assumptions in a study examining the relationship between 
education and myopia (Taken from Cuellar-Partida (95)). ......................................................................... 20 
Figure 1.8. Gene-environment Interaction for ocular refraction (128). ...................................................... 24 
Figure 1.9. High-frequency A-scan ultrasonography system and holding device (205). ............................. 34 
Figure 2.1. RNA electrophoresis showing the 28S and 18S ribosomal subunits (upper and lower bands, 
respectively). .............................................................................................................................................. 44 
Figure 2.2. Chick sexing using allele-specific PCR and gel electrophoresis. ................................................ 45 
Figure 3.1.Relationship between IBW and FBW. (n=959) ........................................................................... 58 
Figure 3.2.Correlation between pre-treatment AXL in the right eye and initial body weight (IBW) in the 
full sample (n=959). .................................................................................................................................... 60 
Figure 3.3.Correlation between body weight and myopia susceptibility after FD (n=959). ....................... 62 
Figure 3.4.Coefficient plot showing the relationship between ∆AXL and confounding factors (full study 
sample). ...................................................................................................................................................... 64 
Figure 3.5.Relationship between change in MSE and change in AXL in 959 chicks. ................................... 67 
Figure 3.6.Coefficient plot showing the relationship between ∆MSE and confounding factors (n=959).... 68 
Figure 3.7. Number of chicks selected from each batch. ............................................................................ 71 
Figure 3.8. Phenotype distribution in selected chicks. ................................................................................ 71 
Figure 3.9.Coefficient plot showing the relationship between ∆AXL and confounding factors (selected 
chicks, n = 380). .......................................................................................................................................... 73 
Figure 3.10.Coefficient plot showing the relationship between ∆MSE and confounding factors (selected 
chicks, n = 380). .......................................................................................................................................... 78 
Figure 4.1. Example of a significant GxE effect yet non-significant G effect. ............................................. 86 
Figure 4.2. An explanation of genotyping techniques. ............................................................................... 88 
Figure 4.3. Workflow of the Affymetrix genotyping process (296). ............................................................ 90 
Figure 4.4. Flowchart of quality control. .................................................................................................... 95 
Figure 4.5. Relatedness coefficients of the genotyped samples. ................................................................ 98 
Figure 4.6. Manhattan plot for GWAS of non-normalized residual ΔAXL, after genomic control correction.
.................................................................................................................................................................... 99 
Figure 4.7. Q-Q plot for GWAS of non-normalized residual ΔAXL, after genomic control correction. ........ 99 
Figure 4.8. Manhattan plot for GWAS of residual from normalized ΔAXL, after genomic control correction.
.................................................................................................................................................................. 100 
Figure 4.9. Q-Q plot for GWAS of residual from normalized ΔAXL, after genomic control correction. ..... 100 
Figure 4.10. Regional plot for chromosome 1. ......................................................................................... 101 
Figure 4.11. Manhattan plot for GWAS of ∆AXL modelled as a binary trait, after genomic control 
correction. ................................................................................................................................................ 101 
Figure 4.12. Q-Q plot for GWAS of ΔAXL modelled as a binary trait, after genomic control correction. .. 102 
Figure 4.13. Manhattan plot for GWAS of residual from normalized ΔAXL, including GRM. ................... 103 
Figure 4.14. QQ plot for GWAS of residual from normalized ΔAXL, including GRM. ................................ 103 
Figure 4.15. Manhattan plot for GWAS of non-normalized residual ΔMSE, after genomic control 
correction. ................................................................................................................................................ 105 
Figure 4.16. QQ plot for GWAS of un-normalized residual ΔMSE, after genomic control correction. ...... 106 
Figure 4.17. Manhattan plot for GWAS of residual from normalized ΔMSE, after genomic control 
correction. ................................................................................................................................................ 106 
Figure 4.18. QQ plot for GWAS of residual from normalized ΔMSE, after genomic control correction. ... 107 
Figure 4.19. Manhattan plot for GWAS of residual from normalized ΔMSE, including GRM. .................. 108 
Figure 4.20. QQ plot for GWAS of residual from normalized ΔMSE, including GRM. ............................... 108 
Figure 4.21.Regional plot for SNPs that reached the suggestive threshold in GWAS for ΔAXL. ............... 110 
Figure 5.1. RNA-seq Using Next Generation Sequencing. ........................................................................ 122 
Figure 5.2.Sample relationships and frequency of mean counts per gene. .............................................. 128 
XI 
 
Figure 5.3. Mean-variance relationship. .................................................................................................. 129 
Figure 5.4. Dispersion plots generated by edgeR and DESeq2, and Mean-Variance plot by Limma after 
fitting the models. .................................................................................................................................... 130 
Figure 5.5. Venn-diagram showing overlap in differentially-expressed transcripts identification between 
FD and control eyes using analysis Model 1 with 3 software packages (edgeR, DEseq2, and Limma). ... 131 
Figure 5.6.Venn-diagram showing overlap in identification of differentially-expressed transcripts between 
High vs. Low myopia groups using analysis Model 1, with 3 software packages (edgeR, DEseq2, and 
Limma). .................................................................................................................................................... 133 
Figure 5.7.Venn-diagram showing overlap in identification of differentially-expressed transcripts between 
FD-treated vs. control eyes using analysis Model 2, with 3 software packages (edgeR, DEseq2, and 
Limma) ..................................................................................................................................................... 135 
Figure 5.8.Venn-diagram showing overlap in identification of differentially-expressed transcripts between 
FD-treated vs. control eyes using analysis Model 2, when analyzing high and low group separately. .... 136 
Figure 5.9.Venn-diagram showing transcripts differentially-expressed between FD-treated and control 
eyes, that also differed in level between High and Low group chicks (interaction between treatment x 
group, FDR <0.05) using Model 3. ............................................................................................................ 137 
Figure 5.10. Venn-diagram showing genes differentially-expressed between FD-treated and control eyes 
detected using either Model 1 or Model 2. .............................................................................................. 139 
Figure 6.1.Pathway analysis using MSigDB (except C1) as reference. ...................................................... 156 
Figure 6.2. KEGG pathways with P < 0.05 in DAVID analysis. ................................................................... 160 
Figure 6.3 GO term with P < 0.05 (Before Bonferroni correction) in DAVID analysis. ............................... 162 
Figure 6.4. Enrichment map of the GO terms with P < 0.05 (Before Bonferroni correction) in DAVID 
analysis from DAVID results. ..................................................................................................................... 163 
Figure 6.5. Circle plot of GO terms with P < 0.05 (after Bonferroni correction) from the DAVID analysis of 
differentially-expressed genes. ................................................................................................................. 163 
Figure 6.6.Chord plot demonstrating the inter-connections between the 22 largest/smallest changed 
differentially-expressed genes with the largest/smallest fold-change, and their related GO terms. ....... 165 
Figure 6.7.Enrichment plot of KEGG with FDR < 0.25 from the GSEA analysis of differentially-expressed 
genes. ....................................................................................................................................................... 167 
Figure 6.8.Enrichment map of the KEGG pathways from GSEA results. ................................................... 168 
Figure 6.9. Enrichment plot of top 10 GO term from the GSEA analysis of differentially-expressed genes.
.................................................................................................................................................................. 169 
Figure 6.10.Enrichment map of the GO terms from GSEA results. ........................................................... 170 
Figure 7.1 The Insulin receptor signalling pathway (451). ....................................................................... 178 
Figure 7.2. Illustration of the PI3K involved ECM remodelling process (462). .......................................... 180 
 
 
XII 
 
List of Tables 
Table 1.1 Myopia gene loci identified by linkage analysis. ......................................................................... 11 
Table 1.2. Association study design. Reproduced from (70). ...................................................................... 14 
Table 1.3. Summary of linkage analysis, family-based association studies and GWAS. Reproduced from 
(63) ............................................................................................................................................................. 18 
Table 1.4. Summary of different animal models of myopia. Reproduced from Schaeffel & Feldkaemper 
(191). .......................................................................................................................................................... 29 
Table 2.1 Allele-specific PCR primer information. ....................................................................................... 46 
Table 3.1. Prior studies investigating the association between height, weight, BMI and ocular 
biometry/myopia in human subjects .......................................................................................................... 53 
Table 3.2.Prior studies investigating the association between sex and ocular biometry/myopia in human 
subjects....................................................................................................................................................... 55 
Table 3.3. Chick parameters on day 7, before form deprivation ................................................................ 59 
Table 3.4. Chick parameters after FD for 4 days in the full sample (n=959). .............................................. 61 
Table 3.5. Comparison of ocular parameters in right versus left eyes after 5 days of FD. Values are 
presented as Mean ± SD ............................................................................................................................. 61 
Table 3.6.Relationship between ∆AXL and confounding factors (full study sample). ................................. 65 
Table 3.7. Relationship between ∆MSE and confounding factors (n=959). ................................................ 69 
Table 3.8.Relationship between ∆AXL and confounding factors (selected chicks, n = 380). ....................... 74 
Table 3.9. Relationship between ∆MSE and confounding factors (selected chicks, n=380). ....................... 79 
Table 4.1. Power estimation calculated using Quanto, based on different effect sizes () and MAFs. ....... 92 
Table 4.2. All SNPs with minus log10 P-values exceeding suggestive significance threshold (P <1.64e-05) 
in GWAS for ΔAXL. .................................................................................................................................... 104 
Table 4.3. All SNPs with minus log10 P-values exceeding suggestive significance threshold (P <1.64e-05) 
in GWAS for ΔMSE. ................................................................................................................................... 109 
Table 5.1.Sample information. ................................................................................................................. 127 
Table 5.2. Transcripts differentially expressed (FDR <0.05) between FD-treated eyes and control eyes 
using analysis Model 1, with 3 software packages. ................................................................................. 132 
Table 5.3. Transcripts differentially expressed (FDR <0.05) between High vs. Low myopia groups using 
analysis Model 1, with 3 software packages. ........................................................................................... 134 
Table 5.4. Transcripts differentially-expressed between FD-treated and control eyes, that also differed in 
level between High and Low group chicks (interaction between treatment x group, FDR <0.05) using 
Model 3. ................................................................................................................................................... 138 
Table 5.5. The PI3K family (Reproduced from (381)). ............................................................................... 143 
Table 5.6.Comparison of edgeR, DESeq2 and limma. (Modified from(370)) ............................................ 146 
Table 6.1Top 10 genes from MAGMA gene-based analysis. ..................................................................... 154 
Table 6.2.Top 5 KEGG pathways from pathway analysis using MAGMA .................................................. 157 
Table 6.3. Top three gene sets of each GO category from pathway analysis using MAGMA. .................. 157 
Table 6.4.KEGG pathways with P < 0.05 in DAVID analysis. ..................................................................... 159 
Table 6.5.GO terms with P <0.05 (after Bonferroni correction) in DAVID analysis of differentially-expressed 
genes. ....................................................................................................................................................... 164 
Table 6.6.KEGG with FDR <0.25 in GSEA analysis of differentially-expressed genes. ............................... 166 
Table 6.7.GO term with FDR <0.05 in GSEA analysis of differentially-expressed genes. ........................... 171 
 
XIII 
 
List of abbreviations 
ACD Anterior Chamber Depth  
AD Autosomal Dominant 
AL-CR Axial Length - Corneal Radius Ratio 
ALSPAC Avon Longitudinal Study of Parents 
and Children 
APL Association in the Presence of 
Linkage 
AR Autosomal Recessive 
ATOM Atropine for the Treatment of 
Myopia 
AXL Axial Length  
BC Before Century 
BMI Body Mass Index  
bp base pair 
BP Biological Process 
BrM Bruch’s Membrane  
BRS Baseline Refractive Status 
C Control 
CC Cellular Component 
CHD Chromo Helicase DNA-binding 
CPM Counts Per Million  
cr Call Rate 
CREAM Consortium for Refractive Error and 
Myopia 
CT Corneal Thickness 
D Dioptre 
ddNTPs di-deoxynucleotidetriphosphates  
DEG Differentially-Expressed Genes  
DOPAC 3,4-dihydroxyphenylacetic acid  
DQC Dish Quality Control  
ECM Extra Cellular Matrix  
eQTLs expression QTLs 
FBW Final Body Weight  
FCS Functional Class Scoring  
FD Form Deprivation 
FDM Form-Deprivation Myopia 
FDR False Discovery Rate 
FFQ Food Frequency Questionnaire  
fld Fisher’s Linear Discriminant  
G × E Gene-Environment Interactions  
GLM General Linear Model 
GO Gene Ontology 
GRM Genetic Relationship Matrix 
GSEA Gene Set Enrichment Analysis  
 
 
 
 
 
GWAS Genome-Wide Association Studies 
het-so Heterozygous Strength Offset  
het-so-otv Heterozygous Strength Offset off 
Target Variant  
HGF Hepatocyte Growth Factor 
hom-ro Homozygous Ration Offset 
HWE Hardy-Weinberg Equilibrium  
IBW Initial Body Weight  
ILM Internal Limiting Membrane  
IOP Intraocular Pressure 
IV Instrumental Variable 
KEGG Kyoto Encyclopedia of Genes and 
Genomes 
LD  Linkage Disequilibrium 
LIM Lense-Induced Myopia 
LT Lens Thickness  
MAF Minor Allele Frequency  
MDS Multidimensional Scaling  
MF Molecular Function 
MR Mendelian Randomization  
MSE Mean Spherical Equivalent  
NES Normalized Enrichment Score 
NHANES National Health and Nutrition 
Examination Survey 
NMDA N-methyl-d-aspartic acid  
ORA Over-Representation Analysis  
PCA Principal Components Analysis 
PCR Polymerase Chain Reaction  
PDT Pedigree Disequilibrium Test 
PKAs protein kinase family  
QC Quality Control  
QTL  Quantitative Trait Loci 
RE Refractive Error 
RFLP Restriction Fragment Length 
Polymorphism 
SE Spherical Equivalent  
SNP Single Nucleotide Polymorphism 
SNV Single-Nucleotide Variant  
T Treated 
TDT Transmission Disequilibrium Test 
USA United State of America 
VA Visual Acuity 
VCD Vitreous Chamber Depth 
VDR Vitamin D Receptor  
  
 
 
1 
 
Chapter 1 Introduction
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1.1 Definitions 
Myopia, also known as nearsightedness, is a highly prevalent ophthalmic disorder 
which is known to have affected people for more than a thousand years. It is 
believed that Aristotle (384-321 BC) was the first person to distinguish between the 
conditions of myopia and hyperopia, when both of these words had not yet been 
invented. Many years later, some people found that they could see things more 
clearly by partially closing their eyes, so the Greeks created the word myopos – a 
combination of myein (‘to close’) and ops (‘eye’) – to describe this condition (1). At 
this stage, people’s understanding of myopia only related to their subjective feelings; 
there was no systematic theory of its aetiology. With the development of modern 
science, an objective and systematic definition of myopia became widely accepted, 
which specifies myopia as a condition of the unaccommodated eye where parallel 
light focuses in front of, instead of on, the retina (2) (Figure 1.1). 
 
Figure 1.1. In the myopic eye, parallel light focuses in front of the retina. 
F’e represents the power of the eye (3). 
1.2 The prevalence of myopia – from the past to the present 
The prevalence of myopia has increased during the past 2-4 decades, especially in 
Southeast Asian countries. In China, where one-fourth of the world’s population lives, 
the overall prevalence of reduced visual acuity (VA) in children (most of which is 
caused by myopia) had been increasing from 1985 to 2010. Among teenagers aged 7 
to 18 year-old, the prevalence of reduced VA was 28.6% in 1985. Gradually it rose to 
38.6% in 1991, 41.0% in 1995, 38.5% in 2000, 49.5% in 2005, and 56.8% in 2010, with 
the reduced VA being more widely observed in urban areas than in rural areas (4). In 
another similar study in Guangzhou, China, from 1988 to 2007, the same trend was 
seen: the prevalence rate of myopia continued to increase and the proportion of 
moderate and severe myopia rose among grade 1–12 students (5). In Taiwan, from 
1983 to 2000, five surveys pertaining to ocular refraction of 7 to 18 year-old students 
were conducted, and an increase in myopia prevalence was observed (6). Another 
convincing study performed in Singapore investigated 18–19 year-old male conscripts 
for nearly 20 years and found in later birth cohorts, there was a significant increase 
in the prevalence of myopia (7). 
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In other parts of the world, the myopia rate has risen steadily in the last few decades. 
In the Middle East region, Dayan et al. (8) conducted a retrospective study and found 
that between 1990 and 2002, the overall prevalence of myopia increased from 20.3% 
to 28.3% in young Israeli adults. In European countries, like Finland and Sweden, the 
same trend was reported. In Finland, the prevalence of myopia was <10% among 
adults born during the first three decades of the 20th century, whereas there was a 
rapid rise in the prevalence during the second half of the 20th century, reaching 21–
30%. Although the prevalence of myopia did not change significantly in 7 year-old 
children, it doubled in 15 year-old teenagers over the past half-century (9). In the 
Goteborg area of Sweden, among 12 to 13 year-old school children, Villarreal et al. 
(10) found 49.7% of children were myopic. They concluded that the tendency towards 
myopisation in the teenage population in Goteborg was similar to that found in other 
parts of the world. A recent meta-analysis for refractive error in adults across Europe 
was done by Williams (11). In this study, fifteen population-based cohort and cross-
sectional studies generated from 1990 to 2013 were combined for analysis. After 
stratifying the 61,946 individuals by age, a higher prevalence of myopia was found in 
the younger age groups, which suggested an increasing myopia rate in more recent 
years (11); Figure 1.2.
 
Figure 1.2．Prevalence of myopia in European adults.  
The prevalence of myopia according to age (with 95 % confidence intervals). Low 
myopia was defined as -3D < SE ≤ −0.75D, moderate myopia −6D < SE ≤ −3D, high 
myopia SE ≤ −6D (SE, spherical equivalent; D, Dioptres; taken from Williams et al, 
page 312.(11) ).  
In the USA, approximately 25% of individuals aged 12 to 54 year-old were myopic in 
the 1980s, while in 2004 the myopia prevalence increased to ~33% in people aged 20 
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(12, 13). According to the population-based National Health and Nutrition 
Examination Survey (NHANES), the myopia prevalence was substantially higher in 
1999–2004 than in 1971–72 for non-Hispanic participants (14). 
In the Southern Hemisphere, a similar trend has also been observed. The Blue 
Mountains Eye Study (15) and the Melbourne Visual Impairment Project (16) both 
reported a decrease in myopia prevalence with increasing older age. Rose and 
colleagues (17) summarized a series of studies from both USA and Australia and 
suggested that the decreasing myopia prevalence in elder cohorts was not purely 
caused by increasing presbyopia prevalence with age (Figure 1.3). 
 
 
 
 
 
 
 
 
Figure 1.3. The prevalence of myopia in age cohorts older than 25 years in 
epidemiological studies in the USA and Australia (Taken from Rose et al, page 118. 
(17)). 
Most epidemiology studies show a tendency towards a rising prevalence of myopia 
regardless of demographic differences. An exception is the study in Denmark by 
Jacobsen et al. (18), who reported a significant decrease in the myopia prevalence 
rate amongst Danish conscripts in 2004 compared with 1964. However, in this study, 
the comparability has been questioned since in different years the methodologies 
were different. Meanwhile, a study comparing the differences in myopia prevalence 
between 1996-1997 and 2009-2010 in young Singaporean males found similar myopia 
, National Health and Nutrition Examination Survey (NHANES); 
, NHANES, data as recalculated by Mutti and Zadnik; 
, Beaver Dam Eye Study; 
, Framingham Offspring Eye Study; 
, Baltimore Eye Survey, non-African American subjects; 
, Baltimore Eye Survey, African American subjects; 
, Blue Mountains Eye Study; 
, Melbourne Visual Impairment Project. 
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prevalence rates between the two periods, but the high myopia and refractive 
astigmatism rates increased (19). Thus, overall, the world has experienced an 
increasing prevalence of myopia in recent decades. 
 
1.3 The prevalence of myopia – from the east to the west 
The prevalence of myopia varies markedly with geographic location and ethnicity; 
individuals of Han Chinese ancestry show the highest prevalence while Africans show 
the lowest prevalence. For example, in 2014, the prevalence of myopia among 7-18 
year-old Beijing students was 64.9% (-0.5 ≤ SE) (20), in France 2013, among teenagers 
(10 to 19 year-old), it was 42% (21); in 2003 South Africa, the prevalence was only 4% 
among 5-15 year-old children (22). Studies performed in countries with multi-
ethnicity also found the Chinese were most susceptible to myopia. In Singapore, the 
odds of becoming myopic was 2.04 times higher in Chinese compared to Malays (23). 
In Australia, 39.5% of the East Asian children were myopic, compared to 4.6% in 
European Caucasian and 6.1% in Middle Eastern individuals (24). In the USA, Asians 
again had the highest rate of myopia (18.5%), followed by Hispanics (13.2%). African 
and white Americans had the lowest myopia rate (6.6% and4.4%, respectively) (25); 
Pan et al. (26) had summarized the worldwide prevalence of myopia in children and 
concluded that Chinese children had a higher myopia prevalence than European 
children (Figure 1.4). 
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    Figure 1.4. Prevalence of myopia in different countries or ethnicities. (Modified from (26)) 
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1.4 Impact of myopia 
It is noteworthy that not just the prevalence of myopia is increasing, the severity of 
the disorder is also increasing. According to previous studies (6, 19), along with the 
increasing prevalence rate of myopia, a concomitant increasing shift towards higher 
degrees of myopia has been observed. Holden et al. (27) predicted that by 2050, 49.8% 
of the global population might be myopic and around 1/5 of the myopes might 
eventually become high myopes. If this rapidly increasing trend is not suspended, an 
increase in corrected and uncorrected refractive error and visual impairment will be 
expected.  
The complications of high myopia will be the main cause of visual impairment. There 
is evidence that the risk of myopic macular degeneration (28, 29), retinal 
detachment (30, 31), retinal atrophy (32), glaucoma (33) and cataract (34) are all 
greater in highly myopic eyes. Furthermore, in East Asian countries, myopic macular 
degeneration is now the leading cause of monocular blindness (35, 36). This global 
trend will also lead to an economic burden. To manage patients with vision 
impairment, it is estimated the cost will be 202 billion USD each year globally (37). 
 
1.5 Aetiology of myopia 
The aetiology of myopia is complicated. Since Cohn (38) suggested that going to 
school increases the risk of myopia, reading and other forms of near work have been 
implicated in causing axial myopia. However, twin-based, family-based and 
population-based studies have shown convincing evidence that refractive error also 
has a genetic cause. It is now widely accepted that a complex interplay between 
genetic factors and environmental factors drives the development of myopia (39). 
However, how exactly genes and the environment interact with each other is still an 
area of active research.  
 
1.5.1 The genetic theory 
1.5.1.1 Heritability of myopia 
Heritability is defined as the genetic contribution to a population's phenotypic 
variance. For myopia, it had long been observed that myopic parents tended to have 
myopic children, which suggested the condition is heritable. However, it was not 
until people began to study twins and families that the heritability of refractive error 
could be estimated quantitatively. In these studies, the theoretical level of genetic 
sharing (kinship) between family members is estimated. For example, the kinship 
between monozygotic twins is 1, between dizygotic twins is 0.5, and between 
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parents and offspring is 0.5. Heritability can be estimated using the correlation 
coefficient of the difference in phenotype between family members divided by their 
kinship. However, this estimation is prone to bias, since it does not account for the 
fact that individuals in a family typically share the same environment.  
Recently, it has become possible to estimate the genetic similarity between pairs of 
individuals much more precisely, allowing for the study of sets of essentially 
unrelated individuals. For example, after genome-wide genotyping, single nucleotide 
polymorphism (SNP) genotypes can be used to calculate the genetic similarity 
between every pair of individuals in a population, building up a genetic relationship 
matrix (GRM) describing their kinship. A heritability estimate (called the “SNP 
heritability”; h2SNP) can be calculated based on the GRM and phenotype information. 
In family-based studies, the heritability of refractive error has been estimated at 
between 0.10 and 0.70, while twin studies have generally yielded higher estimates of 
between 0.50 and 0.96 (40). For axial length, the estimated heritability varies from 
0.20 to 0.95 (41). Such relatively high heritability implies that genetic factors play a 
major role in the aetiology of myopia. However, the SNP heritability for ocular traits 
is estimated to be lower. For example, in studies examining 15-year-old participants 
of the Avon Longitudinal Study of Parents and Children (ALSPAC), h2SNP = 0.28 for 
refractive error (42), h2SNP = 0.46 for axial length (43) and h
2
SNP = 0.42 for corneal 
curvature (43). The difference between heritability estimated from SNPs and from 
twins is called missing heritability and the underlying reason for the underestimation 
using SNPs will be discussed in Chapter 4, section 4.1.1. 
Heritability analysis estimates the effect of genes as a whole in explaining inter-
individual variation in refractive error; it does not identify specific genes or loci 
connected with the trait. Hence, further studies such as linkage analysis or genome-
wide association studies (GWAS) are needed.  
 
1.5.1.2 Linkage studies and candidate regions 
Genetic linkage analysis is a method based on Mendelian genetics designed to 
identify a particular region of the genome that co-segregates with a specific disease 
phenotype. Familial occurrence of myopia within one or more pedigrees showing a 
monogenic pattern of phenotype segregation is necessary to perform linkage analysis. 
In familial myopia, among all the regions following Mendelian modes of inheritance 
that have been reported to date, the autosomal dominant (AD) mode is the most 
frequent pattern (40). This is likely because linkage analysis is more powerful in AD 
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pedigrees than recessive pedigrees, and because AD pedigrees are usually easier to 
ascertain. 
In 1990, Schwartz et al. (44) performed a linkage study in a family with Bornholm Eye 
Disease (a Mendelian disorder featuring high myopia, amblyopia, and deuteranopia) 
and identified a locus on the X chromosome which showed strong evidence that it 
might be linked to this disease for the first time. This gene locus was named MYP1 
(Table 1.1). Since then many regions harbouring myopia genes have been reported: in 
1998, Young and her colleagues (45, 46) used linkage analysis to discover two gene 
loci that linked to high myopia, named MYP2 and MYP3. These were the first AD gene 
loci for non-syndromic high myopia. In 2002, Naiglin et al. (47) recruited 23 high 
myopia families with at least one person affected and found a novel locus on 
chromosome 7q36 linked to myopia, which they named MYP4. However, in 2008, 
Paget et al. (48, 49) studied 26 high myopic families including those Naiglin et al. (47) 
had analyzed and found no significant linkage to chromosome 7q36. Instead, they 
found chromosome 7q15 (MYP17) showed significant linkage, and this result was 
replicated in the same year (49). The discordance among different studies could be 
caused by the difference in sample size or genotyping error. 
It was not until 2004 that linkage analysis was first applied to mild or moderate 
myopia pedigrees. High myopia was hypothesized to be a genetic disease caused by a 
rare mutation which directly led to the uncontrollable elongation of the eye. 
Inheritance of such a mutation would yield a high prevalence of high-grade myopia in 
the family. Linkage analysis provides a method to identify such mutations. However, 
mild or moderate cases of myopia were believed to be ‘complex’ (multifactorial) 
quantitative traits, which were difficult to investigate by linkage analysis (for 
statistical reasons, linkage analysis has extremely low power to detect small genetic 
effects). A research team from the USA performed a genome scan for common-
myopia susceptibility loci for the first time among an Ashkenazi Jewish sample of 
multiplex pedigrees and found Chromosome 22q12 (MYP6) was statistically 
significantly linked to the disease (50). At the same time, another study used 221 
dizygotic twin pairs and performed a genome-wide linkage scan which located 4 
regions linked to refractive error, including chromosome 11p13 (MYP7), chromosome 
3q26 (MYP8), chromosome 4q12 (MYP9), and chromosome 8p12 (MYP10) (51). These 
studies implied that linkage analysis could also be used to identify quantitative trait 
loci (QTLs) influencing refractive error.  
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Similar methods to those described above were used between 2004-2006 to identify 3 
additional loci: MYP11, MYP12 and MYP13 (52-54). In 2006, Wojciechowski et al. (55) 
measured refractive error in 49 multigenerational Ashkenazi Jewish families with at 
least 2 affected persons, which were previously studied by Stambolian et al. (50). 
Instead of using microsatellite polymorphisms as genetic markers, they used SNPs as 
markers and performed a QTL linkage analyses; they identified a novel QTL for ocular 
refraction on the short arm of chromosome 1(MYP14) (55). Later, MYP15 
(chromosome 10q21.1) (56), MYP16 (chromosome 5p15.33-p15.2) (57), MYP18 
(chromosome 14q22.1-q24.2) (58) and MYP19 (chromosome 5p15.1-p13.3) (59) were 
identified. The above loci were all autosomal dominant except MYP18 (chromosome 
14q22.1-q24.2), which showed autosomal recessive inheritance. To date, more than 
24 loci have been identified by family-based linkage studies. 
A major innovation took place in 2011, when Shi et al. (60) conducted a GWAS in 419 
high myopia cases and 669 controls from a Han Chinese cohort, and then identified a 
variant at 13q12.12 that was significantly associated with high myopia. They 
subsequently added four additional SNPs –rs9510902, rs3794338, rs7325450, and 
rs7331047 –which were in the same LD block with rs9318086 and rs1886970 according 
to the Han Chinese Beijing in the HapMap database, and all these SNPs showed a 
significant association with high myopia. The most strongly associated haplotype 
corresponded to a 1.35-fold increased risk of high myopia. This was the first myopia 
study to identify a linkage block by GWAS but not using linkage analysis. In the same 
year, the same group used exome sequencing to identify a mutation responsible for 
causing high myopia (61). (Table 1.1)
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Table 1.1 Myopia gene loci identified by linkage analysis. 
Symbol Inheritance Map location Research subjects Country Reference Myopia range 
MYP1 XR Xq28 Pedigrees Danish Schwartz et al. (44) −6.75 to −11.25 D 
MYP2 AD 18p11.31 Pedigrees American and Chinese Young et al. (45) −6 D to −21 D 
MYP3 AD 12q21-q23 A large pedigree German/Italian Young et al. (46) −6.25 D to −15 D 
MYP4 AD 7q36 Pedigrees French and Algerian Naiglin et al. (47) Mean −13.05 D 
MYP5 AD 17q21-q22 A large pedigree English/Canada Paluru et al.(62) −5.5 D to −50 D 
MYP6 AD/QTL 22ql2 Large pedigrees Ashkenazi Jewish descent Stambolian et al. (50) < −1 D 
MYP7 QTL 11p13 Dizygotic twin pairs Britain Hammond et al. (51) < 0 D 
MYP8 QTL 3q26 Dizygotic twin pairs Britain Hammond et al. (51) < 0 D 
MYP9 QTL 4q12 Dizygotic twin pairs Britain Hammond et al. (51) < 0 D 
MYP10 QTL/AD 8p23 Dizygotic twin pairs Britain Hammond et al. (51) < 0 D 
MYP11 AD 4q22-q27 A large pedigree Chinese Zhang et al. (52) −5 D to −20 D 
MYP12 AD 2q37.1 A large pedigree American Paluru et al. (53) −0.50 to −10.25 D 
MYP13 XR Xq23-q25 A large pedigree Chinese Zhang et al. (54) −6 D to −20 D 
MYP14 QTL 1p36 Pedigrees Ashkenazi Jewish descent Wojciechowski et al. (55) Mean −3.46 D 
MYP15 AD 10q21.1 A large pedigree Hutterite population from South 
Dakota 
Nallasamy et al. (56)  < −5 D 
MYP16 AD 5p15.33-p15.2 Large pedigrees Hong Kong Chinese Lam et al. (57) < −6 D 
MYP17 QTL 7p15 Pedigrees French and Algerian Paget et al. (48) Mean −2.87  D 
MYP18 AR 14q22.1-q24.2 Pedigrees Chinese Yang et al.(58) < −6 D 
MYP19 AD 5p15.1-p13.3 Pedigrees Chinese Ma et al.(59) < −6 D 
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1.5.1.3 Association studies and GWAS 
Genetic association is found when genotypes within a population co-occur with a 
phenotypic trait with statistical significance. Generally speaking, association studies 
can be conducted with large cohorts of families, population-based samples of 
unrelated subjects, or groups of unrelated cases and controls. Unlike linkage studies, 
which have high power to detect rare disease-causing variants, association studies 
have high power to detect common disease-causing variants. They rely on the fact 
that individuals who carry the risk allele of a specific gene variant will have a slightly 
increased risk of getting the corresponding disease (accordingly, the frequency of the 
risk allele will be higher in cases than in controls). Association studies have 
contributed a wealth of new findings in myopia genetics research. (Figure 1.5) 
 
Figure 1.5. Gene effect size and frequency in the population for different study 
designs(63). 
For linkage analysis, it is assumed that the disease is inherited in a Mendelian 
manner and is caused by a genetic variant with a large effect but low frequency. For 
an association study, diseases are considered to be common, and to be caused by 
gene variants exhibiting small effects but with high frequency (Taken from Tang et 
al. page10 (63)).  
 
1.5.1.3.1 Family-based association study 
According to the law of independent assortment (‘Mendel’s Second Law’), alleles at a 
locus will be transmitted randomly from parents to an offspring, which means the 
probability of transmitting either of the two alleles will be 0.5 vs. 0.5. For a specific 
phenotype, a genetic association will occur when transmission of the alleles deviates 
from random occurrence (so-called ‘transmission disequilibrium’). The most common 
approach to test for this genetic association is the transmission disequilibrium test 
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(TDT), which tests for distortion (or disequilibrium) in the inheritance of an allele 
from heterozygous parents to affected offspring in terms of the McNemar Chi-
squared test (64). Accordingly, the typical study design for a family-based association 
study will be the use of family ‘trios’ containing one affected child with two parents 
(only heterozygous parents are actually used in the test).  
This family-based association study design has been applied in myopia research, 
albeit infrequently. In 2000, Li and colleagues (65) found out that HLA-DQB1 might be 
associated with the progression of pathological myopia by using a restriction 
fragment length polymorphism (RFLP) as a genetic marker. This study applied family-
based association analysis and a transmission disequilibrium test to 58 individuals 
from 8 families with 23 affected individuals. Similar methods but with more families 
and new genetic markers like SNPs were used in later studies; subsequently, more 
loci associated with myopia were detected. In 2006, Han et al. (66) performed a 
family-based association study in 128 nuclear families which contained 133 severely 
myopic offspring; a variant in the hepatocyte growth factor gene (HGF) was found to 
be associated with the condition. Similar methods were used by the same research 
team in demonstrating that a genetic variant in the paired box 6 (PAX6) gene was 
also associated with high myopia in southern Han Chinese (67). In 2009, Yanovitch et 
al. (68) sought to replicate the association between HGF and myopia. They recruited 
146 multiplex families consisting of 649 Caucasian subjects and measured their 
refractive status. After genotyping ‘haplotype-tagging’ SNPs within HGF, they 
analyzed data with two family-based association methods: the pedigree 
disequilibrium test (PDT) and the association in the presence of linkage (APL) test 
and found a significant association with mild to moderate myopia compared to 
emmetropia. An association between extreme high myopia and the HGF gene variants 
was also reported (68). In the same year, Metlapally et al. (69) used families 
recruited from the USA and UK to identify that COL2A1, but not COL1A1, variants 
were associated with refractive error. 
 
1.5.1.3.2 Population-based association study 
Currently, the most widely used genetic association method is the population-based 
association study design. In this kind of study, the sample is a set of unrelated 
individuals. A direct association test between a genetic marker and the phenotype is 
done. Either the phenotype can be analyzed as a continuous trait, or subjects can be 
assigned as cases or controls. According to the scale of genetic association, 
population-based association studies can be categorized as shown in Table 1.2 (70). 
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Table 1.2. Association study design. Reproduced from (70). 
Type Description 
Candidate 
polymorphism 
Focus on an individual polymorphism, e.g. a single SNP, which is 
suspected of being involved in disease causation. 
Candidate gene Focus on 5–50 SNPs within a gene. The candidate gene can be 
chosen from a prior linkage study or a functional candidate. 
Fine mapping Focus on a candidate region of 1–10 Mb, typically involving several 
hundred SNPs. The candidate region might have been identified 
by a previous linkage study and contain 5–50 genes on average. 
Genome-wide Focus on the whole genome, and require ≥300,000 well-chosen 
SNPs. The main purpose is to identify common causal variants 
throughout the whole genome. 
 
Small-scale association studies can test for association in a single gene region and are 
relatively cheap to fund. For example, in 2009, Nishizaki et al. (71) performed 
association study using 39 SNPs distributed around a previously reported myopia 
susceptibility gene and suggested that a SNP (rs2839471) - located in the frequent 
recombinant region within the UMODL1 gene – was associated with high myopia in the 
Japanese population. One previous exome sequencing study in 2011 reported linkage 
between ZNF644 (MYP21) and high myopia (61), and then in 2014, by candidate gene 
association study, five novel ZNF644 high myopia susceptibility variants were 
identified in the Chinese Han population (72). In 2012, Hysi et al. (73) reported an 
association between SERPINI2 gene variants and refractive error in a European birth 
cohort. In this study, they genotyped 1536 SNPs that covered 3 myopia linkage peaks 
in 590 individuals. In another study the vitamin D receptor (VDR) was chosen as a 
candidate gene; SNPs within this gene region were tested for association with myopia 
(74). Four SNPs within VDR: rs2853559, rs2239182, rs3819545and rs2853559 were 
significantly associated with both high and mild to moderate myopia in a multivariate 
analysis.  
With improvements in genotyping technology, performing whole genome genotyping 
or sequencing is becoming cheaper. Meanwhile, the completion of the HapMap 
Project and the 1000 Genomes Project provided a detailed reference panel for the 
human genome. By genotyping the whole genome with a high-density array of SNPs 
and then imputation of additional non-genotyped variants, scientists now have the 
chance to capture the variations of QTLs that contribute tiny effects to a trait. By 
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adding all these effects together, the contribution of these loci markers to the 
variation of the phenotype (heritability) can be calculated.  
The first large-scale GWAS study of myopia was conducted in 2009 by Nakanishi et al. 
(75). In order to identify genetic variations which might be implicated in pathological 
myopia, they performed a two-stage GWAS. After analyzing 411,777 SNPs with 830 
cases and 1,911 general population controls, they set P-values smaller than 10e-4 as 
their threshold and identified 22 associated SNPs. By testing for association in the 
second stage and combining the results, they identified a single locus at chromosome 
11q24.1, which showed an association with the disease. Hysi et al. (76) reported that 
the transcription initiation site of RASGRF1 was related to myopia, while Solouki et al. 
(77) reported a significant association at chromosome 15q14 (rs634990, P = 2.21 × 
10e-14) near the GJD2 gene, which was expressed in the retina, and was considered 
a strong candidate. In 2013, two very large GWAS were published, which identified a 
total of nearly 40 gene loci associated with refractive error. One of the studies was 
carried out by the Consortium for Refractive Error and Myopia (CREAM) group (78). At 
the time, it was the largest myopia GWAS meta-analysis using data from 32 studies 
from Europe, the USA, Australia and Asia. In their study, they first identified 18 
distinct genomic regions strongly associated with myopia in European ancestry 
populations and then tested these results in Asian cohorts and found 10 showed 
evidence of association. To explore more loci, they carried out a gene-based analysis 
and identified eight additional loci. In all, 26 new loci associated with refractive 
error were identified. In another study, a genome-wide survival analysis study was 
carried out by Kiefer et al. (79). In their study, based on the assumption that SNPs 
with a large effect size will be associated with an earlier age-of-onset of myopia, 
they used a Cox proportional hazards model with age of onset of myopia as the 
endpoint and identified 20 new loci. Compared to a case-control study, this study was 
believed to have higher power, and furthermore, its results suggested that there 
might be similar genetic factors underlying myopia age of onset and refractive error. 
The most recent GWAS for myopia, which was performed with 106,086 European 
ancestry cases and 85,757 European ancestry controls, identified 51 association hits 
with the phenotype ‘self-reported nearsightedness’ (80). 
To date, 16 genome-wide studies related to refractive error and axial length have 
been reported, with more than 170 SNPs related to these phenotypes being identified. 
(Please refer to http://www.ebi.ac.uk/gwas/search?query=myopia for more details 
about the 16 GWAS for refractive error.) 
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Although genome-wide association studies have tremendously advanced our 
understanding of the genetic factors in myopia, to date only a small fraction of the 
variation in refractive error can be explained by the variants identified (78). To get 
more precise results, studies in larger populations are needed. 
 
1.5.1.4 DNA sequencing 
DNA sequencing is a more comprehensive method to detect DNA variants compared to 
genotyping.  In DNA sequencing, every base is assessed, and thus, rare mutations will 
be captured. The application of this technique to explore relatively rare myopia 
mutations has become more popular. Several mutations causing high myopia have 
been identified by exome and whole genome sequencing in pedigrees showing 
monogenic transmission. For instance, Guo et al. (81) studied a 3-generation Chinese 
family in which 5 members were affected by high myopia. They identified a mutation 
in the SLC39A5 gene. Jin et al. (82) performed trio-based exome sequencing in family 
trios and identified 29 de novo single-nucleotide variant (SNV) mutations in early-
onset high myopia, some of which may be causal. Sun et al. (83) carried out exome 
sequencing in 298 probands with early-onset high myopia, and reported 34 
potentially pathogenic mutations in 71 probands. Among the reported genes, 11 had 
been implicated in myopia development in previous studies. 
 
1.5.1.5 Comparison between linkage analyses, family-based association 
study, GWAS and sequencing 
Linkage studies, association studies and DNA sequencing studies for myopia research 
all have the potential to provide evidence for the role of genetic factors in myopia 
development. These research methods should be applied to different datasets 
because they each have their own strengths and weaknesses. 
Linkage analysis performs optimally when the trait is a simple Mendelian disease 
(driven by one rare causal gene), and data from a large family pedigree are available. 
The main limitation of linkage analysis is that it can only identify a candidate region, 
which requires follow-up studies to fine map the candidate genes at the locus.  
Compared to linkage analysis, association studies have a vastly better resolution, i.e. 
they can pinpoint individual genes, rather than highlighting a large chromosomal 
region that may contain hundreds of genes. However, GWAS results are not always 
reliable due to population stratification, and because so many variants are tested, 
their results need to be replicated in independent samples even for loci with very 
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low P-values (84). Figure 1.6 illustrates the potential for false positive association in 
GWAS caused by population stratification (85).  
 
Figure 1.6. Illustration of Population stratification (85). 
The white shapes represent cases, and the black shapes represent controls. 
Association test is carried out for a putative risk allele – the plus sign (+). In a and b, 
the proportions of individuals carrying the risk allele are doubled in the case 
population compared to the control population. In a, true-positive association: in 
either ethnic group, the greater frequency of the risk alleles is observed in cases 
than in the controls. In b, false-positive association due to the mixture of ethnicities, 
80% of ethnic group 1 and 20% of ethnic group 2 carry the risk allele in both of the 
cases and controls. However, while mixing the population, the overall risk allele 
frequency in the cases is twice greater than the controls. This false positive 
association is caused by population stratification: the target allele is more prevalent 
in ethnic group 1, meanwhile ethnic group 1 is overrepresented in the cases. (Taken 
from Hirschhorn et al., page 60 (85)) 
 
Family-based association studies require family trios and require at least one of the 
parents to be heterozygous, which makes the recruitment of participants more 
difficult than for GWAS studies. However, family-based association studies are robust 
against population stratification. Table 1.3 summarized the features of linkage 
analysis, family-based association study and GWAS (63).  
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It is now straightforward to identify mutations for monogenic diseases using whole 
genome sequencing. The limiting factor in applying these methods to high myopia is 
that pedigrees showing monogenic inheritance are very rare – instead, most cases of 
high myopia appear to be polygenic.  
Table 1.3. Summary of linkage analysis, family-based association studies and 
GWAS. Reproduced from (63) 
 Linkage analysis Family-based association 
study 
GWAS 
Study 
population 
Large pedigrees 
with many affected 
subjects 
Small nuclear families 
including cases and their 
parents; TDT requires 
heterozygous parents 
Unrelated individuals 
Mode of 
inheritance 
Assumption of mode 
of inheritance (AD, 
AR and X-linked) 
Additive model Additive model 
Statistical 
power 
High for Mendelian 
diseases 
Low for complex 
diseases 
Low for Mendelian diseases 
Lower than case-controlled 
study for alleles with small 
genetic effects 
Low for Mendelian 
diseases in small 
numbers of pedigrees 
High for detecting 
small genetic effects 
in complex disease 
Advantages Highest power for 
Mendelian diseases 
More efficient using 
a genome scan 
approach 
Presence of internal control 
to avoid the potential for 
population stratification 
 
Systematic assessment 
across the genome 
Convenient sample 
collection, e.g. 
population-based 
sampling 
Disadvantages Need to ascertain 
suitable pedigrees  
Limited by genetic 
heterogeneity if 
present 
Need to ascertain large 
numbers of nuclear 
families; 
Recruitment more difficult 
than case-controlled 
studies, especially for late-
onset diseases 
False positive 
association due to 
ethnically mismatched 
cases and controls 
(population 
stratification) 
AD – autosomal dominant; AR – autosomal recessive 
 
1.5.2 Environmental factors 
Myopia was first thought to be an environmentally-determined disorder, as proposed 
by Cohn (38). He observed that children began to get myopic only after they went to 
school, and therefore concluded that it was going to school and overuse of the eyes 
that made people myopic. After he announced his findings, many studies focused on 
the environmental factors that might trigger the onset or progression of myopia. 
Epidemiologists have found many important risk factors that directly or indirectly 
associated with the development of myopia. 
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1.5.2.1 Near work and education 
With industrialization and modernization, people begin to spend more and more time 
performing indoor activities such as reading, writing, and watching electronic screens. 
This near work was suggested to be the leading cause both for myopia onset and 
progression. Time spent reading (86, 87) - as well as reading distance - are indeed 
risk factors for myopia. In 2011, Muhamedagic et al. (88) recruited 100 myopic 
students and performed a retrospective-prospective study. They found that the time 
spent performing near work had a statistically significant impact on both subjective 
and objective visual acuity examinations. To explore a potential hypothesis regarding 
the underlying mechanism, Ghosh et al. (89) used an optical biometer to investigate 
the change of eye biometrics after a 10-minute near task performed in downward 
gaze. Axial length increased post-task, accompanied by choroidal thinning. These 
findings thus provide an interesting new biological mechanism through which near 
work/down gaze may link to myopia development. A cross-sectional study was 
conducted in Singapore, which recruited 1005 school children aged 7 to 9 years. After 
adjusting for several factors, children who read more than two books per week had 
an odds ratio for myopia of 3.05 (95% CI, 1.80-5.18). However, children who read for 
more than 2 hours per day or with more than 8 diopter hours, had an odds ratio for 
myopia not significantly different to one (OR=1.50; 95% CI.0.87-2.25 and 
OR=1.04;95%CI,0.61-1.78, respectively) (90). Importantly, several studies have 
observed only a weak or even absent association between near work and myopia (91). 
In two studies, one in Singapore and another in Orinda, near work such as reading 
was not associated with myopia development (92, 93). More research is needed to 
identify the cause of the different findings in studies of near work and myopia. 
Usually, studies of near work have examined school-age children, while studies 
investigating the role of education have tended to analyze a wider age range. 
Education has been reported to be a risk factor for myopia development in many 
studies. A population-based cross-sectional study in Germany found both the 
prevalence and magnitude of myopia were associated with education level (94). 
Williams et al. (11) pointed out that increasing education levels were associated with 
an increasing prevalence of myopia in Europe (although education alone could not 
fully explain the trend of the increasing prevalence of myopia over recent decades).  
Interestingly, a recent Mendelian Randomization (MR) study suggested a causal role 
for education in myopia development (95). The estimated causal effect was 
significantly higher than the conventionally-observed effect, suggesting that other 
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environmental influences partially buffer against the adverse causal effect of 
education.  
 
 
Figure 1.7 Mendelian randomization assumptions in a study examining the 
relationship between education and myopia (Taken from Cuellar-Partida (95)). 
“(1) Educational attainment polygenic risk score (instrumental variable, IV) is 
robustly associated with educational attainment (exposure variable); (2) IV is only 
associated with refractive error (outcome variable) via educational attainment 
(exposure variable); (3) IV is not associated to the confounders.” (Taken from 
Cuellar-Partida, page 12, (95),) 
 
1.5.2.2 Time spent outdoors 
Time spent in outdoor activities is another environmental factor related to refractive 
error. In 2013, He and Xiang (96) finished a 3-year randomized controlled trial (RCT) 
among grade 1 children from 12 primary schools. In their study, the intervention 
group had an additional 40-minute class of outdoor activities, and parents were 
involved to encourage their children to have outdoor activities. After 3 years of 
intervention, compared to the control group, the cumulative incidence rate of 
myopia was significantly lower, the myopia progression was significantly slower, 
although the axial length change was similar. In another RCT performed in Taiwan 
(97), 571 students participated. Among them, 333 students were encouraged to 
spend time outdoors during recess, which in total was approximately 6.7 hours of 
time outdoor per week. After 1 year of follow up, the myopia incidence rate was 
reduced and the myopic shift was lower in the intervention group, all of which 
suggested a significant role of outdoor activities in myopia control. 
For other studies, Sherwin and colleagues pooled the results from 7 cross-sectional 
studies to perform a meta-analysis and found that each additional hour of outdoor 
activities per week was associated with a reduction in the odds of myopia by 2% (98). 
Rose et al. (99) reported higher levels of total time spent outdoors, rather than sport, 
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were related to less myopia and a more positive mean refraction; Jin et al. (100) 
suggested that outdoor activities are a potential prophylactic measure which could 
prevent the onset of myopia. A prospective cohort by Guggenheim et al. also showed 
a similar result that increasing time spent outside is associated with a reduced 
incidence of myopia (101).  
The underlying mechanism of this effect is not well understood, however, the ‘light-
dopamine’ theory is the best supported. During time outdoors, the increased light 
intensity will stimulate the release of dopamine, a neuromodulator which has been 
shown in animal models to be associated with reduced experimentally-induced eye 
elongation (102).  
However, not all studies have observed an association between outdoor activities and 
myopia. In one study, Bei et al. (103) recruited 1892 school-age children in Xichang, 
China, to examine the relationship between near work, outdoor activity and myopia. 
After adjusting for age, sex and parental education, neither time spent on near work 
nor time outdoors were associated with myopia. Although lack of accuracy in the 
self-assessment of time outdoors is a limitation of this school-based study, it still 
questions the true nature of the association between outdoor activity and myopia. 
Another study investigated 874 full sibling families (i.e. families in which each child 
within a family has the same parents) and conducted a heritability analysis. After 
adjusting for sex and ethnicity, the heritability of myopia was approximately 73%. 
After further adjusting for time spent outdoors and time spent reading, the 
heritability was essentially unchanged, suggesting that outdoor activities (and near 
work) did not account significantly for the difference in refractive error between 
siblings (104). 
 
1.5.2.3 Diet and physical activity 
When evaluating environmental risk factors that potentially increase the incidence of 
myopia, lifestyle factors such as diet and physical activity may be relevant. In most 
societies, individuals typically take in more nutrition than is actually needed. The 
excess protein, fat, and cholesterol not only leads to overweight or other metabolic 
diseases, but may also be related to the development of myopia. As early as 1956, 
Gardiner proposed that diet might be a risk factor for myopia. By comparing the diets 
between 33 progressing myopes and 251 stable myopes, Gardiner reported that 
stable myopes consumed more protein but less fat and carbohydrate than the 
progressing myopes (105). Forty - four years later, Cordain et al. (106) speculated 
that a high glycemic load and the resulting hyperinsulinaemia might cause rapid 
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scleral growth via insulin-related growth factors. More recently still, Lim et al. (107) 
applied a comprehensive food frequency questionnaire (FFQ) to school-age students 
to assess the relationship between dietary factors and refractive error. They found 
that higher saturated fat as well as cholesterol intake were associated with longer 
axial length although not with severity of myopia. However, in a 1993 study, Edwards 
et al. (108) compared the diets of 24 myopes and 68 non-myopes and reported that 
myopes had lower protein, energy, fat, and cholesterol intake. These inconsistencies 
between the findings of these studies are likely to be the result of differences in 
sample size as well as the methods of dietary assessment. 
As well as these studies examining protein or fat intake, some researchers have 
focused on vitamin D. Studies in Korea and Australia reported an association between 
serum vitamin D level and myopia, however, other researchers attributed this 
association to differences in outdoor activity, which would increase serum levels of 
vitamin D (109-111). A recent Mendelian randomization study also supported this idea: 
Cuellar-Partida et al. (112) analyzed data for 37,382 and 8,376 adult participants of 
European and Asian ancestry, respectively, and used SNPs with known effects on 
vitamin D concentration as instrumental variables. The study found essentially no 
relationship between the IVs and refractive error, suggesting vitamin D levels were 
not causally associated with myopia development.  
Some studies report that myopes spend less time engaged in sports (93, 113). 
However, such studies typically did not distinguish whether this sporting activity 
occurred outdoors or indoors. In 2008, Rose et al. (99) separately investigated indoor 
versus outdoor activities and reported that time spent outdoors was much more 
strongly associated with refractive error than time spent indoors or physical activity. 
Indeed, indoor sports activity was not associated with myopia. A study conducted by 
Guggenheim et al. (101) also suggested that the association between myopia and 
‘sports/ outdoor activities’ was due mainly to time outdoors rather than physical 
activity. In the latter study, time outdoors was assessed using a questionnaire and 
physical activity was assessed using activity monitors.  
 
1.5.2.4 Physical stature and social status  
As a component of the whole body, the growth of eyes is co-ordinated with the 
growth of the body (i.e. height or stature). Saw et al. (114) examined the association 
of birth parameters with biometry and refraction in Singapore Chinese children and 
found that birth weight, birth length, head circumference and gestational age were 
related to axial eye length. However, these parameters were not associated with 
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refraction. A research group in Australia conducted a similar study and reached the 
same conclusion (115). Northstone et al. (116) did a further study on body stature 
growth trajectories during childhood and reported that, during the linear phase of 
height increase (2.5 to 10 year-old), faster-growing children had a small increased 
risk of myopia by the time they reached 11 to 15 in age. 
In addition to physical characteristics, specific aspects related to social and 
demographic status have also shown an association with myopia. It was reported that 
in Australia and Beijing, school-age children living in rural districts had a lower risk of 
becoming myopic (20, 117, 118). High education level, non-manual worker status, 
and higher income were all associated with the prevalence of myopia (119-122). It 
has been suggested that these associations derive from genetic or lifestyle factors. 
 
1.5.2.5 Parental factors 
Certain parental characteristics have been recognized as potential risk factors for 
myopia, such as maternal age, parental education level, parental smoking, 
gestational age, breastfeeding, and birth order (123-126). However, these studies 
may have been biased by confounders such as socioeconomic status and education.  
In all, there is convincing evidence that environmental factors influence the 
development of myopia. However, although epidemiologists have discovered a 
diverse array of environmental risk factors, together they explain only a small 
proportion of the inter-subject variation in refractive error (127). 
 
1.5.3 Gene-environment interactions 
Although much evidence supports a role for both genes and environmental factors in 
myopia development, the involvement of gene-environment interactions (G × E) is 
less well understood. In one novel twin study of 114 monozygotic twin pairs, Lyhne et 
al. (128) detected a significant correlation between the sum of the intra-pairwise 
refractions and the absolute difference in intra-pairwise refraction (Figure 1.8). 
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Figure 1.8. Gene-environment Interaction for ocular refraction (128).  
The x-axis shows the sum of ocular refraction of each monozygotic twin pair, which 
reflects the effect of shared genes and common environment. The y-axis represents 
the variance between monozygotic twin pairs that reflects the effects of purely 
environmental differences. A correlation was observed (r = −0.32, P <0.05), which is 
evidence of an interaction (Taken from Lyhne et al. page 1475, (128)). 
 
The method was proposed by Jinks and Fulker (129), based on the theory that the 
individual environmental difference could be estimated by variation between MZ 
twins, whereas the sum of MZ twins' scores could represent the shared genetic effect 
and the shared common environment effect. However, this method does not provide 
a quantitative measurement of gene-environment interaction. In another study, Saw 
et al. (130) reported that an interaction between parental myopia and near work 
influenced the risk of moderate to high myopia (SE < -3.00 D) in Singaporean children.  
These two studies provide evidence of G × E in myopia. However, they were designed 
to detect general effects rather than the influence of specific genes. To discover 
which genes interact with a specific environmental factor, detailed genotyping and 
careful measurement of the environmental risk factor of interest are needed. This 
topic is discussed in more detail in Chapter 4, section 1. 
 
1.6 Treatment interventions for myopia 
The most popular method used to improve the visual quality of myopic patients is 
prescribing concave spectacle lenses, which is economical and convenient. However, 
this approach is not a treatment of the underlying cause, but simply a way to remove 
the symptoms of myopia. Refractive surgery and contact lenses are also effective in 
treating the symptoms of blurred vision but do not address the high risk of ocular 
pathology in myopic eyes (due to glaucoma, retinal detachment and chorioretinal 
atrophy). 
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There are several therapeutic contact lenses, which were designed based on the 
theory that fully correcting the central vision but imposing myopic defocus on the 
peripheral retina would slow down axial length elongation and myopia progression 
(131-133). Ortho-K contact lenses, which re-shape the cornea during overnight wear, 
provide clear vision in the daytime. Clinical trials suggest that wearing Ortho-K lenses 
slows the progression of myopia (134, 135). Other lens types including bifocal or 
multifocal contact lenses also showed the effect of controlling myopia progression 
(136-138). However, the potential of having contact lens-associated infectious 
keratitis is one of the factors limiting their adoption. 
In recent years, using muscarinic receptor antagonists such as atropine is considered 
to be the first-tier therapeutic method. Clinical experiments conducted in many 
countries, including Singapore (139), China (140), Rotterdam (141), and the USA (142) 
all suggested topical atropine treatment could slow down the progression of myopia. 
In the Singapore-based Atropine for the Treatment of Myopia (ATOM2) clinical trial, 
the effect of different atropine concentrations (0.5%, 0.1%, and 0.01%) was compared. 
It was found that increasing atropine concentration was positively correlated with 
the therapeutic effect, however, it was also potentially related to an increased 
incidence of side effects, such as allergic conjunctivitis, photophobia and near blur. 
Chia et al. (139) suggested 0.01% atropine for controlling myopia progression with 
minimal side effects.  
Although many methods have been tested, and many others are being developed, 
none is fully effective at halting the incidence of myopia and preventing future 
progression. Thus, new or improved therapeutic intervention strategies are needed. 
 
1.7 Animal models of myopia 
As early as 1977, Wiesel and Roviola (143) found that monocularly or binocularly 
suturing the eyelid of neonatal monkeys could induce myopia and enlarge the lid-
sutured eye. Since then, different animal models have been evaluated to examine 
their response to the deprivation of sharp vision (so-called “form deprivation” [FD]). 
It has been found that myopia can be induced by FD in tree shrew (144), monkey 
(143), chick (145), kestrel (146), marmoset (147), rabbit (148), mouse (149), guinea 
pig (150) and fish (151).  
As with form deprivation, minus lens wear can induce myopia in juvenile animals. In 
1988, Schaeffel et al. (152) imposed a serious of lenses ranging from +4D to -8D to 
young chicks eyes, and both hyperopia and myopia could be induced. A similar effect 
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was also observed in tree shrew (153), guinea pig (154), mouse (155), marmoset (156) 
and fish (157).  
Comparing these models to the process of myopia development in humans, they are 
similar in many ways. Firstly, both experimental myopia and human myopia show 
similar characteristic features. For example, in both animal models and humans, the 
myopic eyes tend to have an increased axial length, particularly as regards the 
vitreous chamber depth (158, 159), as well as retinal, choroidal and scleral thinning 
(150, 160-162). Secondly, both animal models and humans exhibit a susceptible 
period for myopia at younger ages (158, 163, 164). Moreover, form deprivation 
myopia has also been reported to occur in human infants with congenital cataract or 
disorders of the eyelids (165).  
The discovery of experimentally-induced myopia was a milestone in myopia research 
history. The availability of animal models has allowed researchers to manipulate 
experimental conditions and investigate their effects on myopic eye growth, and to 
take physiological measurements and tissue samples of myopic animals to learn more 
about the mechanisms controlling refractive development.  
 
1.7.1 Key findings from animal experiments 
1.7.1.1 Light intensity and wavelength  
Light intensity is important for emmetropisation. It was found that just increasing 
the ambient illuminance level reduced the effects of form deprivation. In chicks, 
exposure to bright light (15,000 lux) 5 hours per day retarded the development of 
form-deprivation myopia (FDM) by roughly 60% (166), and with increasing light 
intensities, lesser myopic refraction and shorter axial length were found (167). For 
short-duration bright light exposure, the effect depended on the time of day of the 
exposure, with maximum impact occurring with exposure at mid-day (168). Similar 
findings have been observed in rhesus monkeys (169). Bright light can also influence 
the rate of lens-induced myopia development (170). 
Apart from light intensity, the wavelength of the light is another important factor. 
Chicks reared in red light became more myopic than those reared in blue light (171). 
However, rhesus monkeys reared under red light remain more hyperopic than those 
reared in blue light (172), and the same phenomenon was observed in tree shrews 
(173). The wavelength effects might be explained by longitudinal chromatic 
aberration (LCA), which means long wavelength (“red”) light is focused farther from 
a lens than short wavelength (“blue”) light is. Thus, red light will produce hyperopic 
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defocus if the medium wavelengths (“yellow”) of white light are focused on the 
retina (173).  
Furthermore, light flicker frequency is also found to be related to myopia 
development. Di et al. (174) reared guinea pigs under flicker with a flash rate of 5, 1, 
0.5, 0.25 or 0.1Hz, and found 0.5Hz flicker maximally induced myopia. In another 
study in chicks treated with ±10 D or 0 D lenses, or without lenses, a temporal 
modulation of flicker-induced a myopic shift, with 1Hz flicker having the strongest 
impact (175). 
 
1.7.1.2 Signalling pathways and molecules  
Signalling pathways and molecules involved in myopia development are of interest to 
many researchers. To date, signalling molecules including dopamine, melatonin, 
ZENK, and retinoic acid have been reported to be involved in experimentally-induced 
myopia. 
Dopamine 
In 1989 Stone and colleagues (176) first reported a decrease of dopamine and its 
metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) in FD eyes. Since then the 
mechanism of dopamine’s effect on eye growth has been studied widely.  In rhesus 
monkeys (177), guinea pigs (178), and tree shrews (179), activation of retinal 
dopamine receptor 2 (D2 receptor) was found to reduce the degree of FD-induced 
myopia development. In eyes recovering from FD, dopamine, DOPAC and the 
DOPAC/dopamine ratio increased rapidly within 2 days (180).  
Light intensity and both spatial and temporal contrast also affect retinal dopamine 
levels. Megaw et al. (181) reported that an increase in light intensity increased the 
dopamine level and dopaminergic activity in chick vitreous. Feldkaemper and 
colleagues (182) reported that, compared to eyes treated with frosted diffusers, eyes 
covered with neutral density filters (which only reduce light level but keep Michelson 
contrast constant), had a higher level of DOPAC. Thus, both luminance and spatial 
contrast in the retina image are connected to dopamine release.  
ZENK 
ZENK, also known as early growth response protein 1 (Egr-1), nerve growth factor-
induced protein A (NGFI-A), zinc finger protein 225 (zif268), tis8, cef5, and Krox24, 
was found to be up-regulated in retinal amacrine cells when plus lens defocus was 
imposed. In contrast, ZENK was found to be down-regulated in FD or minus lens-
treated eyes. In chick retina, the glucagon amacrine cells contribute mostly to the 
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regulation of ZENK under defocus condition (183), which suggests that glucagon cells 
might guide ocular growth. 
To better understand the role of ZENK in eye growth, Schippert and colleagues (184) 
studied refractive development in ZENK knockout mice. It was found that knocking 
out ZENK mainly influenced axial length since mice experienced a myopic shift due to 
having longer eyes, while lack of ZENK had only minor effects on anterior chamber 
depth and corneal curvature.  
 
1.7.2 Comparison between different animals  
The ideal animal model for myopia research would be an animal that spontaneously 
develops myopia without any experimental intervention, which is the situation in 
humans. However, spontaneously-occurring myopia is rare in natural animal 
populations. It has been reported that rhinoceroses (185), thoroughbreds horses (186), 
and certain dog breeds (187-189) have a high prevalence of myopia. However, 
conducting experiments on these animals might require a great deal of space and 
very high financial support. Jiang et al. (190) found a wild-type guinea pig strain 
(Cavia porcellus) which 28 out of 220 of them had spontaneous axial myopia (less 
than -1.5D in both eyes). However, after visual function measurement using an 
optomotor drum, they also showed that the affected animals displayed deficits in 
pupil responses and accommodation.  
The various animal models of myopia have different features that make some models 
better suited for addressing specific research questions than others. A summary of 
different animal models (191) is listed below in Table 1.4. 
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Table 1.4. Summary of different animal models of myopia. Reproduced from Schaeffel & Feldkaemper (191). 
 
Animal model 
Character features 
Advantages Disadvantages 
Chick 1. Relatively large eyes (8 to 14 mm);  
2. Rapid eye growth;  
3. Highly sensitive control of refractive state by retinal image quality and 
focus;  
4. Excellent optics (diffraction-limited at 2.0mm pupils);  
5. Active accommodation (about 17 D);  
6. High visual acuity (7 cycles/degree);  
7. Easy drug delivery by intravitreal injection;  
8. Friendly, co-operative nature; 
9. Inexpensive and easy to keep. 
1. Lack of a fovea; 
2. Differences in scleral composition; 
3. Different mechanism of accommodation (corneal and 
lenticular) compared to mammals; 
4. Differences in ciliary muscle composition. 
Tree Shrew 1. Closely related to humans;  
2. Can induce myopia by FD and negative lenses, and eye growth is 
modulated to compensate for defocus;  
3. Single layered sclera, similar to human. 
1. Lack of a fovea; 
2. Longer treatment period; 
3. No clear indication of accommodation; 
4. More complex handling and breeding. 
Primates 1. Closely related to humans; 
2. Parallel ocular anatomy with human, such as their retinal vascular 
structure and fovea are similar to humans; 
1. Limited availability; 
2. Longer treatment period; 
3. High expense for large-scale studies. 
Guinea pigs 1. Easy to maintain and breed, “friendly” and co-operative; 
2. Large pupils and reasonably large eyes (axial length 8.0 mm); 
3. Easy to perform measurements. 
1. Lower visual acuity than chicks; 
2. Lack of evidence of accommodation. 
Mouse 1. Well-established animal model for a range of human diseases with a 
wealth of knowledge on its biochemistry and genetics; 
2. Lots of well-established transgenic versions; 
3. Easily obtained and bred. 
1. Small eye size (around 3.3 mm axial length); 
2. Difficult to measure eye parameters; 
3. Poor optics, no accommodation and no fovea;  
4. Difficult to induce myopia; 
5. Not as friendly as Guinea pigs, difficult to handle.  
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1.7.3 Interventions for inducing myopia 
1.7.3.1. Form-deprivation myopia (FDM) 
Myopia can be induced by continuously blocking an eye’s sharp vision; so-called 
‘form-deprivation myopia’ (FDM). In an animal undergoing form deprivation, the 
illuminance level will be different in the treated eye versus the control eye, and the 
contrast and sharpness of the image projected onto the retina will be reduced. Under 
this stimulation, eyes show a reduced expression level of dopamine and ZENK, 
thinning of the choroid, and an increase in axial length. One of the features of FDM is 
that there is no plane of focus, which means there is no end point for the eyes to 
grow towards. Hence form-deprived eyes become progressively more and more 
myopic with time. In animals treated with FD, some might be very susceptible while 
the others might be less sensitive. The ‘open-loop’ character of FD, therefore, 
maximizes the variance in the degree of induced myopia among treated animals. 
 
1.7.3.2. Lens-induced myopia (LIM) 
Placing a minus lens in front of the eye causes the image to focus behind the retina. 
This signals the eye to accelerate its growth rate such that the retina moves towards 
the focal plane, i.e. producing an increase in axial length. This process is presumed 
to mimic the natural emmetropisation process during eye development, which guides 
the positioning of the retina relative to the image focal plane. Unlike FDM, LIM does 
not markedly reduce the illuminance level, and the image quality may be improved 
immediately by accommodation. In chicks, the accommodation ability is greater than 
in man, at approximately 20 D (192, 193). An intervention to eliminate the ability to 
accommodate did not prevent LIM from occurring, although it did impair its accuracy 
(194). Importantly, the accelerated growth of axial length will stop when the eye has 
compensated for the refractive power of the imposed lens. This ‘closed-loop’ 
characteristic, therefore, leads to limited variability in the final refractive state of 
animals undergoing LIM once full compensation for the lens has occurred. 
 
1.8 Overview of the research design strategy for the PhD project 
A selective breeding experiment carried out in chicks by Chen et al. (195) provided 
strong evidence that genetic factors regulate susceptibility to FDM. The aim of this 
PhD project was to build on this finding in order to discover some of the genes that 
mediate this genetic susceptibility to myopia. The chosen study design was a GWAS in 
a chick population treated by monocular FD based on the hypothesis that a GWAS is 
able to identify genetic loci conferring myopia susceptibility in an animal population 
exposed to a myopia-inducing environmental stimulus (For more details, please refer 
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to Chapter 4, section 4.1.2). Monocular FD treatment was selected in preference to 
binocular FD since the within-animal monocular treatment design provides a more 
sensitive measure of the effect of the treatment (196). 
 
1.8.1 Animal selection for the PhD project 
The chick was selected as the animal model for this study for the following reasons. 
First, chicks rely on vision as their primary sense; thus chicks have relatively large 
eyes and a highly developed visual system (197, 198). The large eye size of the chick 
would facilitate accurate measurement of the degree of experimentally-induced 
myopia in each individual animal. Second, chicks are a well-established animal model 
for myopia. Like human eyes, chicks are typically mildly hyperopic soon after they 
are hatched (born) and undergo emmetropization during juvenile development. Post-
hatch ocular growth is relatively fast in chicks, about 100 µm per day, and FD causes 
rapid and robust myopia development in chicks (199, 200). Third, genetic variation 
has already been shown to modify susceptibility to FDM in chicks in the selective 
breeding experiment of Chen et al. (195). Thus, searching for genes associated with 
chick FDM is feasible. Finally, chicks are inexpensive and easy to keep. In this study, a 
large number of animals are needed, and thus the economical cost makes chicks a 
good choice.  
 
1.8.2 Method to induce myopia 
1.8.2.1 Form-deprivation myopia vs. lens-induced myopia 
In this study, FD was selected to induce myopia. Compared to the ‘closed loop’ LIM 
paradigm, FD is an ‘open-loop’ treatment and therefore has the advantage that 
highly-susceptible individuals could not fully compensate for the treatment stimulus. 
 
1.8.2.2 Method of attaching occluders to produce form deprivation 
Instead of using a matched pair of Velcro rings (201), sutures were selected to fix the 
occluder in place in front of the eye. There are several advantages of using sutures. 
Firstly, compared to Velcro, sutures provide better fixation of the occluder (occluders 
attached with sutures very rarely fell off). Secondly, occluders attached using Velcro 
can prevent moisture from evaporating, which can ‘mist up’ the occluder. Sutures 
provide tiny gaps that allow airiness between the occluder and the underlying 
feathers and avoided this problem. Moreover, sutures were considered more humane 
since they prevented the adverse tissue reaction to the glue used to attach the 
Velcro, which can result in tissue inflammation around the eye. By cutting the suture 
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knots, sutures could be quickly removed without detectable tissue damage, to allow 
eye measurements to be carried out. 
 
1.8.2.3 Age and duration of form deprivation 
Myopia can be induced in chicks from the day of hatch to at least 1 year of age, 
although the magnitude of the response to FD declines rapidly with age (202). Here, 
a period of FD of 4 days was selected, beginning when the chicks were 7 days old. 
Under this regimen, the degree of induced myopia had not yet reached its plateau, 
and the inter-animal variability in response to FD was known to be sufficient to 
distinguish differences in genetic susceptibility (195). Chickens reach sexual maturity 
at approximately 6 months of age and can live for 20 years, therefore the FD period 
in this experiment corresponds to the neonatal period in children.  
 
1.8.3 Method to assess the degree of FD myopia 
In this study, both spherical equivalent (SE) of the chick eye and axial length were 
recorded. Measurement of treatment-induced axial elongation was selected as the 
method for quantifying the degree of induced myopia in each chick (Chapter 2, 
section 2.2.3). According to previous studies (203, 204), FD would cause enlargement 
of the whole eye in chicks, with the major contribution from vitreous chamber 
elongation, accompanied by crystalline lens thickening and anterior chamber 
deepening/corneal flattening. Ocular component dimensions can be measured more 
reproducibly than the refractive error in chicks (i.e. the coefficient of variation of 
repeat readings is lower for A-scan ultrasonography measurements than for 
retinoscopy measurements). Therefore, ocular biometry was selected as a more 
precise measure of the degree of induced myopia than the retinoscopy findings. Of 
the ocular component dimensions, the change in axial length shows a closer 
correlation to the degree of induced myopia than does the change in vitreous 
chamber depth in chicks (205) Therefore, treatment-induced axial elongation was 
selected as the main outcome measure. 
 
1.8.4 Method used to measure axial length 
A-scan ultrasonography is a diagnostic test used in optometry or ophthalmology. This 
technique is widely used by myopia researchers to measure the degree of treatment-
induced axial elongation in animal models (191). Although more accurate techniques 
have become available for measuring axial length in recent years (206) the new 
instruments are expensive. The most accurate meanwhile cost-effective technique 
available to us was A-scan ultrasonography. 
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When ultrasound waves travel from one medium to another of a different density, an 
echo will bounce back when the ultrasound beam strikes the interface. In an A-scan 
device, sound waves of a specific frequency are emitted from a probe tip driven by 
electrical pulses, causing a crystal element to vibrate. As the sound beam passes 
through the eye, it is partially reflected back at each interface of different acoustic 
impedance, forming a series of echoes. These echoes are detected by the probe tip 
(this time, the sound vibration is converted into an electrical signal). From the front 
to the back of the eye, the echoes correspond to the interfaces of: air/anterior 
corneal surface, the posterior corneal surface/aqueous interface, the 
aqueous/anterior lens surface, the posterior lens capsule/anterior vitreous, the 
posterior vitreous/retinal surface, the retina/choroid interface and the 
choroid/anterior scleral surface (Figure 1.9). 
Waveform peaks reflected from the eye can be displayed along an x-axis of time. The 
velocity of sound varies when it passes medium with different density and thus, the 
ocular component dimension can be calculated by a simple formula:  
Distance = Velocity × Time 
Waveform peak heights can be used to gauge the quality of the measurement. Peak 
height is not only affected by the difference in density at the interface but also by 
the alignment of the ultrasound beam and the visual axis. Sound waves can be 
reflected and refracted in the same way as light rays; if they are parallel with the 
visual axis and perpendicular to the corneal vertex, sound waves will be maximally 
reflected back towards the probe. 
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Figure 1.9. High-frequency A-scan ultrasonography system and holding device 
(205). 
(A) Explanation of A-scan echo spikes in ultrasonography and the corresponding 
ocular component of the chick eye. (B) Custom-made holding device, with animal 
position fixing holder and a holder for the transducer (Taken from Chen, page 
39,(205)).  
 
1.8.5 Method used to measure spherical equivalent 
Retinoscopy is a technique to obtain an objective measurement of the refractive 
error of the eye. When a light beam passes through a lens and is projected onto a 
screen, if the focal plane is between the lens and the screen, the reflex will move 
opposite to the light source (an ‘against’ movement); on the contrary, if the focal 
plane is behind the screen, the reflex will move with the light source (a ‘with’ 
movement); while if the focal plane is exactly on the screen, the reflex will stay still 
(“neutralized”). The same principle is utilised in retinoscopy. Through a peephole in 
the retinoscope mirror, the observer can determine if the refractive power of the eye 
it is too strong (indicating myopia) or too weak (hyperopia). The refractive error of 
the eye can be corrected by adding minus or plus lenses until a neutral point is 
achieved.  
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1.8.6 Method to detect gene loci influencing susceptibility to form 
deprivation myopia 
In this study, GWAS was selected as the optimal method for this project. Details 
explaining how the GWAS was performed in chicks and selection of the genotyping 
platform will be discussed in Chapter 4, section 4.1.4.  
In this study, instead of genotyping all chicks that were phenotyped, a ‘selective 
genotyping’ strategy was used, in which only chicks that exhibited extreme 
phenotypes were genotyped (in this study, extreme high and low FD-induced axial 
elongation). The selective genotyping strategy was designed to reduce the cost but 
retain sufficient statistical power. This issue is discussed in Chapter 4, section 4.4.8. 
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Chapter 2 Material and methods
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2.1 Material 
2.1.1 Experimental animal 
The animal experiments were carried out at Hong Kong Polytechnic University. The 
experiments complied with the Animals (Control of Experiments) Ordinance Chapter 
340 of the Hong Kong Department of Health. White Leghorn chicks (Gallus gallus 
domestics) were used as the myopia model. Chicks were obtained from specific-
pathogen-free (SPF) eggs obtained from a local supplier (Tin Hang Tech Ltd, China) 
and hatched in batches of approximately 20 per week. It was assumed that chicks 
from the company were randomly mated as part of a very large population of chicks 
and hence that the chicks would exhibit sufficient genetic diversity to permit genetic 
association mapping.  
 
2.1.2 Occluders 
Translucent occluders for depriving the eye of form vision were made from a sheet of 
0.8 mm-thick polypropylene with an absorbance of 0.07 log units. The polypropylene 
sheet was cut into 2x2 cm squares, heated for 20 seconds at 180C and compression 
moulded into appropriately sized hemispheres. A mechanical punch was used to 
remove extraneous material, leaving a 2-3mm rim around the edge of the occluder. 
The edges were smoothed by sandpaper. Four holes (0.4 mm diameter) were drilled 
in the occluder rim, at positions corresponding to 12, 4, 6 and 8 o’clock, to allow the 
occluder to be sutured in position. 
 
2.2 Method 
2.2.1 Myopia model: Form deprivation  
After hatching, chicks were reared in wire-mesh cages with a suspended infrared 
heat lamp controlling the temperature to 25°C under a 12/12 hr light/dark diurnal 
cycle (lights providing 500 lux illumination were turned on at 7 am and off at 7 pm). 
They were given access to water and fed commercial chick starter ad libitum.  
On day 7 after hatching, chicks were monocularly form deprived. The treated eye 
was alternatively selected between right and left eye. Chicks were anaesthetized by 
intramuscular injection of ketamine 50 mg/kg and xylazine 3.5 mg/kg. A translucent 
occluder was affixed to the periorbital skin surrounding the orbit of the treated eye 
using 3-4 sutures in the 12, 4, and 8 o’clock positions (195). The treated eye was 
observed after recovery from anaesthesia to confirm it locates in the middle of the 
lens and it could open freely.  
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2.2.2 Measurement and quantification of eye parameters 
2.2.2.1 High-frequency A-scan ultrasonography 
Prior to FD when chicks were 7 days old (‘baseline’), A-scan ultrasonography was 
performed on both eyes of the anaesthetized chicks. After the 4-day treatment 
period, when chicks were 11 days old, the occluder was temporarily removed to 
perform A-scan ultrasonography for a second time. During the measurements, the 
eyelids of the anaesthetized chicks were kept open with a speculum. The ultrasound 
system was calibrated each day, prior to use, by measuring an aluminium block of 
known dimensions.  
The A-scan system consisted of 4 parts: 1) a 20 MHz transducer of focal length 25 mm; 
2) a 15 mm saline stand-off with autoclaved saline being perfused at a rate of 0.15 
ml/min; 3) a Panametrics model 5073PR pulser-receiver; 4)a personal computer 
fitted with an Acqiris DP-110 data acquisition card. Waveforms were sampled at 100 
MHz, and for each measurement, 50 waveforms were taken and the average value 
was calculated. The resolution of the A-scan was 10 m (203). For each eye, 3 to 6 
measurements were performed, data would be taken only if the difference between 
two measurements was smaller than 0.05 mm. The average value of all the 
measurements was used for further analysis.  
Two custom-made holding devices were used to assist the alignment of the 
ultrasound probe with the visual axis of the chick’s eye. The first device consisted of 
a platform to hold the chick and maintain its head in a fixed position. The second 
was an opto-mechanical stage used to control the position of the ultrasound probe, 
which allowed translational movements along the X, Y and Z axes, plus rotational 
movement in the vertical (pitch) and horizontal (yaw) axes. When clear echo spikes 
exhibited an amplitude size profile: cornea > anterior lens > posterior lens and retina 
< choroid < sclera, it was assumed that the alignment of the probe to the visual axis 
was optimal. Dimensions of each eye component were analysed in real-time using a 
custom-written software according to the formula given in Chapter 1, section 1.8.4, 
by assuming an ultrasound velocity of 1.6078 mm/µs in the lens and 1.5340 mm/µs in 
the other ocular media (158). The average value of the three highest readings was 
used in the data analysis. The measurements included: corneal thickness (CT), 
anterior chamber depth (ACD), lens thickness (LT) vitreous chamber depth (VCD) and 
axial length (AXL). 
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2.2.2.2 Retinoscopy 
Streak retinoscopy was performed on both eyes of awake chicks at the 11 days-old 
assessment, before anaesthesia and A-scan measurements. Cycloplegic eye drops 
were not used because, unlike in mammals, avian ciliary muscle is striated not 
smooth muscle and is controlled primarily by nicotinic receptors. A minus-power lens 
bar and a plus-power lens bar were clamped upright to a bench and positioned at a 
‘working distance’ of 33 cm (3.00 D) from a marker position where the retinoscope 
was held. Retinoscopy was performed under dim illumination, and chicks were gently 
restrained such that each eye in turn was positioned approximately in the middle of 
the correction lens and perpendicular to the light beam of the retinoscope. Spherical 
refractive error was measured in both the horizontal and vertical meridians and 
entered into a custom-designed database program that converted values to sphere 
and cylinder powers automatically.  
Retinoscopy measurement in small eyes such as those of the chick is subject to a 
source of systematic bias (in the direction of hypermetropia) known as the ‘small eye 
artefact of retinoscopy’ (207). The bias arises from light being reflected from the 
retina/vitreous interface rather than the retinal photoreceptor layer. No account was 
taken of the small eye artefact in this study, because the primary interest was in the 
relative refractive error between treated and control eyes, not their absolute 
refractive error.   
Chicks have both cornea and lens accommodation (208). Accommodation by chicks 
during retinoscopy was evident as a fluctuation in the measurement and constriction 
of the pupil. Therefore, to increase measurement accuracy, a dark and quiet 
environment was created, and measurements were performed once the pupil size 
was maximal.   
 
2.2.2.3 Quantification of eye parameters 
To quantify the change in ocular dimensions due to FD, the following formulae were 
used: 
Change in CT (ΔCT) = ΔCTT  - ΔCTC 
Change in ACD (ΔACD) = ΔACDT  - ΔACDC 
Change in LT (ΔLT) = ΔLTT  - ΔLTC 
Change in VCD (ΔVCD) = ΔVCDT  - ΔVCDC 
Change in AXL (ΔAXL) = ΔAXLT  - ΔAXLC 
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Where, 
Change in CT of treated eye (ΔCTT) = CT (after FD) - CT (baseline)   
in treated eye 
Change in CT of control eye (ΔCTC) = CT (after FD) - CT (baseline) 
in control eye 
Change in ACD of treated eye (ΔACDT) =  ACD (after FD) - ACD 
(baseline) in treated eye 
Change in ACD of control eye (ΔACDC) = ACD (after FD) - ACD 
(baseline) in control eye 
Change in LT of treated eye (ΔLTT) = LT (after FD) - LT 
(baseline) in treated eye 
Change in LT of control eye (ΔLTC) = LT (after FD) - LT (baseline) 
in control eye 
Change in VCD of treated eye (ΔVCDT) = VCD (after FD) - VCD 
(baseline) in treated eye 
Change in VCD of control eye (ΔVCDC) = VCD (after FD) - VCD 
(baseline) in control eye 
Change in AXL of treated eye (ΔAXLT) = AXL (after FD) - AXL 
(baseline) in treated eye 
Change in AXL of control eye (ΔAXLC) = AXL (after FD) - AXL 
(baseline) in control eye 
The actual mean spherical equivalent (MSE) was calculated using the following 
formula: 
MSE = Sphere + 1/2 Cylinder – 3 Dioptres  
Where 3 Dioptres corresponds to the working distance of 33cm. In this study, since 
the working distance was consistent, it was not corrected. 
2.2.3 Measurement of body weight 
Body weight was measured on day 4 and day 11 using a digital balance, before 
anaesthesia, as an indicator of the chick’s health status. Chicks with extremely low 
body weight on day 4 (< 30 g) were excluded from the study.  
 
2.2.4 Biological sample collection 
In pilot experiments, it was found that the neural retina strongly adhered to the RPE 
layer if the chick was sacrificed immediately after a sodium pentobarbital overdose 
during anaesthesia with ketamine/xylazine. However, it was found that if the chick 
was sacrificed by CO2 asphyxiation without prior anaesthesia, the neural retina would 
swell and become edematous over the next few minutes, which allowed it to be 
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isolated easily. The reason for the tight adherence of the retina and choroid after 
ketamine/xylazine anaesthesia and sodium pentobarbital sacrifice, versus the ease of 
separation after CO2 asphyxiation was unclear. One possible explanation is that 
during the process of cell death, N-methyl-d-aspartic acid (NMDA) receptors are 
activated, producing an influx of Ca2+. Ketamine may deactivate the NMDA receptors 
in retinal cells, producing a neuroprotective effect which may postpone cell death 
and oedema (209-211). Furthermore, ketamine itself could directly reduce cell 
swelling subsequent to anoxia-hypoxia, which may help maintain the normal tight 
adherence between the neural retina and the RPE. (212) Xylazine is an alpha-2 
adrenergic agonist, and it has both analgesic and sedative properties (213). It was 
found that ketamine/xylazine combination could protect rat photoreceptor cells 
against apoptosis induced by strong light (211).  
Applying ketamine/xylazine combination prevented collection of a retina sample free 
from the adherent choroid. Consequently, this study followed a protocol whereby 
after the ultrasound measurements had been completed at the 11 days-old 
assessment, the occluder was re-fixed in position, the chick was allowed to recover 
from the anaesthesia and returned to its home cage. After one further day of form 
deprivation, animals were sacrificed by CO2 asphyxiation, and then blood samples 
were collected, and retinal dissections were performed 7 minutes after death. 
 
2.2.4.1 Blood sample collection 
After the chick was sacrificed, cardiocentesis was performed to obtain a blood 
sample (> 1ml). Before performing cardiocentesis, a 3ml syringe with a 21g needle 
was prefilled with 50 μl of 200 mM EDTA as an anticoagulant. The feathers and skin of 
the chest were disinfected with ethanol, and the needle was inserted perpendicular 
to the chest cavity along the upper edge of the sternum to obtain the blood sample. 
After collection, the syringe was inverted several times to disperse the EDTA. For 
each chick, two 1 ml blood samples were collected and were stored at -20C in 1.5 
ml screw-cap centrifuge tubes for approximately 10 days (prior to DNA extraction). 
 
2.2.4.2 Retina sample collection 
After collecting the blood sample, retina samples from both the treated and control 
eyes were collected. The feathers and skin around the orbit were disinfected with 
ethanol, and the eyes were removed and placed on an ice-cooled aluminium plate. 
Each eye was sectioned along the equator and the anterior segment discarded. The 
neural retina from the posterior hemisphere was carefully separated from the 
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pigment epithelial layer using fine forceps. Neural retina samples were transferred to 
a 1.5 ml screw-cap vial containing 150 μl of ‘RNALater’ solution and stored frozen 
after the tissue was fully saturated, and then were stored at -20C. 
 
2.2.5 Nucleic acid extractions 
2.2.5.1 DNA extraction 
Unlike humans, chick red blood cells possess nuclei, thus DNA can easily be extracted 
from whole blood. After thawing blood samples to room temperature, DNA was 
extracted with the following protocol: 
i. A 15μl aliquot of each blood sample was mixed with 800μl TES solution 
(250mM Tris, 25mM EDTA and 2% Sodium dodecyl sulfate, pH=8.0) by gentle 
trituration until the solution was homogeneous.  
ii. 1.5μl RNase solution (100mg/ml stock, RNase A, Qiagen Ltd.) was added and 
the mixture was incubated at 37°C for 30 minutes.  
iii. After cooling the solution to room temperature, 200μl of cold ammonium 
acetate (7.5M, 4°C) and 100μl chloroform were added. The sample was vortex 
mixed for 20 seconds and centrifuged at 14,000g for 3 minutes. 
iv. The upper liquid phase was transferred to a fresh 1.5ml tube. DNA was 
precipitated by adding 700μl cold isopropanol, mixed gently, and centrifuged 
at 14,000g for 2 minutes.  
v. The pellet was washed with 200μl 70% ethanol, and air dried for 15 minutes. 
vi. The DNA pellet was then re-suspended in 100μl TE solution (10mM Tris, 1mM 
EDTA) by incubation overnight at 37°C. 
 
2.2.5.2 DNA concentration measurement 
DNA was used for genotyping, which required a concentration of 50 μg/μl. Thus, the 
concentration of DNA was measured using a spectrophotometer. 
i. The spectrophotometer (GeneQuant II, Pharmacia Biotech Ltd.) was 
calibrated with deionized water and a reference sample (50 μg/μl calf thymus 
DNA in water).  
ii. 5μl of chick genomic DNA was diluted in 995ul autoclaved deionized water and 
mixed by vortexing. 
iii. The absorbance at 260 nm and 280 nm was recorded (OD260 and OD280, 
respectively). Any sample with an OD260/OD280 ratio less than 1.8 was re-
extracted. 
iv. DNA was diluted to 50 μg/μl with Te solution (10mM Tris, 0.1mM EDTA).  
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2.2.5.3 RNA extraction 
RNA was extracted using the RNase-free DNase set (Qiagen#79254) and RNeasy mini 
kit (Qiagen#74101) following the manufacturer’s instructions: 
i. Retina samples in RNAlater were allowed to warm to room temperature, 
removed from the RNAlater solution, and frozen in liquid nitrogen.  
ii. The frozen sample was powdered using a freezer mill (Dismembrator, Braun 
Biotech Ltd) at 1600rpm for 2 minutes together with 100μl buffer RLT-DTT 
from the Qiagen kit.  
iii. For complete homogenization, another 250μl buffer RLT-DTT was added and 
dismembratation was continued for a further 5 minutes.  
iv. After collecting the tissue suspension in a 1.5ml tube, it was centrifuged at 
12000rpm for 3 minutes.  
v. The supernatant was transferred to a fresh tube, mixed with 350μl 70% 
ethanol, applied to an RNeasy spin column, followed by a wash step.  
vi. Contaminating DNA was degraded by applying 80μl Buffer RDD-DNase-I to the 
spin column and incubating at room temperature for 10 minutes.  
vii. After 2 further wash steps, the RNA was eluted in 35μl water.  
 
2.2.5.4 RNA quality test 
The quality of the extracted RNA was tested by gel electrophoresis.  
i. 100ml of 1% agarose in 1× running buffer (‘SB buffer’, 36mM boric acid, pH 
8.0 ) was heated to boiling point, cooled to 55C and poured into a gel mould. 
ii. A 10μl RNA sample was premixed with 2μl 6× loading buffer (New England 
BioLabs, #B7025S) and 0.25μl SYBR gold stain (Thermo-Fisher, #10358492). 
iii. A 10μl sample was loaded into the well, and electrophoresis was carried out 
for 15 minutes at 120 volts. 
iv. The gel was photographed under UV light. 
 
Approximately 70-80% of RNA in tissues is ribosomal RNA (rRNA), which is composed 
of 5.8S, 18S and 28S subunits. The latter two subunits are readily visualised on 1% 
agarose electrophoresis gels (Figure 2.1), while 5.8s rRNA is selectively excluded 
during the extraction procedure due to its low molecular weight. The presence of 
strongly-staining 18S and 28S bands was taken as evidence of good RNA integrity. 
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Figure 2.1. RNA electrophoresis showing the 28S and 18S ribosomal subunits 
(upper and lower bands, respectively). 
2.2.6 Polymerase chain reaction (PCR) sexing test 
To test the quality of the extracted DNA and simultaneously test the sex of the chicks, 
a PCR-based assay was performed, based on the following mechanism: 
Male chicks carry two copies of the Z chromosome whilst females carry one Z and one 
W chromosome. Based on the sequence of the CHD (Chromo Helicase DNA-binding) 
gene, which is present on both Z and W chromosomes, the sexes can be inferred by 
performing an allele-specific PCR (214). For this assay, 3 PCR primers were used 
(Table 2.1): a forward primer that is complementary to both the Z and W 
chromosome CHD gene sequence. The other two primers are reverse primers specific 
for the Z and W chromosome copies of CHD, respectively. The two reverse primers 
were designed to yield PCR products of markedly different size when combined with 
the forward primer (322 vs. 418bp). After PCR and electrophoresis, male chicks show 
one band while females show two bands (Figure 2.2). This 3-primer allele-specific 
PCR method is faster than previously-published methods, which require a restriction 
enzyme digestion step. 
The PCR reaction was performed as follows: 
i. A 20μl ‘master mixture’ was prepared for each sample, comprising: 5.0μl 
chick DNA, 2.0μl 10× PCR Buffer (New England BioLabs), 0.4μl 0.2mM of each 
dNTP (New England BioLabs), 1.0 μl 1μM forward primer, 1.0μl 1μM of each 
reverse primer, 9.4μl water and 0.2μl (1.0 unit) Taq DNA polymerase (New 
England BioLabs). 
ii. Samples were placed in the thermal cycler (MJ Research Dyad PCR Dual Block), 
with a setting of heating at 95°C for 5 min, following by 35 cycles of 94°C for 
1 minute, 67°C for 1 minute and 72°C for 1 minute.  
PCR products were visualised using agarose gel electrophoresis: 
i. 100ml of molten 1.5% agarose in 1× running buffer (‘SB buffer’, 36mM boric 
acid, pH 8.0) was poured into a gel mould. 
ii. 10μl PCR product was premixed with 2μl 6× loading buffer (New England 
BioLabs, #B7025S) and 0.25μl SYBR gold stain (Thermo-Fisher, #10358492). 
18S 
28S 
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iii. 10μl of the PCR product mixture was loaded into an electrophoresis well and 
run for 15 minutes at 150 volts. 
iv. The gel was photographed under UV light. 
 
 
Figure 2.2. Chick sexing using allele-specific PCR and gel electrophoresis. 
Female DNA samples yield 2 bands, male samples 1 band. The samples shown were 
classified as (left to right): F, M, F, F, F, M, F, M. The bright bands at the bottom of 
the gel are primer-dimer artefacts. 
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Table 2.1 Allele-specific PCR primer information. 
 
 
Chromosome 
CHD(Z) CHD(W) 
Forward primer CCCAGAGRTACCTGTTTTGCACAGT CCCAGAGRTACCTGTTTTGCACAGT 
Reverse primer CTGGTTAAAATTATTACAGTGTGGGTACAGTTT GAGCCCCCTCTTTATATTCAGCTATCTT 
PCR product size (bp) 322bp 418bp 
 
 
 
 
 
 
Detailed information 
Galgal4:Z:51129165:51130709 
TTACTAAAATAAGAAATATTTATGAATGTGTTAATGACTGCAATTCTG
GGTTGTGTTGTCTTCATGCCTTTGATTAAGCATCTGTGGTGTTTTT
AAACACAATAATTGATGACTTTTAGAAAGTACTTTCAGCCCTGAAGT
ATACCTGAGTGCCGTATATTTTGTGTTACTGGTTAAAATTATTACAGT
GTGGGTACAGTTTATAGATGCATAAAATACAGAACTTAGTTTCCCTA
AAATACTAGCTGCTAAGCCATATTTAAATAAAGCCATGTATTTACTACA
TATGTTCTGATGCATAAGGTGGCGAACTTTTCCAATATGGATGAAGA
TGATATTGAGTTGGAACCAGAAAGAAATTCAAGAAATTGGGAAGAA
ATCATCCCAGAATCCCAACGGAGAAGGATAGAGGAGGAGGAAAGA
CAAAAAGAACTTGAAGAAATATACATGCTCCCGAGGATGAGAAACT
GTGCAAAACAGGTACCTCTGGGTTTTGACTGTCTTGCGTCTTTATG
TTGATATTTTCATTTGAGTTTTTGCCTTTTTTCCCCCTTCTCTGAAT
TCATATTTTTGTCAGGCTAGATAAGACTTTACTATGTTTGAGATAATC
ATGTGGTTTTGAATTCTCATGCTGAAATTCCA 
CHD-W chrW_JH375235_random:22838-23562 
TACATTAACTTGAATGTTCAAATGCTGTTAGCCCTGCTTTGAAGGAAA
TTAAACAACAGTTGCACAGCTATTGAGAAGGTATTTCATAGTGTTTCT
ATATTAATTAACTTTTAAAATTAAAAAGAGCCCCCTCTTTATATTCAGCT
ATCTTGAATGGAACGTATGTATTTCATATATGAAAAATACTTTCATTAGA
GATGTTGCTTCATGAAGTATTTTATATGCATACGTTACTTTTATATAAAT
AAAATATGCCATTCCAAACTATTTTCCTAAAATGATATTTACTGAGTCCT
TGTTTAAATAAAATCATGTATCTATTTGGTGAAAATACTTATGTTCCAAA
ACATAAGGTAGCTAACTTTTCCAATATGGATGAAGATGACATTGAATTG
GAACCAGAACAAAATCTAAGAAACTGGGAAGAAATCATTCCAGAAGT
TCAGTGGCGACGAATAGAAGAGGAGGAAAGACAAAAAGAACTTGAA
GAAATATATATGCTTCCAAGAATGAGAAACTGTGCAAAACAGGTATCTC
TGGGTTCTGACTGATTTTTTTCTTTGATACTTCTATTGCTGATGTTTT
GACTTGTACTTTTGTGTTGTGTGGTTTTCGTGTGTTTTTCCCCCAAA
ATATTTTTATGGACTAGGTAACACATAAATAAAATGTTTTAGT 
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2.3 Statistics 
All the statistical analysis were performed using R version 3.4.2. The statistical 
methods and packages are described in each chapter. 
 
2.4 Ethical statement 
This work was approved by the Animal Subjects Ethics Sub-committee of The Hong 
Kong Polytechnic University. The care and use of the animals in this experiments 
were in compliance with the ARVO Statement for the Use of Animals in Ophthalmic 
and Vision Research.  
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2.6 Flowchart of the experiment design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transcriptomic 
pathway analysis 
Chicks 7 days old: 
(1044  chicks; approximately 20 per batch) 
A Scan ultrasonography. Monocular FD for 4 days.  
Treated eye alternated between right and left. 
Chicks 11 days old: 
(987 chicks) 
Retinoscopy. A-Scan ultrasonography. 
Continue monocular FD for 1 further day 
  
Take blood sample Take retina samples 
DNA extraction RNA extraction 
Sexing by PCR 
(959 chicks) 
Selective genotyping: 
in each batch, chicks were ranked 
according to ∆AXL, the top 20% and 
the bottom 20% were selected for 
genotyping. (n=190 ‘high-
susceptibility’ and n=190 ‘low-
susceptibility’ chicks) 
RNA sequencing: 
4 chicks with the greatest ∆AXL 
and 4 chicks with minimum 
∆AXL were selected, matching 
by sex. 
(n=16 retina samples from 8 
chicks) 
 
GWAS 
Transcriptome 
analysis 
Genomic 
pathway analysis 
57 chicks excluded 
due to death, loss of 
occluder or  
peri-orbital 
infection. 
28 chicks excluded 
due to DNA quality 
Quality control by 
matching the sex 
Chicks 12 days old: 
(987 chicks) 
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Chapter 3  Characteristics of 
myopia in form deprived chicks
50 
 
3.1 Introduction 
Epidemiology studies have identified a series of risk factors for myopia such as 
education level (94, 215), socioeconomic status (215) and time spent outdoors (101). 
Apart from these modifiable environmental risk factors, other biological traits such 
as height and sex have also been found to be related to ocular traits. This chapter 
focuses on the identification of potentially confounding factors associated with 
myopia in the chick form deprivation (FD) model, in order to control for their effects 
and thus increase statistical power in the subsequent chick myopia susceptibility 
GWAS (Chapter 4).  
  
3.1.1 Height  
Height, as a quantitative trait, has been found to be associated with eye size: many 
studies have reported that taller people have larger eyes (216-219). In a population-
based cross-sectional survey of Singapore Chinese adults, after controlling for 
confounding factors (age, sex, education, occupation, housing type, income, and 
weight), it was found that taller persons tended to have longer axial lengths, deeper 
anterior chambers, thinner lenses, longer vitreous chambers, and flatter corneas, 
although refractive status was independent of stature (217). Another cross-sectional 
study focussing on the relationship between anthropometric determinants and ocular 
biometry among Singapore Chinese students revealed that 7-9 year-old children of 
taller stature had eyes with longer axial lengths, along with deeper vitreous 
chambers, thinner lenses, deeper anterior chambers, flatter corneas and more 
negative refractive errors (218). Similar results were found in a study of Chinese 
twins (219) and in the Singapore Malay Eye Study (220). Studies in European cohorts 
have reached similar conclusions. A survey of 790 Finnish twins revealed that the 
myopic subjects were taller compared to the non-myopic subjects, among males 
(221). However, an association between height and refractive error has not been 
observed in all studies. Rosner et al. (222) conducted an investigation among 106,926 
male military recruits aged 17 to 19 years, and found that those who were highly 
myopic were slightly shorter compared to those with mild myopia and non-myopes. 
Another study of 3,294 Danish conscripts found no relationship between height and 
myopia (18). Sharma’s (223) study of 14 year-old students and Jung’s (224) study of 
19 year-old Korean males also found no association between height and refractive 
error (Table 3.1).   
 
 
 
51 
 
3.1.2 Body weight and body mass index (BMI) 
Body weight is another important biological characteristic that reflects body size. In 
many studies that investigated the relationship between stature and myopia, body 
weight and BMI were also considered along with height. Studies conducted in the UK 
(225), USA (226) and Finland (227) in the 1950-1980’s all reported that heavier body 
weight was associated with a more myopic refractive error. In recent years, studies 
that addressed this question were performed in Israel (222), Croatia (228), Myanmar 
(229), Taiwan (230), Japan (231), Singapore (217, 218, 220), Korea (224) and India 
(232). Nonetheless, evidence for an association between body weight and myopia was 
conflicting. Studies in Croatia (228), Singapore (217) and Japan (231) suggested body 
weight was positively related to axial length; in the Myanmar study (229), heavier 
persons had longer axial lengths but tended to be less myopic; the study of 106,926 
Israeli males (222) found non-myopes were heavier than severe myopes; the studies 
conducted in Taiwan (230) and Korea (224) found no correlation between body weight 
and myopia (Table 3.1). 
 
3.1.3 Sex  
Sex has been found to be associated with myopia. An early survey of myopia 
prevalence in the USA revealed that, across all age groups, the prevalence of myopia 
in females was higher than in males (12). This result was replicated in several other 
studies (227, 233-235). A recent multi-centre study conducted on 469 children who 
were 6-11 years old revealed that female sex was an independent risk factor for 
myopia after adjusting for age, ethnicity and other confounding factors; girls 
developed -0.16 D (P < 0.01) more myopia than boys after three years of observation 
(236). However, in the same study, there was no association between sex and axial 
length elongation, indicating a complex relationship. Lu et al. (103) performed a 
study of 1,892 adolescent students (average age 14.6 years) in rural China. They 
found that girls had worse uncorrected vision than boys and that girls spent more 
time on homework and reading and less time on outdoor activities and playing video 
games. After accounting for age, parental education, near work and outdoor activity, 
there was no difference in refractive error between the sexes.  
Many other studies did not find an association between myopia and gender. A study of 
307 Danish children found no difference between the sexes in myopia rate, refractive 
error, or best-corrected visual acuity (237). However, the boys had longer axial 
lengths, deeper anterior chamber depths and flatter corneas (237). Richter’s (238) 
study of 4,071 Chinese American participants also confirmed these findings: 
refractive status was similar between the two sexes, but males had longer axial 
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lengths. Similar results were reported in the Tanjong Pagar Survey (239) and the 
Liwan Eye Study (240).  
In some studies, female sex was found to be related to a lower prevalence of myopia. 
In the Singapore Longitudinal Aging Study (241), male gender was associated with a 
higher rate of myopia after adjusting for race, age, height, education, diabetes and 
hypertension. The Blue Mountains Eye Study, which examined individuals aged 49-97 
year-old, identified that women were slightly more hyperopic than men, after 
adjusting for age (15). Shimizu et al.’s (242) study of a Japanese cohort suggested 
that women were more hyperopic than men (Table 3.2).
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Table 3.1. Prior studies investigating the association between height, weight, BMI and ocular biometry/myopia in human subjects 
Study 
 
Date 
Population 
(Sample size) 
Age  Height  Weight BMI Covariates 
Gardiner 
(225) 
1954 
 
England 
(463) 
3 ~ 16 
Taller in myopes 
Heavier in myopes NA NA Rapid growth rate with 
fast myopia development 
Krause 
(227) 
1982 
 
Finland 
(1939) 
up to 15 
Taller in those wearing 
spectacles (Girls) 
Heavier in those 
wearing spectacles 
(Girls) 
NA Social status 
Teikari 
(221) 
1987 
Finland 
(790) 
30 ~ 31 
Taller in myopes  
(male only) 
N.S. 
Smaller in 
myopes  
height, weight, BMI 
Rosner 
(222) 
1995 
Israeli 
(106926 male) 
17 ~ 19 Shorter in severe myopes 
Lighter in severe 
myopes 
Smaller in 
myopes 
Sex, education, intelligence 
Wong (a) 
(217) 
2001 
Singapore 
(951) 
40 ~ 79  N.S. with RE + RE + RE 
Age, sex, education, SES and weight or 
height 
Saw 
(218) 
2002 
Singapore 
Chinese 
(1449) 
7 ~ 9 
- RE  + RE 
N.S. 
Age, gender, parental myopia, 
books read per week, school, Height, 
weight, BMI + AXL, VCD, CC, AL-CR -VCD 
Shimizu 
(242) 
2003 
Japan 
(2168) 
40 ~ 79 N.S. + RE (males only) NA 
For body stature: age, education,  
smoking, social status, diabetics, 
hypertension 
Selović 
(228) 
2005 
Croatia 
(1600) 
6 ~ 16 + AXL + AXL NA NA 
Wu 
(229) 
2007 
Myanmar 
(2418) 
≥ 40 
 
–N.S. with RE + RE 
+ RE Age and sex + AXL,ACD,VCD, CC and 
CT 
+ AXL, ACD, VCD , 
CC and CT 
Jacobsen 
(18) 
 
2007 
Danish 
(4681 male) 
19.3 –N.S. –N.S. –N.S. NA 
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Lee 
(243) 
2009 
USA 
(1968) 
50 ~ 100 + AXL NA NA 
For height, adjusted for age, gender, 
education; For Sex, adjusted for age 
Lim 
(220) 
2010 
Singapore and 
Malay 
(2788) 
40 ~ 80 + AXL,CC + AXL,CC NA 
Age, sex, education, height, weight, 
number of reading hours, diabetes,  
and current smoking 
Sharma 
(223) 
2010 
Chinese 
(1371) 
14.5  N.S. N.S. NA Age, height, and parental education 
Zhang 
(219) 
2011 
China 
(565) 
7 ~15 + AXL NA NA Sex, age and sex age interaction 
Jung 
(224) 
2012 
South Korea 
(23616 male) 
19 N.S. with RE N.S. with RE 
N.S. with 
RE 
Multivariate model include  
education, height, weight and BMI 
Huang 
(230) 
2014 
Taiwan 
(88) 
7 ~ 9 
N.S. with RE  
N.S. NA Sex and age 
+ AXL 
Roy 
(232) 
2015 
India 
(152) 
7 ~ 15 + AXL, ACD, VCD –N.S. + RE NA 
Terasaki 
(231) 
2017 
Japan 
(122) 
8 ~ 9 N.S. + AXL + AXL Sex and parental myopia 
Note: ‘+’ indicates a positive correlation, ‘-’ indicates a negative correlation, for example, ‘+ RE’ means positively associated with the trait-of-interest; AXL, VCD, 
CC, CT, AL-CR, RE are abbreviations for axial length, vitreous chamber depth, corneal curvature, corneal thickness, axial length - corneal radius ratio, refractive 
error, respectively. N.S. – none significant.  
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Table 3.2.Prior studies investigating the association between sex and ocular biometry/myopia in human subjects. 
Study Date 
Population  
(sample size) 
Age Sex Covariates 
Angle (235) 1980 USA 12 ~ 17 Females more often myopic NA 
Krause (227) 1982 Finland (1939) up to 15 Females wore spectacles more often Social status 
Sperduto (12)  1983 USA (9882) 12 ~ 54 Females more often myopic NA 
Wang (233) 1994 USA (4533) 43 ~ 84 Females more often myopic Age 
Attebo (15) 1999 Australia (3654) 49 ~ 79 Males were more myopic Age 
Wong (b) 
(239) 
2001 Singapore (1717) 40 ~ 79 
Non – significant with RE 
Age 
Males had longer AXL 
Midelfart (234) 2002 Norway (3137) 20 ~ 45 Females more often myopic NA 
Shimizu (242) 2003 Japan (2168) 40 ~ 79 Males were more often myopic NA 
Hyman (236) 2005 
USA (469) 
(mixed ethnic) 
6 ~ 11 Males had slower myopia progression 
Age, ethnicity, BRS, treatment, interaction 
between BRS and treatment 
He (240) 2009 
Guangzhou China 
(1269) 
> 50 
Non – significant with RE 
Age 
Males had longer AXL 
Lu (103) 2009 
Xichang China 
(1829) 
14.6 
Girls had worse VA and a higher myopia rate Age, parental education, near work, 
outdoor activity Non – significant (after adjusted for covariates) 
Lee (243) 2009 USA (1968) 50 ~ 100 Men had longer AXL, flatter CR and deeper ACD Age 
Tan (241) 2011 Singapore (1835) 55 ~ 85 Male were more often myopic 
Race, age, height, education, diabetes, 
hypertension 
Huang (230) 2014 Taiwan (88) 7 ~ 9 Non – significant Age 
Roy (232) 2014 India (152) 7 ~ 15 Non - significant NA 
Lundberg (237) 2017 Danmark (307) 14 ~ 17 
Non – significant with RE 
NA 
Males had longer AXL 
Richter (238) 2017 
Chinese American 
(4071) 
60.5 
Non – significant with RE 
Age, height 
Males had longer AXL 
Terasaki (231) 2017 Japan (122) 8 ~ 9 Males had longer AXL Parental Myopia 
Abbreviations: AXL, RE, BRS represent axial length, refractive error and baseline refractive status, respectively. 
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3.1.4 The influence of body weight and sex on animal ocular biometry. 
Stature (height), body weight and sex have also been considered as potential 
confounders for variation of animal ocular component dimensions.  
The difference in eye size between animal species is related to differences in body 
size. Moreover, within the same animal species, body weight has also been found to 
be related to eye size in fish (157), mice (244) and birds (245). In herring, eye 
diameter increases allometrically with body length and the cubic root of body weight 
(246). To understand the relationship between body size and eye size, Zhou and 
William (247) did an experiment in mice. The eyes of approximately 700 mice from 
26 BXD strains (recombinant inbred mice strains derived from crossing C57BL/6 (B) 
and DBA/2 (D) mice) were examined, and it was found that eye weight was positively 
associated with brain weight and body weight, while sex had no independent effect if 
body weight was accounted for.  
It was reported that eye traits were related to sex. In mice, after adjusting for body 
weight, eyes of female mice were proportionally larger than male mice (247) ; 
according to Puk et al. (248), the sex-related differences of ocular parameters were 
not obvious in every strain of mice, but only significant in C57BL/6J and 
129S2/SvPasCrl strain mice; however, in many studies, sex had no effect on eye size 
or myopia development. In Murphy et al.’s study (249), the refractive error of 240 
dogs of various breeds was measured, and a tendency towards myopia was found in 
several breeds, but sex was not correlated with refractive error (249). Black et al.’s 
(189) study on canine inherited myopia also supported Murphy’s finding. In form 
deprived tree shrews, the level of induced myopia was not statistically different 
between the sexes (250). According to Valentini et al. (251), in neonatal foal, the 
ocular parameters were not influenced by sex.  
In many myopia experiments using chick models, body stature and sex have been 
considered. Zhu et al. (252) found that, during form deprivation, male chickens had 
deeper anterior chambers and were more susceptible to form deprivation. In 
Guggenheim et al.’s study (203), myopia was induced in 3 strains of chicks. Male 
chicks showed a 0.2mm increase in the vitreous chamber and axial length elongation 
as compared to female chicks, however, the level of induced myopia was similar 
between the sexes. A later study conducted by Chen et al. (253) reported that sex 
explained 6.4% of the variation in FD-induced VCD elongation, but that sex did not 
affect the degree of induced myopia. Body weight, as an indicator of eye size, 
showed no association with myopia development (253). In Schmid and Wildsoet’s (204) 
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study of White Leghorn chickens form deprived by lid suturing, susceptibility to 
myopia was not associated with sex.  
 
3.2 Methods 
3.2.1 Experiment models 
The procedures used to induce myopia in chicks and to determine the sex of chicks 
are described in Chapter 2, sections 2.1 and 2.2. 
 
3.2.2 Statistical Analysis 
The frequency distribution of the eye size parameters, initial body weight (IBW) and 
final body weight (FBW) were tested for normality by using the Kolmogorov-Smirnov 
test. Because the data for the level of induced myopia (ΔMSE) and for IBW were not 
normally distributed, the Spearman correlation coefficient was used to test the 
relationship between ΔMSE versus ΔAXL, and IBW versus FBW. Comparisons between 
treated versus control eye, or right versus left eye, ocular component dimensions 
were made using paired t-tests. Either the 2-sample t-test or the Mann–Whitney U 
test was used to test the difference between the sexes, according to the normality of 
the data.  
To examine potentially confounding factors that might influence myopia susceptibility, 
multivariate linear regression analyses were carried out, with myopia susceptibility 
(∆AXL or ∆MSE) as the dependent variable and the following phenotypic 
characteristics as independent variables: sex, hatch-to-hatch variability (‘batch 
effect’), initial body weight (IBW), final body weight after treatment (FBW), 
interaction between sex and IBW (sex × IBW) and interaction between sex and FBW 
(sex × FBW). There was a high correlation between IBW and FBW (R = 0.83, P < 2.2e-
16; Figure 3.1), IBW and FBW were tested in different models to avoid collinearity. 
Meanwhile, since a subsample of chicks was selected for genotyping, the above 
potential confounding factors were also tested in this subsample of selected chicks. 
The R packages ‘qqplot2’ and ‘coefplot’ were used to produce the figures in this 
chapter. The statistical models tested were as follows:  
Testing confounding factors for ∆AXL in all 959 chicks: 
Model 1: ∆AXL ~ sex + batch + IBW + (sex × IBW) 
Model 2: ∆AXL ~ sex + batch + FBW + (sex × FBW) 
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Testing confounding factors for ∆MSE in all 959 chicks: 
Model 1: ∆MSE ~ sex + batch + IBW + (sex × IBW) 
Model 2: ∆MSE ~ sex + batch + FBW + (sex × FBW) 
 
Testing confounding factors for ∆AXL in the 380 selected chicks: 
Model 1: ∆AXL ~ sex + batch + FBW + (sex × FBW) 
Model 2: ∆AXL ~ sex + FBW + (sex × FBW) 
Model 3: logit(case/control status) ~ e0 + (1 x Batch) + (2 x Sex) + (3 x FBW) +  
(4 x Sex x FBW) 
Model 4: logit(case/control status) ~ e0 + (1 x Sex) + (2 x FBW) + (3 x Sex x FBW) 
 
Testing confounding factors for ∆MSE in the 380 selected chicks: 
Model 1: ∆MSE ~ sex + batch+ FBW + (sex × FBW) 
Model 2: ∆MSE ~ sex + FBW + (sex × FBW) 
 
 
Figure 3.1.Relationship between IBW and FBW. (n=959) 
 
3.3 Results 
3.3.1 Characteristics of chick traits prior to form deprivation 
A total of 987 chicks from 48 batches were form deprived. Among all the chicks, 959 
of them had sex information while 38 chicks had poor quality DNA and could not be 
sexed. PCR sex-testing revealed that 501 (52%) were male and 458 (48%) female. On 
day 7, before the treatment, mean body weight of the chicks was 54.26 ± 6.36g 
(mean ± standard deviation), and the mean body weight of male and female chicks 
was 54.33 ± 6.18g and 54.19 ± 6.55g, respectively; there was no difference between 
male and female chick body weight (P=0.72; Table 3.3). However, when comparing 
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the eye parameters, male chicks had longer eyes compared to female chicks in both 
right and left eyes (Table 3.3). In the right eyes, for example, the mean axial length 
was 8.74 ± 0.16mm in males while it was 8.59 ± 0.16mm in females (P<0.01). Similar 
differences were also observed for ACD, LT and VCD for both eyes. When comparing 
the right eye with the left eye, irrespective of sex, the right eye was found to be 
slightly longer on average than the left eye for ACD, LT, VCD and AXL (all P<0.01; 
Table 3.3). In general, it was found that the initial body weight was positively 
associated with the initial AXL (e.g. r = 0.45, P < 0.01 in the right eye, Figure 3.2).  
Table 3.3. Chick parameters on day 7, before form deprivation 
  Male 
mean ± SD 
(n=501) 
Female 
mean ± SD 
(n=458) 
All 
mean ± SD 
(n =959 ) 
P-value 
(M vs. F) 
IBW(g)  54.33±6.18 54.19±6.55 54.26±6.36 0.72 
ACD 
(mm) 
Right eye 1.38±0.04 1.35±0.04 1.37±0.04 <0.001 
Left eye 1.38±0.04 1.35±0.04 1.36±0.04 <0.001 
P-value (R vs. L)  <0.001 <0.001 <0.001  
LT  
(mm) 
Right eye 2.00±0.05 1.97±0.05 1.98±0.05 <0.001 
Left eye 1.99±0.05 1.96±0.06 1.98±0.05 <0.001 
P-value (R vs. L)  <0.001 0.007 <0.001  
VCD 
(mm) 
Right eye 5.36±0.14 5.27±0.14 5.32±0.14 <0.001 
Left eye 5.32±0.14 5.24±0.14 5.28±0.14 <0.001 
P-value (R vs. L)  <0.001 <0.001 <0.001  
AXL 
(mm) 
Right eye 8.74±0.16 8.59±0.16 8.67±0.18 <0.001 
Left eye 8.69±0.16 8.55±0.16 8.62±0.18 <0.001 
P-value (R vs. L)  <0.001 <0.001 <0.001  
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Figure 3.2.Correlation between pre-treatment AXL in the right eye and initial 
body weight (IBW) in the full sample (n=959). 
 
3.3.2 Characteristics of chick traits after form deprivation  
After monocular form deprivation for 4 days, the average body weight was 77.72 ± 
10.54g, which again was not different between the sexes (P = 0.42). Average AXL in 
control eyes was 9.02 ± 0.21mm, and males had longer eyes compared to females 
(9.10 ± 0.19mm vs. 8.94 ± 0.20mm, P < 2.2e-16). In treated eyes, the average AXL 
elongated to 9.57±0.28mm; the difference in absolute AXL between male and female 
treated eyes was 0.16 mm (P < 2.2e-16). The average axial elongation (∆AXL) due to 
FD was 0.55 ± 0.17 mm, with male and female chicks showing similar responses (P= 
0.80; Table 3.4).  
For mean spherical equivalent (MSE; analysed without subtracting the retinoscopy 
working distance), the average MSE in control eyes was 6.50 ± 1.05 D and, on average, 
female chicks were more hyperopic than male chicks (6.62 ± 1.00 D vs. 6.42 ± 0.91 D, 
P < 0.001; Table 3.4). In treated eyes, male chicks were slightly more myopic than 
female chicks, but the difference was not statistically significant (-4.22 ± 3.08 D in 
male and -4.10 ± 2.95 D in females, P = 0.56). Treated eyes were more myopic than 
control eyes: (-4.16 ± 3.02 D vs. 6.52 ± 0.96 D, P < 2.2e 16). The level of induced 
myopia was similar in males and females (-10.64 ± 3.07 D in males and -10.73 ± 2.97 
D in females, P = 0.64; Table3.4). 
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Table 3.4. Chick parameters after FD for 4 days in the full sample (n=959). 
 
A further comparison between the right eye and the left eye was performed. After FD, 
in treated eyes, right eyes were slightly longer and more myopic than the left eyes (P 
< 0.01 and P = 7.0e-4 respectively); in control eyes, right eyes were longer than left 
eyes (P = 0.04), while the corresponding MSE levels were not asymmetric (P = 
0.6).Furthermore, right eyes were more susceptible to FD-induced myopia than the 
left eyes. (Table 3.5) 
Table 3.5. Comparison of ocular parameters in right versus left eyes after 5 
days of FD. Values are presented as mean ± SD 
 Chicks whose  
right eye is  
treated eye 
(n=485) 
Chicks whose 
left eye is 
treated eye 
(n=474) 
P 
AXL in treated eye 9.62 ± 0.28 9.52 ± 0.27 <0.001 
AXL in control eye 9.01 ± 0.21 9.04 ± 0.20 0.04 
MSE in treated eye -4.49 ± 2.87 -3.81 ± 3.13 <0.001 
MSE in control eye 6.54 ± 1.02 6.50 ± 0.89 0.6 
∆AXL 0.56 ± 0.17 0.53 ± 0.17 0.004 
∆MSE -11.03 ± 2.9 -10.31 ± 3.1 <0.001 
  Male 
mean ± SD 
(n=501) 
Female 
mean ± SD 
(n=458) 
All 
Mean ± SD 
P-
value 
(M vs. 
F) 
FBW 
(g) 
 77.98±10.6 77.43±10.48 77.72±10.54 0.42 
ACD 
(mm) 
control eye 1.46±0.04 1.43±0.04 1.45±0.04 <0.001 
treated eye 1.57±0.08 1.53±0.08 1.55±0.08 <0.001 
P-value (T vs C) <0.001 <0.001 <0.001  
ΔACD  0.11±0.07 0.10±0.06 0.10±0.06 0.08 
LT 
(mm) 
control eye 2.15±0.05 2.11±0.04 2.13±0.05 <0.001 
treated eye 2.15±0.05 2.12±0.05 2.14±0.05 <0.001 
P-value (T vs C) <0.001 <0.001 <0.001  
ΔLT  0.004±0.04 0.01±0.04 0.01±0.04 0.34 
VCD 
(mm) 
control eye 5.49±0.17 5.40±0.17 5.45±0.17 <0.001 
treated eye 5.93±0.22 5.84±0.22 5.88±0.22 <0.001 
P-value (T vs C) <0.001 <0.001 <0.001  
ΔVCD  0.43±0.14 0.44±0.14 0.44±0.14 0.17 
AXL 
(mm) 
control eye 9.10±0.19 8.94±0.2 9.02±0.21 <0.001 
treated eye 9.65±0.27 9.49±0.27 9.57±0.28 <0.001 
P-value (T vs C) <0.001 <0.001 <0.001  
ΔAXL  0.54±0.17 0.55±0.17 0.55±0.17 0.80 
MSE 
(D) 
control eye 6.42±0.91 6.62±1.00 6.52±0.96 <0.001 
treated eye -4.22±3.08 -4.10±2.95 -4.16±3.02 0.56 
P-value (T vs C) <0.001 <0.001 <0.001  
ΔMSE  -10.64±3.07 -10.73±2.97 -10.68±3.02 0.64 
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The relationship between body weight and eye parameters after FD was also 
investigated. Among all of the 959 chicks, final body weight was found to be 
correlated with change in AXL and MSE (r=0.22, P < 0.001 and r=-0.09, p = 0.004 
respectively). A similar correlation was also identified between the change in body 
weight and myopia susceptibility, whereas the correlation coefficients were slightly 
smaller (r=0.21, P < 0.001 and r=-0.08, p = 0.01, respectively) (Figure 3.3). 
 
Figure 3.3.Correlation between body weight and myopia susceptibility after FD 
(n=959). 
The body weight correlation coefficients shown are sex-averaged values. Correlation 
between (a) final body weight and ∆AXL; (b) final body weight and ∆MSE; (c) change 
in body weight and ∆AXL. (d) change in body weight and ∆MSE. 
 
3.3.3 Myopia susceptibility in response to form deprivation (full study 
sample) 
The parameters ∆AXL and ∆MSE were analysed separately as indicators of myopia 
progression among the 959 chicks. ∆AXL was selected as the main outcome measure 
(Chapter 1, section 1.8.3), with ∆MSE analysed additionally to guard against 
important findings being missed. 
3.3.3.1 Chick characteristics associated with treatment-induced axial 
elongation (full study sample) 
Two multivariate linear regression models were used to test for the confounding 
factors for ∆AXL (Chapter 3, section 3.2.2; n=959 chicks).  
(a) (b) 
(c) (d) 
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In the first model, sex, batch, IBW and sex × IBW were tested. In this model, sex, 
batch, and the interaction between sex and IBW were associated with ∆AXL (Figure 
3.4, Table 3.6). In the multivariate model, male chicks had a ΔAXL that was 
approximately 0.2mm shorter than female chicks, however, this was countered by a 
sex × IBW interaction. Certain batches (specifically, batches 1, 30, 31, and 43) 
developed less AXL elongation (by approximately -0.1mm). In totality, the covariates 
explained 3.2% of the variation in ∆AXL. 
In the second model, sex, batch, FBW and sex × FBW were tested. In this model, sex, 
batch, FBW and sex × FBW were associated with ∆AXL, with similar effect sizes to 
those observed in the first model (Figure 3.4, Table 3.6). The second model explained 
5.8% of the variance in ∆AXL.  
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Figure 3.4.Coefficient plot showing the relationship between ∆AXL and 
confounding factors (full study sample). 
 
 
 
 
65 
 
Table 3.6.Relationship between ∆AXL and confounding factors (full study 
sample).  
 Dependent Variable: 
 ∆AXL 
Independent variable Model 1 Model 2 
Β (95% confidence interval ) Β (95% confidence interval ) 
Sex (female as reference) 
Male -0.220** (-0.407, -0.034) -0.211** (-0.371, -0.051) 
Batch (Batch 1 as reference category) 
Batch2 0.004 (-0.123, 0.131) -0.007 (-0.132, 0.119) 
Batch3 -0.055 (-0.173, 0.064) -0.051 (-0.168, 0.066) 
Batch4 -0.032 (-0.159, 0.095) -0.021 (-0.146, 0.104) 
Batch5 -0.04 (-0.154, 0.074) -0.046 (-0.158, 0.066) 
Batch6 -0.051 (-0.168, 0.066) -0.059 (-0.174, 0.055) 
Batch7 0.037 (-0.117, 0.192) 0.017 (-0.135, 0.170) 
Batch8 -0.044 (-0.192, 0.104) -0.047 (-0.193, 0.099) 
Batch9 -0.058 (-0.179, 0.062) -0.041 (-0.160, 0.078) 
Batch10 -0.052 (-0.182, 0.077) -0.05 (-0.178, 0.077) 
Batch11 -0.033 (-0.164, 0.097) -0.002 (-0.132, 0.127) 
Batch12 -0.077 (-0.193, 0.040) -0.075 (-0.190, 0.039) 
Batch13 -0.052 (-0.167, 0.064) -0.061 (-0.175, 0.053) 
Batch14 -0.023 (-0.155, 0.109) -0.017 (-0.146, 0.113) 
Batch15 -0.087 (-0.211, 0.037) -0.081 (-0.203, 0.040) 
Batch16 -0.008 (-0.122, 0.107) 0.007 (-0.106, 0.119) 
Batch17 -0.016 (-0.129, 0.096) -0.025 (-0.136, 0.086) 
Batch18 -0.032 (-0.150, 0.085) -0.026 (-0.141, 0.088) 
Batch19 0.004 (-0.123, 0.131) -0.003 (-0.128, 0.122) 
Batch20 0.001 (-0.112, 0.114) -0.001 (-0.113, 0.111) 
Batch21 -0.048 (-0.161, 0.066) -0.068 (-0.180, 0.044) 
Batch22 0.005 (-0.108, 0.117) -0.011 (-0.122, 0.100) 
Batch23 0.027 (-0.094, 0.149) 0.012 (-0.108, 0.131) 
Batch24 -0.041 (-0.153, 0.070) -0.039 (-0.149, 0.072) 
Batch25 -0.084 (-0.195, 0.026) -0.106* (-0.215, 0.004) 
Batch26 -0.022 (-0.135, 0.091) -0.04 (-0.151, 0.071) 
Batch27 -0.011 (-0.141, 0.119) -0.024 (-0.152, 0.103) 
Batch28 -0.071 (-0.186, 0.043) -0.076 (-0.189, 0.037) 
Batch29 -0.083 (-0.197, 0.032) -0.097* (-0.209, 0.016) 
Batch30 -0.112** (-0.223, -0.001) -0.127** (-0.236, -0.017) 
Batch31 -0.115** (-0.229, -0.001) -0.131** (-0.244, -0.018) 
Batch32 -0.057 (-0.170, 0.057) -0.084 (-0.196, 0.028) 
Batch33 -0.114* (-0.234, 0.006) -0.135** (-0.254, -0.017) 
Batch34 -0.042 (-0.154, 0.070) -0.063 (-0.174, 0.047) 
Batch35 -0.121 (-0.284, 0.042) -0.135* (-0.296, 0.025) 
Batch36 -0.072 (-0.184, 0.041) -0.084 (-0.195, 0.027) 
Batch37 -0.042 (-0.167, 0.083) -0.051 (-0.174, 0.072) 
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Batch38 -0.061 (-0.180, 0.059) -0.064 (-0.181, 0.054) 
Batch39 0.016 (-0.102, 0.133) -0.009 (-0.125, 0.106) 
Batch40 -0.104* (-0.222, 0.014) -0.104* (-0.220, 0.012) 
Batch41 -0.055 (-0.167, 0.057) -0.062 (-0.172, 0.048) 
Batch42 -0.011 (-0.122, 0.100) -0.03 (-0.139, 0.078) 
Batch43 -0.119** (-0.232, -0.006) -0.113** (-0.223, -0.002) 
Batch44 -0.049 (-0.162, 0.065) -0.056 (-0.167, 0.056) 
Batch45 -0.066 (-0.180, 0.048) -0.081 (-0.194, 0.031) 
Batch46 -0.021 (-0.137, 0.095) -0.031 (-0.145, 0.082) 
Batch47 0.002 (-0.127, 0.131) -0.009 (-0.136, 0.119) 
Batch48 -0.078 (-0.192, 0.037) -0.083 (-0.196, 0.029) 
IBW 0.003* (-0.0001, 0.005)    
Interaction (Female × IBW as reference)  
Male × IBW 0.004** (0.001, 0.007)   
FBW   0.003***  (0.001, 0.004) 
Interaction (Female × FBW as reference)  
Male × FBW   0.003** (0.001, 0.005) 
Constant 0.456*** (0.280, 0.632)      0.397*** (0.240, 0.555) 
Observations 958 958 
R2 0.083 0.107 
Adjusted R2 0.032 0.058 
Residual Std. Error (df 
= 907) 
0.168 0.165 
F Statistic (df = 50; 
907)   
1.637*** 2.180*** 
Note:*p<0.1; **p<0.05; ***p<0.01 
 
3.3.3.2. Chick characteristics associated with the treatment-induced 
degree of myopia (full study sample).  
In the full study sample (n=959 chicks), there was a high correlation between change 
in MSE and change in AXL (r = 0.74, P < 0.001; Figure3.5). 
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Figure 3.5.Relationship between change in MSE and change in AXL in 959 chicks.  
Two multivariate linear regression models were used to test for confounding factors 
for ∆MSE. In the first model, only the batch effect term was associated with ∆MSE 
(Figure 3.6, Table 3.7); more than half of the batches showed evidence of less 
myopia susceptibility than in the reference batch (batch 1). In model 2, both batch 
and FBW were associated with ∆MSE, while sex and the interaction between sex and 
FBW were not. Models 1 and 2 explained similar proportions of the variance in ∆MSE 
(model 1: adjusted R2 = 7.2%, model 2: adjusted R2 = 8.8%; Figure 3.6, Table 3.7)  
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Figure 3.6.Coefficient plot showing the relationship between ∆MSE and 
confounding factors (n=959). 
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Table 3.7. Relationship between ∆MSE and confounding factors (n=959). 
 Dependent Variable: 
 ∆MSE 
Independent variable Model 1 Model 2 
Β (95% confidence interval ) Β (95% confidence interval ) 
Sex (female as reference) 
Male 2.347 (-0.899, 5.594) 2.047 (-0.860, 4.954) 
Batch (Batch 1 as reference category) 
Batch2 0.398 (-1.803, 2.600) 0.594 (-1.592, 2.780) 
Batch3 2.333** (0.252, 4.414) 2.266** (0.205, 4.326) 
Batch4 1.153 (-1.046, 3.352) 0.984 (-1.198, 3.165) 
Batch5 2.733*** (0.763, 4.703) 2.854*** (0.901, 4.807) 
Batch6 2.493** (0.466, 4.519) 2.556** (0.557, 4.556) 
Batch7 0.368 (-2.314, 3.049) 0.584 (-2.067, 3.235) 
Batch8 4.263*** (1.699, 6.826) 4.314*** (1.773, 6.855) 
Batch9 2.275** (0.185, 4.365) 1.981* (-0.094, 4.057) 
Batch10 1.807 (-0.436, 4.051) 1.741 (-0.483, 3.965) 
Batch11 0.954 (-1.307, 3.214) 0.463 (-1.790, 2.717) 
Batch12 2.760*** (0.742, 4.778) 2.719*** (0.722, 4.717) 
Batch13 2.367** (0.363, 4.370) 2.452** (0.472, 4.431) 
Batch14 3.497*** (1.207, 5.786) 3.425*** (1.159, 5.690) 
Batch15 2.729** (0.583, 4.875) 2.608** (0.487, 4.730) 
Batch16 1.925* (-0.056, 3.906) 1.642 (-0.324, 3.608) 
Batch17 2.468** (0.516, 4.420) 2.570*** (0.636, 4.503) 
Batch18 3.275*** (1.240, 5.311) 3.106*** (1.103, 5.110) 
Batch19 1.424 (-0.779, 3.626) 1.487 (-0.692, 3.667) 
Batch20 2.028** (0.063, 3.993) 2.050** (0.102, 3.998) 
Batch21 4.100*** (2.138, 6.062) 4.430*** (2.476, 6.385) 
Batch22 2.116** (0.165, 4.067) 2.323** (0.390, 4.257) 
Batch23 2.539** (0.436, 4.642) 2.750*** (0.663, 4.836) 
Batch24 2.385** (0.433, 4.338) 2.357** (0.422, 4.293) 
Batch25 3.724*** (1.807, 5.640) 4.037*** (2.128, 5.945) 
Batch26 1.869* (-0.088, 3.826) 2.071** (0.138, 4.004) 
Batch27 0.464 (-1.750, 2.678) 0.502 (-1.681, 2.685) 
Batch28 2.447** (0.452, 4.443) 2.651*** (0.670, 4.631) 
Batch29 3.289*** (1.309, 5.270) 3.452*** (1.489, 5.415) 
Batch30 3.594*** (1.667, 5.521) 3.770*** (1.861, 5.678) 
Batch31 3.091*** (1.112, 5.069) 3.314*** (1.350, 5.278) 
Batch32 3.657*** (1.693, 5.620) 4.022*** (2.069, 5.975) 
Batch33 4.390*** (2.309, 6.470) 4.694*** (2.630, 6.757) 
Batch34 2.441** (0.504, 4.378) 2.724*** (0.800, 4.648) 
Batch35 4.207*** (1.381, 7.034) 4.463*** (1.659, 7.267) 
Batch36 3.129*** (1.177, 5.080) 3.297*** (1.361, 5.233) 
Batch37 3.316*** (1.149, 5.483) 3.416*** (1.273, 5.560) 
Batch38 4.937*** (2.844, 7.029) 4.911*** (2.845, 6.977) 
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Batch39 4.394*** (2.361, 6.427) 4.711*** (2.695, 6.726) 
Batch40 2.754*** (0.705, 4.803) 2.709*** (0.687, 4.731) 
Batch41 2.844*** (0.906, 4.782) 2.915*** (0.995, 4.835) 
Batch42 2.677*** (0.759, 4.594) 2.916*** (1.018, 4.814) 
Batch43 4.263*** (2.309, 6.216) 4.133*** (2.202, 6.063) 
Batch44 1.482 (-0.484, 3.448) 1.567 (-0.381, 3.514) 
Batch45 2.209** (0.227, 4.191) 2.397** (0.435, 4.359) 
Batch46 2.068** (0.063, 4.073) 2.161** (0.181, 4.141) 
Batch47 1.704 (-0.538, 3.945) 1.827 (-0.393, 4.047) 
Batch48 2.250** (0.265, 4.234) 2.283** (0.317, 4.248) 
IBW -0.034 (-0.080, 0.013)    
Interaction (Female × IBW as reference)  
Male × IBW -0.042 (-0.101, 0.018)   
FBW   -0.042*** (-0.074, -0.011) 
Interaction (Female × FBW as reference)  
Male × FBW   -0.025 (-0.062, 0.012) 
Constant -11.56*** (-14.614, -8.505) -10.20*** (-13.125, -7.275) 
Observations 955 955 
R2 0.121 0.136 
Adjusted R2 0.072 0.088 
Residual Std. Error  
(df = 904) 
2.909 2.884 
F Statistic 
(df = 50; 904)            
2.481*** 2.837*** 
Note: *p<0.1; **p<0.05; ***p<0.01 
 
3.3.4 Phenotypic characteristics of chicks selected for genotyping 
To reduce costs, not all of the chicks were genotyped; instead, only chicks in the 
myopia susceptibility phenotype extremes were genotyped (see Chapter 4, section 
4.4.8). Chick selection was based on the phenotype ∆AXL, rather than ∆MSE (see 
Chapter 1, section 1.8.3). Thus, it was planned that the chicks would be ranked 
according to ∆AXL, and the top 20% and the bottom 20% of the full sample selected 
for genotyping. However, according to the results above (section 3.3.3.1), there was 
a batch effect. Therefore, in order to avoid bias from the batch effect, instead of 
selecting chicks from the whole population at once, chicks were selected within each 
batch separately. Thus, from within each batch, the 20% of the chicks with largest 
treatment-induced AXL change and the 20% with the smallest change were selected. 
A total number of 380 chicks, comprising 190 chicks with a relatively low ∆AXL and 
190 with a relatively high ∆AXL, were selected for genotyping (Figure 3.7). For the 
low ∆AXL chicks, the average ∆AXL was 0.31 ± 0.08 mm while for high ∆AXL chicks, 
the average ∆AXL was 0.78 ± 0.08 mm (Figure 3.8a). The difference in ∆AXL between 
high and low chicks was 0.47 mm (P < 2.2e-16). The average ∆MSE was -13.55 ± 2.29D 
71 
 
in the high ∆AXL subsample and -7.14 ± 2.29D in the low ∆AXL subsample. The 
difference of ∆MSE between the selected chicks was 6.41D (P < 2.2e-16). (Figure 3.8b)  
 
Figure 3.7. Number of chicks selected from each batch. 
A total of 48 batches of chicks were examined. Each bar represents the number of 
chicks in the batch, with the red section and the black section representing the 
number of high ∆AXL and low ∆AXL chicks selected, respectively. The total sample 
size=959. 
 
 
Figure 3.8. Phenotype distribution in selected chicks. 
Red bars represent chicks in the high ∆AXL subsample, black bars represent chicks in 
the low ∆AXL subsample, and grey bars represent all chicks. Panel (a) shows the 
distribution of ∆AXL and panel (b) the distribution of ∆MSE. The total sample 
size=959. 
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3.3.5 Myopia susceptibility in response to form deprivation in selected 
chicks 
According to the analyses described above (section 3.3.3), the FBW of chicks 
explained more of the variance in ∆AXL than did IBW, hence FBW and sex would be 
considered in the following analysis. The main difference between selected chicks 
and the full sample was the adjustment for batch effect. To explore if these were 
also true in the chicks after selection by batch, the relationship of potential 
confounders was re-evaluated in the 380 selected chicks. 
 
3.3.5.1 Chick characteristics associated with treatment-induced axial 
elongation (selected sample, n=380) 
As before, two multivariate linear regression and two logistic regression models were 
fitted (see section 3.2.2), with ∆AXL as the dependent variable (n=380). The results 
are shown in Table 3.7.  
In model 1, sex, FBW, and the interaction between sex and FBW were associated with 
∆AXL. There was no evidence for a batch effect, consistent with chicks being 
selected within each batch separately. In model 2, which was similar to model 1 
except that a term for batch effects was not included, sex and the interaction 
between sex and FBW were associated with ∆AXL. Model 2 explained more of the 
variance in ∆AXL than model 1 (model 1, adjusted R2 = 3.2%; model 2, adjusted R2 = 
9.8%; Figure 3.9, Table 3.8).  
In model 3, case/control status (i.e. high ∆AXL versus low ∆AXL) was associated with 
sex and the interaction between sex and FBW. Again, no batch effect was observed. 
In model 4 which did not contain a term for batch effects,) the model fit was better 
than model 3: model 3, Akaike information criterion –-AIC = 565.6; model 4, AIC = 
494.3, Figure 3.9, Table 3.8. 
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Figure 3.9.Coefficient plot showing the relationship between ∆AXL and 
confounding factors (selected chicks, n = 380). 
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Table 3.8.Relationship between ∆AXL and confounding factors (selected chicks, n = 380). 
 Dependent Variable 
Independent variable ∆AXL   
Linear regression 
 Case-control status  
Logistic regression 
Model 1 Model 2 Model 3  Model 4  
Β (95% confidence interval) Β (95% confidence interval) Β (95% confidence interval) Β (95% confidence interval) 
Sex (Female as reference) 
Male -0.503** (-0.905, -0.101) -0.543*** (-0.903, -0.184) -5.421*** (-9.399, -1.442) -5.497*** (-9.100, -1.893) 
Batch (Batch 1 as reference category) 
Batch2 0.045 (-0.245, 0.334)   -0.253 (-2.754, 2.248)   
Batch3 -0.007 (-0.272, 0.258)   0.036 (-2.272, 2.345)   
Batch4 0.048 (-0.243, 0.339)   0.581 (-1.911, 3.073)   
Batch5 -0.017 (-0.268, 0.234)   -0.476 (-2.666, 1.714)   
Batch6 0.004 (-0.242, 0.250)   0.395 (-1.718, 2.509)   
Batch7 0.052 (-0.255, 0.359)   0.008 (-2.715, 2.731)   
Batch8 -0.009 (-0.315, 0.298)   -0.248 (-2.858, 2.361)   
Batch9 0.05 (-0.209, 0.309)   1.121 (-1.156, 3.399)   
Batch10 -0.028 (-0.294, 0.237)   0.126 (-2.164, 2.417)   
Batch11 0.154 (-0.124, 0.431)   1.495 (-0.938, 3.929)   
Batch12 -0.102 (-0.391, 0.188)   -1.34 (-4.128, 1.448)   
Batch13 -0.008 (-0.253, 0.238)   0.059 (-2.063, 2.181)   
Batch14 0.01 (-0.265, 0.284)   -0.315 (-2.754, 2.123)   
Batch15 -0.05 (-0.340, 0.241)   -0.378 (-2.910, 2.155)   
Batch16 0.106 (-0.144, 0.356)   1.08 (-1.079, 3.240)   
Batch17 0.021 (-0.225, 0.266)   0.025 (-2.104, 2.154)   
Batch18 0.056 (-0.192, 0.304)   0.731 (-1.454, 2.916)   
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Batch19 0.054 (-0.234, 0.341)   0.429 (-2.123, 2.982)   
Batch20 0.103 (-0.161, 0.368)   0.789 (-1.556, 3.135)   
Batch21 -0.032 (-0.295, 0.231)   -0.581 (-2.878, 1.715)   
Batch22 -0.007 (-0.253, 0.239)   -0.447 (-2.564, 1.671)   
Batch23 0.053 (-0.222, 0.329)   0.53 (-1.948, 3.009)   
Batch24 0.012 (-0.226, 0.251)   0.087 (-1.984, 2.158)   
Batch25 -0.075 (-0.314, 0.163)   -0.58 (-2.664, 1.504)   
Batch26 0.041 (-0.215, 0.297)   0.812 (-1.477, 3.101)   
Batch27 0.006 (-0.269, 0.282)   0.419 (-1.967, 2.804)   
Batch28 -0.06 (-0.306, 0.186)   -0.661 (-2.860, 1.539)   
Batch29 -0.153 (-0.418, 0.112)   -1.215 (-3.572, 1.143)   
Batch30 -0.116 (-0.361, 0.130)   -0.873 (-3.019, 1.272)   
Batch31 -0.102 (-0.348, 0.143)   -0.542 (-2.641, 1.558)   
Batch32 -0.014 (-0.261, 0.232)   -0.384 (-2.533, 1.766)   
Batch33 -0.129 (-0.418, 0.160)   -1.659 (-4.583, 1.264)   
Batch34 -0.042 (-0.291, 0.206)   -0.853 (-3.025, 1.318)   
Batch35 -0.226 (-0.617, 0.165)   -1.108 (-4.378, 2.162)   
Batch36 -0.089 (-0.336, 0.157)   -0.74 (-2.916, 1.436)   
Batch37 0.022 (-0.236, 0.279)   -0.041 (-2.314, 2.232)   
Batch38 0.019 (-0.239, 0.277)   0.49 (-1.735, 2.714)   
Batch39 0.035 (-0.229, 0.299)   0.247 (-2.115, 2.609)   
Batch40 0.031 (-0.236, 0.298)   0.738 (-1.699, 3.176)   
Batch41 -0.015 (-0.261, 0.231)   0.084 (-2.027, 2.195)   
Batch42 0.022 (-0.216, 0.259)   0.089 (-2.000, 2.177)   
Batch43 -0.034 (-0.292, 0.224)   -0.511 (-2.893, 1.870)   
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Batch44 -0.025 (-0.270, 0.221)   -0.133 (-2.271, 2.004)   
Batch45 -0.028 (-0.274, 0.219)   -0.107 (-2.236, 2.022)   
Batch46 -0.013 (-0.259, 0.232)   -0.035 (-2.188, 2.118)   
Batch47 0.085 (-0.204, 0.373)   0.382 (-2.084, 2.848)   
Batch48 -0.035 (-0.283, 0.212)   0.283 (-1.881, 2.448)   
FBW 0.005** (0.001, 0.010) 0.003* (-0.0003, 0.007) 0.057*** (0.018, 0.095) 0.025 (-0.005, 0.055) 
Interaction (Female × FBW as reference)  
Male × FBW 0.006** (0.001, 0.011) 0.007*** (0.002, 0.011) 0.068*** (0.017, 0.118) 0.069*** (0.023, 0.115) 
Constant 0.139 (-0.245, 0.524) 0.307** (0.039, 0.575) -4.348** (-7.781, -0.915) -1.918 (-4.269, 0.432) 
Observations 380 380 380 380 
R2 0.16 0.105 / / 
Adjusted R2 0.032 0.098 / / 
Log Likelihood / / -231.788 -243.175 
Akaike information criterion / / 565.575 494.349 
Residual Stander Error 0.242 (df = 329)             0.234 (df = 376) / / 
F Statistic 1.25 (df = 50; 329) 14.693*** (df = 3; 376) / / 
     Note: *p<0.1; **p<0.05; ***p<0.01 
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3.3.5.2 Chick characteristics associated with treatment-induced degree of 
myopia (selected sample, n=380) 
Chick characteristics associated with ∆MSE in the selected sample were tested in two 
multiple linear regression models (see section 3.2.2). In the first model, ∆MSE was 
associated with the batch, despite the chicks having been selected within each batch 
separately (Figure 3.10, Table 3.9). A reason for this may be that although ∆MSE and 
∆AXL are highly correlated, they have different relationships with potential 
confounders (see Table 3.6 versus Table3.7). Sex and FBW were also associated with 
∆MSE. In the second model 2 (in which a batch effect was not included), sex and the 
interaction between sex and FBW were associated with ∆MSE. Model 1 and model 2 
explained a similar proportion of the variance in ∆MSE (model 1, adjusted R2 = 5.0%; 
model 2, adjusted R2 = 5.9%; Figure 3.10, Table 3.9) suggesting that the influence of 
batch was minimal. 
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Figure 3.10.Coefficient plot showing the relationship between ∆MSE and 
confounding factors (selected chicks, n = 380). 
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Table 3.9. Relationship between ∆MSE and confounding factors (selected chicks, 
n=380). 
 Dependent Variable: 
Independent variable ∆MSE 
Model 1 Model 2 
Β (95% confidence interval) Β (95% confidence interval) 
Sex (female as reference) 
Male 6.730** (0.354, 13.105) 7.799*** (1.914, 13.685) 
Batch (Batch 1 as reference category) 
Batch2 0.577 (-4.011, 5.165)    
Batch3 2.857 (-1.352, 7.066)    
Batch4 0.587 (-4.026, 5.201)    
Batch5 3.177 (-0.803, 7.158)    
Batch6 2.508 (-1.400, 6.416)    
Batch7 0.863 (-4.005, 5.731)    
Batch8 5.405** (0.546, 10.265)    
Batch9 1.746 (-2.364, 5.857)    
Batch10 1.904 (-2.308, 6.117)    
Batch11 -1.242 (-5.644, 3.160)    
Batch12 3.827 (-0.761, 8.415)    
Batch13 3.111 (-0.786, 7.007)    
Batch14 4.232* (-0.122, 8.587)    
Batch15 5.045** (0.435, 9.655)    
Batch16 1.045 (-2.919, 5.010)    
Batch17 2.926 (-0.971, 6.823)    
Batch18 2.589 (-1.347, 6.525)    
Batch19 1.28 (-3.281, 5.841)    
Batch20 1.176 (-3.017, 5.369)    
Batch21 4.372** (0.203, 8.542)    
Batch22 3.131 (-0.767, 7.029)    
Batch23 3.209 (-1.160, 7.578)    
Batch24 2.22 (-1.622, 6.062)    
Batch25 4.231** (0.447, 8.016)    
Batch26 2.197 (-1.870, 6.264)    
Batch27 0.792 (-3.579, 5.163)    
Batch28 4.054** (0.149, 7.960)    
Batch29 4.263** (0.060, 8.466)    
Batch30 4.991** (1.099, 8.883)    
Batch31 3.564* (-0.332, 7.460)    
Batch32 4.213** (0.307, 8.120)    
Batch33 4.765** (0.185, 9.346)    
Batch34 3.317* (-0.623, 7.256)    
Batch35 7.779** (1.578, 13.980)    
Batch36 4.854** (0.950, 8.759)    
Batch37 3.948* (-0.132, 8.029)    
Batch38 3.804* (-0.406, 8.014)    
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Batch39 4.828** (0.638, 9.017)    
Batch40 2.523 (-1.710, 6.755)    
Batch41 2.832 (-1.066, 6.730)    
Batch42 2.952 (-0.816, 6.721)    
Batch43 3.666* (-0.426, 7.757)    
Batch44 2.274 (-1.619, 6.168)    
Batch45 2.707 (-1.202, 6.616)    
Batch46 3.762* (-0.134, 7.658)    
Batch47 1.898 (-2.675, 6.471)    
Batch48 2.351 (-1.575, 6.277)    
FBW -0.079** (-0.147, -0.011) -0.031 (-0.087, 0.026) 
Interaction (Female × FBW as reference)  
Male × FBW -0.079* (-0.160, 0.002)  -0.091** (-0.166, -0.017)  
Constant -7.482** (-13.580, -1.384) -8.266*** (-12.651, -3.880) 
Observations 378 378 
R2 0.176 0.067 
Adjusted R2 0.05 0.059 
Residual Std. Error  3.840 (df = 327) 3.821 (df = 374) 
F Statistic          1.397** (df = 50; 327) 8.892*** (df = 3; 374) 
Note: *p<0.1; **p<0.05; ***p<0.01  
 
3.4 Discussion 
3.4.1 Relationships between body weight, sex and ocular parameters 
before FD 
In 7 day-old chicks examined, before FD was imposed, body weight was around 54 g, 
and there was a positive correlation between body weight and axial length, i.e. on 
average, the heavier the chick, the larger the eye (Figure 3.2). In humans, a positive 
correlation between axial length and body stature has also been observed (Table 3.1). 
Thus, the growth of the eye in the ‘normal’ environment is tuned to stature. 
Interestingly, there was no difference between male and female chicks in pre-
treatment body weight, but it was observed that male chicks had deeper anterior 
chambers, thicker crystalline lenses, longer vitreous chambers, and longer resultant 
axial lengths (Table 3.3). (Note that for the ACD, the means and standard deviations 
reported in Table 3.3 are identical in the right and left eyes when presented to 2 
decimal places. However, given the large sample size and the use of a paired t-test 
comparison, the difference between fellow eyes was statistically significant). These 
findings confirmed those of previous studies (252, 253) and indicated that the 
difference in eye size between male and female chicks is not simply caused by 
differences in body weight, but by other mechanisms related to sex (253). 
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3.4.2 In FD environment, body weight, sex and ocular parameters 
After 4 days of FD treatment, all of the ocular components enlarged and body weight 
increased. As in the 7 day-old chicks, there was not yet any difference in body weight 
between the sexes, but male ocular components remained larger than those of 
females in both control eyes and treated eyes (Table 3.4). 
The average ∆AXL was similar between female and male chicks (according to a simple, 
univariate t-test; Table 3.4). Interestingly, when sex was tested in a multivariate 
regression model that included terms for body weight and a sex-by-body weight 
interaction, it became apparent that there was a complex relationship between sex, 
body weight, and ∆AXL. Such a phenomenon of a difference between univariate and 
multivariate analysis is not uncommon (254, 255). Indeed, Wang et al. (256) have 
suggested that the selection of covariates should not merely be based on univariate 
analysis screening, since this may miss important covariates and lead to biased effect 
estimates. In view of the interaction between sex and body weight, it was decided 
that both parameters should be included as covariates in the subsequent GWAS 
(Chapter 4).  
Spherical equivalent refractive error in control eyes differed between females and 
males, yet not in treated eyes. Conversely, the absolute axial length in treated eyes 
was longer in male chicks, but absolute MSE was similar in the two sexes. When using 
∆MSE as the indicator of myopia susceptibility, there was no evidence of an influence 
of sex in either univariate or multivariate analysis. Likewise, Chen et al. (253) found 
that ∆AXL was greater in male chicks, but the corresponding ∆MSE was similar. These 
results indicated that the anterior segment, e.g. corneal curvature, might be 
different between female and male chicks, both before and after FD.  
Many studies in humans have reported a difference in corneal curvature or 
asphericity between the sexes (257-259). Males tend to have flatter corneas than 
females, which counteracts the tendency for male eyes to be longer. In chick myopia 
studies, researchers have sometimes found that chicks develop a flatter cornea and 
deeper anterior chamber after FD (198, 260), however other studies reported that 
corneal curvature was minimally affected by FD (261). According to Troilo et al. (262), 
for marmosets of different age groups treated with monocular FD, corneal curvature 
changes were only observed in 0-39 day-old marmosets.  
Body weight was also associated with myopia susceptibility. In the multivariate 
regression models, both IBW and FBW were found to be associated with ∆AXL, while 
only FBW was associated with ∆MSE (Table 3.6, 3.7).  
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In human studies, a child’s growth trajectory may be associated with myopia. For 
example in a study of 6,815 children, height and weight growth trajectories at early 
ages were positively associated with axial length and corneal curvature at later ages 
(116). In a study examining 510 inbred chicks, it was found, after being adjusting for 
sex, that body weight, body length and head width predicted 45-49% of the variation 
in eye weight, axial length and corneal radius (263). These studies suggest that 
shared genetic variants contribute to eye size and body stature, however, whether 
the genes that regulate myopia susceptibility also regulate body stature is still 
unclear. 
In previous studies, Schmid and Wildsoet (204) found similar susceptibility to FD-
induced myopia in female and male chicks, while Chen et al., Guggenheim et al. and 
Zhu et al. (203, 252, 253) found that the increase of eye size in response to FD was 
greater in male chicks. None of these prior studies included a sex-by-body weight 
interaction in their analysis models, as the present did. This, coupled with 
differences across White Leghorn strains, and the choice of ∆MSE or ∆AXL to quantify 
myopia susceptibility may explain the conflicting findings in the literature. 
As summarized in Table 3.2, some studies have reported female sex to be a risk 
factor for myopia in humans. My study also suggested that the response to FD differs 
between the sexes in chicks. Sex hormone receptors were found in various ocular 
tissues such as cornea, lens and retina, and changes in sex hormone levels in women 
have been shown to influence corneal thickness (264, 265). More research would be 
needed to uncover the underlying mechanisms for the sex and body weight 
differences in susceptibility to form deprivation myopia that I observed. 
 
3.4.3 Differences between right and left eyes 
An interesting finding in this study was that right eyes were longer than left eyes, as 
has been reported previously (266). In normal, untreated chicks, all of the ocular 
components were asymmetric in size between the right and left eyes. To further 
investigate this phenomenon, eye parameters after FD were analyzed and our results 
confirmed previous findings (Table 3.5). One possible explanation is that the visual 
pathways in avians are fully separated, i.e. decussation at the optic chiasm is 
complete. Thus visual processing from the two eyes is conducted in different 
cerebral hemispheres (the binocular field of view is much lower than in animals with 
forward-facing eyes). Avian eyes may have evolved subtly different 
functions/preferences for looking at different targets, which may finally influence 
the anatomy of the eyes (267). For instance, in another study, which investigated 
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food search ability in monocularly occluded chicks, it was found that chicks using 
their left eyes performed poorly compared to chicks using their right eyes (268). 
However, during this experiment, eye parameters were always measured in the right 
first, hence the left eye would experience a relatively longer exposure to the 
ketamine/xylazine anaesthetic before being measured. A time-dependent reduction 
of intraocular pressure (IOP) has been observed after anaesthesia in rabbits (269) and 
mice (270), and therefore such a time-dependent decrease in IOP might have caused 
a decrease AXL (271). Further work is required to determine whether this potential 
explanation is correct. 
 
3.5 Conclusions 
In this experiment, ocular phenotyping was performed in chicks before and after FD 
treatment. Before treatment, it was found that male chicks had slightly longer axial 
lengths compared to female chicks and that they were less hyperopic than females. 
After FD, axial length was still longer in male chicks, however, refractive error in 
treated eyes was found to be similar between the sexes. A batch effect was found 
significant in this study, and sex and body weight were also found to subtly influence 
susceptibility to FDM. It was concluded that chicks chosen for genotyping should be 
selected separately within each batch, and that sex and body weight should be 
included as covariates in the subsequent GWA analysis for myopia susceptibility.
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Chapter 4 A genome-wide 
association study (GWAS) of FD 
myopia chicks
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4.1 Introduction 
In Chapter 3, confounding factors for myopia susceptibility were identified. In this 
chapter, a GWAS in the FDM chick population was carried out. 
It has been 8 years since the first GWAS for refractive error was published (75). 
Although this method has been successfully applied to identify genetic risk factors for 
myopia in many studies (77, 78, 272), there are still some limitations. A recent study 
suggested that all commonly-occurring genetic variants together could only explain 
25-35% of the variance in refractive error (42). In the same study, the environmental 
factors, time spent outdoors and time spent reading (ascertained at age 8 using 
questionnaires), each explained less than 1% of the variance (42). Therefore, either 
current analysis models are strongly deficient, additional as-yet unidentified risk 
factors are involved, or a more complicated interplay of the known risk factors needs 
to be considered.  
 
4.1.1 Missing heritability and gene-environment interaction 
A major contribution by gene-environment interactions (GxE) would be one 
explanation for the so-called ‘Missing Heritability’ of myopia (i.e. the gap between 
the heritability estimated in twin/family studies and the heritability explained by 
currently identified genetic variants). In a GWAS, factoring in the influence of 
environmental risk factors and GxE in the statistical model can increase 
interpretability and the heritability estimated by SNPs. For example, in a GWAS 
model that includes a GxE effect, it is easy to understand if both the main genetic 
effect (G) and the GxE effect are significant, the proportion of phenotype variance 
explained by (G + GxE) will typically be more than by G only. More importantly, 
sometimes the main genetic effect may not be detected while the GxE could be 
significant (Figure 4.1). In this situation, if the main G effect is the only 
consideration, a large proportion of phenotype explained by genetic factors 
(heritability) is missed.  
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Figure 4.1. Example of a significant GxE effect yet non-significant G effect. 
The x-axis represents the different genotypes; the grey triangles indicate the means 
of the main genetic effect. For the three genotypes, their mean effect is similar, so 
there might be no observable genetic effect in a standard GWAS. E1 and E2 indicate 
two different environments, which modify the genetic risk; a strong GxE effect can 
be observed. The slope of E1 is positively related with the phenotype, while the 
slope of E2 is negatively related with the phenotype. 
 
Among the published studies focusing on the role of GxE influencing myopia, only a 
limited number have reported significant findings. One study, which analysed 40,036 
adults from 25 studies of European ancestry and 10,315 adults from 9 studies of Asian 
ancestry, reported an interaction effect between education level and genetic 
variants close to the AREG, GABRR1 and PDE10A genes (273). Another study in 4461 
children, which examined 39 genetic variants previously reported to be (directly) 
associated with refractive error in prior GWAS, found that only 5 variants showed 
nominal evidence of interactions with near work, and that none showed convincing 
evidence of an interaction with time spent outdoors (274). For other studies (see 
below), due to lack of sample size, an interaction effect was difficult to identify. In a 
myopia candidate gene replication study, 30 SNPs within or near matrix 
metalloproteinase gene coding regions were tested for association with ocular 
refraction in 1,913 people. GxE with education level were also evaluated. While no 
marker met the statistical significance threshold after stringent multiple-testing 
correction, one marker was marginally significant (275). One ALSPAC study 
investigated whether childhood longitudinal refractive error trajectories varied 
depending on the interaction effect between APLP2 gene variants and time spent on 
near work or time spent outdoors; only time engaged in near work showed evidence 
of an interaction (276). 
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4.1.2 Hypothesis – an animal model to detect G × E interactions 
Detecting GxE is difficult when individuals within a population are exposed to highly 
variable lifestyles (277-279). Reducing the complexity of environmental exposures 
can increase the power to detect GxE effects (280). However, in human studies, it is 
not feasible to control the variability in environmental exposures. Performing 
carefully-controlled animal experiments under simple and uniform environments, 
therefore, provide an attractive alternative (280). Thus, I tested the following 
hypothesis: if a GWAS was performed in an animal population exposed to a myopia-
inducing environmental stimulus, genetic loci conferring myopia susceptibility in that 
particular environment could be identified. 
 
4.1.3 Comparison between GWAS in chicks and GWAS in human 
There are several differences between conducting a GWAS in chicks and in humans. 
First, the composition of the genome is different. Chicks have 76 autosomal and 2 sex 
chromosomes, while humans have 44 autosomal and 2 sex chromosomes. Unlike in 
primates, male chicks are the homogametic sex (ZZ) and females are the 
heterogametic sex (ZW). Second, there is no imputation reference panel available for 
the chick genome. By contrast in human GWA studies, large-scale scientific 
endeavours such as the 1000 Genomes Project have provided fine-scale reference 
panels for the human genome, making high-density imputation feasible.  
 
4.1.4 Genotyping techniques 
Currently, there are two main companies that offer technologies for high-throughput 
genotyping of human and non-human samples: Affymetrix and Illumina. Both 
companies have their own genotyping platforms and associated techniques. 
For Affymetrix, there are two genotyping technologies, Axiom genotyping technology 
and GeneChip technology while Illumina mainly uses BeadChip technology. Figure 4.2 
illustrates these three genotyping technologies in detail. Comparing all these 
methods, the main feature of the Axiom technique is that it uses a DNA ligase 
enzyme to connect a biotinylated probe with the capture probe. The DNA ligase will 
recognize the adjacent DNA sequence, which ensures high-fidelity complementation 
(281). The GeneChip approach, by contrast, purely relies on perfect hybridization 
between the capture probe and target DNA sequence (282, 283). While for the 
Illumina bead array, a DNA polymerase-catalyzed single-base extension method is 
used to detect the genotype (283).  
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 (a) 
 (b) 
 (c) 
Figure 4.2. An explanation of genotyping techniques.   
(a). Illustration of Affymetrix Axiom technique. The capture probe (red bar) 
hybridizes with the target DNA fragment (green bar), and 1 of 4 biotinylated probes 
hybridizes with the target SNP. A DNA ligase then links the biotinylated probe to the 
capture probe to detect the genotype. (b). Illustration of GeneChip technique. The 
complementary target SNP is placed in the middle of the capture probe. Genotyping 
is based on a perfect match between the capture probe and target DNA fragment. 
(c). Illustration of the Illumina technique. The captures probe is attached to a bead 
(grey disc). The capture probe hybridizes with the target DNA sequence preceding 
the target SNP. It then incorporates one of the 4 ddNTPs and the genotype is 
detected by a single-base extension reaction.  
In addition to the difference in chip manufacture process and the genotyping 
technology, another distinction involves the two platforms' SNP-selection strategies. 
For human genotyping chips, Illumina's probes are mainly selected from haplotype-
tagging 'tagSNPs' which are identified by the International HapMap Consortium. For 
Affymetrix, except for the tagSNPs which account for half of the array probes, the 
rest are ‘unbiased SNPs chosen to cover the genome while accommodating sequence 
restraints imposed by the assay itself’ (284).  
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4.1.5 Selection of chick genotyping platform 
For chicken data, both companies have designed genotyping chips: the Illumina 3k 
chicken SNP array (285), the Illumina 12,945 SNP chip (286), the Illumina 18k chip 
(287), the Illumina 60K chicken SNP chip (288) and the Affymetrix high-density 600K 
SNP genotyping array (289). Fu et.al (290) studied the LD pattern of broiler chickens 
using the 60k chip; using the same type of chip, Luo analyzed the antibody response 
to Newcastle disease virus (291); Morota et.al (292) analyzed QTL for body weight, 
ultrasound area of breast meat (BM) and hen house production using the Affymetrix 
600k chip while Abdollahi‐Arpanahi et.al (293) calculated the SNP heritability of 
these three traits.  
 
Although the two chips have been widely used, they differ in coverage and SNP-
selection strategies. The Illumina chip was constructed using genetic data from only 
two ‘broiler’ chickens and two ‘layer’ chickens (288), while the Affymetrix array 
employed genetic data from twenty-four chicken lines, including fifteen commercial 
lines, eight experimental inbred layers and one unselected layer line (289). The 
Affymetrix chip covers more chick lines and contains almost 10 times more SNPs than 
the Illumina 60K chip. This allows a better resolution of chicken genome compared to 
the lower density chips (294), hence, in the current study, the Affymetrix (Axiom) 
chip was selected. 
 
4.2 Method 
4.2.1 Sample size 
To minimize ‘batch effects’, the 20 per cent of chicks with the largest treatment-
induced AXL change and the 20 per cent with the smallest change were selected from 
each batch. A total of 380 chicks (190 from the high and low tail of the induced-
myopia frequency distribution) were selected for genotyping (please refer to Chapter 
3, section 3.3.4). 
 
4.2.2 Genotyping 
DNA samples were sent to Aros-Eurofins Ltd for genotyping on the 600K Affymetrix 
Axiom Chicken Genotyping Array (Affymetrix, Inc. Santa Clara, CA, USA). The DNA 
extraction process is described in Chapter 2, section 2.5.1. Since the genotyping was 
to be performed in 96-well plates, the 380 DNA samples were randomly assigned to 
the wells of four 96-well plates (in order to avoid ‘plate effects’ from confounding 
the statistical analyses). One well of each plate was assigned an “internal duplicate” 
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sample for the purpose of quality control. The genotyping process carried out by the 
company was as follows (295): 
i. Total DNA was amplified, and then randomly fragmented into 25 to 125 bp 
fragments. 
ii. Fragments were precipitated and then resuspended. 
iii. The suspension was hybridized to the Affymetrix Axiom Chicken Genotyping 
Array. 
iv. The hybridized chip was washed under stringent conditions and thus, 
background noise caused by random ligation events was reduced. 
v. Four different biotinylated probes were added and the second hybridization 
was performed. 
vi. The DNA ligase was added to specifically link the biotinylated probes to the 
chip surface. 
vii. After ligation, the arrays were stained and imaged on the GeneTitan™ Multi-
Channel Instrument, so that the genotype of each SNP could be recorded. 
The working flow is shown in Figure 4.3. 
 
Figure 4.3. Workflow of the Affymetrix genotyping process (296). 
Five days’ workflow is illustrated from left to right. 
 
4.2.3 Quality control 
Of the 380 genotyped samples, 4 were duplicate DNA samples included for the 
purpose of quality control (QC); one pair of duplicates was included on each of the 
four 96-well plates used for genotyping. 
 
 
 
91 
 
4.2.3.1 Quality Control carried out by the genotyping company 
Dish quality control (DQC) for all samples and SNP quality control (QC) for 20001 SNPs 
were performed by the company. All samples passed DQC, with a threshold of DQC 
not smaller than 0.82 and sample call rate not smaller than 97%. For SNP QC, the 
threshold was set as call rate (cr) -cutoff ≥ 97, Fisher’s linear discriminant (fld)-
cutoff ≥ 3.6, Heterozygous Strength Offset (het-so)-cutoff ≥ −0.1, Heterozygous 
Strength Offset off target variant (het-so-otv)-cutoff ≥ −0.3, homozygous ratio offset 
(hom-ro)-1-cutoff ≥ 0.6. After QC by the genotyping company, genotypes for 580,961 
SNPs were released.  
 
4.2.3.2 Additional Quality Control procedures  
Additional quality control (QC)was carried out using PLINK v1.90 (297). 
Marker-based QC included several criteria: 
1) Remove SNPs with a call rate less than 95%.  
SNP call rate is defined as the proportion of individuals in the study for which the 
corresponding SNP information is not missing. A call rate of 95% for a certain SNP 
means that 95% of the individuals have data for this SNP. In most published GWA 
studies, SNPs with a call rate less than 95% are removed, though some studies have 
chosen higher thresholds (e.g. 99%) for rare mutations (298). This step was designed 
to remove SNPs that were poorly genotyped (some SNPs are inherently difficult to 
genotype due to the surrounding DNA sequence). 
2) Remove or merge duplicate SNPs. 
When multiple variants share the same genomic position and allele codes, they are 
likely to be duplicates. In published GWA studies, they are either merged or removed 
to reduce the false positive rate. In this study, duplicates were removed. 
3) Remove SNPs with no annotation information. 
Chicks have 38 pairs of autosomes and 1 pair of sex chromosomes; some of the 
chromosomes are small in comparison to mammalian chromosomes. SNPs in these 
“micro-chromosomes” may lack detailed annotation information, such as rs ID, bp 
coordinate or allele codes. To increase power and reduce the false positive rate, 
SNPs lacking annotation information were not included in the GWAS. 
4) SNPs on sex chromosomes were not included. 
In chicks, males carry two copies of the Z chromosome whilst females carry one Z 
and one W chromosome. Hence, the conventional additive model used in GWAS 
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cannot be applied to the sex chromosomes. Although studies performing GWAS 
including the sex chromosomes have been reported for chicks (299, 300), the present 
study had limited power, thus only the autosomes were considered. 
5) Power calculation and minor allele frequency (MAF). 
To calculate the statistical power, the software package Quanto (301) was utilized. 
According to previous GWAS for human myopia, statistical power was sufficient to 
identify variants that contributed ~0.01 D of change in refractive error (78). Based on 
the sample size and experimental design of this study (Table 4.1), it was found that 
testing SNPs with a MAF <10% would provide insufficient statistical power. For 
example, to detect a SNP with more than 80% power, using MAF 5% was able to 
detect an effect of increasing AXL by 0.05mm per copy of the risk allele, while a SNP 
with MAF 10% would yield an effect 0.04mm, which is more powerful. In this study, 
MAF ≥ 10% was selected as the criterion for choosing SNPs. 
6) Hardy-Weinberg equilibrium (HWE) test was not performed in this study. 
Genotyping errors can cause SNPs to fail a test for HWE. However, in this study, 
chicks with extreme phenotypes were selected for genotyping and the chicks were 
partially inbred. Therefore SNPs with genotypes that did not conform to HWE were 
not excluded. 
Table 4.1. Power estimation calculated using Quanto, based on different effect 
sizes () and MAFs. 
MAF β Power R2 
0.05 0.01 0.0879 0.0003 
 0.02 0.207 0.0013 
 0.03 0.4015 0.003 
 0.04 0.6261 0.0053 
 0.05 0.8143 0.0082 
 0.06 0.9289 0.0118 
 0.07 0.9795 0.0161 
 0.08 0.9956 0.021 
 0.09 0.9993 0.0266 
 0.1 0.9999 0.0329 
0.1 0.01 0.1229 0.0006 
 0.02 0.3482 0.0025 
 0.03 0.6538 0.0056 
 0.04 0.8818 0.01 
 0.05 0.9759 0.0156 
 0.06 0.9972 0.0224 
 0.07 0.9998 0.0305 
 0.08 0.9999 0.0399 
 0.09 0.9999 0.0504 
 0.1 0.9999 0.0623 
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Sample-based QC included the following criteria: 
1) Exclude chicks whose PCR-determined sex conflicted with the genotyping chip-
inferred sex. 
In this study, sex was identified by PCR (Chapter 2, section 2.6). To ensure the 
samples were not mixed up during the preparation stage, a comparison between PCR-
determined sex and genotyping chip-inferred sex was necessary. Samples were 
removed if there was a sex mismatch (however, there were none). 
2) Remove samples with a call rate of < 95%. 
The sample call rate is defined as the fraction of called SNPs in each sample over the 
total number of SNPs in the dataset. The sex chromosomes were not included while 
calculating the call rate due to unequal information between different sexes. If the 
sample call rate is too low, it infers the sample quality is not good enough. In this 
study, the threshold for excluding samples with a low call rate is 95%, which is 
applied in most GWAS. 
3) Remove chicks with extreme heterozygosity. 
Heterozygosity for an individual refers to the fraction of loci within an individual that 
is heterozygous. Usually, heterozygosity varies among different ethnic groups but is 
relatively stable within a single ethnic group. If an individual’s heterozygosity 
deviates from the average level in a population with the same ethnic background, it 
could be due to inbreeding or sample contamination (e.g. 2 DNA samples being 
pipetted into the same well of a 96-well plate). Heterozygosity outliers (+/- 5 
standard deviations from the mean level) were excluded.  
4) Remove internal duplicate samples. 
For each 96 well plate, one duplicate sample was intentionally included to estimate 
the reproducibility rate within a 96 well plate, and to quantify the reproducibility of 
the genotyping process. One of each pair of duplicate samples was removed. 
5) Estimation of kinship coefficients.  
Kinship is a confounding factor in GWAS that can increase the false positive rate of 
tests of association (302). In this study, since the chicks were partially inbred, it was 
necessary to estimate their relatedness. The effects of relatedness can be corrected 
by genomic control or by including a genetic relatedness matrix in the association 
test model. Since there were several ways to control the genetic relatedness among 
the chicks, to maximise the sample size in order to gain maximal power, no samples 
were excluded in this study on the grounds of relatedness.  
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Marker-based QC was performed first in order to retain as many samples as possible. 
However, in some instances, sample QC must be done prior to marker QC. For 
example, sex inconsistency between the report from genotyping chip and the result 
from PCR must be checked before removing SNPs from sex chromosomes, and the 
sample call rate must be checked before filtering by MAF because the purpose of 
testing sample call rate is to ensure the quality of DNA samples. Unless there is a 
technical problem with specific SNPs (i.e. those with a low call rate), including more 
SNPs in sample call rate analysis will provide more confidence. Taking these factors 
into consideration, the QC procedure adopted is shown in the flowchart (Figure 4.4).  
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SNPs in autosome 
N-sample: 384, N-SNPs: 308,576 
 
Heterozygosity check 
N-sample: 383, N-SNPs: 308,576 
 
SNPs with full information 
N-sample: 383, N-SNPs: 304,963 
 
Sample without duplicates 
N-sample: 379, N-SNPs: 304,963 
 
Raw data from the company 
N-sample:384, N-SNPs: 580,961 
SNPs with call rate ≥ 95% 
N-sample: 384, N-SNPs: 570,885 
 
Sample call rate ≥ 95% 
N-sample: 384, N-SNPs: 570,885 
 
MAF ≥ 10% 
N-sample: 384, N-SNPs: 315,334 
 
SNPs without duplicates 
N-sample: 384, N-SNPs: 315,272 
 
Sex inconsistency check 
N-sample: 384, N-SNPs: 315,272 
 
10076 SNPs with 
call rate < 5% were 
removed 
255551 SNPs with 
MAF < 10% were 
removed 
62 duplicated SNPs 
were removed 
6696 SNPs on sex 
chromosomes were 
removed 
1 chick with 
extreme 
heterozygosity 
was removed 
3613 SNPs without 
annotation 
information were 
removed 
4 duplicated 
chicks were 
removed Figure 4.4. Flowchart of 
quality control. 
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4.2.4 Association analysis 
In this study, PLINK served as the primary analytical tool. Single-locus association 
tests were performed for each marker; genotypes were coded as 0, 1, or 2 according 
to the number of minor alleles carried. A trend test for association was conducted 
within different statistical models and both phenotypes – change in AXL (∆AXL) and 
change in MSE (∆MSE) – were tested separately in independent models. For each 
phenotype, different regression models were designed as follows: 
Model 1: Residual-∆AXL ~ SNP + plate number 
After adjusting for sex, final body weight and sex-body weight interaction (sex × 
body weight), the ∆AXL residuals were then analysed as a quantitative trait 
(dependent variable), with each SNP and plate number (a categorical variable, coded 
as 1, 2, 3 or 4) as the independent variable. Instead of using ∆AXL as a dependent 
variable and taking sex, FBW and a sex × FBW interaction term together with SNP 
into the model (∆AXL ~ Sex + FBW + Sex × FBW + SNP + plate number), 
this two-step method has some advantages. It can control the confounding factors 
like sex and FBW, at the same time, it reduces the degrees of freedom in the 
regression model and improves the power. This approach is common in the genetics 
literature (303, 304).  
Model 2: Residual-normalized-∆AXL ~ SNP + plate number 
Since ∆AXL was derived from extreme samples, the distribution of the trait was non-
normal. Therefore, in the second model, the ∆AXL values were rank-normalized, 
regressed against sex, FBW and a sex × FBW interaction term, and the residuals taken 
as the phenotype. In this model, the phenotype was analysed as a quantitative trait, 
as above.  
Model 3: logit(case/control status) ~ e0 + (1 x SNP) + (2 x Sex) + 
(3 x FBW) + (4 x Sex x FBW) +(5 x plate number) 
In the third model, ∆AXL was modelled as a binary (case/control) trait. Chicks 
selected from the low tail of the phenotype distribution (low ∆AXL) were assigned as 
controls while chicks with high ∆AXL were assigned as cases. In this model, sex, FBW, 
sex × FBW and plate number were included as covariates. 
Model 4: Residual-normalized-∆AXL ~ SNP + GRM + plate 
number 
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The previous models did not include the GRM. Therefore, to correct for relatedness, 
results from the first three models needed to be corrected by the genomic control 
(GC) method. However, this GC method is overly conservative since LD is not 
considered. By contrast, in a mixed model, including GRM as a random effect can 
correct for relatedness while accounting for LD. GEMMA (305) was used to perform 
the mixed model association analysis. 
The same sets of models were also applied for the ∆MSE phenotype, except that a 
logistic regression model was not included: the case/control status was based on the 
phenotype extremes. Thus this would be the same no matter whether AXL or MSE was 
considered. Therefore, in GWAS for MSE, the models were as follows: 
Model 1: Residual-∆MSE ~ SNP + plate number 
Model 2: Residual-normalized-∆MSE ~ SNP + plate number 
Model 3: Residual-normalized-∆MSE ~ SNP + GRM + plate 
number 
 
4.3 Results 
4.3.1 Genotyping data quality  
For the 580,961 SNPs that passed the QC filtering steps carried out by Aros/Eurofins, 
the average call rate was 99.5%. The average concordance rate for the 4 
intentionally-included duplicate samples was also 99.5%. After quality control, 379 
chicks and 304,936 SNPs with MAF  10% were analysed. A genome-wide significance 
threshold of 0.05/304,936=1.64e-07 was set according to a Bonferroni correction for 
testing 304,936 SNPs. However, this threshold would be highly conservative since 
SNPs in LD are not independent. A genetic relationship matrix was calculated for the 
selected chicks. The relatedness coefficients ranged from -0.10 to 0.34, with a 
median value of -0.00326 (Figure 4.5). To reduce false positive results due to the 
inflation of test statistics caused by relatedness (306), the genomic control inflation 
factor (GC) was calculated based on the equation: GC = median (
2)/0.456 (306), and 
genomic control correction was applied by correcting the 2 with GC (
2 (adjusted) = 
2 / GC ).  
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Figure 4.5. Relatedness coefficients of the genotyped samples. 
(a) Box plot of the relatedness coefficients; (b) density plot showing the relatedness. 
Relatedness coefficients ranged from -0.10 to 0.34, with a median value of -0.00326.  
 
4.3.2 GWAS for AXL 
In the first model (Residual-∆AXL ~ SNP + plate number), after adjusting for 
sex, final body weight and sex-body weight interaction, the residual of ∆AXL was 
considered as a dependent variable. In the association model, plate number was 
added as a covariate. After genomic control correction (λGC = 1.19), none of the SNPs 
reached the genome-wide significance threshold; however, 5 SNPs on chromosome 1 
and 9 SNPs on chromosome 7 were found to exceed an arbitrary ‘suggestive 
significance threshold’ of 1.64e-05 (following Reed et al. (307), 100 times the 
genome-wide significance threshold was adopted as the suggestive association 
threshold). The most strongly associated SNPs on chromosome 1 were: rs317386235 
(P = 9.67e-07) with β = -0.12, rs312695428 (P = 4.85e-06, β = -0.11), rs315478126 (P = 
7.71e-06, β = -0.10), rs15195233 (P = 8.11e-06, β =-0.10) and rs316726738 (P = 1.46e-
05, β =-0.10). On chromosome 7, the SNPs that reached the suggestive threshold 
were: rs316636360 (P = 1.04e-05, β = -0.09), rs313790665 (P = 1.08e-05, β = -0.09), 
rs313627312 (P = 1.14e-05, β = -0.08), rs16579210 (P = 1.14e-05, β = -0.08), 
rs312720765 (P = 1.40e-05, β = -0.08), rs14603638 (P = 1.40e-05, β = -0.08), 
rs314035281 (P = 1.46e-05, β = -0.08), rs317497540 (P = 1.48e-05, β = -0.08) and 
rs313006277 (P = 1.50e-05, β = -0.08) (Table 4.2, Figures 4.6 & 4.7). 
 
 
(a) (b) 
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Figure 4.6. Manhattan plot for GWAS of non-normalized residual ΔAXL, after 
genomic control correction.  
X-axis represents chromosome number and genomic position, y-axis represents minus 
log10 P-value. Red line represents the genome-wide significance threshold of 1.64e-
07, blue line represents the genome-wide suggestive threshold of 1.64e-05. 
 
Figure 4.7. Q-Q plot for GWAS of non-normalized residual ΔAXL, after genomic 
control correction.  
 
For the second model (Residual-normalized-∆AXL ~ SNP + plate number), 
rank normalized ∆AXL values were adjusted for sex, FBW and sex × FBW, and the 
residuals of this model were analysed as a continuous trait. After genomic control 
correction (λGC = 1.16), SNP rs317386235 was again the most strongly associated 
marker and now exceeded the genome-wide significance threshold (P = 1.39e-07, β 
= -0.50). Another 9 SNPs – rs312695428, rs15195233, rs315398501, rs315478126, 
rs316320493, rs13829591, rs317899999, rs316726738 and rs313934866 in chromosome 
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1 - also exceeded the suggestive significance threshold (Table 4.2, Figures 4.8, 4.9 & 
4.10). However, no signals from chromosome 7 exceed the suggestive threshold. All 
the SNPs at the chromosome 1 locus were in the region of the genes PRKAR2B and 
PIK3CG. After conditioning on the top SNP (rs31738623), the other SNPs no longer 
reached the suggestive threshold.  
 
Figure 4.8. Manhattan plot for GWAS of residual from normalized ΔAXL, after 
genomic control correction.  
X-axis represents chromosome number and genomic position, y-axis represents minus 
log10 P-value. Red line represents the genome-wide significance threshold of 1.64e-
07, blue line represents the genome-wide suggestive threshold of 1.64e-05. 
 
Figure 4.9. Q-Q plot for GWAS of residual from normalized ΔAXL, after genomic 
control correction.  
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Figure 4.10. Regional plot for chromosome 1.  
Plot (a) shows the top SNPs in chromosome 1 and it’s mapping region. Plot (b) shows 
after conditioning on SNP rs317386235, the signals from other SNPs were no longer 
associated with the phenotype. 
 
In the third model (logit(case/control status) ~ e0 + (1 x SNP) + (2 x Sex) + 
(3 x FBW) + (4 x Sex x FBW)+( 5 x plate number)), ∆AXL was modelled as a binary trait. 
After GWA analysis and genomic control correction (λGC = 1.0), none of the SNPs 
reached the suggestive significance threshold (Table 4.2, Figures 4.11 & 4.12). 
However, the top SNP was still rs317386235 (P = 5.75e-05, OR = 0.38) from 
chromosome 1; the 9 next most significant SNPs were located on chromosome 7: 
rs316636360, rs313627312, rs16579210, rs313006277, rs313790665, rs312720765, 
rs14603638, rs314035281 and rs317497540. 
Figure 4.11. Manhattan plot for GWAS of ∆AXL modelled as a binary trait, after 
genomic control correction.  
X-axis represents chromosome number and genomic position, y-axis represents minus 
log10 P-value. Red line represents the genome-wide significance threshold of 1.64e-
07, blue line represents the genome-wide suggestive threshold of 1.64e-05. 
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Figure 4.12. Q-Q plot for GWAS of ΔAXL modelled as a binary trait, after 
genomic control correction. 
 
In the fourth model (Residual-normalized-∆AXL ~ SNP + GRM + plate 
number), instead of using genomic control, a GRM was included as a random effect 
in a mixed model to correct for relatedness. In this model, the phenotype was the 
same as in model 2. A total of 14 SNPs reached the suggestive significance threshold 
(Table 4.2, Figure 4.13&4.14), and among them, rs317386235 on chromosome 1 also 
exceeded the genome-wide significance threshold (P = 9.54e-08, β = -0.49). Of the 
remaining 13 SNPs, 12 were in the same cluster as rs317386235 on chromosome 1, 
while the final SNP rs313633102 from chromosome 12 was just above the suggestive 
significance threshold (P = 1.62e-05, β = -0.29).  
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Figure 4.13. Manhattan plot for GWAS of residual from normalized ΔAXL, 
including GRM. 
X-axis represents chromosome number and genomic position, y-axis represents minus 
log10 P-value. Red line represents the genome-wide significance threshold of 1.64e-
07, blue line represents genome-wide suggestive threshold of 1.64e-05. 
 
 
Figure 4.14. QQ plot for GWAS of residual from normalized ΔAXL, including GRM. 
104 
 
Table 4.2. All SNPs with minus log10 P-values exceeding suggestive significance threshold (P <1.64e-05) in GWAS for ΔAXL.  
SNP CHR POS MAF Model 1 Model 2 Model 3 Model 4 Mapped gene 
β P β P OR P β P 
rs312576845 1 13994774 0.31 -0.07 1.71e-03 -0.29 4.92e-04 0.61 9.72e-03 -0.34 1.21e-05 Between CDHR3 and SYPL1 
rs316320493 1 14109926 0.23 -0.09 2.37e-05 -0.41 3.40e-06 0.47 3.82e-04 -0.38 1.77e-05 Up stream of LOC107051631 
rs315762686 1 14133858 0.40 0.07 4.65e-04 0.31 6.50e-05 1.61 7.36e-03 0.31 9.38e-06 unmapped 
rs316260627 1 14134122 0.28 0.06 2.23e-03 0.29 4.10e-04 1.53 2.17e-02 0.31 8.56e-06 LOC107051631 
rs313813218 1 14150933 0.30 0.06 1.87e-03 0.29 3.37e-04 1.54 1.77e-02 0.30 1.13e-05 unmapped 
rs13829591 1 14215009 0.23 -0.09 3.58e-05 -0.40 4.68e-06 0.48 7.94e-04 -0.37 2.90e-05 PIK3CG 
rs317899999 1 14221349 0.23 -0.09 3.58e-05 -0.40 4.68e-06 0.48 7.94e-04 -0.37 2.90e-05 PIK3CG 
rs313934866 1 14222991 0.23 -0.09 5.00e-05 -0.40 6.38e-06 0.49 1.05e-03 -0.36 4.41e-05 PIK3CG 
rs315398501 1 14239675 0.22 -0.10 1.99e-05 -0.43 1.64e-06 0.47 6.30e-04 -0.39 1.39e-05 PIK3CG 
rs13829565 1 14242687 0.32 0.06 1.05e-03 0.28 3.65e-04 1.61 7.23e-03 0.32 2.35e-06 PIK3CG 
rs317386235 1 14264125 0.19 -0.12 9.67e-07 -0.50 1.39e-07 0.38 5.75e-05 -0.49 9.54e-08 2kb upstream of PRKAR2B 
rs316726738 1 14276288 0.21 -0.10 1.46e-05 -0.42 5.14e-06 0.43 2.56e-04 -0.40 5.01e-06 PRKAR2B 
rs312695428 1 14279681 0.21 -0.11 4.85e-06 -0.45 1.46e-06 0.40 1.07e-04 -0.43 1.16e-06 PRKAR2B 
rs15195233 1 14286891 0.19 -0.10 8.11e-06 -0.45 1.59e-06 0.42 2.13e-04 -0.43 1.42e-06 PRKAR2B 
rs315478126 1 14294877 0.21 -0.10 7.71e-06 -0.44 1.83e-06 0.42 1.87e-04 -0.43 1.04e-06 PRKAR2B 
rs14792835 1 14355770 0.23 0.06 7.44e-03 0.26 2.59e-03 1.53 3.00e-02 0.31 1.48e-05 HBP1 
rs312799206 1 14356929 0.22 0.06 8.18e-03 0.26 3.14e-03 1.53 3.15e-02 0.32 1.48e-05 HBP1 
rs312720765 7 5837884 0.30 -0.08 1.40e-05 -0.33 3.10e-05 0.47 7.67e-05 -0.31 9.10e-05 unmapped 
rs14603638 7 5851886 0.30 -0.08 1.40e-05 -0.33 3.10e-05 0.47 7.67e-05 -0.31 9.10e-05 UGT1A1 
rs313790665 7 5856742 0.30 -0.09 1.08e-05 -0.33 2.10e-05 0.47 7.60e-05 -0.32 5.17e-05 UGT1A1 
rs316636360 7 5874170 0.30 -0.09 1.04e-05 -0.33 2.23e-05 0.47 6.20e-05 -0.32 6.51e-05 UGT1A1 
rs313627312 7 5874277 0.30 -0.08 1.14e-05 -0.33 2.21e-05 0.47 7.37e-05 -0.32 5.81e-05 UGT1A1 
rs16579210 7 5887049 0.30 -0.08 1.14e-05 -0.33 2.21e-05 0.47 7.37e-05 -0.32 5.81e-05 UGT1A1 
rs313006277 7 5895999 0.29 -0.08 1.50e-05 -0.33 3.53e-05 0.47 7.53e-05 -0.32 6.27e-05 UGT1A1 
rs314035281 7 5898250 0.3 -0.08 1.46e-05 -0.33 2.86e-05 0.47 9.25e-05 -0.31 6.71e-05 UGT1A1 
rs317497540 7 5903441 0.29 -0.08 1.48e-05 -0.34 2.25e-05 0.47 1.03e-04 -0.32 6.98e-05 USP40 
rs313633102 12 3427410 0.45 -0.07 3.13e-04 -0.28 1.57e-04 0.59 2.74e-03 -0.29 1.62e-05 CENPP 
Note: CHR = chromosome; POS = position in base pair; OR = odds ratio. Genome-wide significance threshold = 1.64e-07, genome-wide suggestive threshold = 
1.64e-05. 
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4.3.3 GWAS for MSE 
In the first model (Residual-∆MSE ~ SNP + plate number), ∆MSE was first 
adjusted for sex, FBW and sex x FBW, and then the residuals from the regression 
model were used for association testing. After genomic control correction (λGC = 
1.15), none of the SNPs reached the suggestive threshold. The top 10 SNPs were 
rs316850156 (P = 1.80e-05, β = -1.72), rs312907731 (P = 2.42e-05, β = -1.66) and 
rs317784343 (P = 8.13e-05, β = -1.65) from chromosome 27, rs312972300 (P = 3.69e-
05, β =1.29) and rs317321618 (P = 4.62e-05, β =1.27) from chromosome 20, 
rs315827399 (P = 5.68e-05, β = -1.28) and rs315815227 (P = 6.83e-05,β = 1.71 ) from 
chromosome 2, rs314929542 (P = 6.45e-05, β = 1.45 ) from chromosome 15, 
rs14099455 (P = 6.63e-05,β = 1.45 ) from chromosome 17 and rs313633102 (P = 7.39e-
05,β = -1.19 ) from chromosome 12 (Figures 4.15 & 4.16).
 
Figure 4.15. Manhattan plot for GWAS of non-normalized residual ΔMSE, after 
genomic control correction. 
X-axis represents chromosome number and genomic position, y-axis represents minus 
log10 P-value. Red line represents the genome-wide significance threshold of 1.64e-
07, blue line represents genome-wide suggestive threshold of 1.64e-05. 
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Figure 4.16. QQ plot for GWAS of un-normalized residual ΔMSE, after genomic 
control correction. 
 
In the second model (Residual-normalized-∆MSE ~ SNP + plate number), 
there were only two SNPs that reached the suggestive threshold after genomic 
control correction (λGC = 1.14), and no genome-wide significant SNPs. The two SNPs 
were rs316850156 and rs312907731 on chromosome 27, which had P-values of 1.15e-
05 and 1.54e-05 respectively (Table 4.3, Figures 4.17 & 4.18). 
  
Figure 4.17. Manhattan plot for GWAS of residual from normalized ΔMSE, after 
genomic control correction.  
X-axis represents chromosome number and genomic position, y-axis represents minus 
log10 P-value. Red line represents the genome-wide significance threshold of 1.64e-
07, blue line represents genome-wide suggestive threshold of 1.64e-05. 
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Figure 4.18. QQ plot for GWAS of residual from normalized ΔMSE, after genomic 
control correction. 
 
In the third model (Residual-normalized-∆MSE ~ SNP + GRM + plate 
number), in which the GRM was included, the residuals from the rank-normalized 
∆MSE were used as the phenotype. No SNP reached the genome-wide significance 
threshold, however, 13 SNPs exceeded the suggestive threshold. Among the 13 SNPs, 
rs316720565 on chromosome 1 had the lowest P-value (P= 9.93e-07), followed by two 
nearby SNPs: rs10722203 (P= 1.46e-06, β =-3.36) and rs13828835 (P= 2.53e-06, β =-
3.33). An independent (distantly-located) SNP on chromosome 1, rs13915147, also 
had a P-value less than the suggestive threshold. On chromosomes 3, 4 and 20, there 
were 3 clusters of strongly-associated SNPs, which were formed by rs313016590, 
rs312671401, rs16241712, rs13720406 and rs313789593 on chromosome 3, 
rs314184000 and rs14481912 on chromosome 4, and rs317266172 and rs316615987 
from chromosome 20 (Table 4.3, Figures 4.19 & 4.20). 
 
108 
 
Figure 4.19. Manhattan plot for GWAS of residual from normalized ΔMSE, 
including GRM.  
X-axis represents chromosome number and genomic position, y-axis represents minus 
log10 P-value. Red line represents the genome-wide significance threshold of 1.64e-
07, blue line represents genome-wide suggestive threshold of 1.64e-05. 
 
Figure 4.20. QQ plot for GWAS of residual from normalized ΔMSE, including GRM.
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Table 4.3. All SNPs with minus log10 P-values exceeding suggestive significance threshold (P <1.64e-05) in GWAS for ΔMSE. 
SNP CHR POS MAF Model 1 Model 2 Model 3 Mapped gene 
β P β P β P  
rs316720565 1 14766013 0.16 -0.71 0.09 -0.17 0.11 -3.50 9.93e-07 Intron of LAMB4 
rs10722203 1 14799410 0.17 -0.87 0.04 -0.21 0.04 -3.36 1.46e-06 ERGIC2 
rs13828835 1 15071070 0.17 -0.50 0.24 -0.11 0.28 -3.33 2.53e-06 C1H12ORF40 
rs13915147 1 103910210 0.14 -0.18 0.65 -0.02 0.84 -2.93 9.49e-06 TIAM1 
rs312671401 3 25956860 0.10 -0.68 0.20 -0.16 0.22 -4.17 2.77e-06 EPAS1 
rs16241712 3 25959747 0.10 -0.67 0.20 -0.16 0.22 -4.13 3.25e-06 EPAS1 
rs313016590 3 25962057 0.10 -0.65 0.22 -0.16 0.22 -4.19 2.73e-06 EPAS1 
rs13720406 3 25965464 0.11 -0.37 0.47 -0.08 0.52 -3.93 7.39e-06 EPAS1 
rs313789593 3 34223859 0.20 -0.53 0.17 -0.15 0.12 -2.84 1.60e-05 Up stream of ZBTB18 
rs314184000 4 62387547 0.13 -0.73 0.05 -0.19 0.04 -2.87 5.09e-06 ASAH1 
rs14481912 4 63352189 0.11 -1.12 0.02 -0.28 0.02 -3.58 1.10e-05 Between TUSC3-LOC107053248 
rs316615987 20 11538043 0.11 -1.15 0.02 -0.28 0.02 -3.79 6.69e-06 VAPB 
rs317266172 20 11848093 0.11 -1.17 0.02 -0.29 0.02 -3.86 5.18e-06 PMEPA1 
rs312907731 27 4377267 0.17 -1.66 2.42e-05 -0.43 1.54e-05 0.20 0.78 CASC3 
rs316850156 27 4379502 0.16 -1.72 1.80e-05 -0.44 1.15e-05 0.19 0.79 Between CASC3-RAPGEFL1 
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4.3.4 Annotation of lead SNPs 
The location and annotation of all SNPs reaching the suggestive significance threshold 
of 1.64e-05 identified by the GWAS are listed in Tables 4.2 and 4.3. For the 27 SNPs 
associated with ∆AXL, 23 of them were situated in the coding regions of 7 genes. The 
most strongly associated SNP in the ∆AXL quantitative trait GWAS analysis, 
rs317386235, is positioned upstream of the PRKAR2B gene on chromosome 1, while 
nearby SNPs rs316726738, rs312695428, rs15195233 and rs315478126 are situated in 
the coding region of the same gene. The next most strongly associated variants, 
rs13829591, rs317899999, rs313934866, rs315398501 and rs13829565, are positioned 
in the coding region of the PIK3CG gene on chromosome 1. Adjacent to the PIK3CG 
gene, rs316320493, rs315762686 with rs316260627 are situated in the coding region 
of LOC107051631 on chromosome 1 with rs313813218 located between LOC107051631 
and CCDC71L. Another two SNPs, rs14792835 and rs312799206, are positioned in an 
intron region of H1B1, and another SNP, rs312576845, is located between CDHR3 and 
SYPL1, all on chromosome 1. There was a cluster of associated SNPs on chromosome 
7. Among them, rs14603638, rs313790665, rs316636360, rs313627312, rs16579210 and 
rs313006277 are situated in the UGT1A1 gene, while rs317497540 is located in an 
intron of UPS40, with rs314035281 falling between these two genes. On chromosome 
12, there was one SNP, rs313633102, in the coding region of CENPP (Table 4.2, Figure 
4.21). 
  
Figure 4.21.Regional plot for SNPs that reached the suggestive threshold in 
GWAS for ΔAXL. 
Panel (a) shows the SNP cluster on chromosome 1, panel (b) shows the SNP cluster on 
chromosome 7.   
 
Among the 15 SNPs that exceeded the suggestive threshold in the GWAS for ∆MSE, 4 
of them – rs316720565, rs10722203, rs13828835 and rs13915147—are from 
chromosome 1 and are situated in intronic regions of LAMB4, ERGIC2, C1H12ORF40 
and TIAM1, respectively. On chromosome 3, rs312671401, rs16241712, rs313016590 
and rs13720406 are clustered and positioned in gene EPAS1. Another SNP on 
(a)                                                           (b) 
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chromosome3, rs313789593, is located upstream of ZBTB18. rs314184000, which falls 
within an intron of ASAH1, and rs14481912 which is located between TUSC3 and 
LOC107053248 are from chromosome 4. rs316615987 and rs317266172 are SNPs on 
chromosome 20, and map to the genes VAPB and PMEPA1, respectively. On 
chromosome 27, rs312907731 is situated in CASC3, while rs316850156 falls between 
CASC3 and RAPGEFL1 (Table 4.3). 
 
4.4 Discussion 
4.4.1 PIK3CG 
The PIK3CG gene codes for PI3K (phosphoinositide 3-kinase) subunit gamma. PI3K is 
involved in diverse cellular activities such as cell growth, proliferation and survival 
(308). PI3K could influence eye growth in many ways, such as insulin-related 
refractive error development. One previous study (309) found that a PI3K inhibitor 
(Ly294002) could partially block the effect of insulin-induced overcompensation of 
negative lens wear in chicks. Meanwhile, it has also been suggested that insulin 
stimulates the PI3K/AKT pathway in normal and in plus lens wearing eyes of chicks 
(310). Another study suggested that PI3K participated in an inflammation mechanism 
that might play an important role in myopia progression (311). 
 
4.4.2 PRKAR2B 
The PRKAR2B gene codes for PKA regulatory subunit II beta. The cAMP-dependent 
protein kinase family (PKAs) are important kinases with roles in a wide range of 
cellular processes, including transcription, metabolism, cell cycle progression and 
apoptosis (312). During the process of cAMP-mediated activation of PKA, the inactive 
tetramer dissociates into a dimer of regulatory subunits and two active catalytic 
subunits. According to the type of regulatory subunit, PKA could be identified as type 
I or type II: PRKAR2B codes for a type II PKA regulatory β subunit (313).  
PRKAR2B has previously been implicated in retinal signalling in emmetropisation 
(314). In an experiment carried out by Schaeffel and colleagues, chicks wore a 
positive lens over both eyes for 24 hours, and then retinal RNA was extracted for RNA 
microarray analysis and compared to retinal RNA from untreated control chicks. The 
mRNA expression of PRKAR2B was up-regulated 1.69-fold compared to control chicks  
(314). Moreover, in the retina, PRKAR2B was selectively expressed in type 3b bipolar 
cells in mice, although the specific role of this cell-type in transferring information 
was not clear (315). PRKAR2B is also found in many other tissues besides retina. In 
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the brain, Leucine-rich repeat kinase 2 (LRRK2) interacts with PKAR2B protein, to 
negatively regulate PKA activity in response to dopamine receptor activation (316). 
 
4.4.3 UGT1A1 
UDP glucuronosyltransferase family 1 member A1 is encoded by the gene UGT1A1. A 
mutation in UGT1A1 has been found to cause several diseases such as Cregler-Najjar 
Syndrome (317) and Gilbert Syndrome(318). UGT1A1 is involved in the metabolism of 
retinol, in which all-trans-retinoate is converted to all-trans retinoyl β-glucuronide. 
Although there is no direct evidence about how the UGT1A1 might affect visual 
system development, retinol and intermediates from the retinoid cycle are believed 
to have an impact on eye development and vision (319, 320). For myopia research, it 
was found that all-trans retinoic acid (RA) levels were increased in the retina of eyes 
with experimentally-induced myopia and reduced in eyes recovering from myopia or 
treated with plus lenses (150, 321, 322). Inhibition of retinal RA synthesis was also 
found to reduce the degree of myopia produced by FD in chicks (323). In the choroid, 
changes in the level of RA due to FD were found to be opposite to those in the retina 
(324). The disruption of UGT1A1 could be a potential cause for abnormal RA 
metabolism, which might be a cause for myopia development.  
 
4.4.4 USP40 
Ubiquitin specific peptidase 40 (USP40) is encoded by the gene USP40. In a previous 
linkage analysis study of a high myopia pedigree, a high myopia locus (2q37) was 
mapped to a critical region between markers D2S1279 and D2S2205 on chromosome 2 
at q37.1, where USP40 is located. Thus, USP40 is a promising candidate gene for high 
myopia (53). 
 
4.4.5 LAMB4 
The LAMB4 gene encodes laminin subunit beta 4. Laminins are high molecular weight 
proteins of the extracellular matrix, which are expressed in basement membranes of 
the cornea, lens capsule, internal limiting membrane (ILM), Bruch’s membrane (BrM) 
and many other eye tissues. They are one of the main components of the 
extracellular matrix, and are essential for stabilizing cellular structures and 
facilitating cell migration. In previous studies, laminin subunit alpha 1 (LAMA1) and 
subunit alpha 2 (LAMA2) were both found to be related to myopia development (78, 
325). However, there are no studies of LAMB4 and its relationship with eye 
development to date.  
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4.4.6 Different results from GWAS for AXL and MSE 
In this GWA study, both the axial length and the mean spherical equivalent were 
tested as phenotypes. According to the GWAS results, there were no overlapping 
genes between these two phenotypes. There could be several reasons for these 
disparate results. First, the corneal curvature – another component that contributes 
to spherical equivalent – may also be sensitive to FD myopia. In one study in which 
chicks were monocularly form deprived for 14 days, the corneal curvature was flatter 
in treated vs. fellow eyes (260). However, the results of corneal changes have been 
inconsistent in other studies. In a study performed by Hayes et al., there was no 
significant difference in corneal curvature between FD and control eyes (326). Chen’s 
(253) study also presented a similar conclusion. Chicks from different stains also 
showed different responses to FD. According to Troilo’s study, 2 weeks of FD in the 
Cornell-K strain (K) results in less elongation of the VCD and flattening of the cornea 
yielding lower levels of induced myopia compared to the Washington H & N Strain 
(198).  
Other species had different responses to FD. In a study of FDM in guinea pigs, after 6 
days of diffuser wearing, the corneas of the treated eyes became steeper and the 
corneal power was greater than the fellow eyes (327). It suggested that the VCD was 
the initial dominant cause of the FDM in guinea pigs, but with longer FD periods, the 
corneal power begins to dominate. In macaque, FD might increase the corneal power 
(328, 329) while, in tree shrews, the corneal curvature is unaffected by FD (164, 330, 
331). 
Second, the measurement of the MSE may not be as accurate as the measurement of 
AL, which could reduce the statistical power to detect association signals. 
Cycloplegic refraction is rarely performed in chicks due to the ciliary muscle being 
striated rather than smooth and the very limited penetration of agents such as 
vecuronium bromide through the avian cornea. Retinoscopy under general 
anaesthesia (which relaxes accommodation in chicks) was ruled out since this 
necessitates the use of a speculum to hold open the eyelids, which can induce 
astigmatism. Thus, retinoscopy was performed on alert, awake chicks. Nevertheless, 
since chicks have a high amplitude of accommodation (over 25 D) and show wide 
fluctuations in accommodation, retinoscopy in chicks is technically challenging. This 
would have led to a degree of measurement error when assessing the refractive error 
of chicks.  
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Thirdly, the selection of chicks for GWAS was based on the change in AXL, not on the 
change in MSE. In the selected chicks, their ΔAXL corresponded to the phenotype 
extremes and therefore could be clearly separated into a high and low group (Figure 
3.6a). By contrast, the ΔMSE of the selected chicks was more widely distributed, 
which meant that chicks with more moderate ΔMSE responses to FD were selected 
(Figure 3.6b). Thus, as a consequence of the limited sample size, a GWAS for ΔMSE 
may not have had sufficient power to detect genetic variants at a genome-wide 
significance level. 
 
4.4.7 GRM and genomic control correction 
Inflation of GWAS results can occur due to polygenicity (many small genetic effects), 
population stratification, and/or cryptic relatedness between samples. In the present 
study, the main concern was the relatedness among the chicks. To correct for this 
effect, in general, there are three methods: genomic control, mixed model analysis 
using a GRM, and LD score regression. Since LD score regression required an LD 
reference panel, which is not available for the chick, the other two methods were 
used in this study. 
Genomic control. Under the null hypothesis, apart from a small number of SNPs that 
show a true association with the trait or disease, the test statistics for other SNPs 
should have chance levels of association with the trait; hence the observed P-value 
distribution should be equal to the null P-value distribution except for the low tail 
(306). Therefore, dividing the median χ2 of the observed test statistics by the 
theoretical median (χ2 = 0.456) under the null hypothesis, an inflation factor (called 
GC) can be empirically determined. However, large-scale GWAS and meta-analyses 
indicate that there can be many causal variants for a particular disease or trait 
(polygenicity), which makes correcting by genomic control a conservative approach 
(332). In this study, although the sample size was small, there is still the concern of 
polygenicity of the trait. Hence, correcting by an inflation factor may not be the 
optimal method.  
Mixed models with a GRM. The GRM approach was used for the association test by Yu 
et al. (333) to account for multiple levels of relatedness. Including a kinship matrix in 
a mixed model can reduce false positives and increase power (334). In the current 
study, the GRM accounted for relatedness amongst chicks, preventing overweighting 
of redundant information due to correlation structure. However, since the candidate 
marker is included in the GRM, this would lead to a small loss in power when testing 
the candidate SNP together with the GRM (334). GEMMA was used in this study 
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because it computes an exact mixed model association test statistic with high 
computational efficiency (305).  
 
4.4.8 Selective genotyping  
Instead of performing a GWAS for the whole chick population (n=956), chicks with 
extreme phenotypes were selected for analysis (n=380). This strategy is based on the 
well-established theory that individuals in the phenotype extremes are enriched with 
trait-influencing alleles and/or alleles with large effects on the trait (335-337). Using 
this extreme phenotype selection approach increases statistical power when 
performing GWAS with a fixed sample size or fixed budget, making it economical 
(338). 
 
4.4.9 Continuous vs. dichotomous phenotype coding 
In this study, phenotypic data were analysed as both a continuous trait and a 
qualitative trait. When analysed as a continuous trait, there is uncertainty regarding 
whether the selective phenotype should be normalized prior to performing the GWAS 
analysis. Normalizing the phenotype would fit a basic assumption of linear regression, 
i.e. that the residuals in a linear regression should be normally distributed. However, 
during the process of normalization, the differences in phenotype between the two 
extremes are decreased. In this study, the results suggested that normalizing the 
phenotype increased statistical power (as judged by the QQ-plots under the 
assumption that association signals were true positives). Specifically, it was found 
that a larger number of genetic variants exceeded the suggestive significance 
threshold when ∆AXL was analysed as a quantitative trait compared to a dichotomous 
trait. The likely reason is that, in classifying ∆AXL as a dichotomous trait, information 
about the precise degree of myopia susceptibility is discarded (298, 335, 339). 
 
4.4.10 Comparison of all models 
In total, GWAS were performed using 7 different models for ∆AXL or ∆MSE. According 
to the QQ plots, the GWAS for ∆AXL using model 4 (Figure 4.14) was the optimal one. 
According to the theory that most genetic markers will not be associated with myopia 
susceptibility, for the majority of markers in a GWAS, the distribution of their p-
values will be the same as that under the null hypothesis; these p-values would align 
with the diagonal in the QQ plot. Only a small proportion of SNPs from a GWAS are 
expected to have extremely small p-values and to deviate above the diagonal of the 
QQ plot at the tail of the p-value distribution. An early deviation of the observed p-
value distribution from the QQ plot diagonal suggests a systematic bias (high false 
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positive rate) of the model, while points mostly under the diagonal suggests a 
systematic overly stringent analysis has been carried out. 
4.5 Conclusion 
This study performed a GWAS in 379 chicks and identified one locus that was 
associated with myopia development at genome-wide significance. However, there 
were a number of limitations. Chicks were obtained from a commercial company 
with a large breeding colony, with the aim of minimizing relatedness between 
individuals. However, the genotypically-inferred kinship matrix showed a moderate 
level of relatedness (inbreeding) amongst the chicks. Relatedness inflates 
significance test P-values in a systematic manner (quantified by λGC), which 
complicated the analysis. A further important limitation is that chicks are 
phylogenetically distant from mammals, which makes the findings from chick studies 
of uncertain relevance to humans. Finally, owing to the relatively small sample size 
used, there was limited power to detect the genetic variants weakly associated with 
myopia susceptibility.  
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Chapter 5  Transcriptomic analysis 
of retinal gene expression in 
chicks developing form-
deprivation myopia
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5.1 Introduction 
Performing GWAS can detect potential associations between genetic variants and a 
phenotype. However, even with large GWAS sample sizes, it is difficult to distinguish 
true causal variants from spurious signals due to LD. What’s more, GWAS results 
usually provide little mechanistic insight, especially when the associated SNPs fall in 
noncoding areas. Indeed, even when SNPs are in coding areas, only if the loci are 
known to be translated into genes, and appropriate functional annotation 
information exists, can important pathways be identified. Another issue in GWAS is 
limited reproducibility. Sometimes, GWAS results are not replicated across studies or 
populations, leading to the report of false positives and suspicion of the validity of 
novel associations (340). To verify GWAS findings, apart from increasing the sample 
size and looking for replication from new GWAS studies, another approach is to verify 
the results in a different dimension, such as looking for complementary evidence 
from transcriptome, proteome, metabolome, or epigenome studies: the so-called 
‘systems genetics’ approach.  
Systems genetics considers the research target as a complicated biological network 
and shows a global view of the molecular architecture of complex traits (341). By 
integration or joint modelling, data from quantitative genetics is analysed with data 
from various high-throughput –omics platforms. Thus, results can be examined at 
different levels of biological organization, so that the underlying mechanisms and 
interactions between different aspects can be explored (341-343).  
Among the different types of dataset that can be combined with GWAS results in 
systems genetics, transcriptomics is one of the most commonly selected –omics 
platforms. GWAS experiments provide the opportunity to identify potential causal 
variants at the DNA level, which is usually fixed (except for mutation) for each 
individual in all tissues during the whole lifetime of the organism, while 
transcriptomics provides dynamic observations linking genes to phenotypes. 
Compared to GWAS, there are two major benefits of transcriptome studies. First, 
transcriptomics is organ or tissue specific. For example, DPYSL3 is a photoreceptor-
specific gene that is only expressed in retina, while ζ-crystallin mRNA is only found in 
lens tissue (344, 345). Unlike GWA studies, which provide a general overview of 
disease pathogenesis, transcriptomic analysis of specific ocular tissues can provide 
complementary information. Second, expression patterns are time-dependent. They 
demonstrate which genes are actively expressed at given time-points, which will vary 
with external cues from the environment. For example, in one particular lens-
induced myopia experiment (346), tree shrews wore a -5D lens over one eye for 2 
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days, 4 days or 11 days, and the mRNA expression patterns in the sclera were then 
analysed. The transcriptomics profiles were similar between the 2-day and 4-day 
treatment groups, but 3 genes showed down-regulated expression specifically in the 
11-day treatment group (perhaps due to the eye having fully compensated to the lens 
by this stage of the experiment). These dynamic fluctuations could not have been 
detected through GWAS. What’s more, transcriptomic analysis permit sub-gene level 
investigation, such as gene splicing analysis. This information is valuable, since 
variation in splicing can regulate protein function and cause phenotypic differences 
(347-349). 
Transcriptome data can be analysed using a variety of methods. First, it can be used 
to test for association between a phenotype and gene expression level. In this 
scenario, one might postulate three potential causal relationships (341, 350): (a) the 
expression levels of the differentially-expressed genes are causal for the phenotype; 
(b) the phenotype causes the changes in expression level of the differentially-
expressed genes; (c) there are confounding factors that influence both gene 
expression and phenotype. Second, transcriptomics data can be used to map gene 
expression levels to chromosomal loci. In this scenario, the expression information is 
considered as an ‘intermediate phenotype’. Genetic variants associated with gene 
expression levels are termed eQTLs (expression QTLs). Co-localisation of phenotypic 
QTLs from GWAS and eQTLs from transcriptomics analyses implies that genetic 
variation in the region contributes to the phenotype via a change in expression level 
of the target genes (e.g. SNP  mRNA  phenotype, or equivalently, eQTL  eGene 
 phenotype). However, it should be noted that co-localisation of QTLs and eQTLs 
does not always signify a causal relationship (351). Thirdly, gene expression and 
GWAS information can be integrated by statistical modelling approaches, such as 
pathway analysis. The integrated modules are then tested for association with the 
phenotype (341, 350). 
Transcriptomic data reflect tissue-specific and dynamic gene expression level 
changes that inherently carry functional information; such data are therefore ideal 
for studying G × E effects.  
In this study, the transcriptome data originated from the retina. Emmetropisation is a 
visually-driven feedback process, which requires an image or light stimulation of the 
retina. Previous studies have shown that blocking the connection between the eye 
and visual cortex, either by severing the optic nerve or inhibition of ganglion cell 
action potentials with tetrodotoxin, does not prevent visual experience-dependent 
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experimental myopia (163, 352, 353). These findings suggest that rather than 
emmetropisation being regulated by top-down signals from the brain completely, that 
the eye itself, at least partially, has the ability to regulate its rate of post-natal 
growth. A range of animal studies (354-359) suggest that the retinal processing of 
visual images signals a “stop” or “go” message to the sclera, via the choroid, in order 
to regulate eye elongation. Based on this evidence, the retina was selected as the 
target tissue for a transcriptomics study of differential gene expression in response 
to FDM. As discussed in section 5.4.2.2 below, transcriptomics studies have been 
widely utilised to investigate changes in gene expression in eyes developing 
experimentally-induced myopia (314, 360-362). An entirely novel aspect of the 
current experiment was the opportunity to examine differential retinal gene 
expression in chicks with either a high or low degree of susceptibility to FDM. 
 
5.2 Methods 
5.2.1 Overview and sample preparation  
Gene expression profiling was carried out for both eyes (treated eye and control eye) 
of 8 chicks. The 8 chicks were selected from amongst the 380 chicks used in the 
GWAS experiment, with 4 selected as having a high degree of susceptibility to FDM 
and 4 chicks with low susceptibility. FDM treatment (section 2.1), tissue collection 
(section 2.4.2), and RNA extraction (section 2.5.3) are described in Chapter 2. 
 
5.2.2 RNA sequencing and mapping 
RNA sequencing and mapping were performed by Wales Gene Park Company. The 
company carried out library preparation using the Illumina TruSeq Stranded mRNA 
Library Prep Kit according to the manufacturer’s protocol, and performed 75 bp 
paired-end sequencing on an Illumina HiSeq 2500 sequencer (30 million reads per 
sample). Before sequencing, RNA quality was analysed by the company using an 
Agilent Bioanalyzer to confirm that all samples had an RNA integrity value (RIV) no 
less than 8.   
Briefly, the company’s sequencing protocol had the following steps. Firstly, mRNA was 
purified by hybridizing with polyT-tailed beads; the purified mRNAs were released 
and sheared into 180-200bp fragments; the fragments were annealed to an arbitrary 
primer containing an upstream adapter sequence and reverse transcribed to yield 
first-strand cDNA, followed by synthesis of the reverse complement cDNA, to form 
double-stranded cDNA; paired-end adaptors (containing a further sequencing binding 
site and a barcode index) were then ligated to both ends of the double-stranded 
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cDNA fragments. This is the cDNA library. Next, individual fragments were isolated in 
glass flow cells; the double-stranded cDNA fragments were denatured into single-
stranded cDNA and PCR-amplified using primers matching the adapter sequence. 
Sequencing was performed using a ‘sequencing by synthesis’ approach using a primer 
targeting the 1st strand cDNA; for each extension cycle, di-
deoxynucleotidetriphosphates (ddNTPs) labelled with different fluorophores were 
added to the buffer (note that ddNTPs cannot be extended any further, which halts 
the sequencing reaction after a single cycle of extension; note also that within each 
flow cell, only one ddNTP that matched with the template would be extended in 
each cycle); the newly-added ddNTPs were then excited by a light source, and the 
fluorescent signal emitted by each flow cell was recorded; the ligated fluorophors 
were then cleaved from the ddNTPs and washed away, and the ddNTPs converted to 
dNTPs (therefore allowing the next synthesis cycle to occur); after completely 
sequencing the 1st strand cDNA in this manner, the sequencing procedure was 
repeated for the 2nd (reverse) cDNA strands. Mapping: the sequences of all of the 
fragments were then assembled, and those with similar reads were clustered; 
forward and reversed reads were paired and converted to contiguous sequences; 
then they were aligned and mapped back to the reference genome (Gallus gallus-4.0). 
In the mapping step, alignment was performed by the HISTA2 program and transcript 
assembly was performed with the String Tie program. All of these steps were carried 
out by the Wales Gene Park company (Figure 5.1).
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(b) 
Figure 5.1. RNA-seq Using Next Generation Sequencing.  
(a) Library preparation using TruSeq stranded kit (363); (b) Sequencing process (364). 
123 
 
5.2.3 Analysis pipeline 
After count-based data were obtained (i.e. the number of reads mapping to each 
gene in the reference genome), further analyses were performed as follows:  
              
5.2.4 Statistical model 
In recent studies, many software packages have been developed to analyse 
transcriptomics data and to identify differentially-expressed genes (DEG). Most 
packages make use of general linear models (GLMs). To identify DEGs between FDM vs. 
control eyes, and/or between High vs. Low myopia susceptibility group animals, 
several GLM models were used (in technical language, each model was chosen with a 
‘design matrix’ that allowed the desired ‘contrasts’ to be specified and tested).  
Model 1– Independent design 
Expression Level ~ Sex + Treatment + Myopia_group  
In the first model, the design matrix included contrasts for: (i) sex, (ii) treatment 
status (FDM vs. control), and (iii) myopia susceptibility group (High vs. Low). In this 
model, all 16 eyes were independent. The main purpose of this model was to detect 
differential expression between FDM vs. control eyes in an ‘unpaired’ manner, and to 
General linear model-based differentially-
expressed genes (DEG) test 
Data structures, normalization 
and fitness checks 
(MV-plot, dispersion plot, BCV 
plot) 
Metadata table construction 
(Containing sample identifiers, 
experimental conditions, group 
factors) 
Count-based data construction 
(Per sample per row, per gene 
per column) 
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detect differential expression between the High vs. Low myopia groups 
independently of treatment status. 
Model 2 – Paired design 
Expression Level ~ 0 + Chick_ID + Treatment  
In this model, the treated eye and control eye from the same chick were paired 
together to account for the similarity of the two eyes within the same chick (this is 
analogous to testing for differential expression between FDM vs. controls with a 
paired t-test). However, it was not possible to test the difference between the High 
vs. Low myopia groups independently using this paired model design, because there 
were linear dependencies between myopia group and Chick_ID (i.e. there would have 
been an infinite number of solutions for the best fit model, making it impossible to 
estimate the model coefficients). 
Model 3 – Interaction design 
Expression Level ~ 0 + Chick_ID + Treatment + Treatment ×
Mypoia_group 
An interaction term (myopia group × treatment) was added to the paired-eye model 
in order to identify genes whose level of differential expression varied depending on 
whether they were in the High or Low myopia susceptibility group.  
 
5.2.5 Software 
For each model, three R packages were used to perform the above analyses: edgeR 
(365), DEseq2 (366) and Limma (367). All 3 packages take count-based data as input, 
however, while edgeR and DEseq2 model the data as a negative binomial distribution, 
Limma applies a transformation (‘Voom’) and models the data as a normal 
distribution. To synthesise results, the R package ‘VennDiagram’ (368) was used. The 
rationale for using 3 R packages for these analyses was to reduce type I errors and to 
examine the robustness of the findings. 
Workflow for edgeR (369): 
i. Exclude outliers and weakly expressed genes; 
ii.  Estimate normalization factors; 
iii.  Inspect relationships between samples (a multidimensional scaling (MDS) plot 
was used to visualise the similarity between samples); 
iv.  Estimate dispersion value; 
v.  Fit a GLM to the design matrix and dispersion estimate; 
vi.  Perform test on the contrast(s) of interest; 
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vii.  Inspect and correct the p–values; 
viii.  Identify differentially-expressed genes at FDR <0.05. 
Workflow for DEseq2 (369): 
i. Estimate and inspect normalization factors; 
ii. Inspect relationships between samples via a principal components analysis 
(PCA) plot; 
iii. Estimate dispersion value; 
iv. Fit linear model; 
v. Perform test on contrast(s) of interest; 
vi. Inspect and correct the p–values; 
vii. Choose genes with adjusted p–values < 0.05. 
Workflow for Limma (367): 
i. Estimate and inspect normalization factors; 
ii. Normalize read counts and estimate the mean-variance relationship; 
iii. Perform voom transformation; 
iv. Fit linear model; 
v. Perform test on contrast(s) of interest; 
vi. Inspect and correct the p–values; 
vii. Choose genes with adjusted p–values < 0.05 
 
5.2.6 Quality control 
A total of 7341 genes had a detectable expression level in all 16 retinal RNAseq 
samples (30 M read depth). Gene expression data were inspected, and counts for 1 
gene (RN7SL1) with extremely high expression level were removed, because extreme 
outliers could influence the power of edgeR, DEseq2 and Limma (370). Genes with 
less than 3 counts in any retina sample were also removed since the differentially-
expressed gene tests are based on asymptotic statistics, hence for each sample and 
each gene, the transcripts or gene counts must not be too small (370). After filtering, 
5688 transcripts were available for analysis and the frequency of mean counts per 
gene after filtering is shown in Figure 5.2a. 
 
5.3 Results 
5.3.1 Sample information and data structure overview 
5.3.1.1 Sample information 
A total of 16 eyes from 8 chicks were studied. Among these 8 chicks, 4 of them 
developed a high degree of myopia during the 4-day FDM treatment period (‘High’ 
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group; mean  SD treatment-induced axial elongation, 1.01  0.057 mm) while the 
other 4 developed only a low degree of myopia (‘Low’ group; 0.079  0.077 mm). 
Chicks were sex matched (2 males and 2 females in both the High and Low groups). 
Note that each chick’s myopia susceptibility status was coded as a binary variable 
(High/Low) since the sample size was too small to permit an analysis using the 
continuous variable AXL as the outcome variable. Information about the RNAseq 
samples is presented in Table 5.1. 
 
5.3.1.2 Library size and normalization factors 
After filtering, the library size of each sample ranged from 5,978,282 counts (sample 
green2054_Right) to 10,907,733 counts (sample white1495_Left). To account for this 
difference and make samples comparable, normalization factors were calculated 
before further analysis (Table 5.1).  
 
5.3.2 Sample quality 
To identify outlier samples, the relationship between samples was analysed. Before 
normalization, a principal components analysis (PCA) showed a low degree of 
similarity between samples (Figure 5.2b). After normalization, edgeR’s 
multidimensional scaling (MDS) plot showed a trend of clustering between the pairs 
of eyes from the same individual chick (Figure 5.2c). In contrast, the DEseq2 PCA 
results suggested that sample white1495_left was an outlier (Figure 5.2d), and 
therefore, for subsequent analysis using DEseq2, samples white1495_right and 
white1495_left were removed.  
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Table 5.1.Sample information.  
Sample ID Sex Myopia  
group 
Chick ID Treatment AXL 
(mm) 
MSE 
(D) 
Library size Normalization factors 
edgeR 
Limma 
DEseq2 
(without 1495) 
white1587_Right Female High white1587 Treated 1.41 -6.00 8000694 1.00 1.05 
white1587_Left Female High white1587 Control 0.38 4.50 6284919 1.02 0.83 
green2006_Right Female Low green2006 Control 0.31 5.50 6769407 1.02 0.90 
green2006_Left Female Low green2006 Treated 0.43 0.50 7988410 1.00 1.04 
white1344_Right Male High white1344 Control 0.37 6.50 8224907 1.01 1.09 
white1344_Left Male High white1344 Treated 1.35 -12.00 9354699 0.99 1.21 
white1907_Right Male Low white1907 Control 0.49 6.00 7106460 1.00 0.92  
white1907_Left Male Low white1907 Treated 0.63 4.00 10377165 1.00 1.34 
green2054_Right Female High green2054 Treated 1.46 -13.00 5978282 1.01 0.78  
green2054_Left Female High green2054 Control 0.52 5.50 8495309 1.00 1.10 
white1495_Right Male Low white1495 Treated 0.56 1.00 8168876 0.98 NA 
white1495_Left Male Low white1495 Control 0.47 5.5 10907733 0.99 NA 
white1401_Right Male High white1401 Treated 1.62 -8.00 6703337 0.99 0.86 
white1401_Left Male High white1401 Control 0.55 6.50 7631079 0.97 0.97 
white1641_Right Female Low white1641 Control 0.50 4.00 7946700 1.03 1.05 
white1641_Left Female Low white1641 Treated 0.47 6.00 8080297 0.98 1.03 
 
 
128 
 
  
 
 
Figure 5.2.Sample relationships and frequency of mean counts per gene. 
(a) Frequency of mean counts per gene after filtering; (b) Principle component 
analysis (PCA) before normalization; (c) Multi-Dimensional Scaling (MDS) plot from 
edgeR; (d) PCA by DESeq2.  
 
5.3.3 Gene expression mean-variance plots 
To investigate gene expression patterns, the mean and variance of the counts of each 
gene were analysed. The mean counts ranged from 5.25 counts to 72013 counts; the 
distribution of the mean counts (after log transformation) is shown in Figure 5.3. The 
variation in gene counts was generally larger than or equal to the mean count, 
ranging from 3.50 to 345081566. The mean-variation relationship before and after 
normalization is shown in Figure 5.3. Both plots confirmed that the variance was 
much larger than the mean value, suggesting the negative binomial model would be 
appropriate. 
(c) (d) 
(a) (b) 
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Figure 5.3. Mean-variance relationship.  
(a) Before data normalization; (b) After data normalization 
5.3.4 Dispersion estimation for different models  
One of the most important steps in these analyses is estimating dispersion. Dispersion 
describes the variance of the gene counts in a negative binomial model. For each 
statistical model, dispersion was estimated by both edgeR and DESeq2 in order to fit 
the negative binomial distribution, while the mean-variance relationship was 
estimated by Limma (Figure 5.4). After this step, differentially expressed genes were 
identified using the various contrasts in Models 1-3. 
(a) (b) 
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Figure 5.4. Dispersion plots generated by edgeR and DESeq2, and Mean-Variance 
plot by Limma after fitting the models. 
edgeR’s plotBCV illustrates the relationship between the biological coefficient of 
variation (BCV, square root of dispersion) versus the mean log counts per million 
(CPM); DESeq2’s dispersion plot illustrates the relationship between the dispersion 
and the mean of normalized counts; Limma’s mean-variance trend plot illustrates 
square-root of standard deviation versus count size on a log(2) scale. 
 
5.3.4 Results for Model 1  
In this model, sex, Treatment (FDM vs. control eye) and myopia susceptibility group 
(High vs. Low) were all considered. 
 
5.3.4.1 DEG between FD eyes and control eyes 
Twenty-two transcripts were differentially expressed between FD eyes and control 
eyes (FDR <0.05) using at least one of the software packages. Among these identified 
transcripts, DEseq2 identified 19 of them, edgeR identified 13, while Limma 
identified only 1. Only one gene, UTS2B, was identified by all 3 methods; 7 genes, 
UNC5C, KCNA4, SIX3, VIP, SPRY4, DUSP4 and MAFF were identified by both edgeR and 
DESeq2. Two genes, MSMO1 and STARD4, were up-regulated in FD treated eyes; the 
remaining 20 genes were down-regulated in FD eyes (Table 5.2, Figure 5.5). 
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Figure 5.5. Venn-diagram showing overlap in differentially-expressed 
transcripts identification between FD and control eyes using analysis Model 1 
with 3 software packages (edgeR, DEseq2, and Limma). 
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Table 5.2. Transcripts differentially expressed (FDR <0.05) between FD-treated eyes and control eyes using analysis Model 1, with 3 
software packages. 
Transcript ID edgeR analysis DEseq2 analysis Limma analysis Gene ID Name 
logFC FDR log2FC P-adj logFC P-adj 
NM_206989 -0.858 1.79e-04 -0.840 0.001 -0.858 0.009 UTS2B Urotensin 2B 
NM_204451 -0.314 0.004 -0.322 0.008 -0.316 0.078 UNC5C unc-5 homolog C (C. elegans) 
NM_204851 -0.354 0.058 -0.328 0.008 -0.344 0.161 SPON1 Spondin 1 
NM_204625 -0.238 0.063 -0.228 0.022 -0.239 0.126 OPN4-1 Photopigment melanopsin like 
NM_204899 -0.287 0.023 -0.288 0.022 -0.284 0.130 KCNA4 Potassium voltage-gated channel, shaker-related subfamily, member 4 
NM_204364 -0.279 0.018 -0.269 0.024 -0.281 0.126 SIX3 SIX homeobox 3 
NM_001177309 -1.011 0.004 -0.895 0.024 -1.068 0.130 VIP Vasoactive intestinal peptide 
NM_205366 -1.003 0.004 -0.890 0.024 -1.059 0.130 VIP vasoactive intestinal peptide 
NM_001079735 -0.908 0.004 -0.841 0.026 -0.887 0.126 SPRY4 Sprouty homolog 4 (Drosophila) 
NM_001079735_2 -0.898 0.004 -0.833 0.026 -0.878 0.126 SPRY4 Sprouty homolog 4 (Drosophila) 
NM_001006438 0.326 0.108 0.359 0.026 0.327 0.219 MSMO1 Methylsterol monooxygenase 1 
NM_205455 -0.521 0.062 -0.563 0.033 -0.530 0.161 TNS1 Tensin 1 
NM_001079742 0.296 0.108 0.314 0.033 0.296 0.161 STARD4 StAR-related lipid transfer (START) domain containing 4 
NM_204838 -1.076 0.004 -1.039 0.034 -1.029 0.161 DUSP4 Dual specificity phosphatase 4 
NM_204212 -0.336 0.160 -0.357 0.034 -0.336 0.258 HK2 Hexokinase 2 
NM_204533 -0.238 0.188 -0.284 0.038 -0.242 0.258 MAB21L1 NM_204533 
NM_204757 -0.547 0.017 -0.525 0.040 -0.556 0.127 MAFF v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog F 
NM_001305256_2 -0.877 0.353 -1.390 0.040 -0.808 0.391 LOC420362 NM_001305256 
NM_205209 -0.251 0.222 -0.219 0.047 -0.251 0.161 SLC2A1 Solute carrier family 2 (facilitated glucose transporter), member 1 
NM_001271902 -0.674 0.043 -0.700 0.115 -0.679 0.161 GLI2 GLI family zinc finger 2 
NM_204114 -0.392 0.029 -0.353 0.117 -0.385 0.161 DIO2 Deiodinase iodothyronine type_II 
NM_001324555 -0.383 0.042 -0.343 0.126 -0.377 0.161 DIO2 Deiodinase iodothyronine type_II 
LogFC – log (10) fold of change; Log2FC – log (2) fold of change; P-adj – adjusted P- value.
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5.3.4.2 Genes differentially expressed between High and Low myopia 
susceptibility groups 
Altogether, 21 transcripts were found to be differentially expressed between the High 
and Low myopia groups. edgeR identified 18 transcripts, DESeq2 found 13, with 10 of 
them overlapping. Limma did not identify any differentially-expressed transcripts. 
The 10 overlapped transcripts represented only 8 genes, which were TTLL12, PIK3R5, 
CR1L, RCHY1, COL8A1, TRPA1, PMEL and 17.5. Among the 21 transcripts, TTLL12, 
EOGT, TPCN3, BTD, CRYBA2 and ASL1 were down-regulated in the High myopia 
susceptibility group, while PIK3R5, RCHY1, MYOZ2, COL8A1, TRPA1, UGT8, MXRA8, 
RGN, DCT, MBP and PMEL were up-regulated in the High myopia susceptibility group 
(Table 5.3, Figure 5.6) 
 
 
Figure 5.6.Venn-diagram showing overlap in identification of differentially-
expressed transcripts between High vs. Low myopia groups using analysis Model 
1, with 3 software packages (edgeR, DEseq2, and Limma). 
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Table 5.3. Transcripts differentially expressed (FDR <0.05) between High vs. Low myopia groups using analysis Model 1, with 3 software 
packages. 
Transcript ID edgeR analysis DEseq2 analysis Limma analysis Gene ID Name 
logFC FDR log2FC P-adj logFC P-adj 
NM_001012540 -0.278 0.024 -0.300 0.006 -0.278 0.307 TTLL12 Tubulin tyrosine ligase like 12 
NM_001030697 0.744 0.031 0.867 0.028 0.785 0.322 PIK3R5 Phosphoinositide-3-kinase, regulatory subunit 5 
NM_001030697_2 0.747 0.001 0.835 0.006 0.757 0.307 PIK3R5 Phosphoinositide-3-kinase, regulatory subunit 5 
NM_001030697_3 0.747 0.039 0.866 0.043 0.786 0.339 PIK3R5 Phosphoinositide-3-kinase, regulatory subunit 5 
NM_001031409 -0.349 0.320 -0.463 0.046 -0.333 0.822 EOGT EGF domain-specific O-linked N-acetylglucosamine (GlcNAc) 
transferase 
NM_001033643 -0.596 0.024 -0.677 0.014 -0.596 0.322 CR1L Complement component (3b/4b) receptor 1-like 
NM_001080888 0.292 0.031 0.208 0.080 0.296 0.322 RCHY1 NM _001080888 
NM_001143931 -0.488 0.045 -0.530 0.074 -0.448 0.380 TPCN3 Two-pore calcium channel 3 
NM_001199624 -0.356 0.027 -0.278 0.131 -0.347 0.322 BTD Biotinidase 
NM_001277827 1.442 0.024 1.093 0.328 1.402 0.574 MYOZ2 Myozenin 2 
NM_001293134 0.659 0.039 0.737 0.043 0.625 0.339 COL8A1 Collagen, type VIII, alpha 1 
NM_001318460 0.890 0.047 1.152 0.014 1.006 0.339 TRPA1 Transient receptor potential cation channel subfamily A member 1 
NM_204179 -3.668 0.014 -2.336 0.095 -1.875 0.998 CRYBA2 Crystallin, beta A2 
NM_204204 0.457 0.029 0.434 0.190 0.452 0.339 UGT8 UDP glycosyltransferase 8 
NM_204636 0.393 0.952 0.597 0.043 0.442 0.786 MXRA8 Matrix-remodelling associated 8 
NM_204729 0.400 0.345 0.509 0.020 0.415 0.440 RGN Regucalcin 
NM_204935 0.829 0.039 0.956 0.050 0.763 0.462 DCT Dopachrome tautomerase 
NM_205112 0.895 0.024 1.033 0.020 0.801 0.380 PMEL Premelanosome protein 
NM_205280 0.542 0.029 0.428 0.279 0.530 0.380 MBP Myelin basic protein 
NM_205429 -0.633 0.024 -0.690 0.020 -0.651 0.322 17.5 NM_205429 
NM_205501 -4.824 0.024 -1.870 0.327 -3.226 0.998 ASL1 Argininosuccinate lyase 
LogFC – log (10) scale fold of change; Log2FC – log (2) scale fold of change; P-adj – adjusted P- value.
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5.3.5 Results for Model 2  
In this model, the design matrix was used to make a paired comparison between 
treated eyes and control eyes, with the aim of increasing the statistical power of the 
analysis. After re-estimating the dispersion and fitting the model to the data, a 
paired comparison was carried out. A total of 537 transcripts were found to be 
differentially expressed between FD eyes and control eyes. edgeR discovered 494 
transcripts (adjusted P <0.05), while Limma and DESeq2 identified 327 and 282 
transcripts, respectively. There were 205 transcripts that were identified by all 3 
methods, 110 transcripts were commonly discovered by Limma and edgeR, 43 
transcripts overlapped between edgeR and DESeq2, and only 3 transcripts were 
common only between Limma and DESeq2. Among the 537 transcripts, 269 transcripts 
were down-regulated and 268 up-regulated in FD-treated eyes (Appendix 5.1, Figure 
5.7).  
 
 
Figure 5.7.Venn-diagram showing overlap in identification of differentially-
expressed transcripts between FD-treated vs. control eyes using analysis Model 
2, with 3 software packages (edgeR, DEseq2, and Limma) 
 
In addition, the high and low myopia groups were analyzed separately using model 2 
(this will be referred to as the “model 2 separate” analysis). In the high myopia 
group, the paired comparison between treated eyes and control eyes identified 181 
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transcripts in total by 3 software packages; in the low myopia group, in total 1077 
transcripts were found. Comparing these two datasets, there were 48 transcripts (45 
genes) overlapped (Figure 5.8). 
 
Figure 5.8.Venn-diagram showing overlap in identification of differentially-
expressed transcripts between FD-treated vs. control eyes using analysis Model 
2, when analyzing high and low group separately.  
 
5.3.6 Results for Model 3 
This model incorporated a paired design along with a test for an interaction between 
treatment (FD vs. control) and group (High vs. Low). A total of 495 transcripts were 
identified by DESeq2 as showing differential expression between FD-treated and 
control eyes that differed in High vs. Low chicks. However, Limma failed to identify 
any transcripts for this analysis, while edgeR only identified 7 transcripts (all of 
which overlapped with the transcripts found by DEseq2). These 7 transcripts 
represented 5 genes: GCG, ACSBG2, AQP9, IGFBP4, and INSIG1 (Table 5.4). Of the 495 
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DEseq2 transcripts, 203 transcripts were down-regulated in FD eyes from the High 
myopia susceptibility group (Appendix 5.2, Figure 5.9).  
 
The candidate gene PIK3CG identified from the GWAS was not amongst the set of 
genes showing evidence of a treatment x group interaction (edgeR: FDR = 0.907; 
DESeq2: P= 942; Limma: P = 0.861). The other candidate gene from the GWAS, 
PRKAR2B, was not present in the RNAseq annotation files, suggesting that its 
expression may have been below the detection threshold of my experiment. 
 
Figure 5.9.Venn-diagram showing transcripts differentially-expressed between 
FD-treated and control eyes, that also differed in level between High and Low 
group chicks (interaction between treatment x group, FDR <0.05) using Model 3. 
138 
 
Table 5.4. Transcripts differentially-expressed between FD-treated and control eyes, that also differed in level between High and Low 
group chicks (interaction between treatment x group, FDR <0.05) using Model 3. 
Transcript ID edgeR DESeq2 Limma Gene ID Name 
 logFC FDR log2FC P-adj logFC P-adj   
NR_073182 -0.651 0.009 -0.758 2.81E-04 -0.648 0.232 GCG Glucagon 
NM_001293238 -0.65 0.009 -0.661 0.002 -0.633 0.232 AQP9 Aquaporin 9 
NM_001293239 -0.648 0.009 -0.659 0.002 -0.631 0.232 AQP9 Aquaporin 9 
NM_001012846 0.477 0.009 0.535 3.49E-04 0.476 0.232 ACSBG2 acyl-CoA synthetase bubblegum family member 2 
NM_204353 -0.5 0.011 -0.57 7.94E-04 -0.503 0.232 IGFBP4 Insulin like growth factor binding protein 4 
NM_001190165 -0.577 0.016 -0.674 7.94E-04 -0.574 0.232 GCG Glucagon 
NM_001030966 0.407 0.037 0.391 0.001 0.407 0.232 INSIG1 Insulin induced gene 1 
LogFC – log (10) scale fold of change; Log2FC – log (2) scale fold of change; P-adj – adjusted P- value.
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5.4 Discussion 
5.4.1 Retinal gene expression differences induced by form deprivation 
5.4.1.1 Comparison between Model 1 and Model 2 
Model 1 identified 22 retinal transcripts that were differentially expressed between 
treated and control eyes after 4 days of FD. The paired design in Model 2 showed 
greater power (accounting for the covariance in paired eye data that was not 
explicitly modelled in the independent Model 1 design); it detected 537 transcripts. 
Except for LOC420362, all of the transcripts identified in Model 1 were also identified 
in Model 2 (Figure 5.10).  
From Figure 5.2, it was observed that the variation between individual chicks was 
greater than the variation between paired eyes. Therefore, a paired eye model (such 
as model 2) would be expected to perform better than a model in which the eyes 
were analyzed independently (model 1). This theoretical expectation was confirmed 
in practice: model 2 detected a larger number of differentially expressed transcripts 
between FD and control eyes than model 1. 
 
Figure 5.10. Venn-diagram showing genes differentially-expressed between FD-
treated and control eyes detected using either Model 1 or Model 2. 
 
5.4.1.2 Comparison with previous findings 
For the 538 transcripts detected by either Model 1 or Model 2 in the current study, 94 
(17.5%) of them replicated findings from previous experimentally-induced myopia 
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studies that have examined either transcriptomics or proteomics. For example, VIP, 
UTS2B and DUSP were also reported by McGlinn (361) in a study analyzing gene 
expression in FD chick retina; differential expression of DIO2, KCNA4 and OPN4-1 
were previously identified in LIM chick model (371); ATP5C1, MBP and UQCRB 
replicated Barathi’s proteomics study in atropine treated LIM mouse model (372). Full 
details are presented in Appendix 5.3. 
 
5.4.1.3 Noteworthy genes 
Vasoactive intestinal peptide (VIP) 
Vasoactive intestinal peptide (VIP) was found down-regulated in FD-treated chick 
eyes by McGlinn et al. (361) as was the case in our study. VIP is a peptide hormone 
from the glucagon family. It causes relaxation of smooth muscle in the 
gastrointestinal system. Landmark studies have shown that VIP has a role in myopia 
development. According to Seltner and Stell (373) and Cakmak et al. (374), 
intravitreal injection of VIP retarded but did not eliminate myopia development in FD 
eyes of chicks. However, in the FD mouse (375), VIP was not significantly 
differentially expressed and in FD primate (376), there was an increase of VIP 
expression in lid-sutured eyes. These contradictory results could be due to 
differences in the molecular architecture of the emmetropisation system between 
species, limited statistical power in the latter studies, or differences in experimental 
conditions, e.g. the precise time-point studied. In the mouse study (375), FD was 
performed for less than 24 hours, while in the monkey study (376) FD lasted for over 
1 month. In contrast, McGlinn et al. used a 3 days FD treatment period. Seltner and 
Stell (373), and Cakmak et al. (374) performed FD for 7-8 days in their VIP 
intravitreal injection study.  
Sprouty RTK Signaling Antagonist 4 (SPRY4) 
Another interesting gene is sprouty RTK signalling antagonist 4 (SPRY4), which was 
identified in Model 1 & Model 2. The SPRY4 gene product is a fibroblast growth factor 
receptor (FGFR) inhibitor and thus regulates the FGF signalling pathway. FGF is 
considered as a candidate myopia susceptibility gene since it can modulate a wide 
variety of downstream effects, including activation of extracellular matrix-associated 
genes (377). In a human study, the fibroblast growth factor 10 (FGF10) gene was 
found to be associated with high myopia in both a Chinese (377) and a Japanese 
cohort(378). In this study, it was found that SPRY4 gene expression was down-
regulated in FD eyes, suggesting reduced inhibition of FGF receptors and therefore 
enhanced activation of the FGF pathway in the retina.  
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5.4.2 Retinal gene expression differences between the High and Low 
myopia susceptibility groups 
5.4.2.1 Comparison between Model 1 and Model 3 
In Model 1, 21 transcripts were identified as differentially expressed between the 
high vs. low myopia group chicks; in Model 3, 495 transcripts were identified. None 
of the identified transcripts overlapped between Model 1 and 3. Therefore, in total, 
Model 1 and Model 3 discovered 516 potential transcripts that were differentially-
expressed between the High and Low myopia groups.  
In Model 1, the ‘treatment effect’ considered both eyes from the same chick as 
independent samples, and thus, the within-chick variation was not fully accounted 
for. This would be expected to lead to a reduction in statistical power. 
In Model 3, the paired design optimally modelled the variation due to FD; however, 
due to the limitation of the design caused by the low sample size, it was not possible 
to directly compare the myopia susceptibility group difference whilst accounting for 
the paired design. Therefore, an alternative method of including an interaction term 
corresponding to treatment x myopia group was used. In this model, genes that 
promoted relatively rapid myopia development in response to FD could be identified.  
As mentioned above, a total of 516 transcripts were detected using the High vs. Low 
myopia group analyses, while a total of 538 transcripts were identified using the FD 
vs. control eye tests. Comparing these two analyses, there were 44 transcripts in 
common (Appendix 5.4). This result suggests that these 44 gene products are not only 
differentially-expressed in response to the FD environment, but also play an active 
role in the myopia development process, making them especially interesting 
candidates for further study.  
5.4.2.2 Comparison between Model 2 and Model 3 
Among the 495 transcripts showing evidence of an interaction effect between 
treatment (FD vs. control) and group (High vs. Low) using model 3, there were 422 
transcripts ( 448 genes) that were also found in the “model 2 separate” analysis. A 
detailed comparison of the treatment x group interaction genes identified by these 2 
competing methods is presented in Appendix 5.5. The evidence was most consistent 
for a set of 7 transcripts which consisted of 6 genes (ANKRD10, OPN4, VIP, AQP9, 
TUBA1C, and SNCB). 
Separate analysis in model 2 allowed an examination of whether the same genes 
were differentially expressed in the high and low group chicks. However, using the 
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“model 2 separate” analysis, the sample size in each group dropped by half. 
Furthermore, the contrast between the high and low group sample in the “model 2 
separate” analysis did not consider the expression level of the transcripts, thus it was 
not a fully quantitative comparison. Model 3 created a matrix for multiple factors, 
which has been suggested previously for edgeR analyses (365, 379). Although model 3 
was testing for treatment x group interactions, the model matrix considered the 
expression level of every transcript when performing contrasts between conditions. 
The “model 2 separate” analysis would not be expected to be as powerful as model 3.   
 
5.4.2.3 Comparison with previous findings 
When comparing the 516 transcripts found in the High vs. Low myopia group analyses 
to previously reported candidate myopia genes, there was an overlap of 140 genes 
(Appendix 5.6). However, none of the studies made a comparison between rapid and 
slow myopia development samples. 
 
5.4.2.4 Noteworthy genes 
Phosphoinositide-3-Kinase Regulatory Subunit 5 (PIK3R5) 
Phosphoinositide-3-Kinase Regulatory Subunit 5 (PIK3R5) is a regulatory subunit of the 
class I phosphoinositide 3-kinases (PI3Ks) gamma complex (Table 5.5). PI3K gamma is 
a dimeric enzyme, which contains a 110 kD catalytic gamma subunit (such as PIK3CG) 
and a regulatory subunit of either 55, 87 or 101 kD (such as PIK3R5). During PI3K 
activation, PIK3R5 recruits PIK3CG from the cytosol to the plasma membrane. 
Previous studies have also provided evidence of co-localization and phenotypic 
enhancement effects between PIK3R5 and PIK3CG (379, 380), indicating a strong 
interaction effect between these two genes. 
In the GWAS results, PIK3CG was identified as a myopia susceptibly gene; meanwhile, 
in this transcriptomics study, an up-regulation of PIK3R5 gene expression in High 
myopia-susceptibility group chick retinas was observed (Model 1). The converging 
evidence from these two lines of experimental work argues that PI3K plays a crucial 
role in myopia development.  
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Table 5.5. The PI3K family (Reproduced from (381)). 
Group Gene Protein 
class 1  catalytic PIK3CA  PI3K, catalytic, alpha polypeptide 
PIK3CB  PI3K, catalytic, beta polypeptide 
PIK3CG PI3K, catalytic, gamma polypeptide 
PIK3CD  PI3K, catalytic, delta polypeptide 
class 1  regulatory PIK3R1  PI3K, regulatory subunit 1 (alpha) 
PIK3R2  PI3K, regulatory subunit 2 (beta) 
PIK3R3  PI3K, regulatory subunit 3 (gamma) 
PIK3R5  PI3K, regulatory subunit 5 
PIK3R6  PI3K, regulatory subunit 6 
class 2 catalytic PIK3C2A  PI3K, class 2, alpha polypeptide 
PIK3C2B  PI3K, class 2, beta polypeptide 
PIK3C2G PI3K, class 2, gamma polypeptide 
class 3 catalytic PIK3C3  PI3K, class 3 
regulatory PIK3R4 PI3K, regulatory subunit 4 
 
GCG, IGFBP4 and INSIG1  
Glucagon – Glucagon has been implicated in eye growth and myopia development in 
several studies (310, 375, 382-387). In the studies conducted by Vessey et al. (385) 
and Zhu and Wallman (387), myopia development was attenuated by intravitreal 
injection of glucagon peptide; in Ashby et al.’s study (382), the pre-proglucagon (PPG) 
transcript level was down-regulated in minus lens-treated and FD-treated chick eyes. 
In chicks, glucagon-synthesizing amacrine cells have been demonstrated to play an 
important role in ocular growth regulation (384). However, there is no glucagon-
containing amacrine cell type in the human retina, and therefore the relevance of 
these findings to human myopia is uncertain. Consistent with previous findings, in my 
study, the expression of glucagon was similarly down-regulated in the FD-treated 
eyes, especially in the High myopia susceptibility group animals.  
IGFBP4 – IGFBP4 encodes Insulin-like growth factor binding protein 4, which binds 
insulin-like growth factors (IGFs) I and II. Previous studies in Caucasian, Chinese, 
Polish and Egyptian individuals found that IGF I polymorphisms were associated with 
extreme high myopia, and that blood serum IGF I levels were increased in patients 
with high myopia (388-391). IGFBP4 has been reported to decrease the binding of  
IGF I to its receptor, thus inhibiting its activity (392, 393). In this study, the down-
regulation of IGGBP4 gene expression in the treated eyes of chicks from the high 
group suggests increased activity of IGF I in eyes developing myopia. 
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INSIG1—Insulin-induced gene 1 encodes a protein that regulates lipogenesis and the 
metabolism of cholesterol and glucose. Although the regulatory mechanism between 
INSIG1 and insulin is still unclear, studies have demonstrated that INSIG1 expression 
could be up-regulated by hypoglycemia (394). This study revealed that the expression 
of INSIG1 was decreased in chicks from the High group (perhaps as a consequence of 
decreased glucagon levels). This could potentially have increased insulin levels 
locally within the eye, which is known to stimulate myopia development (387, 395).  
The GCG, IGFBP4 and INSIG1 genes are all involved in regulating the insulin-signalling 
axis. Coincident with previous findings, results from this study strongly suggest that 
the insulin pathway plays a role in myopia development. 
COL8A1  
COL8A1 encodes one of the two alpha chains of type VIII collagen, a component of 
the extracellular matrix. COL8A1 is a short chain collagen, which is found in the 
sclera and is the major component of the basement membrane of the corneal 
endothelium. Previous studies have indicated that COL8A1 polymorphisms are 
associated with myopia development, corneal thickness, glaucoma, AMD and 
choroidal neovascularization in high myopia (396-398). In this study, the expression of 
COL8A1 was up-regulated in the High myopia group FD-treated eyes. Any role for 
type VIII collagen in the retina was unanticipated, and its relationship to myopia 
development is not clear. 
DCT 
Dopachrome tautomerase (DCT), which takes part in melanin synthesis,  was 
previously reported to be associated with congenital microcoria, myopia, juvenile 
open-angle glaucoma (399) and eye colour (400). One prior study identified a down-
regulation of DCT gene expression in myopic chick retina (314); in another meta-
analysis of transcriptome datasets, differentially expressed genes during hyperopia 
induction were analysed, and DCT was found to be down-regulated in the retina 
during the early stage of hyperopia development (401). However, in this study, DCT 
was found up-regulated in chicks with high myopia susceptibility.  
PMEL 
The protein encoded by the PMEL gene is a melanocyte-specific type I 
transmembrane glycoprotein, which is enriched in melanosomes. PMEL exists 
primarily in pigment cells of the skin and eye. There is no direct evidence linking 
PMEL with myopia development, however, several studies suggest that melatonin is 
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associated with myopia (402). According to the results from my study, PMEL might 
influence the melatonin system to result in myopia development. 
AQP9 
Aquaporins 9 is one member of the water channel family that regulates water 
transportation across the cell membrane. AQP9 was identified in rat and chick retina 
(403, 404) and is known to be to be involved in energy metabolism (405) and ganglion 
cell survival (406). Only one previous study reported that AQP9 was up-regulated in 
the treated eye of form deprived chicks (404); the opposite was found in my study, 
i.e. AQP9 gene expression was lower in treated eyes. AQP4 is also implicated in 
myopia development in chicks (407). More research is needed to understand the role 
of water transport in the retina during myopia development. 
 
5.4.3 Transcript analysis 
During the gene expression process in eukaryotes, the transcribed pre-mRNA may 
undergo alternative splicing to yield different mature mRNAs isoforms. These 
isoforms give rise to different transcripts when RNAseq reads are mapped back to the 
genome. In this study, there were instances when more than one transcript from the 
same gene was differentially expressed. For example, 3 different PIK3R5 transcripts 
were differentially expressed in response to FD (Table 5.3) and 2 different GCG 
transcripts (encoding glucagon) showed a treatment x group interaction (Table 5.4). 
Since alternative splicing varies in different conditions and tissues, and can 
potentially produce proteins with dissimilar functions (408, 409), it would be of 
interest to examine the alternatively spliced genes found to be differentially 
expressed in future work, to find out if the isoforms have different functional 
consequences. Here, the discovery of differential expression for multiple isoforms of 
the same gene provides greater confidence that the differential expression is not a 
false positive finding. The ability to accurately identify and quantify levels of specific 
mRNA transcripts is an advantage of RNAseq over microarrays.  
 
5.4.4 Comparison of analytical software packages 
Three R packages were used to analyse the RNA-Seq data: edgeR, DESeq2, and 
Limma. Due to the relatively low number of replicate tissue samples, distribution-
free rank or permutation-based analysis methods were ruled out. Instead, for small 
sample sizes - and especially for RNA-seq data - negative binomial (NB) analysis 
models (as used by edgeR and DESeq2) have become popular and well-established. 
When estimating the dispersion with these packages, information is ‘shared across all 
genes’ to obtain more accurate estimates. The main differences between edgeR and 
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DESeq2 rely on the way how they share the information, in other words, how they 
estimate the dispersion. For edgeR, it is assumed that all genes have the same 
dispersion parameter and therefore a common dispersion estimation is carried out for 
all genes. Subsequently, a gene-wise dispersion estimation is ‘squeezed’ towards the 
common one. In contrast, DESeq finds the maximum gene-wise dispersion estimate, 
and then calculates a dispersion – mean trend. In general, DESeq2 is less powerful, 
whereas edgeR is more sensitive to outliers (369, 410). 
Limma was originally designed for microarray data, however, it can be used for RNA 
sequencing data analysis if the ‘voom’ step is used. Differently from edgeR and 
DESeq2, limma’s analytical model is based on the normal distribution. One study (370) 
made comparisons among these 3 analysis packages under different simulation 
situations and suggested no single method was optimal under all circumstances. Thus 
the choice of methods for transcriptome analysis depends on the experimental 
conditions (see table 5.6).  
Table 5.6.Comparison of edgeR, DESeq2 and limma. (Modified from(370)) 
Method Features 
DESeq2 - Conservative with default settings. Becomes more conservative when 
outliers are introduced. 
- Generally low true positive rate. 
- Poor FDR control with 2 samples/condition, good FDR control for larger 
sample sizes, also with outliers. 
- Medium computational time requirement, increases slightly with sample 
size. 
edgeR - Slightly liberal for small sample sizes with default settings. Becomes more 
liberal when outliers are introduced. 
- Generally high true positive rate. 
- Poor FDR control in many cases, worse with outliers. 
- Medium computational time requirement, largely independent of sample 
size. 
limma - Good type I error control, becomes more conservative when outliers are 
introduced. 
- Low power for small sample sizes. Medium true positive rate for larger 
sample sizes. 
- Good FDR control. Largely unaffected by introduction of outliers. 
- Computationally fast. 
 
5.5 Conclusion 
In this transcriptomics study, a total 538 transcripts were identified from model 1 and 
model 2 as differentially expressed between FD-treated eyes vs. control eyes, and 
516 transcripts were identified as differentially expressed between FD-treated eyes 
in the High vs. Low myopia groups from model 1 and model 3. There were 44 
transcripts that were identified in both sets of analyses. Components of the PI3K 
pathway and the insulin signalling pathway were the strongest candidates for a role 
in determining susceptibility to myopia development. In the future, these results 
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need to be validated in an independent sample of chicks (ideally using an 
independent method such as reverse transcription-PCR). 
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Chapter 6 Pathway analysis
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6.1 Introduction 
GWAS and RNA-seq experiments have the potential to identify genetic loci associated 
with a phenotype, and genes differentially expressed across different phenotypes, 
respectively. Since the ultimate goal for these types of analysis is to better 
understand the aetiology or mechanism of a disease (in order to develop effective 
strategies to treat the condition) adding functional annotations to these results is 
highly desirable. Gene set or pathway analysis provides such a solution. (For 
simplicity, the term ‘pathway analysis’ is used to cover both types of analysis in the 
remainder of this chapter. However, technically, they are distinct approaches). Based 
on already known taxonomy data from public repositories such as the Gene Ontology 
(GO) or Kyoto Encyclopedia of Genes and Genomes (KEGG) databases, genes of 
interest can be assigned to different meaningful categories. Next, a group of related 
genes can be tested to assess whether they are significantly associated with a 
phenotype (411). This approach is known as knowledge base-driven pathway analysis 
(412).  
Pathway analyses can be applied to both GWAS and RNA-seq data. In fact, pathway 
analysis for GWAS was motivated by approaches for gene expression microarray 
analysis. The statistical hypothesis or principal foundation in pathway analysis is that, 
if a given disease or phenotype is characterized by a specific biological process, the 
underlying (co-functioning) genes should be preferentially selected in an omics study 
(413). There are two main categories of pathway analysis, depending on the 
algorithm used: firstly, ‘self-contained analysis’, and secondly ‘competitive analysis’. 
In the self-contained testing approach, only genes in the gene set are considered, 
and the null hypothesis is that none of these genes is associated with the phenotype. 
By contrast, in the competitive approach, all genes in the database are considered, 
and tests are used to assess whether the genes in each gene set are more strongly 
associated with the phenotype than the other genes. Both GWAS and RNA-seq 
pathway analyses can employ either approach, the main difference being that, for 
GWAS data, pathway analysis starts from the level of SNPs while for RNA-seq data, it 
starts from the level of genes (414).  
 
6.1.1 Pathway analyses for GWAS results 
As discussed below, GWAS experiments have three inherent problems that pathway 
analysis can help to overcome. The first of these is inaccurate mapping. Among SNPs 
identified by a GWAS, only a small proportion are typically located in the coding 
regions of genes; in fact, more than 80% of disease-associated SNPs in the NCBI GWAS 
catalogue are non-coding (415). Secondly, due to LD, the lead GWAS SNP in a region 
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cannot be directly affirmed as the true causal variant. The third limitation of GWA 
studies is that they are usually underpowered (i.e. the sample size is too small), 
which means that they are unable to detect SNPs with small effects. Pathway 
analysis is able to address each of these problems to a certain extent. When mapping 
SNPs to genes, most pathway analysis tools take up- and down-stream SNPs into 
consideration, which accounts for sampling variation-induced inconsistency in 
whether the causal SNP in a region is detected as the lead SNP (416). This also takes 
account that regulatory variants can be situated several kb away from their target 
genes (417). Meanwhile, pathway analysis also reduces the multiple testing burden 
by aggregating SNPs into genes and gene sets. More importantly, by incorporating 
prior biological evidence, functional variants may be prioritized over less functional 
variants even if they have similar effect sizes. Thus, the efficiency of revealing new 
disease-related candidates will be increased (418, 419). For example, in a GWAS 
comprising 401 patients with Crohn’s disease and 433 controls, IL23R was identified 
as a disease-associated gene (420). However, not until a meta-analysis of 3,230 cases 
and 4,829 controls was carried out did a SNP in another gene (IL12B) in the IL23R 
pathway reach the genome-wide significance threshold (421). This example 
demonstrates that genes in the same functional pathway may interplay with each 
other and conspire to the mechanism of a disease, but GWAS may not be able to 
detect every single involved gene owing to limited power. Therefore, pathway 
analysis may be able to highlight potential candidates that would otherwise go 
undetected. 
 
6.1.1.1 Features of post-GWAS pathway analysis 
Based on the data input format, there are two main approaches to post-GWAS 
pathway analysis. The first is the ‘P-value enrichment approach’, which only requires 
SNP rs ID and P-value data from GWAS summary statistics as input. This approach is 
easy to use, however it does not consider gene size, which may cause bias. The 
second approach is the 'raw genotype approach'. This option takes account of LD and 
gene size in the analysis process, however, its requirement of raw genotype data is 
restrictive for collaborative GWAS meta-analysis projects, which typically do not 
permit raw data to be shared (411). Recently, methods have been developed to 
overcome the requirement for raw genotype data by incorporating LD information 
from an ancestry-matched reference sample (422). 
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6.1.1.2 Software 
There are many software packages for performing GWAS-based pathway analysis, 
such as FORGE, JAG, INRICH and MAGMA. In one study comparing the performance of 
several pathway analysis tools, MAGMA and INRICH showed low type-1 error rates 
when gene size, density of SNPs and LD between SNPs were considered as 
confounding factors, and the power of these two tools was similar (414). However, 
the results from INRICH were strongly dependent on the P-value cut-off threshold 
chosen, and computation time was longer than MAGMA, on average (423). For this 
study, therefore MAGMA was chosen for carrying out a post-GWAS pathway analysis. 
 
6.1.2 Pathway analysis for RNA-seq results 
Without the requirement of a step to map SNPs to genes, pathway analysis for RNA-
seq data is simpler than pathway analysis for post-GWAS results. There are two main 
methods of pathway analysis for RNA-seq data: over-representation analysis (ORA) 
approaches and functional class scoring (FCS) approaches.  
 
6.1.2.1 Over-Representation Analysis (ORA) 
In ORA approaches, genes are selected to form an input list according to a set of pre-
specified criteria, e.g. FDR < 0.05. Then, each pathway (GO annotation, KEGG 
pathway etc.) is tested to assess whether genes in this pathway are over-represented 
(enriched) in the predefined gene list. Several tools including DAVID (413), PANTHER 
(424) and GOEAST (425) implement this method. Among these tools, DAVID is one of 
the most popular, because it is easy to use, and it has powerful data-mining 
(functional clustering and functional annotation) capabilities.  
All ORA tools extract biological meaning from a given gene list, using annotations 
applied from different biological perspectives, and report those most likely as output. 
However, there are some limitations to the ORA approach. First, genes are treated 
equally and independently in ORA; the degree of association between gene and 
phenotype is ignored, as is the inter-relationship amongst genes. Second, ORA 
methods ignore genes that do not reach an arbitrarily-set significance threshold. 
Third, ORA methods ignore the relationship between different pathways (412). 
 
6.1.2.2 Functional Class Scoring (FCS) 
Unlike ORA, the FCS approach takes all genes into consideration. Instead of applying 
an arbitrary threshold to select genes, they are ranked according to their relationship 
with the phenotype. The gene-level statistics in the pathway are then summarized 
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into pathway-level statistics, and the statistical significance of that pathway is 
assessed. Among the tools that apply the FCS approach, Gene Set Enrichment Analysis 
(GSEA) (426, 427) is one of the most widely used (428-430).  
FCS methods include more genes, weight each gene’s expression level, and consider 
the dependence among genes. However, even the FCS approach still neglects the 
coordination between different pathways. Because of their different strengths and 
weaknesses, performing both ORA and FCS pathway analysis may increase the power 
to attribute biological meaning to GWAS and RNA-seq data. 
 
6.2 Methods 
6.2.1 Pathway analysis for GWAS 
MAGMA was used to perform pathway analysis for GWAS results. The MAGMA workflow 
was as follows: 
i Annotation: Annotation is a step that maps SNPs to the genome and identifies 
if they fall within genes. SNP information was downloaded from the UCSC 
Genome Browser. Ensemble Gallus_gallus-4.0 version was selected because 
the genotyping chip used in my experiments used Gallus_gallus-4.0 as 
reference. A 5 kb window was applied, i.e. SNPs within a 5kb buffer 5’ or 3’ 
to genes were mapped to that gene. Note that certain SNPs mapped to more 
than 1 gene. 
ii Gene analysis: In gene analysis, SNPs are aggregated to the gene level using 
GWAS summary statistics, and the association between joint markers in the 
gene and the phenotype is tested. The previous GWAS results in this study 
(Chapter 4, section 4.3.2, Model 2) were used in this step. Note that the P-
values in this GWAS were genomic control-corrected to account for 
relatedness between samples. To generate P-values for each gene, MAGMA 
calculates the mean of the 2 statistic for all SNPs within each gene. (Note 
that there were too few unrelated chicks in my GWAS sample to enable the 
LD between markers to be estimated. Hence, MAGMA was unable to take 
account of LD when carrying out its gene-based tests). 
iii Gene set analysis: In this step, individual genes are grouped into gene sets 
for further association testing. Based on results from the gene-based analysis 
(step ii), genes and their corresponding P-values were aggregated according 
to gene set references. The Molecular Signatures Database (MSigDB) was used 
as a reference for classifying genes into gene sets (426). A ‘competitive’ was 
chosen to perform the gene set analysis. 
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6.2.2 Pathway analysis for RNA-seq results 
In order to maximize the biological information extracted from my previous –omics 
analyses, both DAVID and GSEA were applied. 
6.2.2.1 DAVID 
As an ORA approach, DAVID required a gene list as input. In Chapter 5, three analysis 
packages and two models were used to identify differentially expressed genes 
between high vs. low myopia-susceptibility chicks (Chapter 5, section 5.3.4.2 and 
5.3.6). Since each model and each package has its own advantages and disadvantages, 
genes identified by any of the three packages in any of the two models were included 
in the gene list. The workflow was as follows: 
i DEG list submission. The list of differentially-expressed genes was entered; 
the gene identifier was set as ‘Gene symbol’ format; species was set as 
Gallus_gallus; gene background was set as Gallus_gallus; 
ii Select functional annotation categories; GO term, KEGG pathway; 
iii Run Functional annotation chart; 
iv The threshold to select gene sets was: gene sets contain at least 2 genes, the 
expression analysis systematic explorer (EASE) score < 0.05. 
The corresponding Z-score for the DAVID results was generated with the R package 
‘GOplot’ (431). 
 
6.2.2.2 GSEA 
Before running GSEA, gene expression library from RNA-seq was normalized by 
DESeq2. A phenotype list for the sample was created according to the GSEA manual.  
i The normalized gene expression data and phenotype list were loaded; 
ii Select  gene set databases: GO term, KEGG pathway; 
iii Select permutation type: ‘gene_set’ was selected as the permutation type, 
with 1000 permutations; 
iv Select gene sets criteria: gene sets with >500 genes or <2 genes were 
excluded;  
v Run analysis; 
vi Threshold of suggestive significance: FDR < 25%.  
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6.2.3 Other software packages 
‘ClusterProfiler’ (432) was used to create dot plots. ‘GOplot’ (431) was used to 
create circle plots and bubble plots. ‘Enrichment Map’ (433) from the Cytoscape 
package was used to generate the enrichment map, similarity cut off was set as 0.5 
(default setting), which will create a connection line if two gene sets have a 
similarity over 50%. 
6.3. Results 
6.3.1 MAGMA analysis 
6.3.1.1 Annotation 
From the GWAS result, summary statistics (Chapter 4, section 4.3.1), 304,936 SNPs 
were available for annotation. There were 16,844 genes in the Gallus_gallus-4.0 
Ensemble annotation file. Amongst the SNPs, 168,244 SNPs (55%) mapped to at least 
one gene. Amongst all the reference genes, at least one SNP mapped to 14,072 (84%) 
of the genes. 
 
6.3.1.2 Gene-based analysis 
Among the mapped genes, 628 genes (4.4%) had a P-value less than 0.05. None of the 
genes reached the significance threshold after Bonferroni correction (Appendix 6.1). 
The top gene was PIK3CG (P = 2.67e-05); 11 SNPs had been mapped to this gene. The 
top 10 most strongly-associated genes are shown in Table 6.1. 
Table 6.1Top 10 genes from MAGMA gene-based analysis. 
Gene CHR Start BP Stop BP Number 
of SNPs 
 
Z P 
PIK3CG 1 14208410 14246547 11 4.04 2.67e-05 
ENSGALT00000006673.4 7 5730049 5902491 15 3.94 4.15e-05 
ENSGALT00000039781.2 7 5867755 5878724 3 3.72 9.84e-05 
ENSGALT00000021678.3 13 14376043 14389235 5 3.53 2.04e-04 
USP40 7 5896675 5938176 15 3.48 2.50e-04 
GPR22 1 14513792 14525725 1 3.35 4.03e-04 
DOCK9 1 143955154 144047261 15 3.34 4.17e-04 
SPSB4 9 6118832 6129579 5 3.28 5.19e-04 
OGN 12 3419002 3443509 4 3.13 8.65e-04 
PXYLP1 9 6322526 6382838 29 3.12 8.94e-04 
CHR –Chromosome number, BP – Base pair, Z – Z score. 
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6.3.1.3 Gene set analysis 
In total, 17,453 gene set definitions from MSigDB were selected as the reference 
(note that set C1 was removed, since C1 is categorized by human chromosome 
position, while the gene position in chicks differs from that in humans). However, 
only 17,439 gene sets (containing 10194 unique genes) were available for use in the 
analysis because 14 gene sets could not be mapped to any gene. Then, 10,000 
permutations for multiple testing corrections were performed and a corrected P-
value was given (the significance threshold for permutation was P <1.22e-05). 
Among the gene sets, 969 (5.5%) had uncorrected P-values less than 0.05, but none 
reached the corrected significance threshold of 1.22e-05. The MSigDB classification 
of the 969 gene sets is shown in Figure 6.1a. Some  gene set categories had a higher 
proportion of sets with p <0.05; specifically, 4.0% of the Hallmark gene sets, 4.9% of 
the curated gene sets, 3.8% of the motif gene sets, 4.0% of the computational gene 
sets, 5.3% of the GO gene sets, 8.5% of the oncogenic signatures and 7.1% of the 
immunologic signatures had P <0.05 (Figure 6.1b).  
Including too many irrelevant annotation terms would have increased the type I error 
rate in the above analysis. For example, the top gene set was ‘effector vs. memory 
CD8 T-cell down’ (P = 6.15e-05) from the Immunologic Signatures (C7) category; a set 
of genes down-regulated in effector CD8 vs. memory CD8 T cells. From past research, 
there was minimal evidence to suggest a role for the genes in this set in myopia 
development. Therefore, to focus annotation to pathways and functions that may be 
more relevant, the KEGG and GO gene sets were analyzed independently.  
In gene set analysis using KEGG definitions, 186 gene sets (containing 3,000 unique 
genes) were used. Permutation tests suggested an empirical multiple testing 
significance threshold of P <2.92e-04. None of the gene sets had a corrected P-value 
below the significance threshold. The top 5 gene sets are shown in Table 6.2. 
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 (a)  (b) 
Figure 6.1.Pathway analysis using MSigDB (except C1) as reference. 
(a) Pie chart of 969 gene sets with P <0.05 when using MSigDB (except C1) as reference; (b) Comparison of number of gene sets between gene 
sets with p <0.05 (red) and P >= 0.05 (black).
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Table 6.2.Top 5 KEGG pathways from pathway analysis using MAGMA 
Gene Set (KEGG) Number of 
genes 
Beta SE P P 
(Corrected) 
Homologous Recombination 22 0.36 0.17 0.02 0.90 
Sulfur Metabolism 6 0.50 0.26 0.02 0.97 
Circadian Rhythm Mammal 8 0.43 0.22 0.03 0.98 
Dorso Ventral Axis Formation 16 0.33 0.18 0.03 0.99 
Glycosaminoglycan Degradation 13 0.32 0.18 0.04 1.00 
 
In the GO term analysis, 5,911 gene sets were used for analysis (9,401 unique genes). 
The empirical significant threshold was p <9.50e-06. Among the 5,911 gene sets, 
4,436 of them were derived from the GO Biological Process Ontology, 897 were from 
the GO Molecular Function Ontology and 578 were from the GO Cellular Component 
Ontology. None of the gene sets attained the significance threshold after correction 
for multiple testing. For each GO category, the top three gene sets are shown in 
Table 6.3.  
Table 6.3. Top three gene sets of each GO category from pathway analysis using 
MAGMA. 
 Gene set (GO) Number 
of genes 
Beta SE P p 
(Corrected) 
BP Regulation Of Mitotic Cell Cycle 313 0.14  0.04  1.19e-04 0.33 
BP Regulation Of Cell Cycle Process 365 0.13  0.04  2.70e-04 0.59 
BP Bone Development 109 0.22  0.07  4.69e-04 0.76 
MF Sequence Specific DNA Binding 521 0.10  0.03  3.79e-04 0.26 
MF Nucleic Acid Binding Transcription 
Factor Activity 
540 0.09  0.03  1.48e-03 0.67 
MF Double Stranded DNA Binding 386 0.10  0.03  2.29e-03 0.82 
CC Heterochromatin 41 0.31  0.10  1.29e-03 0.47 
CC Cytoplasmic Exosome RNase 
Complex  
12 0.54  0.19  1.92e-03 0.60 
CC Multivesicular Body 17 0.51  0.18  1.94e-03 0.60 
BP – Biological Process; MF – Molecular Function; CC – Cellular Component 
 
6.3.2 Results for RNA-Seq data 
6.3.2.1 KEGG analysis using DAVID 
The 516 transcripts that were differentially expressed between high and low myopia-
susceptibility chicks (Chapter 5, section 5.3.4.2 and 5.3.6) yielded 467 genes. 
Pathway enrichment for 467 genes was analyzed using DAVID. In the ‘over-
representation’ analysis, 178 differentially expressed genes were mapped to the 74 
KEGG pathways. 12 pathways had an EASE score (a modified Fisher’s exact test P-
value from the Expression Analysis Systematic Explorer software program) less than 
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0.05. However, only 1 pathway – ‘Ribosome’ – surpassed the Bonferroni correction 
threshold (P = 8.93e-05). The ‘Ribosome’ pathway had 3.94 fold of enrichment, and 
the 19 genes that mapped to this pathway were all down-regulated (Z-score = -4.36). 
Among the other pathways, ‘Oxidative Phosphorylation’ and 
‘Glycolysis/Gluconeogenesis’ had relatively low EASE scores. Nine of the 12 top-
ranked pathways had a minus Z-score, suggesting the genes in these pathways were 
generally down-regulated. Details of all the 12 pathways are listed in Table 6.4 and 
Figure 6.2.
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 Table 6.4.KEGG pathways with P < 0.05 in DAVID analysis. 
KEGG ID Gene set  Number  
of genes 
EASE 
(P value) 
Fold of 
Enrichment 
Bonferroni 
Correction 
Gene 
Ratio 
Z-score 
gga03010 Ribosome 19 8.76e-07 3.94 8.93e-05 19/178 -4.36 
gga04530 Tight Junction 14 1.21e-03 2.81 0.12 14/178 0.53 
gga01130 Biosynthesis Of Antibiotics 17 2.66e-03 2.28 0.24 17/178 -2.18 
gga00010 Glycolysis / Gluconeogenesis 8 4.15e-03 3.84 0.35 8/178 -2.83 
gga00190 Oxidative Phosphorylation 12 6.58e-03 2.55 0.49 12/178 -3.46 
gga01200 Carbon Metabolism 10 0.02 2.55 0.79 10/178 -2.53 
gga03013 RNA Transport 12 0.02 2.24 0.82 12/178 -1.15 
gga04810 Regulation Of Actin Cytoskeleton 14 0.03 1.93 0.94 14/178 1.60 
gga04145 Phagosome 11 0.03 2.15 0.95 11/178 -2.11 
gga01230 Biosynthesis Of Amino Acids 7 0.03 2.90 0.96 7/178 -2.65 
gga04260 Cardiac Muscle Contraction 7 0.03 2.85 0.97 7/178 -0.38 
gga04510 Focal Adhesion 14 0.04 1.86 0.97 14/178 1.60 
Gene Ratio – the number of genes mapped to the particular pathway vs. number of genes mapped to the reference, Z-score = (log fold of change for up-
regulated gene –log fold of change for the down-regulated gene)/(total number of genes in the pathway)  
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Figure 6.2. KEGG pathways with P < 0.05 in DAVID analysis.  
(a) Circle plot of KEGG pathway from the DAVID pathway analysis. The outer circle 
shows a scatter plot for each term of the logFC (log fold change) of the assigned genes. 
Red circles denote up-regulation and blue down-regulation. The colours of the inner 
circle represent Z-scores. (b) Dot plot of DAVID results. The x-axis shows gene ratio of 
each pathway, dot size shows the number of genes in that pathway, and colour 
represents the P-value for the pathway (c) Enrichment map of the KEGG pathways most 
strongly ranked in the DAVID analysis. Red circles represent gene sets that were up-
regulated. Connecting lines represent more than 50% of genes overlapped between the 
two gene sets, with the thickness of the line representing the overlap strength.
(a) 
(b) (c) 
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6.3.2.2 GO term analysis using DAVID 
Altogether, 709 GO terms were linked to at least 2 of the differentially expressed 
genes, and 72 GO terms had EASE scores that were less than 0.05 (Appendix 6.2). A 
total of 10 GO terms had EASE P-values below 0.05 after Bonferroni correction. 
Among the 72 gene sets, 30 were annotated by ‘biological processes’ terms, 26 were 
annotated by ‘cellular component’ terms (7 of which exceeded the corrected 
significance threshold), and 16 were annotated by ‘molecular function’ terms (3 of 
which exceeded the corrected significance threshold) (Figure 6.3a). 42 genes were 
not able to be mapped to any of the GO terms. 
Amongst the 72 gene sets, GO categories ‘cytoplasm’ (GO:0005737) and ‘nucleus’ 
(GO:0005634) had less than a 1.5 fold enrichment, while ‘pre-miRNA binding’ 
(GO:0070883) had the greatest enrichment (24.1-fold). The gene ratio ranged from 
0.01 to 0.29. GO categories ‘dense body’ (GO:0097433) and ‘mitochondrial 
respiratory chain complex IV’ (GO:0005751) had the smallest gene ratio, while 
‘extracellular exosome’ (GO:0070062) had the largest gene ratio. There were 27 GO 
terms for genes primarily down-regulated in chicks with a high susceptibility to 
myopia, and 45 GO terms for genes primarily up-regulated. Z-scores of these terms 
ranged from -4.24 (‘structural constituent of ribosome’; GO:0003735) to 4.24 
(‘transcription, DNA-templated’; GO:0006351) (Figure 6.3). The interconnection of 
all 73 GO terms is presented in Figure 6.4. The 10 top-ranked GO terms (P < 0.05 
after Bonferroni correction) are shown in Table 6.5 and Figure 6.5. 
Among the differentially-expressed genes that were used for pathway analysis, the 
20 genes that had the largest log fold change and the 20 genes with the smallest log 
fold change were identified and mapped to the 72 significant GO annotation terms. 
Only 22 of the selected genes had GO term annotations available; the 
interconnections between these 22 differentially-expressed genes and their related 
GO terms are shown in Figure 6.6. 
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 (a) 
 
(d) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
(c) 
Figure 6.3 GO term with P < 0.05 (Before Bonferroni correction) in DAVID analysis.  
(a) Bubble plot of 73 GO terms from the DAVID analysis of DEGs. Red bubbles represent GO terms in the ‘biological process’ category, blue 
represent ‘cellular component’, and yellow represent ‘molecular function’. (b) Corresponding dot plot of the ‘biological process’, (c) ‘cellular 
component’, and (d) ‘molecular function’ category.
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Figure 6.4. Enrichment map of the GO terms with P < 0.05 (Before Bonferroni 
correction) in DAVID analysis from DAVID results. 
Red circles represent gene sets that were up-regulated. Connecting lines represent 
more than 50% of genes overlap between the two gene sets, the thickness of the line 
representing the overlap strength. 
 
 
Figure 6.5. Circle plot of GO terms with P < 0.05 (after Bonferroni correction) 
from the DAVID analysis of differentially-expressed genes. 
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Table 6.5.GO terms with P <0.05 (after Bonferroni correction) in DAVID analysis of differentially-expressed genes. 
Gene Ratio – the number of genes mapped to the particular pathway vs. number of genes mapped to the reference, Z-score = (log fold of change for up-
regulated gene –log fold of change for the down-regulated gene)/ (total number of genes in the pathway). 
GO ID Gene Set Number 
of genes 
EASE 
(P-value) 
Fold of 
Enrichment 
Bonferroni 
correction 
Gene 
Ratio 
Z-score 
GO:0070062 Extracellular Exosome 113 4.60e-14 2.02 1.65E-11 113/389 -3.67 
GO:0043209 Myelin Sheath 22 1.91e-09 4.99 6.86E-07 22/389 -2.98 
GO:0044822 Poly(A) RNA Binding 55 4.31e-08 2.19 1.95E-05 55/354 -0.94 
GO:0022625 Cytosolic Large Ribosomal Subunit 11 9.38e-06 6.05 3.36E-03 11/389 -3.32 
GO:0005634 Nucleus 107 2.53e-05 1.45 9.06E-03 107/389 2.42 
GO:0005925 Focal Adhesion 25 3.72e-05 2.58 0.01 25/389 -2.20 
GO:0003735 Structural Constituent Of Ribosome 18 4.67e-05 3.17 0.02 18/354 -4.24 
GO:0005886 Plasma Membrane 67 5.11e-05 1.63 0.02 67/389 2.32 
GO:0016020 Membrane 45 9.41e-05 1.84 0.03 45/389 -1.94 
GO:0005516 Calmodulin Binding 8 1.09e-04 6.89 0.05 8/354 2.12 
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Figure 6.6.Chord plot demonstrating the inter-connections between the 22 largest/smallest changed differentially-expressed genes with 
the largest/smallest fold-change, and their related GO terms. 
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6.3.2.3 KEGG analysis using Gene Set Enrichment Analysis (GSEA)  
In GSEA, differentially-expressed genes from my high vs. low myopia susceptibility 
RNA sequencing study were ranked according to their correlation with the myopia 
susceptibility phenotype using the default ‘signal-to-noise ratio’ method. Hence, a 
ranking list was formed. Then, GSEA weighted whether members of a gene set were 
randomly distributed across the ranking gene list or they tended to occur toward the 
top (or bottom) of the rank list. Thus, GSEA determined whether any gene set 
correlated with myopia susceptibility.  
Of the 7,341 RNA-seq genes provided as input for GSEA, 5229 mapped to 183 KEGG 
pathways after applying the exclusion criteria. Among these 183 pathways, 121 
pathways were up-regulated in chicks with high-susceptibility to myopia. Of these, 5 
pathways exceeded the suggestive threshold, FDR < 0.25, which was considered to be 
a reasonable threshold for exploratory results. Two of them – the ‘Parkinson’s Disease’ 
pathway and the ‘Oxidative Phosphorylation’ pathway – had an FDR q-value <0.05. 
The other 62 pathways were up-regulated in chicks with low susceptibility to myopia. 
Of these, only 1 reached FDR <0.25 and none reached FDR <0.05. The normalized 
enrichment score (NES) ranged from -1.80 to 2.12; the Parkinson’s Disease KEGG 
pathway had the largest NES (Table 6.6, Figures 6.7 and 6.8). 
Table 6.6.KEGG with FDR <0.25 in GSEA analysis of differentially-expressed 
genes. 
Gene Set 
(KEGG) 
Count NES Nominal 
P-Val 
FDR  Rank At 
Max 
Leading Edge 
Parkinsons  
Disease 
53 2.11 0 1.31e-3 1697 tags=74%, list=32%, 
signal=108% 
Oxidative 
Phosphorylation 
60 2.00 0 3.97e-3 1319 tags=55%, list=25%, 
signal=73% 
Ribosome 53 1.85 2.12e-3 0.05 1585 tags=60%, list=30%, 
signal=86% 
Alzheimers 
Disease 
73 1.72 2.02e-3 0.18 1654 tags=60%, list=32%, 
signal=87% 
Huntingtons 
Disease 
79 1.71 0.002 0.15 1319 tags=43%, list=25%, 
signal=57% 
DNA Replication 20 -1.80 0 0.08 1048 tags=50%, list=20%, 
signal=62% 
Annotation - Leading edge: Since not all of the genes in the gene sets will participate in the 
biological process, the core members that account for the enrichment signal will be extracted 
by leading edge analysis. Tags - the percentage of genes contributing to the enrichment score; 
List - The percentage of genes in the ranked gene list before (for positive ES) or after (for 
negative ES) the peak in the running enrichment score. This gives an indication of where in 
the list the enrichment score is attained; Signal - The enrichment signal strength that 
combines the two previous statistics.
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Figure 6.7.Enrichment plot of KEGG with FDR < 0.25 from the GSEA analysis of 
differentially-expressed genes. 
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Figure 6.8.Enrichment map of the KEGG pathways from GSEA results.  
Red circles represent gene sets that were up-regulated, blue circles represent gene 
sets that were down-regulated. Connecting lines represent more than 50% of genes 
overlap between the two gene sets, the thickness of the line representing the 
overlap strength.   
 
6.3.2.4 GO term analysis using Gene Set Enrichment Analysis (GSEA) 
In the enrichment analysis of GO terms, there were 5,765 gene sets that contained 
more than 2 genes. Of these, 3,198 gene sets (55%) were relatively up-regulated in 
high-susceptibility chicks, of which 95 gene sets reached FDR <0.25 (Appendix 6.3). 
The other 2,567 gene sets (45%) were up-regulated in low-susceptibility chicks, of 
which 10 had an FDR <0.25 (Appendix 6.3). Among the 95 and 10 suggestive gene sets, 
there were 6 gene sets with an FDR <0.05; these related to ‘inner mitochondrial 
membrane protein complex’, ‘secondary metabolic process’, ‘multivesicular body’, 
‘mitochondrial protein complex’ , ‘terpenoid metabolic process’ and ‘mitochondrial 
membrane part’ (Table 6.7). The NES for these gene sets ranged from -2.02 to 2.15. 
The GO terms ‘transcription factor activity direct ligand regulated specific DNA 
binding’ had the lowest NES and ‘inner mitochondrial membrane protein complex’ 
had the highest score. The 10 gene sets with the most extreme enrichment scores are 
shown in Figure 6.9 The interconnections of all the gene sets is shown in Figure 6.10. 
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Figure 6.9. Enrichment plot of top 10 GO term from the GSEA analysis of differentially-expressed genes. 
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Figure 6.10.Enrichment map of the GO terms from GSEA results. 
Red circles represent gene sets that were up-regulated, blue circles represent gene sets that were down-regulated. Connecting lines 
represent more than 50% of genes overlap between the two gene sets, the thickness of the line representing the overlap strength.
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Table 6.7.GO term with FDR <0.05 in GSEA analysis of differentially-expressed 
genes. 
Gene Set 
(GO) 
Count NESs Nominal 
P-Val 
FDR Q-
Val 
Rank 
At 
Max 
Leading Edge 
Inner Mitochondrial 
Membrane Protein 
Complex 
50 2.11 0 0.02 1654 tags=72%, list=32%, 
signal=104% 
Secondary Metabolic 
Process 
14 2.15 0 0.02 400 tags=50%, list=8%, 
signal=54% 
Multivesicular Body 16 2.08 0 0.02 523 tags=38%, list=10%, 
signal=42% 
Mitochondrial Protein 
Complex 
61 2.04 0 0.03 1654 tags=67%, list=32%, 
signal=97% 
Terpenoid 
Metaboliprocess 
42 1.98 2.01e-3 0.05 1001 tags=52%, list=19%, 
signal=64% 
Mitochondrial 
Membrane Part 
74 1.97 0 0.05 1319 tags=54%, list=25%, 
signal=71% 
 
6.4 Discussion 
Gene set pathway analyses were carried out using both GWAS results and RNA-seq 
results. In the analyses of GWAS results, no genes or gene sets reached statistical 
significance. For the RNA-seq results, 2 gene set analysis approaches were used: 
DAVID and GSEA. In DAVID analysis, 12 KEGG pathways and 73 GO terms had EASE 
<0.05; In GSEA analysis, 6 KEGG pathways and 105 GO terms reached FDR <0.25. 
 
6.4.1 Gene-based association study 
Using MAGMA, SNP-level information was synthesized to gene-level information. The 
top-ranked gene in the MAGMA analysis was PIK3CG. This was not surprising, since in 
the GWAS, the top associated SNPs were situated between PIK3CG and PRKAR2B, and 
the evidence suggested there was only one causal SNP in the region. Due to the lack 
of LD information for my chick population, the MAGMA results should not be 
considered to add weight to the hypothesis that PIK3CG, rather than PRKAR2B, is 
likely to be the causal gene associated with high susceptibility to myopia 
development in FD chicks.  
The second strongest signal from the MAGMA analysis was on chromosome 7, 
implicating the gene USP40 (ubiquitin specific peptidase 40). In the GWAS study, SNPs 
in the vicinity of USP40 reached the suggestive significance threshold. In a previous 
linkage analysis study of a high myopia pedigree, a high myopia locus was mapped to 
a critical region between markers D2S1279 and D2S2205 on chromosome 2 at q37.1, 
where UPS40 is located. Thus, USP40 is a promising candidate gene for high myopia 
(53).  
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6.4.2 Gene-set-based association study 
Among the potential pathways suggested by pathway analysis, several have been 
implicated in myopia development in previous studies.  
 
6.4.2.1 Circadian rhythms 
The KEGG pathway ‘circadian rhythm’ was highlighted by the MAGMA analysis, as was 
the ‘regulation of circadian rhythm’ pathway by DAVID. In previous studies, circadian 
rhythms have been shown to influence myopia development. For example, in chicks, 
both constant light (434, 435) and constant dark (260) result in hyperopia and corneal 
flattening (436), while tree shrews reared in constant darkness developed a myopic 
shift (437). Variation in photoperiod (length of the daylight period) also affects the 
degree of FDM in chicks (438).  
There is a hypothesis (439) that, in FD chicks, the lack of normal visual transients 
might mimic the ‘constant conditions’ encountered in constant light or constant dark. 
With reference to this study, chicks highly susceptible to FDM might be especially 
sensitive to such cues from the diurnal circle. 
 
6.4.2.2 Gene sets relating to extracellular matrix (ECM) and structural 
remodelling  
There were many GO terms enriched for ECM pathways, for example 
‘glycosaminoglycan degradation’, ‘positive regulation of extracellular matrix 
disassembly’, ‘complex of collagen trimers’ and ‘ keratan sulfate metabolic process’. 
According to previous studies, glycosaminoglycan synthesis was reduced in the sclera 
during myopia development (440, 441). It is well known that the ECM is important in 
determining the biomechanical properties of the sclera and that there are dynamic 
changes to scleral “creep rate” during myopia development (442).  
Several other annotations related to cell structure and adhesion, such as ‘cell 
adhesion’, ‘focal adhesion’, ‘calcium-dependent cell-cell adhesion via plasma 
membrane cell adhesion molecules’, ‘actomyosin structure organization’ and 
‘positive regulation of Rho protein signal transduction’. This suggests that, during 
myopia development, cell adhesion may change, or even mediate ECM remodelling. 
Cell adhesion has previously been implicated in refractive astigmatism (443) and 
experimentally-induced myopia (444).  
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6.4.2.3 Energy generation and oxidative stress 
Many pathways relating to the respiratory chain and oxidative stress were enriched, 
for example, ‘mitochondrial respiratory chain complex assembly’ and ‘oxidative 
phosphorylation’. There could be two possible reasons for this enrichment in energy 
generation-related terms. First, a difference in energy generation capability may 
contribute to the degree of axial elongation during FDM, for example, if energy 
generation is rate-limiting in this process. Thus, chicks that develop high myopia may 
have greater energy generation capabilities than chicks that develop low myopia 
under the same FD conditions. Second, a high level of energy generation could be a 
consequence of fast ocular elongation. The vertebrate retina has a very high demand 
for oxygen (445). Therefore rapid axial elongation could cause even greater than 
normal consumption of oxygen and energy. Unfortunately, gene set analysis cannot 
distinguish between these possible mechanisms. 
Oxidative stress could potentially be a negative consequence of myopia development, 
as previously suggested from microarray studies in form deprived chicks (446) and 
studies of ocular pulse amplitude in human high myopia (447, 448). 
 
6.4.2.4 Glycometabolism and lipid metabolism 
Glucose and lipid metabolism also feature prominently in the pathway annotations, 
for example: ‘Glycolysis and gluconeogenesis’, ‘glycolytic process’, ‘positive 
regulation of insulin secretion involved in cellular response to glucose stimulus’, 
‘positive regulation of triglyceride metabolic process’ and ‘positive regulation of lipid 
biosynthetic process’. In one recent study conducted by Yang et al., retinal metabolic 
changes were analyzed in FD guinea pigs, and the authors concluded that myopia 
progression was associated with increases in glucose accumulation and decreases in 
lipid levels (449). These gene sets support those discussed above relating to energy 
expenditure/generation, as glucose and lipid metabolism provide substrates for the 
tricarboxylic acid (TCA) cycle. Other potential mechanisms may also link 
glycometabolism and lipid metabolism to myopia (450). 
 
6.4.2.5 Other terms  
In addition to those annotations discussed above, independent but potentially 
meaningful terms/pathways highlighted by DAVID and/or GSEA analysis included: 
‘melanin metabolic process’, ‘melanosome’, ‘ionotropic glutamate receptor activity’ 
and ‘AMPA glutamate receptor activity’. 
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6.4.3 KEGG and GO  
Previous studies of genes differentially expressed in myopia models performed gene 
set analysis using gene sets derived from KEGG pathways or GO terms. KEGG 
pathways are a collection of pathway maps that reflect experimental knowledge of 
metabolism and various other functions of cells and organisms. KEGG contains 6 
major categories: metabolism, genetic information processing, environmental 
information processing, cellular processes, organismal systems, and human diseases 
and drug development. GO is another widely used annotation reference. Unlike KEGG, 
which is manually curated by experts, GO terms are generated by a computer. Thus, 
GO contains more gene sets but has less accuracy than KEGG. GO covers a more 
comprehensive set of cellular processes, molecular functions and cellular 
components. Although KEGG and GO cover a wide range of gene set definitions, 
including different organisms, most of the definitions are based on human studies 
and human diseases; therefore, since I attempted to map chicken data to the 
pathways and annotations, care should be taken to confirm their relevance in 
chickens.  
 
6.4.4 Comparison of pathway analysis methods 
Although DAVID and GSEA are both widely used tools, they yielded different results in 
my study, especially as regards the level of statistical significance. There could be 
several reasons for the differing results. First, DAVID only took as input genes those 
that were statistically significant in a previous analysis, while GSEA took all available 
genes into consideration. For example, regarding the KEGG pathway ‘oxidative 
phosphorylation’, which was highlighted by both DAVID and GSEA, in the DAVID 
analysis, only 8 genes were mapped to the pathway while, in GSEA, 60 genes were 
mapped. Furthermore, the method of computing Z-scores is different. DAVID took 
account of accurate fold-change information calculated using a negative binomial 
model to generate Z-scores, while GSEA used its own ranking list calculation, which is 
unlikely to be as accurate. 
Results from all of these tools should be taken as exploratory rather than definitive. 
Pathway analysis provides a broader view of genomic and transcriptomics data than 
do SNP-level or gene-level results, yet at the expense of making more assumptions.  
 
6.5 Limitations  
In this study, the pathway information was primarily based on human studies, which 
may have caused some bias. Also, in the GSEA analysis, to make the results 
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comparable with the DAVID analysis, the minimum number of genes in each gene sets 
was set as 2, which may have reduced statistical power. Most importantly, however, 
the use of only 16 RNA samples from 8 animals – while being a larger sample size than 
most previous gene expression studies in myopia models – will have severely limited 
statistical power to robustly identify molecular pathways.
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Chapter 7 General discussion and 
future work
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To identify myopia susceptibility loci, a GWAS was performed in a sample of chicks 
with FD-induced myopia. Transcriptomics analysis of chick retina was also performed 
with the aim of integrating genomic (GWAS) and transcriptomic data (RNA-seq) to 
pinpoint retinal genes that modulate the signalling pathway linking visual experience 
to ocular growth. Gene-based and gene set-based analyses were conducted using 
GWAS and transcriptomics analysis results, with the aim of enhancing the power of 
each method alone and improving the biological interpretation of the findings.  
 
7.1 Discussion of the key results 
Form-deprivation myopia was induced in a large sample of chicks (n=959). It was 
found that batch-to-batch variation, body weight, sex and a sex-by-body weight 
interaction were associated with the degree of axial eye elongation and the level of 
induced myopia (Chapter 3). A GWAS was carried out using 380 chicks (190 selected 
from each of the phenotype extremes of the myopia susceptibility distribution; i.e. 
high myopia susceptibility and low myopia susceptibility). Using the form-
deprivation-induced increase in axial length (∆AXL) as the primary outcome of 
interest, and after controlling for the effects of batch, sex and body weight, the 
GWAS identified a single genome-wide significant locus on chick chromosome 1 (lead 
SNP rs317386235) located between the genes PRKAR2B and PIK3CG (Chapter 4, 
section 4.3.2). Furthermore, 26 additional SNPs from chromosomes 1, 7 and 12 
exceeded the suggestive significance threshold of P <1.64e-05. Retinal RNA-seq-based 
transcriptomics analysis was performed for 16 eyes of 8 genotyped chicks; 4 selected 
as having a high degree of susceptibility to FDM and 4 selected as having a low 
myopia susceptibility. In a comparison of chicks with a high versus a low level of 
myopia susceptibility, 516 differentially-expressed genes were identified (FDR <0.05; 
Chapter 5, section 5.4.2.1). Although neither PRKAR2B nor PIK3CG were amongst 
these differentially expressed genes, the PIK3R5 gene was found to be differentially 
expressed. Furthermore, the PIK3CD (PI3K catalytic subunit delta) gene was also 
identified as being differentially expressed between high and low myopia chicks 
(Appendix 5.2, section 5.3.6).  
Phosphoinositide-3-Kinase Regulatory Subunit 5, encoded by PIK3R5, is an interaction 
partner of PIK3CG, suggesting that signalling through the enzyme PIK3 may partly 
determine myopia susceptibility. Gene-based analysis (Chapter 6, section 6.3.1.2) 
also suggested PIK3CG was the gene most strongly associated with the change in axial 
due to FD. Gene set-based analysis (Chapter 6, section 6.3.1.3) found no overlap 
between GWAS and RNA sequencing gene sets, but gene sets relating to circadian 
rhythm, extracellular matrix (ECM) structural remodelling, energy generation, 
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oxidative stress, glycometabolism and lipid metabolism were highlighted at a 
suggestive significance threshold. 
 
7.2 Pathways controlling myopia susceptibility 
My findings implicated several potential pathways that confer a difference in 
susceptibility to form-deprivation myopia. 
 
7.2.1 Insulin – PI3K – AKT signalling 
 
Figure 7.1 The Insulin receptor signalling pathway (451).  
 
In transcriptomics analysis, a down-regulation of glucagon and IGFBP4, and an up-
regulation of IGF1R were observed in the retina of chicks with high susceptibility to 
FD (Chapter 5, section 5.3.6). This suggests an up-regulation of signalling via insulin 
or an insulin-like growth factor (Figure 7.1). Pathway analysis further suggested 
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glycometabolism and lipid metabolism processes were involved in myopia 
susceptibility (Chapter 6, section 6.2.4). I speculate that all of these pathways were 
involved in the fast axial elongation occurring in the eyes of chicks with high 
susceptibility to FD, since they all relate to cellular metabolism, growth and survival 
(452). Previous studies had already identified the importance of insulin and insulin-
related genes in myopia development (310, 453, 454), although few researchers have 
investigated the downstream pathways. Nevertheless, one study reported that 
inhibition of PI3K by Ly294002 could partially block the effect of insulin-induced 
overcompensation to negative lens wear in chicks (309). This study by Penha et al. 
(309) demonstrated two findings, first, insulin could accelerate the elongation of 
axial length under form deprivation situation; second, the effect of insulin exerted 
its effect through activation of PI3K. These findings suggest the insulin – PI3K 
pathway might be involved in myopia formation, and, naturally-occurring variants 
controlling either the expression level or activity of PI3K might be associated with 
myopia susceptibility.  
 
7.2.2 PI3K and scleral extracellular matrix remodelling  
The scleral extracellular matrix (ECM) contains collagen fibres, proteoglycans, elastic 
fibres, and chondrocytes (442). During myopia development, there is a dynamic 
modulation of the ECM, including a reduction of type I collagen content (441, 455), a 
decrease in glycosaminoglycan content (441), and an increased expression of ECM-
degrading enzymes such as MMP-2 (456, 457). In chicks, proteoglycan synthesis 
increases after one day of FD and prior to vitreous chamber elongation (458). Several 
previous studies have identified the involvement of PI3K signalling pathways in the 
ECM remoulding process. In retinal pigment epithelial cells (459, 460) and the human 
renal proximal tubular cell line (HKC) (461), the PI3K pathway was activated during 
ECM remodelling (Figure 7.2) (462). 
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Figure 7.2. Illustration of the PI3K involved ECM remodelling process (462). 
 
However, in this study, due to the limitation of the experimental design, ECM related 
signals could only be detected if they derived from the retina. In transcriptomics 
analysis of chicks with high vs. low susceptibility to FD, differentially-expressed 
genes related to ECM, such as COL8A1, COL12A1, COL5A1, MXRA8, MMP16, CDH13 
(cell migration), CDH4, CDH8, ACTG1 and ARHGAP21 were found (Chapter 5, section 
5.3.6). Accordingly, in the subsequent pathway analysis, several pathways such as 
‘glycosaminoglycan degradation’, ‘positive regulation of extracellular matrix 
disassembly’, ‘complex of collagen trimers’ and ‘ keratan sulfate metabolic process’ 
reached a suggestive level of statistical significance (Chapter 6, section 6.3). 
Considering all of this information together, I hypothesize that during the FD-induced 
axial elongation process, PI3K is involved in extracellular matrix remodelling. Genetic 
variation in the expression level of PI3KCG might influence the rate of the 
remodelling process. From my results, it is not possible to infer whether the ECM 
related genes and pathways detected in retina play a role that is solely restricted to 
the retina, or if they are in some way connected to – or indicative of – ECM 
remodelling in the sclera.  
 
7.3 Strengths of the study 
This was the first study to perform a GWAS for myopia susceptibility in an animal 
model of myopia. Compared to conventional GWAS in humans, the current work has 
several notable features, as described below.  
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Firstly, in human populations, each individual is exposed to a different set of 
environmental risk factors. Therefore, detecting a specific gene-environment 
interaction requires an extremely large sample size (Chapter 4 section 4.1.2). In 
contrast, in the current experiment, all individuals in this study were exposed to a 
highly uniform environment; namely, they were treated with a single, specific visual 
exposure – form deprivation – known to robustly induce myopia. This uniformity was 
expected to dramatically increase statistical power to detect gene-environment 
interactions conferring susceptibility to myopia. 
Secondly, both refractive error and axial length were measured in the current study. 
Indeed, the main outcome measure (∆AXL) was an objectively-assessed ocular 
parameter that could be measured with high accuracy and reproducibility (463). To 
maximise the accuracy of quantifying the myopia susceptibility of individual chicks, 
axial length was recorded in both treated eyes and control eyes, both before and 
after FD. This enabled me to quantify myopia susceptibility (ΔAXL) in a manner that 
took account both of the eye size at baseline and the extent of eye growth in the 
fellow, non-treated eye. By contrast, in human GWAS investigations, the end-point 
ocular phenotype has generally been assessed, such as the refractive error in 
adulthood. This approach in human studies neglects the rate at which myopia 
develops. In this study, the use of ΔAXL accounted for baseline axial length before 
treatment and normal physiological growth, hence it represented a precise measure 
of susceptibility to FD.  
Thirdly, ‘systems genetics’ is already a well-known concept (341) that has been 
applied in a prior myopia study (78), however, human studies cannot access retinal 
tissue from GWAS participants during the critical period when myopia is developing. 
Using a chick myopia model provided a novel solution to this problem, and allowed a 
much more complete integration of transcriptomic data with GWAS data, providing 
the opportunity for a multi-dimensional, systematic assessment of myopia 
development.  
Fourthly, whereas past myopia transcriptomics studies have compared gene 
expression profiles between FD-treated eyes and control eyes, this study is the first 
to evaluate how myopia susceptibility impacts these treated eye versus control eye 
differences. When the comparison is between FD eyes and control eyes, it is difficult 
to know whether differential gene expression has occurred simply as a secondary 
consequence of having an enlarged, form-deprived eye, or whether the 
differentially-expressed gene is playing a potentially vital, causal role in signalling 
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the eye to grow. Moreover, the luminance level beneath a goggle is lower than 
normal, which could confound the results of conventional treated eye versus control 
eye comparisons. Here, making comparisons between high and low myopia 
susceptibility chicks removed this potential source of confounding. 
7.4 Limitations of the study 
Firstly – relatedness of the chick population. The chicks used in this study were 
obtained from a commercial supplier with a large breeding colony, which was done 
with the aim of minimizing relatedness between individuals. Nevertheless, kinship 
analysis showed a moderate level of relatedness amongst the majority of the chicks. 
Relatedness inflates association test statistics in a systematic manner (quantified by 
λGC), and therefore complicates the identification of ‘true positive’ GWAS signals. 
Although in this study, genomic control correction and mixed linear models were used 
to correct for or account for relatedness; both of these correction methods have 
limitations (Chapter 4, section 4.4.7).  
A second important limitation is that chicks are phylogenetically distant from 
mammals, which makes the findings from chick studies of uncertain relevance to 
humans. Comparing chick eyes with human eyes, chicken eyes have major 
differences such as lack of a fovea, a cartilaginous as well as a fibrous layer of the 
sclera, the presence of both corneal and lenticular accommodation, and a greater 
diversity of cone photoreceptor cell types (191). Researchers need to be cautious in 
assuming that findings in chick studies will translate to humans, considering all of 
these differences. 
Thirdly, owing to the relatively small sample size used, my study had limited power 
to detect genetic variants weakly associated with myopia susceptibility. This was 
especially true for the transcriptomics analysis in which funds permitted only 8 chicks 
to be investigated. This factor limited the power to detect differential gene 
expression, and also eliminated the chance to search for expression QTLs (eQTLs). 
Fourthly, form deprivation myopia is rare in humans (it can occur if congenital 
cataract or corneal opacification is not treated in infancy (464). Typically, children 
who develop myopia have clear ocular media, and thus the mechanism is different 
from form deprivation. Hence, another limitation is that the FD model I used does 
not fully replicate the nature of the cause of myopia in humans. Other myopia 
models exist, for example, chicks can be raised wearing negative lenses (LIM) or 
exposed to low ambient light (465). However, since the cause of myopia in children is 
largely unknown, no animal model can fully recapitulate the human situation. 
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 Finally, no imputation reference panel is available for the chicken, so it was not 
possible to impute genotypes at sites known to be polymorphic but that were not 
directly genotyped. Similarly, biological/physiological pathway databases for 
chickens are also limited in comparison to those available for humans.  
7.5 Future work 
In this study, a chick GWAS was used for mapping myopia susceptibility QTL, and 
transcriptomics analysis was used to refine the GWAS findings. Proposed future work 
to extend this approach would include the following sections. 
 
7.5.1 Expanding the number of genotyped chicks 
Only 380 chicks were genotyped in this study. Genotyping the full study cohort of 959 
chicks would improve statistical power to detect new genetic loci such as those with 
a small effect. Alternatively, to reduce costs, instead of performing whole genome 
genotyping, selected regions showing suggestive evidence of association in the 
original GWAS could be genotyped to enable fine-mapping to be performed in each 
selected region. 
 
7.5.2 eQTL analysis and validation of RNA-Seq results 
In GWAS analysis, the most strongly associated SNP (rs31738623) was located 
between the coding regions of the PRKAR2B and PIK3CG genes, which implied that 
the SNP might be an eQTL. To test the hypothesis that rs31738623 is a retinal eQTL 
for the protein encoded by either PRKAR2B or PIK3CG – or indeed a different nearby 
gene, would require the expression level of these genes to be quantified in retinal 
samples from a relatively large number of chicks, e.g. the 380 chicks that were 
genotyped here. Ideally, I would use RNA-seq to test this hypothesis (since this would 
allow a search for other eQTLs as well). However, the hypothesis could also be tested 
by using quantitative RT-PCR to measure the expression level of just the candidate 
genes in the PRKAR2B and PIK3CG region, in order to reduce the cost of the 
experiment. 
In the transcriptomic analysis using 8 chicks, hundreds of transcripts showed 
suggestive evidence (FDR <0.05) of differential expression in response to FD, and 
dozens of transcripts showed suggestive evidence of a treatment x group (High vs. 
Low) interaction. To validate these results, it will be necessary to examine retinal 
samples from an independent sample of chicks. While this could be done using 
RNAseq again, the use of an independent technique for assessing gene expression, 
such as quantitative RT-PCR, would provide stronger evidence.  
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7.5.3 Integration of findings from this study of chicks with human myopia 
studies 
The primary aim of my project was to identify myopia susceptibility genes, so that 
their role in human myopia development could be examined. There are several 
potential ways that my findings could be extended to humans. Firstly, I suggest 
performing a GWAS for the ‘rate of myopia progression’ in children. Using data from 
a longitudinal study such as ALSPAC (466), the growth trajectory of refractive error 
could be quantified using a linear mixed model, and this trait could serve as the 
phenotype for a GWAS. In the model, the longitudinal records of educational 
attainment, time spent outdoors, and near work could be adjusted as potential 
confounding factors. I hypothesize that the comparison between such a ‘rate of 
myopia progression GWAS’ in children and my chick study would highlight mechanisms 
relating to fast versus slow myopia development. Secondly, an inverse pathway 
analysis could be carried out in a human GWAS dataset. My pathway analysis results 
implicated the PI3K signalling pathway in regulating visually-guided refractive 
development. Hence, selecting genes in the PI3K pathway and applying an inverse 
pathway analysis using human GWAS summary statistics might provide a powerful 
strategy to detect genetic variants with small but important effects on myopia 
susceptibility. Thirdly, my results suggest it would be worthwhile to perform a 
Mendelian Randomization study testing for a causal role of insulin resistance (the 
‘exposure’) on myopia (the ‘outcome’). A relationship between insulin resistance and 
myopia progression has already received support from prior studies (106, 395, 467-
469). However, whether myopia and insulin resistance are linked through pleiotropic 
effects or if instead insulin resistance is a truly causal factor for myopia still needs to 
be determined. A Mendelian Randomization study would be a feasible method to test 
this hypothesis. As chicks have also been proposed as a diabetes model (470-472), 
testing diabetes and myopia in the same chick model may also determine the causal 
relationship between these two disorders. 
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Appendices 
Appendix 5.1. Transcripts differentially expressed (P < 0.05) between FD-treated 
eye and control eye using analysis Model 2, with 3 software packages. 
Gene ID 
edgeR DESeq2 limma 
logFC FDR  log2FC  P-adj  logFC P-adj 
VIP -1.09 2.67e-09 -0.97 4.07e-09 -1.02 0.01 
VIP -1.08 2.67e-09 -0.96 4.07e-09 -1.01 0.01 
UTS2B -0.87 2.01e-07 -0.86 NA -0.86 3.90e-03 
SPON1 -0.35 5.28e-07 -0.33 1.35e-07 -0.35 3.90e-03 
HK2 -0.33 6.00e-07 -0.36 6.64e-10 -0.33 0.01 
DIO2 -0.39 6.00e-07 -0.34 4.74e-07 -0.39 0.01 
NTS 0.40 6.00e-07 0.40 2.19e-06 0.40 0.01 
SIX3 -0.28 6.00e-07 -0.27 9.60e-04 -0.28 0.01 
DIO2 -0.38 9.03e-07 -0.33 1.18e-06 -0.38 0.01 
KCNA4 -0.28 4.36e-06 -0.29 1.34e-03 -0.28 0.01 
ACSBG2 0.45 4.91e-06 0.46 5.12e-05 0.45 0.01 
UNC5C -0.31 4.91e-06 -0.32 8.02e-04 -0.31 0.01 
TERF1 0.44 4.91e-06 0.39 9.62e-04 0.45 0.01 
APC2 -0.30 6.73e-06 -0.30 1.21e-05 -0.30 0.01 
OPN4 -0.37 6.73e-06 -0.38 4.45e-05 -0.37 0.01 
SWAP70 0.27 1.64e-05 0.25 2.11e-03 0.27 0.01 
MSMO1 0.33 4.03e-05 0.36 1.68e-07 0.33 0.01 
PTPRU -0.28 4.03e-05 -0.29 8.02e-04 -0.28 0.01 
C14orf2 0.34 4.03e-05 0.34 2.17e-03 0.33 0.02 
STARD4 0.30 8.46e-05 0.32 1.21e-05 0.30 0.01 
OPN4-1 -0.24 8.46e-05 -0.23 3.30e-03 -0.24 0.01 
MZT1 0.27 8.46e-05 0.27 0.01 0.27 0.01 
MAFF -0.56 1.24e-04 -0.53 1.67e-03 -0.55 0.02 
RASA4B -0.28 1.59e-04 -0.28 0.01 -0.28 0.01 
GAS2L3 0.72 2.23e-04 0.69 NA 0.74 0.01 
NCOA1 -0.33 2.91e-04 -0.35 1.96e-03 -0.33 0.02 
SPRY4 -0.89 2.91e-04 -0.82 NA -0.89 0.02 
HDAC7 -0.46 3.21e-04 -0.48 1.65e-03 -0.45 0.02 
PCDH19 -0.25 3.39e-04 -0.25 0.01 -0.25 0.02 
SPRY4 -0.88 3.39e-04 -0.81 NA -0.89 0.02 
ARL6 0.24 4.21e-04 0.24 4.49e-03 0.24 0.02 
RAD54L2 -0.25 5.05e-04 -0.26 2.72e-03 -0.25 0.02 
SYT13 -0.24 5.25e-04 -0.22 0.01 -0.24 0.02 
PNPLA6 -0.28 5.37e-04 -0.27 0.02 -0.29 0.02 
TUBB -0.28 5.62e-04 -0.28 0.01 -0.28 0.02 
ATP13A2 -0.38 5.62e-04 -0.38 0.01 -0.38 0.02 
FABP9 0.51 7.82e-04 0.52 2.11e-03 0.52 0.02 
CNTN2 -0.27 7.82e-04 -0.28 0.01 -0.27 0.02 
UFM1 0.25 8.16e-04 0.27 0.01 0.25 0.02 
BRD2 -0.24 8.16e-04 -0.24 0.01 -0.24 0.02 
ST8SIA2 -0.31 8.29e-04 -0.30 0.01 -0.31 0.03 
RHOT2 -0.31 8.55e-04 -0.29 0.02 -0.31 0.02 
TNS1 -0.52 8.99e-04 -0.56 1.67e-03 -0.51 0.02 
MGAT3 -0.20 8.99e-04 -0.19 0.01 -0.20 0.01 
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NPAS2 -0.24 8.99e-04 -0.24 0.01 -0.24 0.02 
MRPL53 0.26 8.99e-04 0.27 0.01 0.26 0.02 
LMBR1 -0.26 9.53e-04 -0.24 0.03 -0.26 0.03 
TGFBI 0.32 9.62e-04 0.33 0.01 0.32 0.02 
C7orf73 0.23 9.72e-04 0.20 0.04 0.23 0.02 
ADORA2B -0.28 1.24e-03 -0.25 0.03 -0.29 0.03 
FOXP1 -0.38 1.35e-03 -0.40 0.01 -0.38 0.02 
P4HB 0.23 1.49e-03 0.23 0.02 0.23 0.02 
COX7B 0.23 1.55e-03 0.24 0.01 0.23 0.02 
CRYAB 0.56 1.66e-03 0.41 0.01 0.58 0.03 
NCAN -0.39 1.66e-03 -0.36 0.02 -0.39 0.01 
DUSP4 -1.06 1.66e-03 -1.00 NA -1.08 0.03 
DNMT3A -0.27 1.68e-03 -0.31 1.96e-03 -0.27 0.03 
ATP6V0D2 0.28 1.73e-03 0.26 0.03 0.28 0.03 
GFRA2 -0.27 1.73e-03 -0.25 0.03 -0.27 0.02 
RARA -0.30 1.75e-03 -0.30 0.02 -0.30 0.02 
LIMS1 0.21 1.81e-03 0.20 0.04 0.21 0.02 
PPAP2B -0.25 1.82e-03 -0.26 0.03 -0.25 0.03 
COX6C 0.21 1.87e-03 0.22 0.01 0.21 0.02 
RAP1GAP2 -0.21 1.87e-03 -0.20 0.02 -0.21 0.02 
MPC1L 0.21 2.01e-03 0.20 0.03 0.21 0.02 
PAN2 -0.25 2.01e-03 -0.25 0.03 -0.26 0.03 
GLI2 -0.67 2.01e-03 -0.69 NA -0.68 0.03 
MRPS17 0.21 2.01e-03 0.21 0.04 0.22 0.02 
CLU -0.29 2.06e-03 -0.26 4.31e-03 -0.29 0.02 
GMFB 0.21 2.06e-03 0.21 0.04 0.21 0.02 
GIT1 -0.32 2.15e-03 -0.33 0.02 -0.32 0.03 
LOC421975 0.21 2.26e-03 0.24 1.65e-03 0.21 0.02 
RBP3 0.23 2.44e-03 0.25 8.60e-05 0.23 0.02 
ETV5 -0.51 2.44e-03 -0.50 1.09e-04 -0.51 0.01 
NUMA1 -0.27 2.44e-03 -0.30 1.88e-04 -0.27 0.02 
BCL6 -0.24 2.44e-03 -0.24 2.08e-04 -0.24 0.01 
UQCRB 0.27 2.44e-03 0.29 2.08e-04 0.27 0.01 
CDKN1A 0.33 2.44e-03 0.35 4.42e-04 0.32 0.02 
CSRP2 0.32 2.44e-03 0.29 4.42e-04 0.32 0.01 
SLC2A1 -0.25 2.44e-03 -0.22 4.51e-04 -0.25 0.01 
LRP1 -0.30 2.44e-03 -0.33 4.51e-04 -0.30 0.02 
MDH1 0.26 2.44e-03 0.28 4.77e-04 0.26 0.03 
MDH1 0.26 2.44e-03 0.28 4.77e-04 0.26 0.03 
BHLHE40 -0.29 2.44e-03 -0.29 6.61e-04 -0.29 0.01 
GLS2 -0.26 2.44e-03 -0.26 7.98e-04 -0.26 0.01 
ME1 0.24 2.44e-03 0.24 7.98e-04 0.24 0.02 
RGS16 -0.39 2.47e-03 -0.35 0.03 -0.38 0.02 
INPP5K 0.24 2.63e-03 0.22 2.66e-03 0.24 0.02 
KCNAB1 -0.21 2.63e-03 -0.17 0.03 -0.21 0.02 
TMEM167A 0.23 2.64e-03 0.24 0.02 0.23 0.03 
CREBL2 0.25 2.64e-03 0.23 0.05 0.25 0.03 
GLI2 -0.65 2.82e-03 -0.68 NA -0.67 0.03 
ELL -0.24 2.90e-03 -0.23 0.05 -0.24 0.03 
SDK2 -0.30 2.93e-03 -0.32 0.01 -0.30 0.04 
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HDAC4 -0.28 2.93e-03 -0.29 0.01 -0.28 0.03 
PDDC1 0.21 2.93e-03 0.20 0.06 0.21 0.02 
GORASP1 0.18 2.98e-03 0.19 0.02 0.18 0.02 
PRELID3A 0.21 2.98e-03 0.21 0.05 0.21 0.02 
KCNIP2 -0.20 3.06e-03 -0.17 0.07 -0.20 0.03 
EWSR1 -0.18 3.12e-03 -0.20 0.01 -0.18 0.02 
TLN1 -0.21 3.12e-03 -0.22 0.03 -0.21 0.03 
PDDC1 0.21 3.12e-03 0.20 0.06 0.21 0.02 
LIMK1 -0.37 3.13e-03 -0.32 0.04 -0.37 0.02 
ZNF384 -0.24 3.13e-03 -0.23 0.05 -0.25 0.03 
KIT -0.19 3.15e-03 -0.21 0.02 -0.19 0.02 
MPHOSPH6 0.24 3.40e-03 0.23 0.04 0.24 0.03 
CORO7-PAM16 -0.24 3.41e-03 -0.23 0.04 -0.24 0.03 
DHCR7 0.22 3.47e-03 0.24 0.01 0.22 0.03 
COL9A2 -0.85 3.54e-03 -0.83 NA -0.84 0.03 
CYB5B 0.23 3.62e-03 0.19 0.07 0.22 0.03 
FABP5 0.21 3.80e-03 0.19 0.03 0.21 0.03 
SZT2 -0.25 3.95e-03 -0.25 0.02 -0.25 0.03 
IGSF11 -0.20 4.03e-03 -0.18 0.06 -0.21 0.03 
STK10 -0.21 4.04e-03 -0.24 0.01 -0.21 0.03 
DHCR24 0.24 4.11e-03 0.27 0.01 0.24 0.04 
LOC107050474 -0.32 4.21e-03 -0.34 0.01 -0.31 0.03 
UGT8 0.26 4.29e-03 0.25 0.04 0.25 0.03 
COX20 0.26 4.29e-03 0.25 0.04 0.27 0.03 
SLC6A9 -0.25 4.51e-03 -0.21 0.01 -0.25 0.03 
UNC5B -0.23 4.51e-03 -0.23 0.05 -0.23 0.03 
PCDHGA2 -0.45 4.55e-03 -0.48 0.01 -0.45 0.04 
HYAL6 0.28 4.55e-03 0.29 0.02 0.27 0.03 
KIAA0907 -0.19 4.64e-03 -0.16 0.06 -0.19 0.03 
PCDH8 -0.23 0.01 -0.20 0.08 -0.23 0.03 
DPY30 0.21 0.01 0.21 0.05 0.21 0.03 
PHOSPHO1 -0.25 0.01 -0.24 0.05 -0.25 0.03 
C5H14ORF166 0.21 0.01 0.22 0.02 0.21 0.03 
SNRPF 0.29 0.01 0.31 0.02 0.30 0.03 
FBXL21 0.19 0.01 0.19 0.02 0.19 0.03 
17.5 -0.50 0.01 -0.56 2.72e-03 -0.52 0.03 
SSR3 0.20 0.01 0.23 0.01 0.20 0.03 
ZNF335 -0.17 0.01 -0.17 0.04 -0.17 0.02 
FBXL21 0.19 0.01 0.19 0.02 0.19 0.03 
CNGA1 0.23 0.01 0.26 0.02 0.23 0.04 
LACTB2 0.23 0.01 0.26 0.02 0.23 0.04 
DCTD 0.34 0.01 0.36 0.02 0.32 0.03 
CRABP1 0.26 0.01 0.26 0.04 0.27 0.04 
PCDHGA2 -0.23 0.01 -0.25 0.01 -0.23 0.04 
SMPX 0.78 0.01 0.89 NA 0.77 0.03 
SRC -0.31 0.01 -0.32 0.03 -0.31 0.03 
UCHL3 0.18 0.01 0.19 0.04 0.18 0.03 
UQCRHL 0.20 0.01 0.21 0.04 0.20 0.03 
GPR137B -0.30 0.01 -0.23 0.07 -0.30 0.03 
CAMK2B -0.39 0.01 -0.42 0.03 -0.39 0.02 
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TET2 -0.31 0.01 -0.32 0.02 -0.31 0.05 
KCNH6 -0.28 0.01 -0.28 0.03 -0.28 0.05 
NME3 0.18 0.01 0.19 0.04 0.18 0.03 
FBXO32 -0.17 0.01 -0.17 0.07 -0.17 0.03 
MAEA 0.19 0.01 0.21 0.02 0.19 0.03 
APEH -0.25 0.01 -0.26 0.04 -0.25 0.04 
ZNF609 -0.20 0.01 -0.21 0.02 -0.20 0.03 
HSPE1 0.18 0.01 0.16 0.07 0.18 0.03 
GNG10 0.27 0.01 0.27 0.05 0.27 0.02 
OPTC -0.33 0.01 -0.31 0.04 -0.32 0.05 
LINGO1 -0.17 0.01 -0.15 0.11 -0.17 0.03 
TFAP2B -0.22 0.01 -0.21 0.06 -0.22 0.04 
CHCHD4 0.26 0.01 0.25 0.05 0.26 0.03 
FABP7 0.34 0.01 0.28 0.05 0.36 0.05 
ST3GAL5 0.19 0.01 0.20 0.06 0.19 0.03 
MERTK -0.38 0.01 -0.35 0.07 -0.39 0.02 
HBP1 -0.19 0.01 -0.16 0.11 -0.19 0.03 
ACTR6 0.20 0.01 0.22 0.01 0.20 0.04 
COPS2 0.18 0.01 0.19 0.02 0.18 0.03 
ZDHHC5 -0.20 0.01 -0.19 0.08 -0.20 0.04 
FOSL2 -0.45 0.01 -0.46 NA -0.44 0.03 
MYH11 -0.34 0.01 -0.37 0.02 -0.34 0.03 
HMGCS1 0.21 0.01 0.23 0.01 0.21 0.03 
UCHL1 0.26 0.01 0.28 0.01 0.26 0.04 
SELENOF 0.20 0.01 0.20 0.04 0.20 0.04 
CYCS 0.23 0.01 0.23 0.05 0.23 0.04 
FAM103A1 0.24 0.01 0.27 0.01 0.24 0.05 
RSL24D1 0.19 0.01 0.18 0.06 0.19 0.04 
GLCCI1 -0.18 0.01 -0.19 0.04 -0.18 0.03 
FAM103A1 0.23 0.01 0.26 0.01 0.23 0.05 
PTK7 -0.18 0.01 -0.18 0.06 -0.18 0.03 
MBP 0.24 0.01 0.27 1.68e-03 0.24 0.03 
ATP5G3 0.20 0.01 0.22 0.01 0.20 0.04 
LAMB2 -0.39 0.01 -0.43 0.02 -0.40 0.03 
EMC2 0.20 0.01 0.18 0.05 0.20 0.04 
PPP1R12B -0.38 0.01 -0.36 0.06 -0.37 0.03 
PALM -0.20 0.01 -0.19 0.07 -0.20 0.05 
OLA1 0.18 0.01 0.17 0.09 0.18 0.04 
IGHMBP2 -0.18 0.01 -0.18 0.09 -0.18 0.03 
EIF1AX 0.23 0.01 0.23 0.01 0.23 0.03 
HSBP1 0.21 0.01 0.21 0.02 0.21 0.04 
MAB21L1 -0.24 0.01 -0.28 0.01 -0.24 0.05 
NT5C2 -0.17 0.01 -0.16 0.04 -0.17 0.03 
LOC431499 -0.28 0.01 -0.25 0.09 -0.30 0.03 
UBE2L3 0.19 0.01 0.21 0.01 0.19 0.04 
IL17RD 0.32 0.01 0.31 0.06 0.32 0.03 
ATP5G3 0.19 0.01 0.22 0.02 0.19 0.04 
XYLT2 -0.21 0.01 -0.22 0.06 -0.21 0.03 
PBX1 -0.22 0.01 -0.22 0.06 -0.22 0.05 
CSNK1E -0.18 0.01 -0.17 0.11 -0.18 0.04 
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ATP5G3 0.19 0.01 0.22 0.02 0.19 0.04 
NET1 0.19 0.01 0.21 0.03 0.19 0.05 
EFNB1 -0.25 0.01 -0.23 0.08 -0.25 0.04 
MTERF3 0.24 0.01 0.27 0.02 0.23 0.03 
PER3 -0.24 0.01 -0.26 0.02 -0.24 0.05 
FBXL16 -0.32 0.01 -0.33 0.04 -0.32 0.03 
SP1 -0.42 0.01 -0.43 0.04 -0.44 0.04 
TXNDC12 0.21 0.01 0.22 0.06 0.21 0.04 
ODF2 -0.19 0.01 -0.19 0.08 -0.19 0.04 
FUNDC1 0.17 0.01 0.16 0.06 0.17 0.03 
CKB 0.22 0.01 0.25 4.31e-03 0.22 0.05 
WWP2 -0.19 0.01 -0.19 0.09 -0.19 0.04 
LZIC 0.16 0.01 0.17 0.04 0.16 0.03 
HSP90B1 0.22 0.01 0.18 0.02 0.21 0.03 
EPB41 -0.26 0.01 -0.27 0.01 -0.26 0.04 
NRBP1 -0.16 0.01 -0.18 0.03 -0.16 0.03 
RWDD3 0.20 0.01 0.20 0.09 0.20 0.04 
LIN7C 0.18 0.01 0.18 0.01 0.18 0.03 
GNRH1 0.29 0.01 0.30 0.04 0.29 0.03 
SLC9A1 -0.40 0.01 -0.38 0.04 -0.38 0.06 
NLGN3 -0.34 0.01 -0.38 0.02 -0.34 0.05 
DCK 0.21 0.01 0.25 0.02 0.21 0.05 
RGMA -0.31 0.01 -0.30 0.06 -0.30 0.03 
NDUFB1 0.20 0.01 0.17 0.06 0.20 0.04 
ARL8BL 0.23 0.01 0.25 0.04 0.23 0.05 
RNF7 0.18 0.01 0.17 0.08 0.18 0.05 
HSDL1 0.21 0.01 0.23 0.04 0.21 0.04 
FBF1 -0.18 0.01 -0.21 0.02 -0.18 0.04 
FN3KRP 0.20 0.01 0.19 0.04 0.20 0.04 
LMF2 -0.25 0.01 -0.20 0.11 -0.25 0.05 
FUNDC1 0.16 0.01 0.16 0.06 0.16 0.03 
ARNT -0.17 0.01 -0.16 0.10 -0.17 0.04 
NREP 0.18 0.02 0.20 7.98e-04 0.18 0.03 
DNMT1 -0.25 0.02 -0.28 0.03 -0.25 0.06 
ACAT1 0.19 0.02 0.21 0.04 0.19 0.05 
GMPR2 -0.17 0.02 -0.18 0.10 -0.18 0.04 
NDUFB1 0.19 0.02 0.17 0.07 0.19 0.05 
NDUFB1 0.19 0.02 0.17 0.07 0.19 0.05 
CNOT8 0.16 0.02 0.16 0.08 0.16 0.04 
PNRC1 -0.18 0.02 -0.18 0.01 -0.18 0.02 
MAB21L2 -0.33 0.02 -0.29 0.09 -0.32 0.04 
SREBF1 -0.28 0.02 -0.29 0.04 -0.29 0.06 
TXN2 0.22 0.02 0.22 0.05 0.22 0.06 
ZNF692 -0.32 0.02 -0.31 0.07 -0.31 0.03 
PHAX 0.16 0.02 0.17 0.05 0.16 0.04 
ATG9A -0.21 0.02 -0.19 0.11 -0.21 0.06 
MCFD2 0.20 0.02 0.20 0.04 0.20 0.05 
PALM -0.21 0.02 -0.20 0.09 -0.21 0.06 
GABRQ -0.29 0.02 -0.30 0.05 -0.30 0.05 
CD69L -0.50 0.02 -0.58 0.01 -0.53 0.04 
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COL2A1 -0.19 0.02 -0.20 0.05 -0.19 0.05 
BRINP1 -0.15 0.02 -0.14 0.09 -0.15 0.03 
FOS -0.71 0.02 -0.61 NA -0.72 0.06 
KDM5B -0.17 0.02 -0.17 0.01 -0.17 0.02 
UQCRFS1 0.18 0.02 0.21 0.02 0.18 0.05 
GABRQ -0.29 0.02 -0.30 0.05 -0.30 0.05 
H2AFZ 0.17 0.02 0.19 0.07 0.17 0.05 
FN1 -0.24 0.02 -0.23 0.08 -0.24 0.06 
MAP3K14 -0.18 0.02 -0.18 0.10 -0.18 0.04 
RSPO2 -0.65 0.02 -0.59 NA -0.64 0.04 
LSM7 0.26 0.02 0.22 0.11 0.27 0.05 
OSTC 0.17 0.02 0.19 0.04 0.17 0.05 
ACTN4 -0.17 0.02 -0.20 0.02 -0.17 0.04 
PLXNB3 -0.24 0.02 -0.26 0.02 -0.24 0.05 
DISP3 -0.19 0.02 -0.19 0.07 -0.19 0.05 
GBX2 -0.50 0.02 -0.46 NA -0.50 0.05 
MCTS1 0.20 0.02 0.23 0.04 0.20 0.05 
P4HA1 -0.17 0.02 -0.18 0.01 -0.17 0.03 
P4HA1 -0.17 0.02 -0.18 0.01 -0.17 0.03 
COX4I1 0.21 0.02 0.19 0.03 0.20 0.04 
IGFBP4 -0.28 0.02 -0.28 0.05 -0.27 0.07 
CLCN7 -0.23 0.02 -0.17 0.14 -0.23 0.06 
TWF1 0.17 0.02 0.19 1.03e-03 0.17 0.02 
MPP1 -0.16 0.02 -0.15 0.12 -0.16 0.04 
KCNA3 -0.40 0.02 -0.38 0.08 -0.40 0.05 
CYP51A1 0.18 0.02 0.18 0.05 0.18 0.05 
ZNF512B -0.16 0.02 -0.15 0.12 -0.16 0.05 
ZNF341 -0.20 0.02 -0.20 0.11 -0.21 0.04 
RNF123 -0.19 0.02 -0.18 0.09 -0.19 0.05 
P4HA1 -0.17 0.02 -0.18 0.01 -0.17 0.03 
DUSP1 -0.29 0.02 -0.26 0.09 -0.27 0.07 
ZNF512B -0.16 0.02 -0.15 0.12 -0.16 0.05 
HSP90AB1 0.18 0.02 0.18 0.10 0.18 0.06 
P4HA1 -0.17 0.02 -0.18 0.01 -0.17 0.03 
SUB1 0.19 0.02 0.18 0.02 0.19 0.03 
RAN 0.21 0.02 0.19 0.04 0.21 0.04 
ACADS -0.18 0.02 -0.18 0.10 -0.17 0.05 
PPIF 0.18 0.02 0.21 0.05 0.18 0.05 
MST1 -0.77 0.02 -0.73 NA -0.77 0.06 
ECE1 -0.19 0.02 -0.18 0.12 -0.19 0.05 
MDGA1 -0.21 0.02 -0.23 0.04 -0.21 0.06 
COX7A2 0.17 0.02 0.16 0.06 0.17 0.04 
ZNF512B -0.16 0.02 -0.15 0.12 -0.16 0.05 
OAZ1 0.21 0.02 0.20 0.03 0.21 0.05 
HDDC2 0.21 0.02 0.20 0.10 0.21 0.05 
KCNJ3 -0.32 0.02 -0.29 0.09 -0.31 0.05 
RPAP3 0.17 0.02 0.14 0.12 0.17 0.05 
TNFRSF21 -0.15 0.02 -0.14 0.10 -0.15 0.04 
DCTN1 -0.16 0.02 -0.17 0.01 -0.16 0.03 
ISCA1 0.17 0.02 0.19 0.03 0.17 0.05 
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KRR1 0.18 0.02 0.18 0.10 0.18 0.05 
HMGCR 0.20 0.02 0.20 0.03 0.20 0.04 
OSBPL2 0.20 0.02 0.16 0.04 0.20 0.04 
ASNS 0.20 0.02 0.21 0.08 0.20 0.03 
EMC3 0.15 0.02 0.16 0.08 0.15 0.05 
COL6A1 -0.37 0.02 -0.41 0.03 -0.38 0.05 
TOB1 -0.24 0.02 -0.27 0.03 -0.24 0.07 
SCP2 0.20 0.02 0.20 0.04 0.20 0.05 
PRKAA2 -0.30 0.02 -0.31 0.05 -0.30 0.07 
POLR2L 0.20 0.02 0.21 0.08 0.20 0.04 
TAOK3 -0.22 0.02 -0.22 0.09 -0.22 0.05 
SEPT2L 0.19 0.02 0.19 0.03 0.19 0.04 
CALB1 0.28 0.02 0.21 0.06 0.28 0.07 
ABRACL 0.33 0.02 0.33 0.09 0.33 0.03 
GAS2 0.35 0.02 0.30 0.10 0.36 0.05 
HMGN1 0.20 0.02 0.20 0.04 0.20 0.05 
THOC7 0.18 0.02 0.20 0.05 0.18 0.06 
FGFR1 -0.18 0.02 -0.18 0.08 -0.18 0.06 
GTF2E2 0.19 0.03 0.18 0.11 0.19 0.06 
FURIN -0.22 0.03 -0.22 0.10 -0.22 0.05 
SDC3 -0.22 0.03 -0.20 0.13 -0.22 0.06 
ID2 0.18 0.03 0.21 0.04 0.18 0.06 
PRNP -0.16 0.03 -0.15 0.04 -0.16 0.03 
RER1 0.16 0.03 0.12 0.19 0.16 0.05 
MVB12A -0.17 0.03 -0.16 0.13 -0.17 0.04 
MAFK -0.41 0.03 -0.36 NA -0.41 0.05 
GNAI2 -0.23 0.03 -0.20 0.13 -0.23 0.05 
MAGOH 0.20 0.03 0.23 0.04 0.20 0.06 
PSMD12 0.21 0.03 0.14 0.15 0.22 0.07 
MAGOH 0.20 0.03 0.23 0.04 0.20 0.06 
ARID5B -0.24 0.03 -0.26 0.05 -0.24 0.07 
PARK7 0.19 0.03 0.20 0.04 0.19 0.05 
MED24 -0.24 0.03 -0.23 0.11 -0.25 0.07 
FGL2 0.60 0.03 0.65 NA 0.68 0.05 
PCDHA11 -0.45 0.03 -0.58 1.64e-03 -0.45 0.09 
LOC100858655 -0.37 0.03 -0.40 0.06 -0.36 0.05 
VPS29 0.16 0.03 0.17 0.06 0.16 0.05 
ASMT 0.19 0.03 0.20 0.09 0.18 0.07 
NEK7 0.15 0.03 0.15 0.10 0.15 0.05 
PAK1IP1 0.18 0.03 0.18 0.11 0.18 0.06 
GTF2H5 0.16 0.03 0.16 0.06 0.16 0.05 
SUCLG1 0.16 0.03 0.17 0.04 0.16 0.05 
DLD 0.17 0.03 0.18 0.06 0.17 0.05 
SLC16A9 0.34 0.03 0.35 0.10 0.34 0.04 
PCDHA4 -0.42 0.03 -0.53 2.11e-03 -0.42 0.08 
PSMC1 0.17 0.03 0.17 0.05 0.17 0.05 
SLC5A1 -0.70 0.03 -0.78 NA -0.72 0.07 
PTPN9 -0.38 0.03 -0.37 0.10 -0.38 0.04 
C2H6orf52 0.16 0.03 0.17 0.10 0.16 0.05 
YPEL5 0.18 0.03 0.19 0.02 0.18 0.04 
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CMPK1 0.15 0.03 0.15 0.07 0.15 0.05 
PKP4 -0.14 0.03 -0.14 0.10 -0.14 0.04 
ASXL2 -0.15 0.03 -0.14 0.11 -0.15 0.05 
CLK2 -0.17 0.03 -0.17 0.12 -0.17 0.05 
CALM2 0.22 0.03 0.22 0.03 0.22 0.07 
SNX24 0.19 0.03 0.20 0.10 0.18 0.06 
YIPF5 0.16 0.03 0.17 0.11 0.16 0.06 
CASP3 0.20 0.03 0.19 0.13 0.21 0.05 
EEF1AKMT1 0.28 0.03 0.25 0.12 0.29 0.04 
PDLIM7 -0.47 0.03 -0.48 NA -0.47 0.05 
RHOBTB1 -0.18 0.03 -0.19 0.08 -0.18 0.07 
SORL1 -0.21 0.03 -0.22 0.03 -0.21 0.06 
NDUFA10 0.17 0.03 0.17 0.03 0.17 0.04 
NSUN2 -0.16 0.03 -0.18 0.08 -0.16 0.05 
UQCR10 0.17 0.03 0.20 0.05 0.17 0.07 
TESC -0.46 0.03 -0.53 NA -0.46 0.04 
TWF1 0.15 0.03 0.18 0.05 0.15 0.06 
NDUFB5 0.17 0.03 0.17 0.08 0.17 0.06 
ZFAND6 0.16 0.03 0.15 0.09 0.16 0.05 
NRP2 -0.23 0.03 -0.23 0.11 -0.23 0.06 
SLC51A -0.80 0.03 -0.78 NA -0.79 0.07 
PTN 0.14 0.03 0.15 0.01 0.14 0.05 
NME1 0.20 0.03 0.21 0.03 0.20 0.05 
MAGI3 -0.17 0.03 -0.18 0.03 -0.17 0.04 
SLCO4A1 -0.18 0.03 -0.18 0.12 -0.19 0.06 
TMEM41B 0.16 0.03 0.15 0.13 0.16 0.06 
PHACTR1 -0.15 0.03 -0.15 0.15 -0.15 0.06 
C1D 0.24 0.03 0.25 0.09 0.24 0.05 
Sep-09 -0.15 0.03 -0.13 0.11 -0.15 0.05 
ACVR2B -0.23 0.03 -0.22 0.12 -0.22 0.05 
LOC421792 0.29 0.03 0.27 0.13 0.29 0.04 
DNAJC2 0.15 0.03 0.14 0.18 0.15 0.06 
GLI1 -0.29 0.03 -0.32 0.07 -0.29 0.04 
C26H6ORF125 0.22 0.03 0.20 0.13 0.22 0.05 
HNRNPH3 0.21 0.03 0.19 0.06 0.20 0.06 
ALG12 0.13 0.03 0.13 0.13 0.13 0.05 
C10H15ORF59 -0.21 0.03 -0.20 0.14 -0.21 0.07 
HYDIN -0.21 0.03 -0.23 0.06 -0.21 0.08 
TFCP2 -0.20 0.03 -0.17 0.18 -0.20 0.06 
PCDHA5 -0.44 0.03 -0.57 1.68e-03 -0.43 0.10 
RFK 0.16 0.04 0.13 0.18 0.16 0.07 
ZFAND6 0.16 0.04 0.15 0.09 0.16 0.06 
NEURL1 -0.18 0.04 -0.15 0.15 -0.18 0.07 
TCF3 -0.19 0.04 -0.19 0.11 -0.19 0.07 
PCDHA1 -0.44 0.04 -0.56 1.96e-03 -0.43 0.10 
PSMD5 0.16 0.04 0.18 0.06 0.16 0.07 
CSPG5 -0.18 0.04 -0.14 0.14 -0.18 0.07 
C1D 0.23 0.04 0.24 0.10 0.23 0.05 
LOC425783 -0.40 0.04 -0.51 0.01 -0.44 0.06 
ACAT2 0.20 0.04 0.24 0.04 0.20 0.07 
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THY1 -0.19 0.04 -0.16 0.10 -0.19 0.06 
NDUFS3 0.18 0.04 0.18 0.11 0.18 0.08 
ZFAND6 0.16 0.04 0.15 0.10 0.16 0.06 
RPA2 0.17 0.04 0.18 0.10 0.17 0.05 
PRPSAP2 0.16 0.04 0.15 0.12 0.16 0.06 
TRAPPC2 0.16 0.04 0.17 0.10 0.16 0.07 
OARD1 0.18 0.04 0.17 0.15 0.19 0.07 
ATP6AP1 0.16 0.04 0.19 0.08 0.16 0.05 
DNAJB9 0.15 0.04 0.14 0.18 0.16 0.06 
AP1S2 0.16 0.04 0.14 0.06 0.16 0.04 
HEATR3 0.15 0.04 0.18 0.04 0.15 0.06 
GCLM 0.14 0.04 0.15 0.16 0.15 0.05 
PITPNB 0.17 0.04 0.13 0.20 0.17 0.07 
CECR2 -0.18 0.04 -0.23 0.03 -0.19 0.07 
SNRPA1 0.17 0.04 0.18 0.11 0.17 0.07 
MRPS25 0.19 0.04 0.19 0.14 0.19 0.06 
LDB1 -0.31 0.04 -0.39 0.01 -0.32 0.07 
LHX9 -0.24 0.04 -0.22 0.13 -0.24 0.06 
PCDHA9 -0.44 0.04 -0.57 1.67e-03 -0.43 0.11 
PCDHA8 -0.44 0.04 -0.57 1.67e-03 -0.43 0.11 
TMX4 0.16 0.04 0.16 0.03 0.16 0.04 
DUT 0.16 0.04 0.16 0.16 0.16 0.05 
PIK3R5 0.17 0.04 0.14 0.22 0.17 0.06 
PCDHA3 -0.43 0.04 -0.55 2.11e-03 -0.42 0.11 
CCNL2 -0.15 0.04 -0.16 0.07 -0.15 0.05 
C12orf75 0.25 0.04 0.24 0.12 0.25 0.05 
PCDHA2 -0.43 0.04 -0.55 2.12e-03 -0.42 0.11 
SLC31A1 0.18 0.04 0.21 0.06 0.18 0.06 
SLC31A1 0.18 0.04 0.21 0.06 0.18 0.06 
POLE3 0.20 0.04 0.21 0.09 0.20 0.07 
NR2F2 -0.16 0.04 -0.18 0.09 -0.16 0.07 
ARPC5 0.16 0.04 0.17 0.11 0.16 0.07 
IER3IP1 0.18 0.04 0.19 0.11 0.18 0.05 
NSMCE3 0.14 0.04 0.15 0.13 0.14 0.05 
AXIN1 -0.16 0.04 -0.17 0.14 -0.16 0.06 
SGF29 -0.18 0.04 -0.16 0.16 -0.17 0.08 
MYD88 0.19 0.04 0.21 0.09 0.19 0.04 
C22H2ORF42 -0.25 0.04 -0.26 0.09 -0.25 0.05 
ABCE1 0.16 0.04 0.17 0.04 0.16 0.05 
PEX13 0.14 0.04 0.16 0.10 0.14 0.06 
POLR2D 0.20 0.04 0.20 0.12 0.20 0.04 
RAP1B 0.14 0.04 0.12 0.17 0.14 0.06 
KCNN2 -0.27 0.04 -0.26 0.12 -0.27 0.05 
DNAJC15 0.16 0.04 0.17 0.13 0.16 0.05 
DHFR 0.34 0.04 0.32 0.15 0.36 0.04 
ZC3H3 -0.15 0.04 -0.15 0.16 -0.15 0.07 
RWDD1 0.25 0.04 0.18 0.20 0.27 0.06 
ERH 0.19 0.04 0.15 0.17 0.19 0.08 
VEZF1 -0.24 0.04 -0.25 0.09 -0.24 0.09 
C5H15ORF57 0.15 0.04 0.16 0.09 0.15 0.06 
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ALDH1A1 0.28 0.04 0.28 0.11 0.27 0.08 
CDC25A -0.24 0.04 -0.20 0.19 -0.25 0.05 
CAPN11 -0.15 0.04 -0.13 0.18 -0.15 0.06 
CAPN2 -0.28 0.04 -0.29 0.08 -0.28 0.09 
GXYLT1 0.20 0.04 0.20 0.12 0.20 0.06 
UQCR11 0.18 0.04 0.20 0.06 0.17 0.08 
BLMH 0.16 0.04 0.17 0.09 0.16 0.07 
RNF166 -0.16 0.04 -0.14 0.22 -0.16 0.07 
HIBADH 0.15 0.04 0.12 0.24 0.15 0.07 
EBF1 -0.22 0.04 -0.24 0.10 -0.23 0.06 
TFEB -0.28 0.04 -0.27 0.12 -0.28 0.07 
OTUD6A 0.14 0.04 0.14 0.10 0.14 0.06 
SSB 0.17 0.04 0.15 0.13 0.17 0.07 
CHUK -0.14 0.04 -0.15 0.12 -0.14 0.07 
CAPZA2 0.18 0.04 0.18 0.05 0.18 0.06 
PHB 0.18 0.04 0.17 0.13 0.18 0.08 
MIR1800 -0.62 0.04 -0.68 NA -0.61 0.05 
BDNF -0.45 0.04 -0.42 NA -0.45 0.06 
EXFABP -0.65 0.04 -0.79 NA -0.63 0.07 
GNG13 0.14 0.04 0.15 0.09 0.14 0.06 
COPE 0.15 0.04 0.15 0.09 0.15 0.06 
ID4 0.16 0.04 0.18 0.10 0.16 0.08 
CXCL14 -0.18 0.04 -0.15 0.20 -0.18 0.09 
FLII -0.15 0.05 -0.14 0.14 -0.15 0.07 
RPS2 0.16 0.05 0.17 0.04 0.16 0.05 
KCNT1 -0.26 0.05 -0.28 0.08 -0.26 0.07 
SGK1 -0.17 0.05 -0.14 0.08 -0.17 0.05 
DUSP6 -0.25 0.05 -0.22 0.14 -0.25 0.09 
C20H20ORF24 0.14 0.05 0.15 0.10 0.14 0.06 
DNPEP -0.17 0.05 -0.16 0.15 -0.17 0.08 
TRIM8 -0.22 0.05 -0.23 0.11 -0.23 0.06 
ATG4B 0.17 0.05 0.17 0.14 0.17 0.08 
HS2ST1 0.17 0.05 0.15 0.15 0.17 0.08 
ATOX1 0.17 0.05 0.16 0.17 0.17 0.06 
NAB1 -0.22 0.05 -0.24 0.09 -0.22 0.05 
STRAP 0.14 0.05 0.13 0.16 0.15 0.07 
GID8 0.16 0.05 0.16 0.04 0.16 0.05 
WDR24 -0.20 0.05 -0.22 0.10 -0.20 0.06 
PTPRG -0.20 0.05 -0.22 0.04 -0.20 0.07 
TNFRSF10B -0.84 0.05 -0.81 NA -0.79 0.12 
INSIG1 0.21 0.05 0.25 0.02 0.21 0.08 
OPN1MSW -0.23 0.05 -0.20 0.10 -0.23 0.08 
PDGFA -0.51 0.05 -0.48 NA -0.51 0.07 
SCAF4 -0.16 0.05 -0.17 0.12 -0.17 0.08 
NHLH2 -0.43 0.05 -0.44 NA -0.43 0.06 
MRPL51 0.19 0.05 0.19 0.13 0.19 0.07 
SAP130 -0.28 0.05 -0.35 0.03 -0.28 0.09 
EXOC5 0.15 0.05 0.16 0.04 0.15 0.04 
SFRP1 0.17 0.05 0.17 0.07 0.17 0.06 
ATP6V1D 0.17 0.05 0.18 0.04 0.17 0.06 
216 
 
RAB5B -0.26 0.05 -0.27 0.12 -0.26 0.04 
MAPRE2 -0.15 0.05 -0.14 0.07 -0.15 0.04 
TMEM254 0.15 0.05 0.16 0.03 0.15 0.05 
SMS 0.15 0.05 0.16 0.05 0.15 0.05 
CERK 0.14 0.05 0.13 0.10 0.14 0.05 
BTF3L4 0.15 0.05 0.16 0.05 0.15 0.05 
TMEM254 0.15 0.05 0.16 0.03 0.15 0.05 
GRIN1 -0.14 0.05 -0.13 0.05 -0.14 0.04 
PCDHA1 -0.42 0.06 -0.55 3.31e-03 -0.41 0.12 
ARL6IP5 0.17 0.06 0.19 0.02 0.17 0.06 
CCT2 0.16 0.06 0.18 0.04 0.16 0.06 
ARL6IP1 0.18 0.06 0.19 0.04 0.18 0.07 
CRISPLD1 0.28 0.06 0.28 0.18 0.27 0.05 
GNB1 0.14 0.06 0.14 0.05 0.14 0.06 
NDUFB6 0.18 0.06 0.23 0.05 0.17 0.11 
CTSC 0.21 0.06 0.19 0.19 0.21 0.05 
PRDX1 0.17 0.07 0.18 0.05 0.17 0.07 
DHX30 -0.14 0.07 -0.13 0.08 -0.14 0.05 
PPP3R1 0.15 0.07 0.15 0.04 0.14 0.05 
FDFT1 0.16 0.07 0.18 0.03 0.16 0.07 
SETD5 -0.15 0.07 -0.18 0.03 -0.15 0.07 
CBX3 0.13 0.07 0.12 0.10 0.13 0.05 
TCEB1 0.14 0.07 0.17 0.03 0.14 0.08 
SLC15A2 -0.21 0.07 -0.26 0.04 -0.21 0.12 
ATP5C1 0.15 0.08 0.17 0.05 0.15 0.07 
ATP5C1 0.15 0.08 0.17 0.05 0.15 0.07 
ADCYAP1R1 -0.43 0.08 -0.52 0.04 -0.45 0.10 
CCT8 0.15 0.08 0.17 0.04 0.15 0.08 
CDC42 0.16 0.08 0.18 0.04 0.16 0.08 
PCDHA11 -0.16 0.09 -0.20 0.04 -0.16 0.11 
PCDHA8 -0.16 0.09 -0.21 0.03 -0.16 0.12 
PCDHA5 -0.16 0.09 -0.21 0.03 -0.16 0.12 
PCDHA2 -0.17 0.09 -0.22 0.03 -0.17 0.12 
PCDHA4 -0.16 0.09 -0.21 0.04 -0.16 0.12 
PCDHA3 -0.16 0.10 -0.21 0.04 -0.16 0.12 
SKP1 0.14 0.10 0.16 0.04 0.14 0.09 
PCDHA13 -0.16 0.10 -0.21 0.04 -0.16 0.12 
PCDHA7 -0.16 0.10 -0.21 0.04 -0.16 0.12 
PCDHA1 -0.16 0.10 -0.21 0.04 -0.16 0.13 
GHITM 0.16 0.10 0.18 0.04 0.16 0.10 
AACS 0.14 0.11 0.17 0.02 0.14 0.08 
PCDHA9 -0.16 0.11 -0.21 0.04 -0.16 0.14 
ASL1 0.74 0.51 0.18 NA 7.12 0.02 
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Appendix 5.2. Transcripts differentially expressed (P < 0.05) between High vs. Low 
myopia groups using analysis Model 3, with 3 software packages. 
Gene ID 
edgeR DESeq2 limma 
logFC FDR log2FC P-adj logFC P-adj 
NOVA1 0.48 0.15 0.66 1.02e-05 0.48 0.23 
NOVA1 0.48 0.15 0.66 1.02e-05 0.48 0.23 
ALDOC -0.38 0.18 -0.51 1.02e-05 -0.38 0.23 
SRRM1 0.39 0.15 0.53 3.67e-05 0.39 0.23 
PROX1 0.45 0.11 0.59 4.73e-05 0.45 0.23 
AKAP9 0.27 0.31 0.41 4.73e-05 0.27 0.29 
PGAM1 -0.34 0.19 -0.44 5.75e-05 -0.34 0.23 
USP34 0.38 0.21 0.53 5.99e-05 0.37 0.24 
ANKRD10 0.47 0.17 0.67 5.99e-05 0.47 0.24 
TMEM131 0.51 0.06 0.63 6.68e-05 0.51 0.23 
CACNA1B 0.44 0.15 0.61 6.68e-05 0.44 0.23 
PEBP1 -0.35 0.16 -0.46 6.68e-05 -0.35 0.23 
PGK1 -0.31 0.15 -0.36 1.59e-04 -0.32 0.23 
MAGI2 0.40 0.19 0.55 1.59e-04 0.40 0.23 
ANK3 0.33 0.19 0.45 1.59e-04 0.33 0.23 
SNCB -0.28 0.29 -0.40 1.96e-04 -0.29 0.28 
JARID2 0.29 0.29 0.43 1.96e-04 0.29 0.28 
ANKRD52 0.61 0.15 0.84 2.29e-04 0.62 0.23 
ACACA 0.39 0.15 0.52 2.29e-04 0.39 0.23 
KIAA2018 0.57 0.17 0.82 2.29e-04 0.57 0.23 
GAPDH -0.33 0.15 -0.39 2.30e-04 -0.33 0.23 
SALL3 0.46 0.14 0.62 2.38e-04 0.46 0.23 
KCND3 0.56 0.15 0.75 2.38e-04 0.58 0.23 
RALGAPA1 0.35 0.19 0.47 2.38e-04 0.35 0.23 
RALGAPA1 0.35 0.19 0.47 2.38e-04 0.35 0.23 
RALGAPA1 0.35 0.20 0.47 2.69e-04 0.35 0.23 
FASN 0.31 0.22 0.41 2.69e-04 0.31 0.23 
GRIA3 0.32 0.28 0.49 2.72e-04 0.32 0.29 
CTTNBP2 0.35 0.15 0.44 2.73e-04 0.35 0.23 
ATF7IP 0.36 0.18 0.48 2.73e-04 0.36 0.23 
GCG -0.65 9.00e-03 -0.76 2.81e-04 -0.65 0.23 
RALGAPA1 0.35 0.20 0.47 2.81e-04 0.35 0.23 
RALGAPA1 0.35 0.20 0.46 2.88e-04 0.35 0.23 
ACSBG2 0.48 9.00e-03 0.54 3.49e-04 0.48 0.23 
RPS3 -0.27 0.19 -0.32 3.49e-04 -0.27 0.23 
NBEA 0.29 0.22 0.39 3.49e-04 0.29 0.24 
GRIA3 0.32 0.28 0.48 3.49e-04 0.32 0.29 
BAZ2B 0.29 0.34 0.45 3.62e-04 0.29 0.31 
CHCHD2P9 -0.31 0.15 -0.36 3.68e-04 -0.31 0.23 
PKLR -0.22 0.27 -0.29 3.81e-04 -0.22 0.27 
RPRD2 0.50 0.17 0.70 3.88e-04 0.50 0.24 
ANKRD26 0.29 0.33 0.46 4.48e-04 0.29 0.32 
PABPC1 0.38 0.23 0.55 4.49e-04 0.38 0.27 
NME1 -0.28 0.19 -0.34 4.94e-04 -0.29 0.23 
PPP1R12A 0.30 0.22 0.41 4.94e-04 0.30 0.23 
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NLGN4Y 0.42 0.19 0.60 5.25e-04 0.42 0.26 
RPS10-NUDT3 -0.26 0.29 -0.35 5.25e-04 -0.26 0.27 
TENM2 0.32 0.25 0.44 6.12e-04 0.32 0.25 
PBRM1 0.29 0.23 0.43 6.12e-04 0.29 0.26 
TUBB4B -0.28 0.27 -0.37 6.12e-04 -0.28 0.26 
ARHGAP21 0.23 0.32 0.32 6.12e-04 0.22 0.27 
TET2 0.45 0.11 0.55 6.38e-04 0.45 0.23 
CST3 -0.32 0.16 -0.38 6.52e-04 -0.32 0.23 
DMD 0.28 0.32 0.41 6.52e-04 0.28 0.30 
EEF1A1 -0.22 0.27 -0.29 6.56e-04 -0.22 0.28 
ADGRL2 0.31 0.19 0.40 7.16e-04 0.31 0.23 
CDH2 0.33 0.19 0.46 7.16e-04 0.33 0.23 
FSCN2 -0.29 0.26 -0.39 7.17e-04 -0.29 0.26 
GNG11 -0.27 0.32 -0.39 7.33e-04 -0.26 0.30 
CALB2 -0.34 0.18 -0.41 7.48e-04 -0.34 0.23 
SLIT2 0.34 0.19 0.45 7.62e-04 0.34 0.23 
IGFBP4 -0.50 0.01 -0.57 7.94e-04 -0.50 0.23 
GCG -0.58 0.02 -0.67 7.94e-04 -0.57 0.23 
NR3C2 0.43 0.17 0.58 7.94e-04 0.44 0.23 
EEF1A2 -0.20 0.44 -0.30 7.94e-04 -0.20 0.36 
BSG -0.30 0.15 -0.33 8.08e-04 -0.30 0.23 
ATP6V0E2 -0.31 0.17 -0.41 8.08e-04 -0.31 0.23 
ATP6V0E2 -0.31 0.18 -0.40 8.08e-04 -0.31 0.23 
RYR3 0.38 0.18 0.52 8.08e-04 0.39 0.23 
MYO5A 0.31 0.27 0.43 8.08e-04 0.31 0.27 
GRIA4 0.30 0.23 0.41 8.59e-04 0.30 0.24 
CLTB -0.23 0.40 -0.34 8.59e-04 -0.23 0.32 
CLTB -0.23 0.40 -0.34 8.59e-04 -0.23 0.32 
INSIG1 0.41 0.04 0.39 1.00e-03 0.41 0.23 
SOD1 -0.35 0.15 -0.40 1.00e-03 -0.35 0.23 
BSG -0.29 0.15 -0.32 1.00e-03 -0.29 0.23 
CNIH1 -0.32 0.15 -0.38 1.00e-03 -0.32 0.23 
PCDH15 0.41 0.17 0.54 1.00e-03 0.42 0.23 
CNTRL 0.31 0.19 0.42 1.00e-03 0.31 0.23 
RPLP0 -0.32 0.19 -0.39 1.00e-03 -0.32 0.23 
JMJD1C 0.32 0.19 0.40 1.00e-03 0.32 0.23 
EPB41 0.32 0.20 0.41 1.00e-03 0.32 0.23 
RPL8 -0.23 0.27 -0.29 1.00e-03 -0.23 0.23 
TTC14 0.26 0.25 0.36 1.00e-03 0.26 0.23 
PRKDC 0.31 0.22 0.43 1.00e-03 0.31 0.24 
GRIA4 0.29 0.25 0.40 1.00e-03 0.29 0.25 
PTPRZ1 0.26 0.27 0.35 1.00e-03 0.26 0.25 
GNGT2 -0.24 0.26 -0.30 1.00e-03 -0.24 0.26 
DDX6 0.29 0.27 0.41 1.00e-03 0.29 0.26 
TENM1 0.30 0.27 0.42 1.00e-03 0.30 0.27 
PLEKHB1 -0.24 0.31 -0.31 1.00e-03 -0.24 0.27 
CELF2 0.31 0.26 0.47 1.00e-03 0.31 0.29 
CDK6 0.31 0.29 0.46 1.00e-03 0.31 0.30 
HERC2 0.23 0.36 0.35 1.00e-03 0.23 0.32 
ACTB 0.29 0.37 0.45 1.00e-03 0.29 0.33 
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VPS13A 0.25 0.38 0.41 1.00e-03 0.25 0.34 
AQP9 -0.65 9.00e-03 -0.66 2.00e-03 -0.63 0.23 
AQP9 -0.65 9.00e-03 -0.66 2.00e-03 -0.63 0.23 
GCG -0.56 0.12 -0.69 2.00e-03 -0.56 0.23 
SEPP1 -0.36 0.15 -0.38 2.00e-03 -0.36 0.23 
NOS2 0.51 0.15 0.69 2.00e-03 0.50 0.23 
NRXN3 0.31 0.19 0.38 2.00e-03 0.31 0.23 
NRXN3 0.30 0.19 0.38 2.00e-03 0.31 0.23 
ANKHD1 0.25 0.26 0.33 2.00e-03 0.25 0.23 
RS1 -0.27 0.25 -0.34 2.00e-03 -0.27 0.24 
RIMBP2 0.34 0.22 0.45 2.00e-03 0.34 0.24 
NFAT5 0.36 0.21 0.48 2.00e-03 0.36 0.24 
ATP6V1G1 -0.25 0.27 -0.32 2.00e-03 -0.25 0.24 
PTPRS 0.25 0.27 0.34 2.00e-03 0.25 0.24 
CA2 -0.21 0.25 -0.26 2.00e-03 -0.21 0.26 
DDX6 0.29 0.27 0.40 2.00e-03 0.29 0.26 
GNAT2 -0.26 0.28 -0.33 2.00e-03 -0.26 0.27 
IGF1R 0.31 0.27 0.44 2.00e-03 0.31 0.27 
TUBB2B -0.30 0.33 -0.42 2.00e-03 -0.30 0.30 
GRIA2 0.22 0.40 0.34 2.00e-03 0.22 0.32 
GRIA2 0.22 0.40 0.34 2.00e-03 0.22 0.32 
ATP6V0B -0.27 0.35 -0.42 2.00e-03 -0.27 0.34 
TOP2B 0.24 0.41 0.38 2.00e-03 0.24 0.35 
SRSF5 0.31 0.38 0.51 2.00e-03 0.31 0.37 
SKI 0.43 0.11 0.52 3.00e-03 0.43 0.23 
MYH15 0.73 0.11 0.88 3.00e-03 0.71 0.23 
GPX3 -0.41 0.11 -0.49 3.00e-03 -0.41 0.23 
NDUFB8 -0.34 0.12 -0.42 3.00e-03 -0.34 0.23 
NCALD 0.39 0.15 0.51 3.00e-03 0.39 0.23 
COX4I1 -0.29 0.15 -0.30 3.00e-03 -0.29 0.23 
CXCR4 -0.34 0.17 -0.46 3.00e-03 -0.33 0.23 
MBNL3 0.35 0.19 0.45 3.00e-03 0.35 0.23 
MBNL3 0.35 0.19 0.44 3.00e-03 0.35 0.23 
MBNL3 0.35 0.19 0.45 3.00e-03 0.35 0.23 
MBNL3 0.35 0.19 0.44 3.00e-03 0.35 0.23 
MBNL3 0.34 0.19 0.44 3.00e-03 0.34 0.23 
MBNL3 0.35 0.19 0.44 3.00e-03 0.35 0.23 
RPL7A -0.22 0.27 -0.25 3.00e-03 -0.22 0.23 
MYLK 0.21 0.33 0.29 3.00e-03 0.21 0.26 
MYLK 0.21 0.33 0.29 3.00e-03 0.21 0.26 
EIF4A1 -0.26 0.27 -0.33 3.00e-03 -0.26 0.27 
CTSB -0.27 0.29 -0.37 3.00e-03 -0.27 0.28 
HIST1H3H -0.40 0.26 -0.59 3.00e-03 -0.42 0.28 
HIST1H2B7 -0.33 0.25 -0.46 3.00e-03 -0.33 0.29 
MIA3 0.29 0.28 0.43 3.00e-03 0.29 0.29 
RPL15 -0.24 0.33 -0.33 3.00e-03 -0.24 0.29 
HIST1H2B7 -0.32 0.26 -0.45 3.00e-03 -0.32 0.29 
TPI1 -0.27 0.32 -0.36 3.00e-03 -0.27 0.29 
ACTG1 -0.29 0.32 -0.40 3.00e-03 -0.29 0.30 
ATP5B -0.23 0.38 -0.33 3.00e-03 -0.23 0.32 
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LDHB -0.20 0.40 -0.28 3.00e-03 -0.20 0.32 
ENS-1 0.59 0.08 0.69 4.00e-03 0.58 0.23 
LAPTM4A -0.43 0.08 -0.47 4.00e-03 -0.43 0.23 
SREBF1 0.43 0.15 0.54 4.00e-03 0.43 0.23 
NAV3 0.39 0.15 0.48 4.00e-03 0.39 0.23 
THADA 0.33 0.15 0.43 4.00e-03 0.34 0.23 
RALGAPB 0.34 0.16 0.43 4.00e-03 0.34 0.23 
SBF2 0.29 0.22 0.36 4.00e-03 0.29 0.23 
SLC9A8 0.27 0.23 0.37 4.00e-03 0.27 0.25 
CLTA -0.26 0.30 -0.34 4.00e-03 -0.26 0.27 
ITM2A -0.19 0.40 -0.25 4.00e-03 -0.19 0.32 
CKB -0.22 0.37 -0.30 4.00e-03 -0.22 0.34 
PPIA -0.26 0.38 -0.38 4.00e-03 -0.26 0.34 
KCNMA1 0.26 0.40 0.41 4.00e-03 0.26 0.35 
ERNI 0.55 0.15 0.68 5.00e-03 0.58 0.23 
PODXL 0.56 0.15 0.70 5.00e-03 0.58 0.23 
UBN2 0.30 0.17 0.39 5.00e-03 0.30 0.23 
FAT3 0.41 0.18 0.55 5.00e-03 0.41 0.23 
HARS -0.29 0.18 -0.35 5.00e-03 -0.29 0.23 
ABI1 0.31 0.18 0.42 5.00e-03 0.31 0.23 
CARMIL1 0.29 0.19 0.37 5.00e-03 0.29 0.23 
COL12A1 0.42 0.21 0.59 5.00e-03 0.45 0.25 
HMBOX1 0.42 0.19 0.58 5.00e-03 0.42 0.25 
EPHA7 0.33 0.23 0.48 5.00e-03 0.33 0.28 
PTPRG 0.27 0.29 0.37 5.00e-03 0.27 0.28 
TRPM7 0.27 0.29 0.39 5.00e-03 0.27 0.29 
CACNA2D1 0.24 0.36 0.35 5.00e-03 0.25 0.30 
VIP -0.48 0.43 -0.81 5.00e-03 -0.60 0.32 
SLC15A2 0.28 0.37 0.45 5.00e-03 0.28 0.36 
MIF -0.21 0.50 -0.36 5.00e-03 -0.21 0.45 
SLC38A1 0.32 0.15 0.39 6.00e-03 0.32 0.23 
MID1IP1 -0.32 0.16 -0.41 6.00e-03 -0.32 0.23 
NDFIP2 0.40 0.17 0.49 6.00e-03 0.40 0.23 
SPHKAP 0.26 0.25 0.33 6.00e-03 0.26 0.23 
RPL6 -0.23 0.26 -0.26 6.00e-03 -0.23 0.23 
TIMP2 -0.28 0.20 -0.36 6.00e-03 -0.28 0.23 
SLC8A1 0.25 0.27 0.36 6.00e-03 0.25 0.28 
ITPR1 0.25 0.34 0.36 6.00e-03 0.25 0.30 
VIP -0.47 0.44 -0.79 6.00e-03 -0.58 0.33 
CCNK 0.46 0.36 0.74 6.00e-03 0.46 0.35 
LDHA -0.20 0.41 -0.29 6.00e-03 -0.20 0.37 
HNRNPD 0.27 0.50 0.51 6.00e-03 0.26 0.51 
COL5A1 0.33 0.19 0.41 7.00e-03 0.33 0.23 
HMGCR 0.24 0.26 0.29 7.00e-03 0.24 0.23 
SOBP 0.45 0.27 0.67 7.00e-03 0.45 0.29 
RPL4 -0.19 0.37 -0.23 7.00e-03 -0.19 0.29 
QSOX1 -0.27 0.31 -0.37 7.00e-03 -0.27 0.29 
PHF20L1 0.20 0.42 0.32 7.00e-03 0.20 0.34 
MTSS1 0.31 0.19 0.37 8.00e-03 0.31 0.23 
EIF3I -0.26 0.25 -0.33 8.00e-03 -0.26 0.24 
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CLOCK 0.21 0.30 0.26 8.00e-03 0.21 0.24 
CDC42BPA 0.19 0.38 0.27 8.00e-03 0.19 0.29 
BRSK1 0.24 0.38 0.37 8.00e-03 0.24 0.33 
YWHAG 0.20 0.48 0.33 8.00e-03 0.20 0.40 
HIST1H2A4 -0.37 0.15 -0.46 9.00e-03 -0.37 0.23 
ANKS1B 0.29 0.19 0.37 9.00e-03 0.29 0.23 
RPS4Y1 -0.23 0.27 -0.26 9.00e-03 -0.23 0.23 
CLOCK 0.20 0.31 0.26 9.00e-03 0.20 0.24 
RAB5C -0.29 0.23 -0.40 9.00e-03 -0.29 0.27 
CNTNAP5 0.31 0.25 0.43 9.00e-03 0.31 0.28 
CCSER2 0.23 0.33 0.32 9.00e-03 0.23 0.28 
STMN1 -0.27 0.31 -0.35 9.00e-03 -0.27 0.29 
CDH4 0.28 0.30 0.41 9.00e-03 0.27 0.32 
CLU -0.23 0.38 -0.32 9.00e-03 -0.23 0.32 
LOC776816 -0.18 0.47 -0.27 9.00e-03 -0.18 0.40 
ANKRD44 0.21 0.47 0.36 9.00e-03 0.21 0.40 
ENO1 -0.14 0.54 -0.22 9.00e-03 -0.14 0.47 
PCDHGA2 0.44 0.45 0.75 9.00e-03 0.41 0.48 
KIAA0586 0.30 0.23 0.42 0.01 0.30 0.27 
RORA 0.21 0.38 0.29 0.01 0.21 0.30 
MMP16 0.31 0.15 0.36 0.01 0.31 0.23 
NFIA 0.61 0.15 0.82 0.01 0.62 0.23 
ERNI 0.53 0.18 0.68 0.01 0.57 0.23 
NFIB 0.34 0.18 0.46 0.01 0.34 0.23 
CDH13 0.30 0.19 0.38 0.01 0.30 0.23 
GUCA1A -0.29 0.19 -0.33 0.01 -0.29 0.23 
SRGAP1 0.25 0.25 0.30 0.01 0.25 0.23 
PLN 0.54 0.22 0.73 0.01 0.59 0.24 
CDH8 0.20 0.36 0.27 0.01 0.20 0.27 
ADIPOR1 -0.27 0.26 -0.38 0.01 -0.27 0.29 
KIF2A 0.23 0.37 0.34 0.01 0.23 0.32 
RPS29 -0.26 0.37 -0.39 0.01 -0.26 0.34 
GRM5 0.35 0.36 0.56 0.01 0.37 0.35 
MEIS2 0.24 0.37 0.39 0.01 0.24 0.36 
PPP1CC 0.23 0.43 0.36 0.01 0.23 0.37 
MPDZ 0.18 0.51 0.29 0.01 0.18 0.41 
VTN -0.16 0.57 -0.28 0.01 -0.16 0.48 
TBC1D1 0.30 0.15 0.36 0.01 0.30 0.23 
RAN -0.28 0.17 -0.29 0.01 -0.28 0.23 
OPN4 0.28 0.22 0.35 0.01 0.28 0.23 
GUCA1B -0.26 0.23 -0.30 0.01 -0.26 0.23 
RPL7 -0.23 0.26 -0.25 0.01 -0.22 0.23 
DUSP6 -0.39 0.19 -0.50 0.01 -0.37 0.27 
ZFHX3 0.65 0.19 0.94 0.01 0.65 0.27 
TENM2 0.29 0.26 0.38 0.01 0.29 0.27 
PCDHAC2 0.20 0.37 0.27 0.01 0.20 0.28 
NLGN1 0.31 0.25 0.44 0.01 0.31 0.29 
B3GNT5 0.72 0.21 1.05 0.01 0.68 0.30 
TENM3 0.23 0.36 0.33 0.01 0.23 0.30 
WASL 0.26 0.36 0.37 0.01 0.26 0.32 
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SS2 -0.24 0.40 -0.38 0.01 -0.24 0.39 
EEF2 -0.16 0.54 -0.25 0.01 -0.16 0.45 
RPL19 -0.24 0.28 -0.28 0.01 -0.24 0.25 
SDK2 0.31 0.24 0.41 0.01 0.31 0.27 
SLC9A3R1 -0.25 0.35 -0.34 0.01 -0.25 0.32 
KPNA3 0.25 0.36 0.39 0.01 0.25 0.36 
LIFR 0.34 0.15 0.40 0.01 0.35 0.23 
MEF2D 0.77 0.15 1.04 0.01 0.77 0.23 
QSER1 0.24 0.25 0.34 0.01 0.24 0.26 
SIPA1L1 0.21 0.36 0.29 0.01 0.21 0.28 
CHD2 0.18 0.40 0.24 0.01 0.18 0.29 
FARP1 0.30 0.30 0.44 0.01 0.30 0.32 
FMN1 0.23 0.38 0.36 0.01 0.23 0.35 
DIAPH2 0.20 0.47 0.34 0.01 0.20 0.44 
LOC769852 -0.41 0.15 -0.49 0.02 -0.42 0.23 
BICC1 0.37 0.19 0.50 0.02 0.37 0.23 
RPL26L1 -0.23 0.22 -0.24 0.02 -0.23 0.23 
TGFB2 0.40 0.25 0.57 0.02 0.41 0.27 
SLC8A3 0.22 0.34 0.31 0.02 0.22 0.29 
RGS7 0.21 0.40 0.31 0.02 0.21 0.32 
CLTC 0.18 0.40 0.26 0.02 0.18 0.33 
STRBP 0.17 0.46 0.27 0.02 0.17 0.35 
NRXN3 0.40 0.19 0.53 0.02 0.40 0.23 
LOC101749238 -0.34 0.19 -0.44 0.02 -0.34 0.24 
H3F3B -0.21 0.29 -0.24 0.02 -0.22 0.25 
HRAS -0.35 0.19 -0.44 0.02 -0.34 0.26 
RPS27A -0.20 0.40 -0.28 0.02 -0.20 0.32 
RACK1 -0.18 0.44 -0.25 0.02 -0.18 0.32 
GAPVD1 0.19 0.33 0.24 0.02 0.19 0.24 
CITED4 -0.20 0.33 -0.24 0.02 -0.20 0.26 
ZSWIM8 0.25 0.28 0.32 0.02 0.25 0.26 
TRIM2 0.19 0.35 0.26 0.02 0.20 0.27 
HIST2H4B -0.28 0.27 -0.34 0.02 -0.28 0.27 
HIST1H46 -0.28 0.27 -0.34 0.02 -0.28 0.27 
HIST1H2B8 -0.32 0.25 -0.41 0.02 -0.32 0.28 
NEUROD4 0.36 0.15 0.45 0.02 0.36 0.23 
MAFF -0.51 0.19 -0.65 0.02 -0.50 0.23 
RPL26L1 -0.24 0.22 -0.23 0.02 -0.24 0.23 
EIF3H -0.23 0.25 -0.27 0.02 -0.23 0.23 
ITM2B -0.20 0.30 -0.22 0.02 -0.20 0.24 
ANOS1 0.21 0.30 0.26 0.02 0.21 0.24 
BMPR2 0.21 0.31 0.27 0.02 0.21 0.25 
EIF2S3 -0.22 0.32 -0.27 0.02 -0.22 0.26 
ADAM23 0.24 0.29 0.34 0.02 0.24 0.30 
GLG1 0.23 0.36 0.33 0.02 0.23 0.31 
PPP2CB -0.21 0.40 -0.28 0.02 -0.21 0.32 
MYH9 0.20 0.37 0.30 0.02 0.20 0.32 
UBB -0.20 0.46 -0.29 0.02 -0.20 0.37 
PNISR 0.13 0.75 0.32 0.02 0.13 0.70 
CSRP2 -0.30 0.17 -0.28 0.02 -0.30 0.23 
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RPS28 -0.31 0.18 -0.38 0.02 -0.31 0.23 
AGTPBP1 0.27 0.19 0.33 0.02 0.27 0.23 
PPP3CB 0.25 0.25 0.31 0.02 0.25 0.23 
STAU1 0.21 0.31 0.26 0.02 0.21 0.25 
XPO5 0.24 0.27 0.31 0.02 0.24 0.25 
COPS8 -0.24 0.26 -0.30 0.02 -0.24 0.26 
NCOA1 0.30 0.22 0.40 0.02 0.30 0.27 
TLE4 0.30 0.23 0.41 0.02 0.30 0.27 
PSMC5 -0.24 0.27 -0.32 0.02 -0.24 0.28 
PPIB -0.25 0.27 -0.34 0.02 -0.25 0.29 
SLC25A6 -0.17 0.40 -0.21 0.02 -0.17 0.30 
RPL3 -0.16 0.45 -0.22 0.02 -0.16 0.32 
LSS 0.33 0.12 0.37 0.02 0.33 0.23 
OTX2 0.28 0.17 0.33 0.02 0.28 0.23 
HEBP1 -0.32 0.18 -0.39 0.02 -0.32 0.23 
LTN1 0.26 0.23 0.29 0.02 0.26 0.23 
TOM1L2 0.29 0.25 0.34 0.02 0.29 0.24 
MAPK10 0.24 0.27 0.30 0.02 0.24 0.25 
MAPK10 0.24 0.27 0.30 0.02 0.24 0.25 
HIST1H46L2 -0.30 0.25 -0.36 0.02 -0.30 0.26 
CCNRC01 0.20 0.34 0.27 0.02 0.20 0.27 
SRI -0.26 0.25 -0.36 0.02 -0.26 0.27 
LEPROT 0.31 0.25 0.43 0.02 0.32 0.29 
DGKZ 0.24 0.28 0.34 0.02 0.24 0.29 
ARL6IP5 -0.16 0.48 -0.23 0.02 -0.16 0.35 
USP28 0.27 0.40 0.46 0.02 0.27 0.37 
NDUFV1 -0.24 0.40 -0.36 0.02 -0.23 0.38 
AK1 -0.37 0.41 -0.59 0.02 -0.35 0.41 
LAMTOR3 -0.27 0.15 -0.30 0.02 -0.27 0.23 
TTLL5 0.26 0.17 0.27 0.02 0.26 0.23 
RORB 0.25 0.19 0.30 0.02 0.25 0.23 
FAM213A -0.28 0.22 -0.30 0.02 -0.28 0.23 
SLC38A2 0.23 0.25 0.25 0.02 0.23 0.23 
SELENOT -0.20 0.36 -0.26 0.02 -0.20 0.29 
NCAM1 0.18 0.36 0.23 0.02 0.18 0.29 
HSPA2 -0.23 0.35 -0.33 0.02 -0.23 0.32 
EIF4A3 -0.19 0.43 -0.27 0.02 -0.19 0.34 
CLIP1 0.16 0.48 0.24 0.02 0.16 0.35 
SYP -0.15 0.49 -0.20 0.02 -0.15 0.38 
PER2 0.22 0.46 0.34 0.02 0.22 0.39 
LBH -0.14 0.65 -0.24 0.02 -0.14 0.54 
TFAP2B 0.31 0.12 0.35 0.02 0.31 0.23 
KCNA2 0.30 0.13 0.34 0.02 0.30 0.23 
POU2F1 0.49 0.15 0.57 0.02 0.51 0.23 
TOMM6 -0.28 0.19 -0.36 0.02 -0.28 0.25 
YTHDC1 0.15 0.55 0.25 0.02 0.15 0.43 
ENS-1 0.55 0.19 0.68 0.02 0.61 0.23 
RPL5 -0.25 0.22 -0.23 0.02 -0.24 0.23 
FAM213A -0.28 0.22 -0.30 0.02 -0.28 0.23 
ERNI 0.41 0.27 0.58 0.02 0.46 0.27 
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HIST1H46L2 -0.29 0.27 -0.36 0.02 -0.29 0.27 
GAP43 -0.37 0.27 -0.51 0.02 -0.35 0.31 
FSCN1 -0.23 0.35 -0.34 0.02 -0.22 0.35 
VPS33B -0.29 0.15 -0.32 0.02 -0.29 0.23 
NUDT16L1 -0.33 0.16 -0.41 0.02 -0.33 0.23 
GABRA6 -0.17 0.43 -0.22 0.02 -0.17 0.32 
MYH10 0.16 0.50 0.25 0.02 0.17 0.37 
KDM3A 0.23 0.46 0.36 0.02 0.23 0.40 
DPF3 0.32 0.22 0.42 0.03 0.32 0.27 
STXBP1 0.74 0.25 1.11 0.03 0.74 0.30 
NR2C1 0.29 0.27 0.43 0.03 0.29 0.30 
SYNGR1 -0.19 0.36 -0.26 0.03 -0.19 0.31 
UBE2E3 0.31 0.15 0.33 0.03 0.31 0.23 
AKAP2 0.20 0.28 0.24 0.03 0.21 0.23 
NDUFA4 -0.24 0.26 -0.28 0.03 -0.24 0.23 
KCNH6 0.34 0.19 0.42 0.03 0.34 0.25 
NCAM1 0.18 0.37 0.22 0.03 0.18 0.29 
RPS6 -0.19 0.40 -0.24 0.03 -0.19 0.31 
CHD1 0.17 0.43 0.25 0.03 0.17 0.32 
SMARCA2 0.15 0.48 0.23 0.03 0.16 0.34 
ZCCHC6 0.16 0.47 0.25 0.03 0.16 0.35 
SERINC1 -0.15 0.55 -0.24 0.03 -0.16 0.45 
LOC422214 -0.32 0.15 -0.36 0.03 -0.32 0.23 
SIRT6 -0.34 0.18 -0.42 0.03 -0.34 0.23 
SAP18 -0.23 0.31 -0.31 0.03 -0.23 0.31 
PHB -0.31 0.15 -0.35 0.03 -0.31 0.23 
LPP 0.48 0.25 0.64 0.03 0.50 0.25 
PIK3CD 0.38 0.26 0.52 0.03 0.37 0.29 
SCG5 -0.27 0.34 -0.35 0.03 -0.27 0.32 
ANAPC10 0.39 0.34 0.59 0.03 0.39 0.32 
TUBA1C -0.25 0.40 -0.38 0.03 -0.25 0.39 
VSNL1 -0.15 0.54 -0.22 0.03 -0.15 0.41 
C12ORF57 -0.39 0.15 -0.45 0.03 -0.38 0.23 
SOX5 0.23 0.22 0.30 0.03 0.23 0.23 
SZT2 0.26 0.22 0.32 0.03 0.26 0.25 
MELTF 0.33 0.20 0.43 0.03 0.34 0.26 
EDF1 -0.22 0.30 -0.28 0.03 -0.22 0.29 
SNAP25 -0.20 0.40 -0.25 0.03 -0.20 0.32 
TOX3 0.43 0.36 0.65 0.03 0.44 0.32 
TMSB4X -0.17 0.46 -0.23 0.03 -0.17 0.34 
SLC17A6 0.45 0.34 0.72 0.03 0.45 0.35 
SUGP2 0.16 0.48 0.24 0.03 0.16 0.36 
GHITM -0.17 0.51 -0.25 0.03 -0.17 0.40 
AP2M1 -0.13 0.61 -0.20 0.03 -0.13 0.50 
DICER1 0.41 0.24 0.59 0.03 0.41 0.28 
FUT9 0.37 0.26 0.53 0.03 0.37 0.28 
NACA -0.25 0.31 -0.33 0.03 -0.25 0.31 
LUC7L3 0.12 0.69 0.25 0.03 0.12 0.59 
REPS1 0.32 0.15 0.38 0.03 0.32 0.23 
ST8SIA2 -0.31 0.21 -0.37 0.03 -0.31 0.26 
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HIGD1C -0.22 0.30 -0.28 0.03 -0.22 0.29 
MDGA1 0.24 0.31 0.34 0.03 0.24 0.31 
LOC107053055 0.46 0.27 0.70 0.03 0.47 0.32 
IQGAP2 0.20 0.47 0.31 0.03 0.20 0.39 
MGEA5 0.18 0.55 0.31 0.03 0.18 0.47 
ACLY 0.22 0.25 0.27 0.03 0.22 0.24 
LOC772071 0.21 0.29 0.29 0.03 0.21 0.28 
ANO5 0.26 0.27 0.37 0.03 0.27 0.29 
TOX3 0.43 0.37 0.65 0.03 0.44 0.34 
COX6A1 -0.27 0.17 -0.31 0.03 -0.27 0.23 
FNDC3A 0.22 0.27 0.30 0.03 0.22 0.27 
RAB18 -0.22 0.36 -0.26 0.03 -0.22 0.29 
PARD3 0.24 0.30 0.33 0.03 0.24 0.31 
MLF2 -0.20 0.40 -0.27 0.03 -0.20 0.32 
SCAF11 0.17 0.45 0.25 0.03 0.17 0.34 
PER3 0.23 0.37 0.34 0.03 0.23 0.35 
C4orf48 -0.15 0.50 -0.21 0.03 -0.15 0.35 
RAB3GAP2 0.17 0.47 0.26 0.03 0.17 0.36 
HSPA8 -0.16 0.49 -0.22 0.03 -0.16 0.42 
COX6A1 -0.27 0.17 -0.31 0.04 -0.27 0.23 
CELF1 0.20 0.29 0.28 0.04 0.20 0.27 
PGRMC1 -0.18 0.38 -0.22 0.04 -0.18 0.28 
RPS27A -0.18 0.43 -0.25 0.04 -0.18 0.34 
RPSAP58 -0.16 0.47 -0.21 0.04 -0.16 0.34 
ATP1B3 -0.15 0.53 -0.22 0.04 -0.15 0.40 
TM2D3 -0.31 0.18 -0.37 0.04 -0.31 0.24 
TM2D3 -0.31 0.19 -0.37 0.04 -0.30 0.24 
PCDH1 0.28 0.22 0.35 0.04 0.28 0.26 
UQCR11 -0.22 0.31 -0.32 0.04 -0.22 0.32 
USP7 0.38 0.33 0.58 0.04 0.38 0.32 
ECHS1 -0.35 0.12 -0.38 0.04 -0.35 0.23 
DROSHA 0.28 0.15 0.33 0.04 0.28 0.23 
CNBP -0.23 0.27 -0.24 0.04 -0.23 0.23 
CHUNK-1 0.41 0.22 0.51 0.04 0.40 0.27 
MICALL1 0.48 0.15 0.53 0.04 0.47 0.23 
MBNL1 0.28 0.19 0.35 0.04 0.28 0.23 
MBNL1 0.27 0.19 0.35 0.04 0.28 0.23 
MBNL1 0.28 0.19 0.36 0.04 0.29 0.23 
HIST1H2A4 -0.34 0.27 -0.46 0.04 -0.34 0.29 
XPO1 0.29 0.40 0.48 0.04 0.29 0.36 
SNRNP200 0.19 0.46 0.28 0.04 0.19 0.37 
MDH1 -0.18 0.50 -0.25 0.04 -0.18 0.39 
MDH1 -0.18 0.50 -0.25 0.04 -0.18 0.39 
SLC9A1 0.56 0.15 0.62 0.04 0.56 0.23 
TCP1 -0.21 0.37 -0.25 0.04 -0.21 0.29 
PCDHA3 0.16 0.59 0.30 0.04 0.15 0.54 
NDUFB3 -0.41 0.15 -0.43 0.04 -0.39 0.23 
MBNL1 0.27 0.19 0.35 0.04 0.27 0.23 
ZDHHC8 0.31 0.19 0.39 0.04 0.31 0.23 
MBNL1 0.27 0.19 0.34 0.04 0.27 0.23 
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PCGF5 0.26 0.19 0.33 0.04 0.26 0.23 
HIST1H2A4L3 -0.34 0.26 -0.45 0.04 -0.34 0.28 
RPS15 -0.21 0.38 -0.28 0.04 -0.21 0.32 
TALDO1 -0.21 0.39 -0.27 0.04 -0.21 0.32 
PCDHA13 0.15 0.59 0.30 0.04 0.15 0.54 
RMND5A 0.19 0.40 0.29 0.04 0.19 0.35 
AQP1 -0.38 0.36 -0.55 0.04 -0.32 0.41 
OXCT1 0.14 0.55 0.24 0.04 0.14 0.44 
OPCML 0.51 0.19 0.62 0.04 0.50 0.23 
ATM 0.19 0.43 0.26 0.04 0.19 0.33 
PCM1 0.13 0.57 0.21 0.04 0.13 0.44 
ARR3 -0.14 0.58 -0.23 0.04 -0.14 0.49 
SLC24A5 0.24 0.29 0.35 0.04 0.24 0.30 
ERP29 -0.14 0.55 -0.21 0.04 -0.14 0.42 
GNAI3 -0.27 0.23 -0.29 0.04 -0.27 0.23 
RPS12 -0.22 0.25 -0.21 0.04 -0.22 0.23 
DCX 0.22 0.25 0.29 0.04 0.22 0.26 
BNIP3L -0.17 0.44 -0.20 0.04 -0.17 0.33 
RPL17 -0.17 0.47 -0.23 0.04 -0.17 0.35 
VAV3 0.15 0.54 0.26 0.04 0.15 0.46 
DCX 0.22 0.25 0.29 0.05 0.22 0.26 
YTHDF3 0.20 0.27 0.27 0.05 0.21 0.26 
SPTBN1 0.10 0.80 0.26 0.05 0.10 0.75 
EHMT1 0.21 0.30 0.25 0.05 0.21 0.25 
MYSM1 0.17 0.40 0.25 0.05 0.17 0.34 
LARGE1 0.19 0.44 0.28 0.05 0.19 0.36 
RPL13 -0.17 0.48 -0.23 0.05 -0.17 0.36 
MEF2A 0.15 0.51 0.22 0.05 0.15 0.37 
SAP130 0.30 0.47 0.50 0.05 0.29 0.45 
PRPF19 -0.19 0.53 -0.32 0.05 -0.18 0.50 
WAPL 0.12 0.65 0.22 0.05 0.12 0.52 
HMGN2P46 -0.26 0.22 -0.32 0.05 -0.26 0.25 
YBX3 -0.19 0.36 -0.21 0.05 -0.19 0.26 
CHD7 0.41 0.26 0.57 0.05 0.41 0.28 
ASCC3 0.21 0.32 0.28 0.05 0.21 0.30 
SPATS2L 0.29 0.15 0.32 0.05 0.29 0.23 
PSMA7 -0.22 0.29 -0.28 0.05 -0.22 0.29 
SEC24A 0.23 0.26 0.29 0.05 0.23 0.26 
G0S2 -0.30 0.22 -0.37 0.05 -0.30 0.27 
PHTF2 0.27 0.28 0.36 0.05 0.27 0.30 
PRRG1 0.22 0.31 0.31 0.05 0.22 0.31 
TUBA1C -0.27 0.40 -0.40 0.05 -0.28 0.35 
PSAP -0.14 0.48 -0.19 0.05 -0.15 0.39 
TMEM59 -0.15 0.56 -0.22 0.05 -0.15 0.44 
ATP6V0D1 -0.12 0.71 -0.22 0.05 -0.12 0.60 
CANX 0.12 0.75 0.28 0.05 0.12 0.69 
MIR3526 -0.36 0.18 -0.42 0.05 -0.37 0.23 
NECAB3 -0.30 0.20 -0.36 0.05 -0.29 0.26 
NEGR1 0.20 0.37 0.29 0.05 0.20 0.34 
ARL6IP1 -0.19 0.45 -0.25 0.05 -0.19 0.35 
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Appendix 5.3. Common differentially expressed genes between comparisons for 
treated vs. control and previous studies. 
Gene 
Model. 
Author Year Method Species Tissue 1 2 
FOS 
 
Yes Brand 2007 Microarray Mouse Retina 
ALDH1A1 
 
Yes McGlinn 2007 Microarray Chick Retina/RPE 
ASL1 
 
Yes McGlinn 
    CDKN1A 
 
Yes McGlinn 
    COPS2 
 
Yes McGlinn 
    CTSC 
 
Yes McGlinn 
    DHCR7 
 
Yes McGlinn 
    DHFR 
 
Yes McGlinn 
    DUSP4 Yes Yes McGlinn 
    GAS2 
 
Yes McGlinn 
    GCLM 
 
Yes McGlinn 
    GNG10 
 
Yes McGlinn 
    GXYLT1 
 
Yes McGlinn 
    ID4 
 
Yes McGlinn 
    IL17RD 
 
Yes McGlinn 
    MCFD2 
 
Yes McGlinn 
    NTS 
 
Yes McGlinn 
    PTN 
 
Yes McGlinn 
    SWAP70 
 
Yes McGlinn 
    TCEB1 
 
Yes McGlinn 
    UTS2B Yes Yes McGlinn 
    VIP Yes Yes McGlinn 
    ETV5 
 
Yes Schippert 2008 Microarray Chick Retina 
ID2 
 
Yes Schippert 
    
ATP6V0D2 Yes Ashby 2010 Microarray Chick 
Amacrine  
cell layer 
C26H6ORF125 Yes Ashby 
    GNG13 
 
Yes Ashby 
    GTF2H5 
 
Yes Ashby 
    NT5C2 
 
Yes Ashby 
    AACS 
 
Yes Stone 2011 Microarray Chick Retina/RPE 
ABRACL 
 
Yes Stone 
    ACTR6 
 
Yes Stone 
    ADCYAP1R1 Yes Stone 
    ALG12 
 
Yes Stone 
    ARL6 
 
Yes Stone 
    ARNT 
 
Yes Stone 
    ATG4B 
 
Yes Stone 
    BDNF 
 
Yes Stone 
    CALB1 
 
Yes Stone 
    CCNL2 
 
Yes Stone 
    CDC42 
 
Yes Stone 
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CLCN7 
 
Yes Stone 
    CXCL14 
 
Yes Stone 
    CYB5B 
 
Yes Stone 
    DIO2 Yes Yes Stone 
    FN3KRP 
 
Yes Stone 
    FOSL2 
 
Yes Stone 
    GLCCI1 
 
Yes Stone 
    GMFB 
 
Yes Stone 
    GORASP1 
 
Yes Stone 
    GPR137B 
 
Yes Stone 
    GTF2E2 
 
Yes Stone 
    H2AFZ 
 
Yes Stone 
    HNRNPH3 Yes Stone 
    HSBP1 
 
Yes Stone 
    HSP90AB1 Yes Stone 
    KCNA4 Yes Yes Stone 
    LIMS1 
 
Yes Stone 
    LOC421792 Yes Stone 
    LSM7 
 
Yes Stone 
    MAGI3 
 
Yes Stone 
    MRPL51 
 
Yes Stone 
    MZT1 
 
Yes Stone 
    NAB1 
 
Yes Stone 
    NDUFA10 
 
Yes Stone 
    NPAS2 
 
Yes Stone 
    NSUN2 
 
Yes Stone 
    OARD1 
 
Yes Stone 
    OLA1 
 
Yes Stone 
    OPN4 
 
Yes Stone 
    OPN4-1 Yes Yes Stone 
    OSBPL2 
 
Yes Stone 
    PDDC1 
 
Yes Stone 
    PER3 
 
Yes Stone 
    POLE3 
 
Yes Stone 
    PTPRG 
 
Yes Stone 
    RNF166 
 
Yes Stone 
    RSPO2 
 
Yes Stone 
    SSR3 
 
Yes Stone 
    SZT2 
 
Yes Stone 
    TCF3 
 
Yes Stone 
    TET2 
 
Yes Stone 
    TMEM167A Yes Stone 
    UFM1 
 
Yes Stone 
    ZNF335 
 
Yes Stone 
    CKB 
 
Yes Bertrand 2006 2D GE, MS Chick Retina 
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CRYAB 
 
Yes Zhou 2010 2D GE, MS Guinea Pig 
Posterior 
 Sclera 
PRDX1 
 
Yes Zhou 
    
COL6A1 
 
Yes Frost 2012 2D GE, MS 
Tree 
Shrew Sclera 
CRABP1 
 
Yes Frost 
    CCT8 
 
Yes Frost 
    ATP5C1 
 
Yes Barathi 2014 iTRAQ  Mouse Retina 
MBP 
 
Yes Barathi 
    UQCRB 
 
Yes Barathi 
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Appendix 5.4 Common differentially expressed genes between comparisons for 
treated vs. control and comparisons for high vs. low. 
Transcript ID Gene symbol  
NM_001001604 ST8SIA2 
NM_001006171 ARL6IP1 
NM_001006395 MDH1 
NM_001012605 ARL6IP5 
NM_001012846 ACSBG2 
NM_001012882 NCOA1 
NM_001030577 COX4I1 
NM_001030697_2 PIK3R5 
NM_001030966 INSIG1 
NM_001031217 GHITM 
NM_001031301 SAP130 
NM_001044643 SLC9A1 
NM_001044647 MDGA1 
NM_001044653 OPN4 
NM_001111133_2 PCDHA3 
NM_001111136 PCDHA13 
NM_001168004 EPB41 
NM_001177309 VIP 
NM_001177735 PHB 
NM_001190802 UQCR11 
NM_001204761 NME1 
NM_001277766 SZT2 
NM_001277794 TET2 
NM_001289779 PER3 
NM_001305113 KCNH6 
NM_001316891 MDH1 
NM_001319028 SLC15A2 
NM_204126 SREBF1 
NM_204204 UGT8 
NM_204314 PTPRG 
NM_204353 IGFBP4 
NM_204354 DUSP6 
NM_204485 HMGCR 
NM_204538 SDK2 
NM_204757 MAFF 
NM_204895 TFAP2B 
NM_204900 CLU 
NM_205208 CSRP2 
NM_205258 RAN 
NM_205280 MBP 
NM_205310 CKB 
NM_205366 VIP 
NM_205429 17.5 
NM_205501 ASL1 
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Appendix 5.5. Venn-diagram showing overlap in differentially-expressed transcripts 
identified by “model 2 separate” (i.e. FD treated vs. control eyes in high group; FD 
treated vs. control eyes in low group) and by model 3 (an analysis testing for an 
interaction between FD treatment and high vs. low group). 
 
The overlapped genes are listed 
(a) ANKRD10, OPN4, VIP, AQP9, TUBA1C, SNCB 
 
(b) ST8SIA2, SLC9A3R1, LSS, OXCT1, PLEKHB1, ACSBG2, HEBP1, INSIG1, HIST1H2A4, GPX3, 
FSCN1, GCG, BSG, ALDOC, SYNGR1, TBC1D1, ECHS1, RPS29, HIST1H2A4L3, LOC101749238, 
XPO1, RPS28, MIF, QSOX1, TIMP2, IGFBP4, DUSP6, HMGCR, CXCR4, GNAT2, MAFF, CLU, VTN, 
PKLR 
 
(c) TMSB4X, BMPR2, CDH2, CDH13, GRIA2, STMN1, TENM2, RACK1, RPL7A, LARGE1, SOX5, 
CDH4, TUBB2B, PROX1, HARS, ARL6IP1, PPP1CC, EDF1, CHCHD2P9, PHTF2, RPL3, EIF2S3, 
DDX6, RPL7, RAB18, DROSHA, YTHDF3, MDH1, TCP1, HMGN2P46, LOC422214, NDUFB8, 
TMEM59, TTC14, SELENOT, LAMTOR3, RPL4, RPSAP58, ACTG1, GUCA1B, CDK6, ANAPC10, 
CELF1, EHMT1, ITM2A, MBNL3, ARL6IP5, TMEM131, SNRNP200, ATF7IP, FNDC3A, STAU1, 
JARID2, REPS1, NCOA1, SBF2, ANKRD44, MYSM1, RPRD2, ANKRD52, COX4I1, CLTB, EIF4A3, 
STRBP, NDFIP2, RPS3, RALGAPB, RPL19, MTSS1, HIGD1C, ADIPOR1, LBH, TGFB2, SERINC1, 
PNISR, LAPTM4A, YTHDC1, TALDO1, DGKZ, SRSF5, CCNK, GHITM, SAP130, ATP5B, YWHAG, 
SRRM1, USP28, LUC7L3, PGAM1, LPP, NDUFV1, PABPC1, MEF2D, SEPP1, CNIH1, SLC24A5, 
ZDHHC8, SLC9A8, PHF20L1, ABI1, MGEA5, CLTA, SKI, AQP1, KIAA0586, SLC9A1, MDGA1, 
PCDH15, PCDH1, COPS8, CNTNAP5, CHD7, SLC8A1, AP2M1, HIST1H2B7, LOC772071, 
SRGAP1, CLTC, TUBB4B, SRI, ENS-1, ERNI, NLGN1, ARR3, CTTNBP2, THADA, SOBP, 
CCNRC01, PCDHAC2, PCDHA3, PCDHA13, FAT3, GRIA3, GRIA4, B3GNT5, NCAM1, RS1, 
ADAM23, NR3C2, NAV3, CARMIL1, RAB3GAP2, EIF3I, PPIA, EPB41, SLC17A6, NLGN4Y, ITPR1, 
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CACNA2D1, ARHGAP21, SPHKAP, TRPM7, PHB, FSCN2, ADGRL2, UQCR11, G0S2, FAM213A, 
KPNA3, SUGP2, ZSWIM8, TENM3, RGS7, PEBP1, NFAT5, PTPRZ1, QSER1, USP34, CDC42BPA, 
WASL, BICC1, CCSER2, WAPL, MAGI2, JMJD1C, BRSK1, SLC38A1, NOVA1, MICALL1, ANKHD1, 
AKAP2, NME1, PCDHGA2, ANKS1B, FARP1, NBEA, HERC2, MPDZ, RPS10-NUDT3, SLIT2, 
TOM1L2, PODXL, NRXN3, PGRMC1, ERP29, ANK3, RPL26L1, TOX3, ATP6V0E2, RALGAPA1, 
COX6A1, MIA3, ATP6V0B, XPO5, ATP6V1G1, HMBOX1, RPL8, UBN2, SZT2, TET2, KIAA2018, 
VPS13A, RPS12, GNG11, CHD2, HIST1H3H, ANKRD26, RPS27A, PER3, CLOCK, RORA, SCG5, 
PSMC5, ZFHX3, SLC8A3, C4orf48, UBB, TM2D3, NDUFA4, GNGT2, NDUFB3, GAP43, KCNH6, 
RPL15, SLC38A2, STXBP1, CNTRL, LOC776816, MAPK10, SLC15A2, EEF1A1, MYLK, 
LOC107053055, SREBF1, GRM5, RPL6, LDHB, DIAPH2, KCNMA1, SLC25A6, TLE4, RIMBP2, 
CELF2, PER2, CACNA1B, GAPDH, SAP18, PTPRG, KCND3, KCNA2, USP7, OTX2, RAB5C, 
PCM1, SDK2, EIF4A1, LIFR, RPL5, PSMA7, DPF3, SALL3, PRKDC, BAZ2B, OPCML, MYH15, 
COL5A1, MEIS2, PSAP, CHUNK-1, NEGR1, TENM1, MEF2A, TFAP2B, CNBP, CHD1, NOS2, 
PGK1, RPLP0, RPL13, HSPA8, COL12A1, IGF1R, SOD1, TOP2B, EPHA7, ITM2B, RORB, RPS4Y1, 
AK1, ENO1, PPP1R12A, PPP2CB, SMARCA2, NCALD, FASN, PBRM1, MMP16, MELTF, CSRP2, 
RPS6, VSNL1, RAN, NFIB, NFIA, LDHA, HRAS, H3F3B, DMD, MYO5A, CKB, CALB2, CA2, CTSB, 
SYP, YBX3, PTPRS, PLN, ANOS1, TPI1, SNAP25, POU2F1, MYH9, GLG1, CST3, ACACA, 
ATP1B3, VAV3, RYR3, AKAP9, MID1IP1, MIR3526 
 
(d)  LOC421975, MSMO1, BCL6, RBP3, DNMT3A, SWAP70, RAP1GAP2, SPRY4, STARD4, PCDHA11, 
PCDHA4, PCDHA5, PCDHA8, PCDHA9, MZT1, APC2, NUMA1, COL9A2, BHLHE40, NTS, ETV5, 
RAD54L2, C14orf2, DIO2, UQCRB, HK2, SIX3, TERF1, CDKN1A, UNC5C, PTPRU, OPN4-1, 
SPON1, KCNA4, CRYAB, SLC2A1, LRP1, TNS1, UTS2B 
 
(e) CFDP1, EGF, SUCLG2, CORO7-PAM16, AACS, MTERF3, DHFR, TANGO2, YPEL2, ATP6V0D2, 
AZIN1, DNPEP, DEPDC1, BCL2L1, MON1A, TWF1, TFEB, KDM5B, DHCR24, SGF29, DCTN1, 
CTSA, AOX1, WWP2, EWSR1, LOC395100, OLFML3, HIST1H101, GADD45A, FOSL2, CYP51A1, 
FGL2, NA, DUSP1, FBF1, CDK5, FADS2, PALM, SQLE, P4HA1, COQ8A, DHCR7, RHOBTB1, 
KCNMB4, JUP, UCKL1, SIRT5, GAS2L3, RGS16, TWF1, CREBL2, RASA4B, ELN, C10H15ORF59, 
FAM136A, STK10, PFKL, EGR1, MAB21L2, ILK, GIT1, KIT, THY1, NR2F2, COL2A1, AIP, OPTC, 
SGK1, IL17RD, RARA, RGMA, NA, CXCL14, CSPG5, ANGPT2, DUSP4, MERTK, GFRA4, GBX2, 
ADORA2B, GFRA2, AANAT, NA, SDC3, KCNJ3, HMGCS1, EXFABP, OPN1LW, FOS, FGFR1 
 
(f) UBE2E3, SPATS2L, LOC769852, NEUROD4, VPS33B, C12ORF57, NUDT16L1, TTLL5, SIRT6, 
GUCA1A, AGTPBP1, MBNL1, MBNL1, MBNL1, MBNL1, MBNL1, PCGF5, TOMM6, NECAB3, 
GNAI3, LTN1, DICER1, HIST1H2B8, PPP3CB, LEPROT, HIST1H46L2, ACLY, DCX, DCX, EIF3H, 
SEC24A, PIK3CD, FUT9, PPIB, NR2C1, ANO5, HIST1H46L2, HIST2H4B, HIST1H46, PARD3, 
NACA, PRRG1, ASCC3, CITED4, GAPVD1, HSPA2, TRIM2, CDH8, SIPA1L1, ACTB, KIF2A, 
RPS15, FMN1, SS2, MLF2, RMND5A, ATM, GABRA6, BNIP3L, EEF1A2, SCAF11, KDM3A, 
ZCCHC6, IQGAP2, RPL17, CLIP1, MYH10, HNRNPD, PRPF19, EEF2, ATP6V0D1, CANX, 
SPTBN1 
 
(g) ST3GAL5, SDC2, RTN1, P3H2, CYB5A, LOC414835, CDHR1, LIMS1, GSTA2, CAPZA2, ZYX, 
CCT8, CNTN2, SERPINI1, NFASC, MRPS11, MAP2K1, HSDL1, UQCRFS1, GPI, PPP2CA, SKP1, 
C13H5ORF15, GET4, UBE2L3, SEPT2L, RANBP1, TMED2, XBP1, ACADS, NOL11, CCT6A, 
PSMC2, RPAP3, SLC25A3, PHC1, FKBP4, AP1S2, TRAPPC2, SUCLA2, SPRYD7, RTFDC1, RER1, 
SDF4, PGD, ZDHHC18, NUDC, LSM7, COPE, FABP5, OTUD6A, EIF3E, ARF1, GTPBP4, HIBADH, 
CNDP2, PSME4, MCFD2, LOC421792, LMBRD1, CHMP1B, ABCE1, OSTC, DCTD, COPS4, DCK, 
RPL7L1, ASAH1, NUCB2, API5, ERH, EIF2S1, PSMA3, ACTR10, PSMC6, ASNSD1, BIN1, 
ZNF326, NDUFB5, ANP32E, OAT, GOLGA7, TMEM175, AP3S1, SLC25A46, SYNGR3, VPS29, 
YWHAH, RNF5, GID8, AP1M1, TCEB1, YPEL5, PSMB1, MPP1, RNF141, TMED5, RPL30, 
TRAPPC3, TMEM41B, CD82, GLRX5, SUB1, MRPL51, PNRC1, CCT2, CCT5, GPM6A, EXOC5, 
HNRNPH3, SEC62, MAEA, MGAT3, MAGI3, RBM10, HAGH, RAB14, ODF2, CNOT4, POLDIP3, 
SCAF4, GNB1, ELL, GLCCI1, SCCPDH, TMEM30A, SLC25A14, TMEM164, GTF2E2, SUCLG1, 
CHUK, NEURL1, HSPD1, SELENOF, STX7, PAN2, FOXP1, SELENOK, ERBB4, KCNA3, CRABP1, 
NPAS2, MESDC2, HEATR3, CYB5B, APEH, IMPDH2, CLCN7, NRF1, NET1, SNAP29, SETD1A, 
BG8, BRD2, NUP188, SET, DLD, DNAJB9, NELL2, KRR1, ST13P5, CHMP2B, CBR3, EIF1AX, 
PDCL3, ABCC4, UFM1, SRSF6, EIF6, AURKAIP1, ATP13A2, MEAF6, AGO3, AHCYL1, OARD1, 
PTBP1, FBXO32, GMPR2, RPRD1A, MAPRE2, TIMM17B, SERTAD2, CRIPT, GPR137B, LIN7C, 
RWDD1, OSTM1, ASXL2, GGA3, SEC31A, SGCB, ANGEL1, GMFB, UNC5B, TRIM8, NDUFA10, 
GLS2, PLEKHA3, OLA1, PSMD14, VTG2, SLC6A9, BTF3L4, RNF7, PPP1R2, KIAA0907, MRPL28, 
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MED24, TBL1XR1, H2AFZ, HDAC7, TXN2, SLC30A5, DCTN3, BRIX1, FYB, MAP1LC3B, ZMAT2, 
MPC1L, PCMT1, CCT7, ARPC5, ZC3H3, IRF5, LOC431499, BG8, VDAC1, ATG9A, VEZF1, 
ZNF512B, LY75-CD302, SMARCB1, PITPNB, AGO4, ACP1, FDFT1, FNIP1, ZDHHC5, PRKAA2, 
MRPS26, SPECC1L, CYCS, HMGN4, ZNF384, UBN1, USP48, PFN2, UCHL1, CD69L, NCAPD2, 
RHOT2, GNRH1, PHB2, EVI2A, ARL1, ATP5I, GTF2H5, NDUFA5, THOC7, ADCYAP1R1, PCDH19, 
PCDH8, ZNF692, HSP90AA1, PCDHA1, PCDHA12, PCDHA2, PCDHA7, HSBP1, PNPLA6, 
TMEM167A, CHCHD4, FN3KRP, SCOC, TXNRD3, PPAP2B, CECR2, MEIS1, PSMD4, OAZ2, 
C12orf75, NDUFS3, ABLIM1, HYDIN, NFASC, GABRQ, DYNC1LI1, ODC1, CTSV, LAMTOR5, 
NLGN3, SSB, SUGP1, SRSF3, EAPP, EMC3, YIPF5, MRPS17, MRPS33, COX6C, EMC2, P4HB, 
FN1, COX7A2, DPY30, DISP3, NDUFAF2, TMX4, HIPK3, CFAP36, PLCB4, TTBK1, DACH1, 
ROCK1, ZC3H8, MRPL53, FABP9, C5H15ORF57, PDDC1, CDC25A, XPOT, SYT13, PHF21A, 
RNF111, GNG10, C2H6orf52, PLD5, NOTCH2, RPL32, FNDC3B, ARL8BL, TIAL1, TSPAN3, 
PLXNB3, GPR158, RPL9, LOC427025, ZNF512B, RAB1B, TBX3, C26H6ORF125, GLI2, PRDX1, 
ISCA1, ATP2A2, PTN, FUNDC1, LOC407092, FAM103A1, CNOT1, MPHOSPH6, RPS2, SLIT1, 
SNRPF, PHF5A, CHMP5, LACTB2, PPP1R7, ATP6V1D, NCBP2, SSR3, ZFAND6, NDUFB6, 
ZFAND6, CNRIP1, FAM192A, HYPK, NDUFA8, RPL27A, COX20, UQCRHL, RPL12, PSKH1, 
SLC51A, COPS9, SYAP1, NDUFB1, CWC15, SEC13, ATP5G3, LOC425783, ALYREF, DHRS3, 
HDDC2, DHRS7C, IL16, RPL38, SETD5, WBP2, RAB40B, RCAN1, FZR1, MRPS35, ZNF341, 
ATP5C1, REXO2, MPC2, PCP4, SLCO4A1, FBXL16, TMEM254, NME3, BEND7, INPP5K, 
TXNDC12, MARC1, LOC417414, TICRR, FAXDC2, MYO9B, RSL24D1, RCN2, ZNF609, RCN2, 
GNB5, RNF123, NDUFA1, C7orf73, COX7B, COX17, SPTSSA, COA5, PIGY, ARL6, RELN, SORL1, 
RPL11, SCP2, LOC420362, UCHL5, MAGOH, AGO1, P2RY14, GPR83-L, IGSF11, NLRC5, 
SCN5A, SRPRB, WBP2NL, ZEB2, PIP5K1C, RSPO2, C8B, RPL24, SDK1, PDIA3, BASP1, NRG1, 
NHLH1, PTPRO, ACTN1, LIMK1, LAMB2, LMBR1, ACO2, ARNT, PCBD2, UGT8, CBL, SOD2, 
RPS17, DAB1, IMPG1, KCNIP2, RPL35, BRCA2, ID4, NRP2, HSP90B1, CAMK2A, ME1, HDAC4, 
LEPR, MAGOH, DPF2, TNKS, PPP3R1, CSNK1E, PSMB7, YBX1, PDE6G, PHACTR1, FGFRL1, 
CCNL2, HS2ST1, DPYSL2, HNRNPH2, RGS9BP, TLN1, SH3GL1, SH3GL2, MAB21L1, FET1, 
DYRK1A, SFRP1, KCNT1, NSG1, FKBP1B, ALDH1A1, GJD2, PARK7, SP1, PTPRJ, ACTR6, 
ALDH1A3, SNCG, ZBTB7A, GNAT1, TLL1, RHOA, SALL1, CASP3, PPP1R12B, NCAN, PBX1, 
RDX, EBF1, SOUL, NEUROG2, NHLH2, KCNN2, MTCH2, UCHL3, PHOSPHO1, RBPMS2, LSAMP, 
SCD, HMGB1, KCNAB1, RHOB, OAZ1, PSMC1, FMOD, ID2, CALM2, PSMA1, EFNB1, TGFBI, 
CDC42, RREB1, LRPAP1, HSPE1, LDB1, TSN, TFAP2A, HDLBP, GFRA1, BLMH, HMGN1, 
COL6A1, PPP1CB, ACTN4, GLRX, NTRK3, ALCAM, EFNA5, LRP8, MST1, CNGA1, RAB2A, 
SNRPE, NPM1, NFIC, MYH11, TNR, MBP, HMGB3, COL9A3, FABP7, TUBB, GOT1, RPLP1, 
HNRNPAB, MYL12A, ASMT, GABRG2, RNF13, C5H14ORF166, NREP, INHBA, LOC396380, ISL1, 
IFNA3, 17.5, BG2, SRC, PRNP, RBP4, HMGB2, OPN1MSW, HSPA5, GLUL, CALB1, CAPZA1, 
GOT2, APOA1, AGRN, POPDC2, CCT4, CG-16, EPHB2, DNMT1, HSP90AB1, GRIN1, PLA2R1, 
ATG4B, NDUFC2, PCDH10, PCDHGC3, AMY1AP, MIR1728, MIR1768, ATP2A2, FUNDC1, RPL12, 
COPS9, ATP5G3, TMEM254, UCHL5 
 
 
 
 
 
 
 
 
 
 
 
 
234 
 
Appendix 5.6. Common differentially expressed genes between comparisons for 
high vs. low and previous studies. 
Gene ID 
Model 
Author Year Method Species Tissue 1 3 
BICC1 
 
Yes Verhoeven 2013 microarray Human 
Retinal/RPE/  
photoreceptors / 
choroid. 
RORB 
 
Yes Verhoeven 
   PCGF5 
 
Yes Brand 2007 Microarray Mouse Retina 
REPS1 
 
Yes Brand 
    ASCC3 
 
Yes McGlinn 2007 Microarray Chick Retina/RPE 
ASL1 Yes 
 
McGlinn 
    DCX 
 
Yes McGlinn 
    G0S2 
 
Yes McGlinn 
    LBH 
 
Yes McGlinn 
    LOC422214 Yes McGlinn 
    RGN Yes 
 
McGlinn 
    TOX3 
 
Yes McGlinn 
    VIP 
 
Yes McGlinn 
    WASL 
 
Yes McGlinn 
    CNTRL 
 
Yes Schippert 2008 Microarray Chick Retina 
DCT Yes 
 
Schippert 
    GCG 
 
Yes Schippert 
    GNAT2 
 
Yes Schippert 
    HERC2 
 
Yes Schippert 
    MYLK 
 
Yes Schippert 
    NLGN1 
 
Yes Schippert 
    QSER1 
 
Yes Schippert 
    RALGAPA1 Yes Schippert 
    SPTBN1 
 
Yes Schippert 
    TRPM7 
 
Yes Schippert 
    
CST3 
 
Yes Rada 2009 Microarray Chick 
Retina/RPE/choro
id 
GAPDH 
 
Yes Rada 
    HSPA8 
 
Yes Rada 
    RPLP0 
 
Yes Rada 
    
AP2M1 
 
Yes Ashby 2010 Microarray Chick 
Amacrine cell 
layer 
COL8A1 Yes 
 
Ashby 
    CHD7 
 
Yes Ashby 
    CLTA 
 
Yes Ashby 
    DPF3 
 
Yes Ashby 
    GRIA3 
 
Yes Ashby 
    NEGR1 
 
Yes Ashby 
    NFAT5 
 
Yes Ashby 
    OTX2 
 
Yes Ashby 
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RPL7 
 
Yes Ashby 
    RPS15 
 
Yes Ashby 
    SEPP1 
 
Yes Ashby 
    UBB 
 
Yes Ashby 
    AGTPBP1 
 
Yes Stone 2011 Microarray Chick Retina/RPE 
CCSER2 
 
Yes Stone 
    GRIA4 
 
Yes Stone 
    KCNMA1 
 
Yes Stone 
    AKAP9 
 
Yes Stone 
    ANK3 
 
Yes Stone 
    ANKHD1 
 
Yes Stone 
    ANKS1B 
 
Yes Stone 
    ARHGAP21 Yes Stone 
    B3GNT5 
 
Yes Stone 
    BAZ2B 
 
Yes Stone 
    CACNA2D1 Yes Stone 
    CDC42BPA Yes Stone 
    CDH13 
 
Yes Stone 
    CDK6 
 
Yes Stone 
    CELF1 
 
Yes Stone 
    CLIP1 
 
Yes Stone 
    CLOCK 
 
Yes Stone 
    DICER1 
 
Yes Stone 
    DMD 
 
Yes Stone 
    DROSHA 
 
Yes Stone 
    EDF1 
 
Yes Stone 
    EIF4A3 
 
Yes Stone 
    ENO1 
 
Yes Stone 
    EOGT Yes 
 
Stone 
    EPHA7 
 
Yes Stone 
    ERP29 
 
Yes Stone 
    FARP1 
 
Yes Stone 
    FAT3 
 
Yes Stone 
    FMN1 
 
Yes Stone 
    FNDC3A 
 
Yes Stone 
    FUT9 
 
Yes Stone 
    GAPVD1 
 
Yes Stone 
    GRM5 
 
Yes Stone 
    HARS 
 
Yes Stone 
    HMBOX1 
 
Yes Stone 
    ITPR1 
 
Yes Stone 
    JMJD1C 
 
Yes Stone 
    KDM3A 
 
Yes Stone 
    KIAA0586 
 
Yes Stone 
    KIAA2018 
 
Yes Stone 
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LSS 
 
Yes Stone 
    MAGI2 
 
Yes Stone 
    MIA3 
 
Yes Stone 
    MPDZ 
 
Yes Stone 
    MYH10 
 
Yes Stone 
    MYO5A 
 
Yes Stone 
    NBEA 
 
Yes Stone 
    NOS2 
 
Yes Stone 
    OPN4 
 
Yes Stone 
    PCDH1 
 
Yes Stone 
    PCDH15 
 
Yes Stone 
    PER3 
 
Yes Stone 
    PHTF2 
 
Yes Stone 
    PSMC5 
 
Yes Stone 
    PTPRG 
 
Yes Stone 
    PTPRZ1 
 
Yes Stone 
    RAB3GAP2 Yes Stone 
    RIMBP2 
 
Yes Stone 
    RPS27A 
 
Yes Stone 
    SCAF11 
 
Yes Stone 
    SIRT6 
 
Yes Stone 
    SLC38A2 
 
Yes Stone 
    SNAP25 
 
Yes Stone 
    SPATS2L 
 
Yes Stone 
    SPHKAP 
 
Yes Stone 
    SRI 
 
Yes Stone 
    SZT2 
 
Yes Stone 
    TENM2 
 
Yes Stone 
    TET2 
 
Yes Stone 
    TMEM131 
 
Yes Stone 
    TRIM2 
 
Yes Stone 
    TTC14 
 
Yes Stone 
    USP34 
 
Yes Stone 
    USP7 
 
Yes Stone 
    VPS13A 
 
Yes Stone 
    XPO5 
 
Yes Stone 
    ZDHHC8 
 
Yes Stone 
    ZFHX3 
 
Yes Stone 
    CKB 
 
Yes Bertrand 2006 2D GE, MS Chick Retina 
PGAM1 
 
Yes Lam 2007 2D GE, MS Chick Retina 
TUBB2B 
 
Yes Lam 
    
AK1 
 
Yes Zhou 2010 2D GE, MS 
Guinea 
Pig Posterior Sclera 
EIF3I 
 
Yes Zhou 
    PGK1 
 
Yes Zhou 
    RACK1 
 
Yes Zhou 
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ACTB 
 
Yes Frost 2012 2D GE, MS 
Tree 
Shrew Sclera 
COL12A1 
 
Yes Frost 
    PEBP1 
 
Yes Frost 
    TPI1 
 
Yes Frost 
    CRYBA2 Yes 
 
Li 2012 2D GE, MS Mouse Retina 
CLTC 
 
Yes Barathi 2014 iTRAQ  Mouse Retina 
FSCN1 
 
Yes Barathi 
    LDHA 
 
Yes Barathi 
    MBP Yes 
 
Barathi 
    RPL4 
 
Yes Barathi 
    STXBP1 
 
Yes Barathi 
    CNIH1 
 
Yes Barathi 
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Appendix 6.1 Gene-based analysis by MAGMA (with P < 0.05)  
GENE CHR START STOP ZSTAT P 
PIK3CG 1 14208410 14246547 4.04 2.67e-05 
ENSGALT00000006673.4 7 5730049 5902491 3.94 4.15e-05 
ENSGALT00000039781.2 7 5867755 5878724 3.72 9.84e-05 
ENSGALT00000021678.3 13 14376043 14389235 3.53 2.04e-04 
USP40 7 5896675 5938176 3.48 2.50e-04 
GPR22 1 14513792 14525725 3.35 4.03e-04 
DOCK9 1 143955154 144047261 3.34 4.17e-04 
SPSB4 9 6118832 6129579 3.28 5.19e-04 
OGN 12 3419002 3443509 3.13 8.65e-04 
PXYLP1 9 6322526 6382838 3.12 8.94e-04 
KCNK16 3 28436386 28453914 3.12 9.08e-04 
TSPAN5 4 59387903 59420610 3.09 9.92e-04 
KIF6 3 28290092 28442362 3.07 0.001 
gga-mir-1690 1 83228226 83238330 3.07 0.001 
FOLH1 1 186840640 186881181 3.02 0.001 
ENSGALT00000044890.1 10 12637496 12648801 2.97 0.002 
ENSGALT00000032906.3 7 30705685 30717735 2.92 0.002 
GPC4 4 3745510 3792904 2.90 0.002 
CHRDL2 1 194986363 195015253 2.83 0.002 
TCEANC2 8 24033682 24046647 2.82 0.002 
ENSGALT00000011411.4 1 15230834 15286162 2.82 0.002 
CHRNA5 10 3125408 3140905 2.82 0.002 
FGF20 4 62870509 62884757 2.82 0.002 
WBP11 1 47911129 47929400 2.81 0.002 
SYF2 23 2356271 2368540 2.81 0.003 
DYRK1A 1 106533437 106564176 2.77 0.003 
PUS7 1 13783330 13814208 2.74 0.003 
FCHSD2 1 194312764 194453987 2.71 0.003 
ANO4 1 47287274 47469213 2.69 0.004 
ENSGALT00000044937.1 2 95939287 95949385 2.68 0.004 
TGFBI 13 14290425 14514385 2.68 0.004 
ITPA 8 4683298 4696874 2.68 0.004 
HBP1 1 14351758 14372631 2.67 0.004 
TOP2B 2 38415563 38487069 2.67 0.004 
ENSGALT00000017057.3 8 20799323 20812546 2.67 0.004 
ENSGALT00000045541.1 23 2349968 2369999 2.67 0.004 
HYAL3 12 3226619 3238209 2.67 0.004 
KCTD15 11 10163413 10221329 2.66 0.004 
TMEM59 8 24025292 24043522 2.65 0.004 
PLD4 5 51688868 51710952 2.65 0.004 
ENSGALT00000011337.4 17 3550763 3566244 2.64 0.004 
H2A-VIIId 1 47919628 47930018 2.64 0.004 
ILDR1 1 82607953 82635949 2.63 0.004 
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OGDH 22 4022420 4053078 2.61 0.005 
CNDP2 2 91848634 91872910 2.59 0.005 
DET1 10 12637749 12657973 2.58 0.005 
ENSGALT00000044097.1 1 13811697 13821797 2.58 0.005 
COG5 1 14364254 14558213 2.58 0.005 
VAMP4 8 4689855 4712280 2.54 0.006 
ENSGALT00000014522.4 17 922030 938004 2.53 0.006 
ENSGALT00000044588.1 11 10914215 10928303 2.53 0.006 
ATPAF1 8 20739186 20759041 2.52 0.006 
PEPD 11 9799381 9930979 2.52 0.006 
RNF121 1 193345969 193366446 2.51 0.006 
PKIB 3 60682660 60748857 2.51 0.006 
ENSGALT00000021778.4 1 48012423 48023082 2.51 0.006 
RINT1 1 13805272 13827128 2.50 0.006 
MOB3C 8 20721721 20742106 2.50 0.006 
SCL 8 20805414 20818774 2.50 0.006 
PLEKHG7 1 44466026 44494240 2.49 0.006 
CYBA 11 17888778 17900490 2.48 0.007 
MAML3 4 28841110 28925597 2.48 0.007 
ENSGALT00000043354.1 7 6061699 6071767 2.48 0.007 
CLSTN2 9 5561976 5866817 2.48 0.007 
CCDC69 13 12336372 12349594 2.48 0.007 
ENSGALT00000006953.4 13 12339790 12353418 2.48 0.007 
FAM73B 17 5453245 5477221 2.48 0.007 
HTRA3 4 80433629 80466899 2.47 0.007 
SMAD5 13 14422580 14440845 2.47 0.007 
ENSGALT00000030959.3 2 94083924 94218373 2.46 0.007 
H2A-VIIIc 1 48005461 48032267 2.45 0.007 
ENSGALT00000043224.1 1 48005778 48016912 2.45 0.007 
ANXA4 22 3983992 4003235 2.45 0.007 
gga-mir-1803 2 92558596 92568685 2.44 0.007 
ENTPD8 17 912233 928564 2.44 0.007 
ENSGALT00000007165.4 6 11130324 11142516 2.44 0.007 
SPOCK1 13 13901201 14168956 2.44 0.007 
RAP1GDS1 4 59293213 59392366 2.43 0.008 
ENSGALT00000014517.3 17 928055 953197 2.42 0.008 
SS18L2 11 10370343 10392067 2.41 0.008 
gga-let-7j 26 1586917 1597000 2.40 0.008 
gga-let-7k 26 1587117 1597200 2.40 0.008 
EF1Aa 3 80908075 80921878 2.40 0.008 
HYDIN 11 1532249 1646091 2.39 0.008 
EXOC8 3 39092130 39108582 2.39 0.008 
MYLK 7 26669969 26864021 2.39 0.008 
gga-mir-1816 2 88285497 88295602 2.39 0.008 
ENSGALT00000008831.4 7 6592660 6626009 2.38 0.009 
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gga-mir-214 8 4622232 4632342 2.38 0.009 
CNGB3 2 122948407 122987927 2.38 0.009 
PPARa 1 71406619 71447947 2.38 0.009 
NDUFA10 7 6547330 6597902 2.37 0.009 
ZAR1 1 173854595 173866411 2.37 0.009 
ENSGALT00000027578.4 1 173858588 174007319 2.37 0.009 
RHD 23 2337637 2354134 2.37 0.009 
TBX3 15 12202813 12224746 2.37 0.009 
MICU3 4 62815273 62874495 2.36 0.009 
gga-mir-1555 1 144180922 144191008 2.36 0.009 
MFSD10 4 81831411 81864788 2.36 0.009 
GTF2F2 1 166960969 167062679 2.36 0.009 
gga-mir-383 4 63590604 63600677 2.36 0.009 
KXD1 28 3652471 3664967 2.36 0.009 
GPR146 14 2315567 2336815 2.35 0.009 
LDLRAD1 8 24018107 24030375 2.35 0.009 
FAM193A 4 82044671 82102810 2.35 0.009 
DRD3 1 82392144 82417833 2.35 0.009 
ETS2 1 107162342 107185491 2.34 0.010 
GLIS1 8 23799848 23905621 2.34 0.010 
DSP 2 64606441 64645267 2.33 0.010 
PDZK1IP1 8 20789710 20804010 2.33 0.010 
PHYKPL 13 13609746 13626757 2.33 0.010 
EDF1 17 545446 558619 2.33 0.010 
gga-mir-6600 2 5785772 5795882 2.33 0.010 
ENSGALT00000033803.3 9 5937141 5949259 2.33 0.010 
TMEM57 23 2320806 2341889 2.32 0.01 
ENSGALT00000002125.4 10 2102248 2119518 2.32 0.01 
FKBP8 28 3655482 3670804 2.32 0.01 
STOML1 10 2110124 2123216 2.31 0.01 
EFCAB10 1 13816810 13828862 2.30 0.01 
gga-mir-199-2 8 4616375 4626483 2.30 0.01 
PKHD1 3 107225219 107466810 2.29 0.01 
NEK3 1 169682935 169706053 2.28 0.01 
GORAB 8 4864944 4884119 2.28 0.01 
TMEM203 17 944677 955088 2.28 0.01 
IL17RD 12 8530419 8600065 2.27 0.01 
SMPX 1 118545326 118563867 2.27 0.01 
TSHR 5 40037539 40095213 2.27 0.01 
XKR5 3 107100044 107114160 2.27 0.01 
gga-mir-1579 6 2159857 2169924 2.26 0.01 
FKBP14 2 34420409 34435988 2.26 0.01 
SLC2A13 1 14911516 15059085 2.26 0.01 
GPER1 14 2348428 2361256 2.25 0.01 
RAD54L 8 20466190 20494383 2.25 0.01 
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ENSGALT00000044503.1 3 107098313 107108845 2.25 0.01 
PPIB 10 801483 812487 2.24 0.01 
AMBP 17 630093 645394 2.23 0.01 
VPS8 9 2958832 3035421 2.23 0.01 
CRLF1 28 3646444 3658912 2.23 0.01 
AHNAK2 5 51706520 51741637 2.23 0.01 
MAMDC4 17 549236 570821 2.22 0.01 
KCNK1 3 38001260 38041746 2.22 0.01 
TPT1 1 167053419 167071619 2.22 0.01 
SGPL1 6 11109346 11189726 2.22 0.01 
SNX22 10 802605 814314 2.22 0.01 
ENSGALT00000013424.3 15 12192003 12203222 2.22 0.01 
DNM3 8 4509808 4683962 2.21 0.01 
gga-mir-1783 12 8790544 8800645 2.21 0.01 
HMX3 6 31008802 31019912 2.21 0.01 
GPR15 1 82589872 82600979 2.21 0.01 
BRCA2 1 173815723 173862456 2.20 0.01 
SLC19A2 1 83051656 83075746 2.20 0.01 
ANKRD6 3 74948169 74990332 2.20 0.01 
C15orf61 10 18425851 18437733 2.19 0.01 
MOCOS 2 84807788 85030689 2.19 0.01 
irx2 2 86619613 86636727 2.19 0.01 
EIF4E 4 59492315 59535000 2.19 0.01 
ENSGALT00000007184.4 6 11134585 11155803 2.18 0.01 
GPX3 13 12372502 12384482 2.18 0.01 
PALD1 6 11091826 11115392 2.18 0.01 
ENSGALT00000017926.4 3 38130387 38179625 2.18 0.01 
SOCS6 2 93538028 93572247 2.17 0.01 
KCTD4 1 166990126 167000900 2.17 0.01 
PDE6H 1 47819918 47838585 2.17 0.01 
ZNF385C 27 4758259 4802776 2.17 0.02 
SNORD71 11 19219873 19229960 2.17 0.02 
DMBX1 8 20560275 20588037 2.16 0.02 
FARP1 1 144147282 144339650 2.16 0.02 
KIAA0355 11 10371829 10408785 2.16 0.02 
ATXN7L1 1 13826429 13903855 2.16 0.02 
CRISP1 3 108315647 108338075 2.16 0.02 
N4BP2L1 1 173803325 173825489 2.16 0.02 
METTL13 8 4677861 4692818 2.16 0.02 
ENSGALT00000008462.3 9 6269494 6291125 2.16 0.02 
PHLPP2 11 19233987 19273628 2.15 0.02 
NPTXR 1 50622426 50654375 2.15 0.02 
GDPD5 1 194093030 194261622 2.14 0.02 
CPA6 2 115180936 115278389 2.14 0.02 
CFAP99 4 82156952 82214841 2.14 0.02 
242 
 
EFCAB11 5 42887401 42952303 2.14 0.02 
ENSGALT00000010583.3 12 3232732 3244576 2.14 0.02 
TBCEL 24 3553095 3576802 2.13 0.02 
MADPRT 1 193342494 193354021 2.13 0.02 
PSME3 27 5055693 5072398 2.13 0.02 
EEA1 1 44492301 44567796 2.12 0.02 
ENSGALT00000036276.2 12 3480320 3503864 2.12 0.02 
TAT 11 19275393 19294813 2.12 0.02 
ENSGALT00000010200.3 13 14402282 14421685 2.12 0.02 
DOLK 17 5322458 5409262 2.12 0.02 
ENSGALT00000044726.1 17 5310360 5320455 2.12 0.02 
MVD 11 17890873 17903830 2.11 0.02 
MRPL37 8 24059756 24073753 2.11 0.02 
RABL6 17 576462 634223 2.11 0.02 
ENSGALT00000030452.3 1 82528507 82553223 2.11 0.02 
UBAC2 1 143793560 143889756 2.11 0.02 
GABBR2 2 87951517 88383890 2.11 0.02 
ARL4C 7 5649087 5659666 2.11 0.02 
ENSGALT00000007414.4 6 11370532 11506581 2.10 0.02 
NUFIP1 1 166899654 166932469 2.10 0.02 
ENSGALT00000025631.4 2 124066733 124095805 2.10 0.02 
TWF2 12 2940887 2963336 2.10 0.02 
SOX14 9 3702359 3713061 2.10 0.02 
CHRNB4 10 3098511 3121708 2.10 0.02 
TMEM59L 28 3638256 3655421 2.09 0.02 
ITGB3 27 2297639 2324626 2.09 0.02 
ENSGALT00000034196.1 14 2340371 2352987 2.09 0.02 
ENSGALT00000005098.4 11 19350608 19365270 2.09 0.02 
MRPL46 10 12662220 12674762 2.08 0.02 
RUNX3 23 2404725 2445882 2.08 0.02 
RGS7 3 35233581 35476485 2.08 0.02 
ENSGALT00000039842.2 15 1909171 1948298 2.08 0.02 
ENSGALT00000031457.3 11 19111727 19124502 2.08 0.02 
CHST4 11 19295002 19306139 2.08 0.02 
OCC-1 1 54137066 54163684 2.08 0.02 
NAALAD2 1 186808785 186850023 2.08 0.02 
KCNK17 3 28448896 28483662 2.08 0.02 
HERC1 10 3428413 3533542 2.08 0.02 
RFTN2 7 9748088 9783093 2.07 0.02 
NEK2 3 21499435 21516540 2.07 0.02 
gga-mir-1739 5 38511932 38522025 2.07 0.02 
ENSGALT00000043438.1 4 79577075 80002954 2.07 0.02 
SLMAP 12 8741152 8826988 2.07 0.02 
ENSGALT00000042402.1 1 140637264 140647385 2.07 0.02 
IQCH 10 18363139 18431597 2.07 0.02 
243 
 
FGF14 1 142466031 142611517 2.07 0.02 
SNX1 10 804666 825365 2.07 0.02 
Epm2a 3 45764622 45816385 2.07 0.02 
IL17C 11 17885559 17897594 2.07 0.02 
ENSGALT00000026953.4 3 108469780 108481823 2.06 0.02 
ENSGALT00000044305.1 2 92802128 92812236 2.06 0.02 
PITPNB 15 7525399 7552053 2.06 0.02 
gga-mir-6684 12 11067267 11077377 2.06 0.02 
RGMA 10 14161476 14188190 2.06 0.02 
NCOA4 6 2244005 2262782 2.06 0.02 
gga-mir-6687 3 80907032 80917142 2.06 0.02 
ENSGALT00000032174.3 4 48573788 48584482 2.06 0.02 
GABARAPL2 11 19342940 19361180 2.06 0.02 
PHPT1 17 560838 572461 2.05 0.02 
C9orf172 17 563201 575706 2.05 0.02 
COL22A1 2 144137254 144379426 2.05 0.02 
NR2C2AP 28 3328910 3341777 2.05 0.02 
TTC28 15 7549368 7676872 2.05 0.02 
FOXN3 5 42661772 42850899 2.05 0.02 
cOpn5L2 3 108442860 108457107 2.05 0.02 
ENSGALT00000009756.4 15 8029377 8047034 2.05 0.02 
noxa1 17 897673 920909 2.05 0.02 
LRRC9 5 54540270 54570985 2.04 0.02 
ZFAND2A 14 2367452 2380530 2.04 0.02 
TRIM42 9 5900651 5919210 2.04 0.02 
ENSGALT00000001342.4 11 19358499 19374931 2.04 0.02 
ENSGALT00000022354.4 2 94282865 94304074 2.04 0.02 
RAB33B 4 28772868 28789884 2.04 0.02 
CCDC51 12 11248812 11263331 2.03 0.02 
CNOT7 4 62753273 62782681 2.03 0.02 
WASF2 23 1949482 1985118 2.03 0.02 
ENSGALT00000028011.4 1 194082351 194099501 2.03 0.02 
DTL 3 21359604 21391867 2.03 0.02 
ENSGALT00000031356.3 1 193357030 193369866 2.03 0.02 
ENSGALT00000025078.4 4 79996880 80100152 2.03 0.02 
ENSGALT00000008986.4 12 8632491 8706433 2.03 0.02 
FAH 10 12054479 12075953 2.03 0.02 
IL9 13 14557899 14570599 2.03 0.02 
PLS1 9 9970583 10018804 2.03 0.02 
AP1G1 11 19190951 19242680 2.03 0.02 
ENSGALT00000044263.1 3 47964054 47974166 2.03 0.02 
DHX38 11 19145948 19166411 2.02 0.02 
gga-mir-6714 14 12383338 12393448 2.02 0.02 
BTG1 1 44266337 44278899 2.02 0.02 
ISM2 5 38519086 38532515 2.02 0.02 
244 
 
C6orf132 26 3131185 3153471 2.01 0.02 
FAM135B 2 143850748 144043521 2.01 0.02 
DLC1 4 63974466 64204133 2.01 0.02 
DHODH 11 19157774 19171255 2.01 0.02 
PHIP 3 78921378 79021040 2.00 0.02 
ZDHHC2 4 62782143 62819535 2.00 0.02 
APOV1 1 82604205 82617227 2.00 0.02 
gga-mir-1649 3 21189284 21199382 2.00 0.02 
TRPC1 9 10010076 10041192 2.00 0.02 
gga-mir-1577 9 4937396 4947481 2.00 0.02 
TNIP1 13 12362917 12381206 2.00 0.02 
EFHC1 3 107125487 107152698 2.00 0.02 
QTRTD1 1 82419530 82441617 1.99 0.02 
TMEM66 4 48641934 48659556 1.99 0.02 
EED 1 189664528 189690501 1.99 0.02 
FAM110D 23 3148761 3161554 1.99 0.02 
IST1 11 19161597 19178788 1.99 0.02 
TMX3 2 94230831 94268036 1.99 0.02 
CALM1 5 43130795 43148958 1.99 0.02 
ENSGALT00000044604.1 3 78140678 78150769 1.99 0.02 
SGK3 2 114928091 114973853 1.99 0.02 
TRMT10A 4 59619812 59638939 1.99 0.02 
gga-mir-6612 24 4774926 4785036 1.98 0.02 
ESCO2 3 104785087 104805567 1.98 0.02 
ENSGALT00000000913.4 11 18371039 18383680 1.98 0.02 
NIP7 11 18373689 18385054 1.98 0.02 
B3GALT5 1 107439586 107451093 1.98 0.02 
ENSGALT00000039237.2 6 22933413 22946166 1.98 0.02 
IBTK 3 77654754 77722628 1.98 0.02 
ENSGALT00000036939.2 1 82518358 82536728 1.98 0.02 
VAPA 2 98222824 98259555 1.98 0.02 
LRP8 8 23556279 23715577 1.98 0.02 
LPGAT1 3 21422205 21485741 1.98 0.02 
ZDHHC23 1 82454932 82471590 1.97 0.02 
CALN1 19 950426 1066274 1.97 0.02 
C20H20ORF43 20 12309418 12339709 1.97 0.02 
ZNF821 11 19170525 19191003 1.97 0.02 
DENND6A 12 8717033 8746878 1.97 0.02 
HNRNPA2B1 2 32312344 32332887 1.97 0.02 
TK2 11 10901479 10922656 1.96 0.02 
PFKP 2 11349184 11400733 1.96 0.02 
HES6 9 4937247 4953675 1.96 0.03 
MKI67 6 32885713 32915556 1.96 0.03 
ADAT1 11 19317211 19347909 1.95 0.03 
RNF166 11 17895343 17911187 1.95 0.03 
245 
 
ENSGALT00000034106.3 9 10082483 10093628 1.95 0.03 
ARSI 13 12498422 12512422 1.95 0.03 
CCDC14 7 26875823 26894311 1.95 0.03 
B4GALT4 1 80031446 80066032 1.95 0.03 
TFAP2C 20 12277245 12296290 1.95 0.03 
ENSGALT00000017045.4 8 20778470 20795800 1.95 0.03 
HMX2 6 31013103 31028370 1.95 0.03 
IMPA1 2 121257378 121282486 1.94 0.03 
ZFHX3 11 18931950 19036832 1.94 0.03 
CBLN2 2 92622799 92635335 1.94 0.03 
ENSGALT00000031456.3 11 19136567 19150768 1.94 0.03 
CD8B 4 85435287 85451044 1.94 0.03 
NUP43 3 47484108 47503142 1.94 0.03 
MRPL14 3 29727267 29746085 1.94 0.03 
TIMP3 1 53053720 53096132 1.94 0.03 
FAM81A 10 6211547 6232549 1.94 0.03 
CENPP 12 3328635 3457411 1.94 0.03 
CCDC79 11 10795309 10819201 1.94 0.03 
RFXANK 28 3328910 3347226 1.94 0.03 
IGFBP7 4 48576285 48600158 1.94 0.03 
CRABP2 25 463702 475859 1.94 0.03 
PPDPF 20 9363434 9375742 1.94 0.03 
SNORA84 12 3500490 3510625 1.94 0.03 
GPALPP1 1 166922077 166947984 1.94 0.03 
CKAP2 1 169696517 169715954 1.94 0.03 
C18orf63 2 91916175 91939799 1.93 0.03 
MN1 15 7483964 7526455 1.93 0.03 
gga-mir-6584 2 93539764 93549874 1.93 0.03 
IRAK1BP1 3 79035636 79056664 1.93 0.03 
TSHZ1 2 91337032 91351101 1.93 0.03 
gga-mir-6640 3 21530493 21540603 1.93 0.03 
CNDP1 2 91814975 91842036 1.93 0.03 
gga-mir-1625 15 7563814 7573894 1.93 0.03 
gga-mir-1688 10 864889 874960 1.93 0.03 
WDR77 26 3149032 3161732 1.93 0.03 
ENSGALT00000017904.3 3 37618858 37675716 1.92 0.03 
FAM96B 11 10650811 10663144 1.92 0.03 
TBC1D9B 13 12754005 12781256 1.92 0.03 
MBTPS2 1 118497827 118540488 1.92 0.03 
UQCRH 8 20493969 20505444 1.92 0.03 
ENSGALT00000016586.4 8 19811838 19828208 1.92 0.03 
ERGIC2 1 14772555 14805582 1.92 0.03 
PGM2L1 1 195081449 195125846 1.92 0.03 
F5 1 83005007 83051065 1.91 0.03 
ANXA6 13 12345518 12367997 1.91 0.03 
246 
 
ENSGALT00000045881.1 1 49127164 49137271 1.91 0.03 
gga-mir-1581 1 49128040 49138126 1.91 0.03 
PPM1M 12 2959625 2975401 1.91 0.03 
ENSGALT00000042082.1 2 84972747 84982825 1.91 0.03 
ADAM11 27 1251094 1271189 1.90 0.03 
WDYHV1 2 137617324 137637958 1.90 0.03 
ZFYVE28 4 82204991 82355777 1.90 0.03 
KCNK12 3 8578545 8603351 1.90 0.03 
C3H2ORF43 3 101604617 101724052 1.90 0.03 
DNAJC24 5 5009652 5051383 1.90 0.03 
RPS16 1 39674924 39690489 1.89 0.03 
POLD3 1 195024321 195063322 1.89 0.03 
RBP3 6 17523349 17547877 1.89 0.03 
HYKK 10 3146804 3161695 1.89 0.03 
CHST8 11 10011611 10149234 1.89 0.03 
gga-mir-1699 11 18928028 18938125 1.89 0.03 
SEC22B 8 4125592 4144427 1.89 0.03 
ENSGALT00000034796.2 10 2094479 2105748 1.88 0.03 
TMCC3 1 45032003 45081411 1.88 0.03 
ISLR2 10 2099513 2111613 1.88 0.03 
MEF2BNB 28 3337691 3356021 1.88 0.03 
CHRM3 3 35722537 35882494 1.88 0.03 
C10orf54 6 11470430 11489506 1.88 0.03 
FAT2 13 12263216 12324359 1.88 0.03 
ENSGALT00000003144.3 6 2129546 2160479 1.88 0.03 
CDCP2 8 24040804 24054407 1.88 0.03 
STRA6 10 2084887 2102471 1.88 0.03 
MAP6 1 194002332 194038028 1.87 0.03 
SLC45A4 2 145617307 145660804 1.87 0.03 
DMRTB1 8 23764010 23783972 1.87 0.03 
LTC4S 13 12822840 12836848 1.87 0.03 
ENSGALT00000016927.4 4 35930706 35940859 1.87 0.03 
TACC1 22 2379464 2404036 1.87 0.03 
FKBP9 2 48578320 48604111 1.87 0.03 
RRNAD1 25 454757 466809 1.87 0.03 
TUSC3 4 63223828 63347046 1.86 0.03 
OTOGL 1 39685269 39786595 1.86 0.03 
ZC3H12C 1 178900487 178931969 1.86 0.03 
APOB 3 101875366 101921760 1.86 0.03 
ELL 28 3661227 3705318 1.86 0.03 
SLCO2A1 9 4058858 4093360 1.85 0.03 
IRF2BP2 3 37703941 37714703 1.85 0.03 
MGRN1 14 12344366 12401724 1.85 0.03 
SSBP3 8 24069036 24129115 1.85 0.03 
ACOT11 8 24126386 24145486 1.85 0.03 
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RREB1 2 64730014 64859227 1.85 0.03 
ENSGALT00000018675.4 7 22066157 22094594 1.85 0.03 
CHST2 9 10146973 10159431 1.84 0.03 
FOXO6 23 1186629 1241092 1.84 0.03 
ENSGALT00000014677.4 17 500643 513199 1.84 0.03 
INTS7 3 21381043 21413216 1.84 0.03 
LDLRAP1 23 2302618 2328671 1.84 0.03 
HOXA1 2 32786505 32798226 1.84 0.03 
MDN1 3 74848140 74951896 1.84 0.03 
RNF25 7 21954844 21968533 1.84 0.03 
RYK 9 3980680 4042412 1.84 0.03 
CHRM4 5 22939470 22950943 1.84 0.03 
SLC30A1 3 21525531 21541494 1.84 0.03 
TRMU 1 15515695 15537337 1.83 0.03 
UBE3D 3 77399160 77454989 1.83 0.03 
gga-mir-6661 4 82208018 82218128 1.83 0.03 
ZIC1 9 11390946 11405537 1.83 0.03 
ALK 3 8089159 8389451 1.83 0.03 
ENSGALT00000045050.1 3 104568756 104579824 1.83 0.03 
PTGDS 17 504033 516024 1.83 0.03 
CACHD1 8 26972491 27066474 1.83 0.03 
CTU2 11 17902682 17916287 1.83 0.03 
TBC1D16 18 9840356 9875528 1.82 0.03 
ENSGALT00000010863.4 9 2940064 2953848 1.82 0.03 
ENSGALT00000000929.3 11 18375394 18387865 1.82 0.03 
GPR183 1 143832082 143852582 1.82 0.03 
NDOR1 17 946104 972412 1.82 0.03 
BOC 1 82670888 82701983 1.82 0.03 
NARS2 1 191803031 191926160 1.82 0.03 
ENSGALT00000025383.2 2 93243440 93254914 1.82 0.03 
ADRA1A 22 3929594 3954175 1.82 0.03 
KBP 21 1451790 1471358 1.81 0.03 
TLR4 17 3561453 3576907 1.81 0.03 
SLC29A1 3 29632258 29659613 1.81 0.03 
SLC17A8 1 47107356 47146991 1.81 0.04 
RP9 2 48608434 48625142 1.81 0.04 
ATP2B1 1 43268705 43310815 1.81 0.04 
EXOC6B 4 89397350 89589157 1.81 0.04 
KIFAP3 8 4977259 5044415 1.81 0.04 
Dkk-1 6 9759379 9771014 1.80 0.04 
ST3GAL6 1 83609755 83661869 1.80 0.04 
ENSGALT00000030645.3 1 44269202 44282390 1.80 0.04 
PCMT1 3 47498536 47542193 1.80 0.04 
ENSGALT00000001296.3 11 19267174 19279159 1.80 0.04 
ENSGALT00000010438.4 12 11244995 11258626 1.80 0.04 
248 
 
ENSGALT00000019911.4 2 48622591 48638397 1.80 0.04 
ASB14 12 8622513 8640443 1.80 0.04 
ENSGALT00000021485.4 2 85456254 85640911 1.80 0.04 
PTDSS1 2 126611010 126650632 1.80 0.04 
ENSGALT00000040015.2 27 4642053 4660682 1.80 0.04 
SERINC1 3 60759155 60783623 1.80 0.04 
GPR18 1 143869786 143885033 1.79 0.04 
METTL11B 8 4942463 4969307 1.79 0.04 
HSP90AB1 3 29625921 29641756 1.79 0.04 
GPI 11 10445874 10476700 1.79 0.04 
ENSGALT00000005719.3 14 1584934 1597226 1.79 0.04 
SRSF11 8 27908699 27930763 1.78 0.04 
ENSGALT00000044719.1 1 54169608 54209367 1.78 0.04 
MRPL24 25 453647 464713 1.78 0.04 
POLR2B 4 48590102 48619515 1.78 0.04 
UBE4A 24 4387699 4571947 1.78 0.04 
SPRTN 3 39088468 39135259 1.78 0.04 
SASH1 3 46925246 47054931 1.78 0.04 
CHST15 6 31377329 31430438 1.78 0.04 
CCR7 27 4462062 4481841 1.78 0.04 
IGSF9B 24 2422010 2469846 1.78 0.04 
PHEX 1 118324958 118426519 1.78 0.04 
LARP1 13 11373039 11395962 1.78 0.04 
SGCZ 4 63464830 63824243 1.78 0.04 
NSDHL 4 11226921 11247461 1.77 0.04 
LACTB2 2 116450966 116478097 1.77 0.04 
ENSGALT00000042339.1 1 194193786 194203866 1.77 0.04 
TRAF2 17 526954 552794 1.77 0.04 
ITM2C 9 4861583 4886692 1.77 0.04 
MTG2 20 8099921 8114585 1.77 0.04 
CDC5L 3 108474341 108516164 1.77 0.04 
GPD2 7 35560239 35610889 1.77 0.04 
PANK4 21 1430526 1464981 1.77 0.04 
DAAM2 3 28088814 28290437 1.77 0.04 
cdk6 2 22838080 22967940 1.76 0.04 
ENSGALT00000033720.3 9 4778952 4791016 1.76 0.04 
ATP6V1D 5 28240790 28258755 1.76 0.04 
BFSP1 3 11358003 11386764 1.76 0.04 
TMEM41A 9 3146884 3158694 1.76 0.04 
COG1 18 9253690 9272198 1.76 0.04 
SC5D 24 3520334 3534948 1.76 0.04 
Ex-FABP 17 496841 509845 1.75 0.04 
STK36 7 21943534 21964693 1.75 0.04 
WDR43 3 8483900 8516828 1.75 0.04 
gga-mir-1635 21 1736923 1747030 1.75 0.04 
249 
 
ITGBL1 1 142609260 142757083 1.75 0.04 
DHX58 27 4817591 4831644 1.75 0.04 
MAGOH2 8 23545023 23556699 1.74 0.04 
NSUN4 8 20496439 20510675 1.74 0.04 
ENSGALT00000037436.2 5 51840059 51859861 1.74 0.04 
ZBTB10 2 120778327 120814194 1.74 0.04 
PDIK1L 23 3157644 3173327 1.74 0.04 
RTN1 5 54587266 54693712 1.74 0.04 
COL23A1 13 13573333 13611087 1.74 0.04 
ENSGALT00000028290.4 25 470092 483012 1.74 0.04 
gga-mir-2126 1 14562819 14572965 1.74 0.04 
BCAP29 1 14562865 14596310 1.74 0.04 
DAAM1 5 54634542 54787177 1.74 0.04 
ENSGALT00000017050.4 8 20766031 20785775 1.74 0.04 
SPR 4 89385873 89398991 1.74 0.04 
DYNC1LI2 11 10812083 10846597 1.74 0.04 
EFCAB7 8 26743610 26767766 1.74 0.04 
ALOX5AP 1 174330142 174349760 1.74 0.04 
OSTC 4 37148758 37162890 1.74 0.04 
gga-mir-6658 4 1169076 1179186 1.74 0.04 
DUS4L 1 14548187 14568663 1.74 0.04 
LRRC41 8 20482709 20503624 1.74 0.04 
BDKRB2 5 45616377 45647975 1.73 0.04 
DNAJB11 9 3856049 3878808 1.73 0.04 
C11orf24 5 15651186 15666708 1.73 0.04 
DNAJC6 8 27181949 27222638 1.73 0.04 
gga-mir-1596 1 5673878 5683968 1.73 0.04 
EDN2 23 945278 960659 1.73 0.04 
RYR2 3 36493790 36666068 1.73 0.04 
DHCR24 8 24152605 24170747 1.73 0.04 
SNORD53_SNORD92 3 8492971 8511580 1.73 0.04 
ENSGALT00000031254.3 2 12957516 12968530 1.72 0.04 
COL8A1 1 83656752 83753442 1.72 0.04 
TOM1L1 18 5781850 5812221 1.72 0.04 
RPRML 27 2293588 2303924 1.72 0.04 
KCNK9 2 144599863 144688639 1.72 0.04 
KLHL3 13 13813619 13856076 1.72 0.04 
JKAMP 5 54714446 54730149 1.72 0.04 
MYOC 8 4702986 4715477 1.72 0.04 
ATAD2 2 137581975 137626986 1.71 0.04 
USP28 24 4413800 4442648 1.71 0.04 
ENSGALT00000034299.3 14 1573945 1593403 1.71 0.04 
ADHFE1 2 114782386 114804160 1.71 0.04 
SFT2D1 3 42142562 42167710 1.71 0.04 
ENSGALT00000003257.4 6 2255606 2282212 1.71 0.04 
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ENSGALT00000039707.2 17 5307125 5321669 1.71 0.04 
PSAP 6 11505432 11535618 1.71 0.04 
NPPB 21 5572061 5584681 1.71 0.04 
PLCL1 7 9817435 9948072 1.70 0.04 
IARS 12 3499494 3599440 1.70 0.04 
PROKR2 3 11267176 11286262 1.70 0.04 
MDK 5 22942433 22953426 1.70 0.04 
TOP1 20 5175401 5247581 1.70 0.04 
NME7 1 83099917 83182722 1.70 0.04 
TRPM2 9 4694123 4717793 1.70 0.04 
SLC13A1 1 22189830 22223981 1.70 0.04 
WNT11B 4 1176325 1188490 1.70 0.04 
SHISA5 12 3237718 3258873 1.70 0.04 
PRSS35 3 77125272 77142465 1.70 0.04 
COL21A1 3 86626542 86713701 1.70 0.04 
ENSGALT00000007125.3 4 1169206 1181630 1.70 0.04 
EIF2S1 5 28230900 28250721 1.70 0.04 
GluR1/A 13 11641222 11758641 1.70 0.04 
USPL1 1 174345050 174368188 1.70 0.04 
MTO1 3 80923944 80941582 1.70 0.04 
MYEOV2 9 4719225 4732052 1.70 0.04 
gga-mir-1608 9 4718168 4728261 1.69 0.05 
PPP1R17 2 49062175 49090386 1.69 0.05 
DOK5 20 12593229 12638483 1.69 0.05 
HNRNPAB 13 13619725 13636823 1.69 0.05 
DST 3 86244529 86550594 1.69 0.05 
CASP10 7 10919384 10937701 1.69 0.05 
SSR1 2 64705799 64725473 1.69 0.05 
KIAA1407 1 82431524 82460764 1.69 0.05 
ENSGALT00000002009.2 28 2585048 2603927 1.69 0.05 
ENSGALT00000037006.2 3 86276184 86288796 1.68 0.05 
PHLDA3 26 762672 773044 1.68 0.05 
NBR2 27 5168808 5178871 1.68 0.05 
C12orf40 1 15056969 15074520 1.68 0.05 
PLEKHG1 3 47790130 47938046 1.68 0.05 
SYT6 26 3746476 3783467 1.68 0.05 
MTERF3 2 126592211 126620684 1.68 0.05 
LRP11 3 47533736 47611787 1.68 0.05 
T 3 42228585 42246528 1.68 0.05 
TRIP12 9 9528375 9583184 1.68 0.05 
RAB11FIP2 6 28998776 29052647 1.68 0.05 
SNW1 5 38629499 38656966 1.68 0.05 
UBALD1 14 12391925 12409682 1.68 0.05 
gga-mir-1575 4 28993677 29003781 1.67 0.05 
gga-mir-6574 9 7099152 7109259 1.67 0.05 
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RNF213 18 9766939 9823172 1.67 0.05 
ENSGALT00000041141.2 16 473530 484889 1.67 0.05 
ENSGALT00000022016.4 16 473725 485245 1.67 0.05 
RPS6KC1 3 20971410 21071009 1.67 0.05 
COX20 3 34034071 34048740 1.67 0.05 
PODN 8 23446382 23482433 1.67 0.05 
ENSGALT00000040808.2 6 10378542 10394962 1.67 0.05 
HGF/SF 1 10466387 10539407 1.67 0.05 
TRAK2 7 10957319 10985326 1.67 0.05 
CYB5RL 8 24049756 24068868 1.67 0.05 
ERG 1 106939607 107013750 1.67 0.05 
MAP3K6 23 1925453 1941866 1.67 0.05 
L3HYPDH 5 54718689 54731778 1.67 0.05 
NEK5 1 169661483 169690951 1.67 0.05 
ENSGALT00000045685.1 4 85444697 85463910 1.67 0.05 
KARS 11 19304961 19327126 1.67 0.05 
GPRIN2 6 2236233 2248572 1.67 0.05 
CPNE8 1 15301093 15407789 1.67 0.05 
BECN1 27 5050738 5065519 1.66 0.05 
ABCD2 1 15075339 15131895 1.66 0.05 
CLDN25 24 4409651 4420344 1.66 0.05 
PRKCQ 1 3554594 3600000 1.66 0.05 
TMED8 5 38474796 38490414 1.66 0.05 
MRPS11 10 12658654 12672185 1.66 0.05 
FBXO32 2 137639050 137673702 1.66 0.05 
MCMDC2 2 114965566 114984273 1.66 0.05 
CACNG1b 18 7188266 7206862 1.66 0.05 
TGM4 2 43738130 43758642 1.66 0.05 
ENSGALT00000044541.1 8 28723160 28739974 1.66 0.05 
CCDC101 8 28724100 28738351 1.66 0.05 
AP3B2 10 858777 879957 1.66 0.05 
SOX10 1 50906764 50926215 1.66 0.05 
CUL2 2 12967706 13027987 1.66 0.05 
ENSGALT00000043826.1 1 41512811 41522930 1.66 0.05 
MYCN 3 98773413 98785948 1.65 0.05 
ATRIP 12 3274855 3295698 1.65 0.05 
GCNT7 20 12318249 12332049 1.65 0.05 
ZMYND11 2 9786127 9899465 1.65 0.05 
KLHL29 3 103279323 103645841 1.65 0.05 
ENSGALT00000016958.4 8 20512454 20532586 1.65 0.05 
LIPH 9 3148811 3170001 1.65 0.05 
ZNF800 1 20639894 20664015 1.65 0.05 
FOXL2 9 5195074 5205992 1.65 0.05 
CTNNAL1 2 88494506 88562002 1.65 0.05 
KCNS3 3 99917983 99947855 1.65 0.05 
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Appendix 6.2 GO terms had EASE scores that were less than 0.05 (DAVID). 
Category Term Count 
Fold of 
Enrichment P-Value Bonferroni 
CC extracellular exosome 113 2.02 4.60e-14 1.65e-11 
CC myelin sheath 22 4.99 1.91e-09 6.86e-07 
MC poly(A) RNA binding 55 2.19 4.31e-08 1.95e-05 
CC 
cytosolic large ribosomal 
subunit 11 6.05 9.38e-06 3.36e-03 
CC nucleus 107 1.45 2.53e-05 0.01 
CC focal adhesion 25 2.58 3.72e-05 0.01 
MC 
structural constituent of 
ribosome 18 3.17 4.67e-05 0.02 
CC plasma membrane 67 1.63 5.11e-05 0.02 
CC membrane 45 1.84 9.41e-05 0.03 
MC calmodulin binding 8 6.89 1.09e-04 0.05 
BP 
homophilic cell adhesion 
via plasma membrane 
adhesion molecules 13 3.75 1.54e-04 0.21 
CC nucleosome 9 5.41 2.02e-04 0.07 
BP translation 16 3.04 2.27e-04 0.30 
CC cytosol 48 1.73 2.29e-04 0.08 
BP 
heterophilic cell-cell 
adhesion via plasma 
membrane cell adhesion 
molecules 6 8.97 3.66e-04 0.43 
CC cytoplasm 104 1.36 5.39e-04 0.18 
CC 
cytosolic small ribosomal 
subunit 7 6.46 5.80e-04 0.19 
CC filamentous actin 6 8.16 6.19e-04 0.20 
BP 
transcription, DNA-
templated 32 1.91 6.43e-04 0.63 
MC calcium ion binding 32 1.89 7.67e-04 0.29 
MC RNA binding 19 2.37 1.04e-03 0.37 
BP glycolytic process 6 7.18 1.13e-03 0.82 
CC ruffle 8 4.81 1.17e-03 0.34 
BP neuron development 6 6.52 1.80e-03 0.94 
CC neuron projection 12 3.04 1.86e-03 0.49 
BP cell adhesion 14 2.60 2.75e-03 0.99 
BP gluconeogenesis 6 5.74 3.27e-03 0.99 
MC 
protein 
heterodimerization 
activity 10 3.26 3.29e-03 0.78 
BP cytoplasmic translation 5 7.48 3.63e-03 1.00 
CC cell junction 13 2.57 4.65e-03 0.81 
MC pre-miRNA binding 3 24.10 4.98e-03 0.90 
BP locomotory behavior 8 3.68 5.49e-03 1.00 
BP 
regulation of 
transcription, DNA-
templated 27 1.75 6.28e-03 1.00 
BP glial cell differentiation 4 9.57 6.93e-03 1.00 
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CC 
cytoplasmic 
ribonucleoprotein granule 4 9.40 7.46e-03 0.93 
CC filopodium 6 4.70 8.11e-03 0.95 
MC protein binding 11 2.62 8.76e-03 0.98 
BP 
positive regulation of 
neuron apoptotic process 4 8.70 9.24e-03 1.00 
MC 
AMPA glutamate receptor 
activity 3 18.08 9.69e-03 0.99 
BP 
positive regulation of 
extracellular matrix 
disassembly 3 17.94 9.84e-03 1.00 
CC synapse 9 2.91 0.01 0.99 
BP 
regulation of circadian 
rhythm 5 5.44 0.01 1.00 
BP 
positive regulation of 
guanylate cyclase activity 3 14.35 0.02 1.00 
MC DNA binding 28 1.58 0.02 1.00 
BP protein tetramerization 5 4.78 0.02 1.00 
CC 
mitochondrial respiratory 
chain complex IV 3 12.93 0.02 1.00 
MC GTPase activity 11 2.31 0.02 1.00 
MC 
protein homodimerization 
activity 11 2.31 0.02 1.00 
BP 
positive regulation of 
insulin secretion involved 
in cellular response to 
glucose stimulus 4 6.38 0.02 1.00 
MC proteoglycan binding 3 12.05 0.02 1.00 
BP 
oxidation-reduction 
process 10 2.39 0.02 1.00 
CC cytoskeleton 9 2.56 0.02 1.00 
CC melanosome 5 4.46 0.02 1.00 
BP 
nervous system 
development 8 2.73 0.03 1.00 
CC dense body 3 11.08 0.03 1.00 
CC blood microparticle 6 3.45 0.03 1.00 
CC 
cell-cell adherens 
junction 5 4.17 0.03 1.00 
CC nucleolus 24 1.57 0.03 1.00 
MC 
ionotropic glutamate 
receptor activity 3 10.33 0.03 1.00 
BP 
DNA replication-
independent nucleosome 
assembly 4 5.63 0.03 1.00 
BP mRNA splice site selection 3 10.25 0.03 1.00 
BP 
regulation of calcium ion 
transport 3 10.25 0.03 1.00 
MC nucleosomal DNA binding 4 5.36 0.04 1.00 
BP 
negative regulation of 
endopeptidase activity 4 5.32 0.04 1.00 
BP RNA splicing 5 3.86 0.04 1.00 
CC lamellipodium 8 2.52 0.04 1.00 
MC 
microfilament motor 
activity 3 9.04 0.04 1.00 
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BP lymphangiogenesis 3 8.97 0.04 1.00 
BP 
calcium-dependent cell-
cell adhesion via plasma 
membrane cell adhesion 
molecules 3 8.97 0.04 1.00 
BP forelimb morphogenesis 3 8.97 0.04 1.00 
BP 
actomyosin structure 
organization 4 5.04 0.04 1.00 
BP nucleosome assembly 6 2.99 0.05 1.00 
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Appendix 6.3 GO terms had FDR that were less than 0.25 (GSEA). 
NAME SIZE NES FDR 
GO_INNER_MITOCHONDRIAL_MEMBRANE_PROTEIN_COMPLEX 50 2.11 0.02 
GO_SECONDARY_METABOLIC_PROCESS 14 2.15 0.02 
GO_MULTIVESICULAR_BODY 16 2.08 0.02 
GO_MITOCHONDRIAL_PROTEIN_COMPLEX 61 2.04 0.03 
GO_TERPENOID_METABOLIC_PROCESS 42 1.98 0.05 
GO_MITOCHONDRIAL_MEMBRANE_PART 74 1.97 0.05 
GO_ELECTRON_TRANSPORT_CHAIN 46 1.98 0.05 
GO_SECRETORY_GRANULE_LUMEN 32 1.98 0.06 
GO_PLATELET_DEGRANULATION 49 1.95 0.06 
GO_MULTI_ORGANISM_METABOLIC_PROCESS 69 1.98 0.06 
GO_KERATAN_SULFATE_METABOLIC_PROCESS 14 1.99 0.07 
GO_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ENDOPLASMIC_RETICULUM 62 1.93 0.07 
GO_ISOPRENOID_METABOLIC_PROCESS 47 1.93 0.07 
GO_OXIDATIVE_PHOSPHORYLATION 41 1.93 0.07 
GO_MITOCHONDRIAL_RESPIRATORY_CHAIN_COMPLEX_ASSEMBLY 32 1.91 0.08 
GO_MITOCHONDRIAL_RESPIRATORY_CHAIN_COMPLEX_I_BIOGENESIS 24 1.91 0.08 
GO_DNA_DEPENDENT_DNA_REPLICATION 40 -1.97 0.09 
GO_TRANSCRIPTION_FACTOR_ACTIVITY_DIRECT_LIGAND_REGULATED_SEQUENCE_SP
ECIFIC_DNA_BINDING 22 -2.02 0.10 
GO_NADH_DEHYDROGENASE_COMPLEX 22 1.89 0.10 
GO_VESICLE_LUMEN 38 1.89 0.10 
GO_KERATAN_SULFATE_BIOSYNTHETIC_PROCESS 11 1.88 0.10 
GO_ENSHEATHMENT_OF_NEURONS 43 1.88 0.10 
GO_NEGATIVE_REGULATION_OF_ENDOTHELIAL_CELL_PROLIFERATION 16 1.87 0.10 
GO_POSITIVE_REGULATION_OF_BEHAVIOR 10 1.87 0.10 
GO_MELANIN_METABOLIC_PROCESS 8 1.86 0.11 
GO_DNA_GEOMETRIC_CHANGE 46 -1.92 0.12 
GO_RESPIRATORY_CHAIN 40 1.84 0.12 
GO_LIPOPROTEIN_PARTICLE_RECEPTOR_BINDING 10 1.85 0.12 
GO_POSITIVE_REGULATION_OF_RHO_PROTEIN_SIGNAL_TRANSDUCTION 6 1.84 0.12 
GO_REGULATION_OF_SYNAPTIC_TRANSMISSION_GLUTAMATERGIC 24 1.85 0.13 
GO_PURINE_NTP_DEPENDENT_HELICASE_ACTIVITY 33 -1.94 0.13 
GO_SPECIFICATION_OF_ORGAN_IDENTITY 7 1.85 0.13 
GO_ACTIVATION_OF_MAPK_ACTIVITY 57 1.83 0.13 
GO_MALE_SEX_DIFFERENTIATION 54 -1.97 0.14 
GO_SECONDARY_METABOLITE_BIOSYNTHETIC_PROCESS 7 1.82 0.14 
GO_RIBOSOMAL_SUBUNIT 86 1.83 0.14 
GO_ATP_DEPENDENT_DNA_HELICASE_ACTIVITY 16 -1.92 0.14 
GO_COMPLEX_OF_COLLAGEN_TRIMERS 9 1.82 0.15 
GO_NUCLEAR_TRANSCRIBED_MRNA_CATABOLIC_PROCESS_NONSENSE_MEDIATED_DEC
AY 63 1.81 0.15 
GO_DNA_RECOMBINATION 77 -1.87 0.15 
GO_INDUCTION_OF_POSITIVE_CHEMOTAXIS 5 1.81 0.16 
GO_HELICASE_ACTIVITY 54 -1.87 0.16 
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GO_PHOSPHATIDYLCHOLINE_METABOLIC_PROCESS 22 1.80 0.16 
GO_GROWTH_FACTOR_RECEPTOR_BINDING 50 1.79 0.17 
GO_POSITIVE_REGULATION_OF_MAP_KINASE_ACTIVITY 93 1.79 0.17 
GO_REGULATION_OF_POSITIVE_CHEMOTAXIS 10 1.79 0.17 
GO_MYELIN_SHEATH 95 1.79 0.17 
GO_POSITIVE_REGULATION_OF_FATTY_ACID_BIOSYNTHETIC_PROCESS 7 1.78 0.17 
GO_POSITIVE_REGULATION_OF_LIPASE_ACTIVITY 29 1.79 0.17 
GO_HEPARIN_BINDING 56 1.78 0.18 
GO_REGULATION_OF_GROWTH_HORMONE_SECRETION 6 1.80 0.18 
GO_POSITIVE_REGULATION_OF_FATTY_ACID_METABOLIC_PROCESS 13 1.78 0.18 
GO_POSITIVE_REGULATION_OF_TRIGLYCERIDE_METABOLIC_PROCESS 6 1.77 0.18 
GO_ENDOCRINE_PROCESS 14 -1.88 0.18 
GO_CYTOSOLIC_RIBOSOME 66 1.78 0.18 
GO_SMALL_RIBOSOMAL_SUBUNIT 34 1.77 0.18 
GO_DNA_HELICASE_ACTIVITY 26 -1.88 0.19 
GO_EXTRACELLULAR_SPACE 349 1.77 0.19 
GO_POSITIVE_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION 18 1.76 0.20 
GO_STRUCTURAL_CONSTITUENT_OF_RIBOSOME 96 1.76 0.20 
GO_ETHANOLAMINE_CONTAINING_COMPOUND_METABOLIC_PROCESS 28 1.76 0.20 
GO_CELLULAR_RESPIRATION 68 1.73 0.20 
GO_POSITIVE_REGULATION_OF_CHEMOTAXIS 44 1.73 0.20 
GO_PROTEIN_TARGETING_TO_MEMBRANE 86 1.73 0.21 
GO_REGULATION_OF_LIPASE_ACTIVITY 36 1.75 0.21 
GO_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY_COUPLED_TO_CYCLIC_
NUCLEOTIDE_SECOND_MESSENGER 60 1.74 0.21 
GO_SPROUTING_ANGIOGENESIS 22 1.73 0.21 
GO_SECRETORY_GRANULE 111 1.74 0.21 
GO_MITOCHONDRIAL_ELECTRON_TRANSPORT_CYTOCHROME_C_TO_OXYGEN 9 1.74 0.21 
GO_ACTIVATION_OF_ADENYLATE_CYCLASE_ACTIVITY 16 1.75 0.21 
GO_B_CELL_PROLIFERATION 6 1.74 0.21 
GO_TISSUE_REGENERATION 23 1.74 0.21 
GO_ADENYLATE_CYCLASE_ACTIVATING_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING
_PATHWAY 19 1.75 0.21 
GO_MODULATION_OF_EXCITATORY_POSTSYNAPTIC_POTENTIAL 10 1.72 0.21 
GO_EXTRACELLULAR_MATRIX 134 1.74 0.21 
GO_MYOTUBE_CELL_DEVELOPMENT 7 1.72 0.21 
GO_RESPONSE_TO_PROGESTERONE 17 1.75 0.21 
GO_POSITIVE_REGULATION_OF_LIPID_CATABOLIC_PROCESS 9 1.73 0.21 
GO_REGULATION_OF_LIPID_CATABOLIC_PROCESS 19 1.72 0.21 
GO_TRANSLATIONAL_INITIATION 80 1.74 0.21 
GO_POSITIVE_REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_RECEPTOR_SIGNALI
NG_PATHWAY 5 1.72 0.21 
GO_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS 98 1.73 0.21 
GO_REGULATION_OF_COAGULATION 31 1.74 0.22 
GO_HETEROTRIMERIC_G_PROTEIN_COMPLEX 16 1.72 0.22 
GO_CHEMICAL_HOMEOSTASIS_WITHIN_A_TISSUE 5 1.71 0.22 
GO_INTRAMOLECULAR_OXIDOREDUCTASE_ACTIVITY 22 1.71 0.22 
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GO_REGULATION_OF_TUMOR_NECROSIS_FACTOR_BIOSYNTHETIC_PROCESS 5 1.71 0.23 
GO_PROTEIN_LOCALIZATION_TO_ENDOPLASMIC_RETICULUM 70 1.71 0.23 
GO_PEPTIDASE_REGULATOR_ACTIVITY 54 1.71 0.23 
GO_RETINOL_BINDING 7 1.71 0.23 
GO_COPPER_ION_BINDING 18 1.69 0.23 
GO_REGULATION_OF_EPIDERMAL_GROWTH_FACTOR_ACTIVATED_RECEPTOR_ACTIVIT
Y 9 1.69 0.23 
GO_REGULATION_OF_WOUND_HEALING 49 1.69 0.23 
GO_POSITIVE_REGULATION_OF_LIPID_BIOSYNTHETIC_PROCESS 25 1.69 0.23 
GO_NEGATIVE_REGULATION_OF_CELLULAR_RESPONSE_TO_INSULIN_STIMULUS 12 1.69 0.23 
GO_PHOSPHATIDYLSERINE_BINDING 13 1.70 0.23 
GO_INTERSTITIAL_MATRIX 4 1.69 0.24 
GO_DEVELOPMENTAL_PIGMENTATION 23 1.69 0.24 
GO_INSULIN_LIKE_GROWTH_FACTOR_RECEPTOR_BINDING 6 1.70 0.24 
GO_GLYCOSAMINOGLYCAN_BINDING 70 1.69 0.24 
GO_REGENERATION 68 1.70 0.24 
GO_POSITIVE_REGULATION_OF_MAPK_CASCADE 186 1.69 0.24 
GO_ENDOPLASMIC_RETICULUM_LUMEN 64 1.70 0.24 
GO_CHEMOKINE_MEDIATED_SIGNALING_PATHWAY 6 1.70 0.24 
GO_FATTY_ACID_ELONGATION 6 1.70 0.24 
 
 
 
